pyrimethamine has been researched along with Malaria, Falciparum in 1059 studies
Maloprim: contains above 2 cpds
Malaria, Falciparum: Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.
| Excerpt | Relevance | Reference |
|---|---|---|
| " HIV-uninfected pregnant women between 12 and 20 weeks gestation were randomly assigned (1:1) to monthly intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine or dihydroartemisinin-piperaquine." | 9.30 | Monthly sulfadoxine-pyrimethamine versus dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomised, controlled, superiority trial. ( Ategeka, J; Clark, TD; Dorsey, G; Havlir, DV; Jagannathan, P; Kajubi, R; Kakuru, A; Kamya, MR; Nakalembe, M; Nayebare, P; Ochieng, T; Ochokoru, H; Opira, B; Ruel, T, 2019) |
| "The spread of SP resistance may compromise the effectiveness of intermittent preventive treatment of malaria in pregnancy (MiP) with sulfadoxine-pyrimethamine (IPTp-SP) across Africa." | 9.27 | Intermittent screening and treatment with artemether-lumefantrine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in pregnancy: a facility-based, open-label, non-inferiority trial in Nigeria. ( Berens-Riha, N; Esu, E; Loescher, T; Meremikwu, M; Nwachuku, N; Pritsch, M, 2018) |
| "Intermittent preventive treatment of malaria in pregnancy (IPTp) with dihydroartemisinin-piperaquine (IPTp-DP) has been shown to reduce the burden of malaria during pregnancy compared to sulfadoxine-pyrimethamine (IPTp-SP)." | 9.27 | Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial. ( Aweeka, F; Beeson, J; Charlebois, ED; Clark, TD; Dorsey, G; Drakeley, C; Feeney, ME; Greenhouse, B; Havlir, DV; Jagannathan, P; Kakuru, A; Kamya, MR; Muhindo, MK; Nakalembe, M; Nankya, F; Natureeba, P; Okiring, J; Olwoch, P; Opira, B; Prahl, M; Reiling, L; Rodriguez-Barraquer, I; Ssewanyana, I; Tetteh, K; Wallender, E, 2018) |
| "The World Health Organization recommends intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) in African regions with moderate to high malaria transmission." | 9.22 | Efficacy and Safety of Azithromycin-Chloroquine versus Sulfadoxine-Pyrimethamine for Intermittent Preventive Treatment of Plasmodium falciparum Malaria Infection in Pregnant Women in Africa: An Open-Label, Randomized Trial. ( Ayoub, A; Duparc, S; Kamiza, S; Kimani, J; Orrico, R; Phiri, K; Robbins, J; Rojo, R; Vandenbroucke, P, 2016) |
| "In India, till recently, Chloroquine was used as first-line therapy in areas with Chloroquine sensitive Plasmodium falciparum malaria cases." | 9.15 | Efficacy of chloroquine and sulphadoxine-pyrimethamine either alone or in combination before introduction of ACT as first-line therapy in uncomplicated Plasmodium falciparum malaria in Jalpaiguri District, West Bengal, India. ( Bera, DK; Biswas, A; Das, M; Das, S; Guha, SK; Kundu, PK; Maji, AK; Mullick, S; Ray, K; Roy, D; Saha, P; Sengupta, S, 2011) |
| " In a small study in eastern Sudan, the effects of the treatment of uncomplicated, Plasmodium falciparum malaria with artesunate-sulfamethoxypyrazine-pyrimethamine (AS-SMP) and artemether-lumefantrine (AT-LU) on co-infections with Schistosoma mansoni were therefore investigated." | 9.13 | The antischistosomal efficacies of artesunate-sulfamethoxypyrazine-pyrimethamine and artemether-lumefantrine administered as treatment for uncomplicated, Plasmodium falciparum malaria. ( Abdalla, E; Adam, I; Elhadi, MO; Elhardello, OA; Elmardi, KA; Jansen, FH, 2008) |
| " This study tested the hypothesis that the co-formulated fixed dose combination (FDC) artesunate/sulfamethoxypyrazine/pyrimethamine (As/SMP) administered as a 24-hour therapy with a dose interval of 12 hours is as efficacious and safe as the administration of the same drug over 3 days given with a dose interval of 24 hours, for the treatment of uncomplicated Plasmodium falciparum malaria in Ivory Coast." | 9.13 | Single-day, three-dose treatment with fixed dose combination artesunate/sulfamethoxypyrazine/pyrimethamine to cure Plasmodium falciparum malaria. ( Jansen, FH; Penali, LK, 2008) |
| "Amodiaquine+SP is not well tolerated and a substantial proportion of patients experienced pruritus and fatigue, thus decreasing their compliance and compromising the first line treatment implementation at national level." | 9.12 | Tolerability of amodiaquine and sulphadoxine-pyrimethamine, alone or in combination for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan adults. ( D'Alessandro, U; Fanello, CI; Karema, C; Rwagacondo, CE; van Doren, W, 2006) |
| "Whether administration of folic acid to children with malaria anemia is helpful is controversial." | 9.12 | Folic acid treatment of Zambian children with moderate to severe malaria anemia. ( Bennett, S; Fielding, K; Greenwood, B; Malunga, P; Mulenga, M; Shulman, C; Thuma, P, 2006) |
| "In Zambia, unacceptably high resistance to commonly used antimalarial drugs prompted the choice of artemether-lumefantrine (AL) as first line treatment for uncomplicated Plasmodium falciparum malaria." | 9.12 | Safety and efficacy of lumefantrine-artemether (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Zambian adults. ( Chalwe, V; Chilengi, R; D'Alessandro, U; Dujardin, JC; Moerman, F; Mulenga, M; Mwananyanda, L; Van Overmeir, C; VangGeertruyden, JP, 2006) |
| "the efficacy of fixed co-formulated (f) artesunate-sulfamethoxypyrazine-pyrimethamine (AS+SMP f) administered at time intervals of 12 hours for a 24-hour therapy was compared with the efficacy of the same drug given as a loose combination (AS+SMP l) with a dose interval of 24 hours for 3 days for the treatment of uncomplicated Plasmodium falciparum malaria in eastern Sudan." | 9.12 | A fixed-dose 24-hour regimen of artesunate plus sulfamethoxypyrazine-pyrimethamine for the treatment of uncomplicated Plasmodium falciparum malaria in eastern Sudan. ( Adam, I; Alifrangis, M; Elmardi, KA; Khalil, IF; Magzoub, M; Osman, ME, 2006) |
| "We undertook a trial of artesunate + amodiaquine (AS + AQ) and artesunate + sulphadoxine-pyrimethamine (AS + SP) in 180 children of age 6-59 months with uncomplicated malaria in Democratic Republic of Congo." | 9.12 | Artesunate + amodiaquine and artesunate + sulphadoxine-pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulphadoxine and pyrimethamine-resistant haplotypes. ( Kayembe, G; Montgomery, J; Pota, H; Roper, C; Swarthout, TD; van den Broek, IV, 2006) |
| "An open randomized controlled study of artemether-lumefantrine (AL) and amodiaquine-sulfalene-pyrimethamine (ASP) for the treatment of uncomplicated Plasmodium falciparum malaria was carried out in 181 children." | 9.12 | The effects of artemether-lumefantrine vs amodiaquine-sulfalene-pyrimethamine on the hepatomegaly associated with Plasmodium falciparum malaria in children. ( Adedeji, AA; Amoo, AO; Fateye, BA; Gbotosho, GO; Happi, CT; Sowunmi, A; Tambo, E, 2007) |
| " We tested the hypothesis that artesunate-sulfamethoxypyrazine-pyrimethamine is as efficacious as the four-dose regimen of artemether-lumefantrine for treatment of Plasmodium falciparum malaria." | 9.12 | A randomized trial of artesunate-sulfamethoxypyrazine-pyrimethamine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali. ( Dicko, A; Djimde, A; Doumbo, OK; Fofana, M; Guindo, O; Jansen, HF; Kone, M; Ouattara, A; Sagara, I; Sissoko, M; Sogoba, M; Thera, MA; Tolo, Y, 2006) |
| "Amodiaquine alone or in combination with sulphadoxine-pyrimethamine, although associated with minor side-effects, is effective when used to treat malaria in pregnancy." | 9.12 | Efficacy, safety, and tolerability of amodiaquine plus sulphadoxine-pyrimethamine used alone or in combination for malaria treatment in pregnancy: a randomised trial. ( Browne, E; Bruce, J; Chandramohan, D; Greenwood, B; Randal, A; Tagbor, H, 2006) |
| "The treatment efficacy and effects of artemether-lumefantrine (AL) and amodiaquine-sulfalene-pyrimethamine (ASP) on gametocyte carriage were evaluated in 181 children < or = 10 years of age with uncomplicated Plasmodium falciparum malaria randomized to receive either drug combination." | 9.12 | Therapeutic efficacy and effects of artemether-lumefantrine and amodiaquine-sulfalene-pyrimethamine on gametocyte carriage in children with uncomplicated Plasmodium falciparum malaria in southwestern Nigeria. ( Adedeji, AA; Fateye, BA; Fehintola, FA; Folarin, OA; Gbotosho, GO; Happi, CT; Sowunmi, A; Tambo, E, 2007) |
| "We assessed the ability of ibuprofen to modulate tumor necrosis factor alpha (TNF-alpha), soluble tumor necrosis factor receptor type I (sTNFR-I), and soluble tumor necrosis factor receptor type II (sTNFR-II) responses during the treatment of fever in uncomplicated Plasmodium falciparum malaria, in a placebo-controlled, randomized, double-blind study of 50 pediatric patients in Lambaréné, Gabon." | 9.12 | Ibuprofen does not affect levels of tumor necrosis factor alpha and soluble tumor necrosis factor receptor types I and II in Gabonese children with uncomplicated Plasmodium falciparum malaria. ( Issifou, S; Matsiegui, PB; Mavoungou, E; Missinou, MA; Necek, M, 2007) |
| "A study of the therapeutic efficacy of combined chloroquine and sulfadoxine-pyrimethamine (SP) for the treatment of uncomplicated Plasmodium falciparum malaria was carried out from June to November 2002, using the standard protocol recommended by the WHO for a low-to-moderate transmission area, in two sentinel sites in Bangladesh: Alikadam Upazilla in Bandarban district and Matiranga Upazilla in Khagrachari district." | 9.11 | Efficacy of combined chloroquine and sulfadoxine-pyrimethamine in uncomplicated Plasmodium falciparum malaria in Bangladesh. ( Bangali, M; Das, S; Rahman, M; Rahman, R; Ringwald, P; Talukder, MR, 2004) |
| "The efficacy of amodiaquine (AQ) and sulfadoxine-pyrimethamine (SP) was assessed in 310 symptomatic children from western Kenya with uncomplicated Plasmodium falciparum malaria." | 9.11 | Comparison of the parasitologic efficacy of amodiaquine and sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malaria in the Bungoma District of western Kenya. ( Cobelens, FG; Gikunda, S; Hoogstraatte, SR; Kager, PA; Scheper, FY; Smolders, M; Vreugdenhil, CJ, 2004) |
| "To assess the therapeutic efficacy of sulfadoxinepyrimethamine (SP) after 5 years of use as first-line treatment of uncomplicated Plasmodium falciparum malaria, and thus guide the selection of artemisinin-based combination therapy in Mpumalanga, South Africa." | 9.11 | Therapeutic efficacy of sulfadoxine-pyrimethamine for Plasmodium falciparum malaria. ( Allen, E; Barnes, K; Durrheim, D; Govere, J; La Grange, K; Mabuza, A; Mbokazi, F; Mngomezulu, N; Zitha, A, 2005) |
| "In an open, randomized, clinical trial, conducted in New Halfa, eastern Sudan, in September-October 2004, the efficacies and adverse effects of artesunate plus sulfadoxine-pyrimethamine (SP), in the treatment of uncomplicated, Plasmodium falciparum malaria, were compared with those of SP alone." | 9.11 | A comparison of the efficacy of artesunate plus sulfadoxine-pyrimethamine with that of sulfadoxine-pyrimethamine alone, in the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan. ( A-Elbasit, IE; Adam, I; Elbashir, MI; Idris, SM; Malik, EM, 2005) |
| "A prospective clinical trial was carried out to determine in vivo efficacy of sulfadoxine/pyrimethamine for the treatment of uncomplicated Plasmodium falciparum malaria in children in New Halfa." | 9.11 | Efficacy of sulfadoxin pyrimethamine for uncomplicated Plasmodium falciparum malaria in a small sample of Sudanese children. ( A/elbasit, IA; Adam, I; Elbashir, MI; Ibrahim, MH, 2004) |
| "To evaluate the therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine, and the sulfadoxine-pyrimethamine-amodiaquine combination for the treatment of uncomplicated Plasmodium falciparum malaria in young children in Cameroon." | 9.10 | Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxine-pyrimethamine-amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon. ( Basco, LK; Metoh, T; Ndounga, M; Ngane, VF; Ringwald, P; Same-Ekobo, A; Soula, G, 2002) |
| "The safety and efficacy of amodiaquine (AQ), sulfadoxine-pyrimethamine (SP), and coadministered AQ+SP was assessed in 351 Tanzanian children (age range, 6-59 months) with uncomplicated Plasmodium falciparum malaria." | 9.10 | The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine, and their combination in the treatment of uncomplicated Plasmodium falciparum malaria. ( Alonso, PL; Aponte, JJ; Drakeley, C; Kahigwa, E; Malende, A; Menendez, C; Mshinda, H; Msokame, C; Schellenberg, D; Tanner, M; Wigayi, J, 2002) |
| "Many African countries currently use a sulfadoxine-pyrimethamine combination (SP) or amodiaquine (AQ) to treat uncomplicated Plasmodium falciparum malaria." | 9.10 | Combination of drug level measurement and parasite genotyping data for improved assessment of amodiaquine and sulfadoxine-pyrimethamine efficacies in treating Plasmodium falciparum malaria in Gabonese children. ( Aubouy, A; Bakary, M; Cot, M; Deloron, P; Keundjian, A; Le Bras, J; Makita, JR; Mbomat, B; Migot-Nabias, F, 2003) |
| "In a southern border province of Lao PDR, we compared the efficacy of antimalarial drug combinations in patients aged >or=1 year with uncomplicated Plasmodium falciparum malaria: monotherapy with either mefloquine (MQ), chloroquine (CQ), or sulphadoxine/pyrimethamine (SP) vs." | 9.10 | Therapeutic efficacy of chloroquine plus sulphadoxine/ pyrimethamine compared with monotherapy with either chloroquine or sulphadoxine/pyrimethamine in uncomplicated Plasmodium falciparum malaria in Laos. ( Christophel, EM; Jelinek, T; Jordan, S; Phetsouvanh, R; Phompida, S; Schwöbel, B; Vanisaveth, V; von Sonnenburg, F, 2003) |
| " In order to further understand this relationship, we determined the proportion of gametocyte carriers over time post-treatment in patients with uncomplicated Plasmodium falciparum malaria who were treated with either chloroquine (CQ) or sulfadoxine/pyrimethamine (SP)." | 9.10 | Effects of chloroquine and sulfadoxine/pyrimethamine on gametocytes in patients with uncomplicated Plasmodium falciparum malaria in Colombia. ( Castillo, CM; Ferro, BE; Osorio, L, 2002) |
| "We evaluated the in vivo responses to chloroquine (CQ), the first line antimalarial, and to sulfadoxine-pyrimethamine (SP), the most readily available and affordable alternative treatment, in children under 5 with acute uncomplicated Plasmodium falciparum malaria in seven sites of Democratic Republic of Congo (DRC) between May 2000 and November 2001, using the standard 14-day WHO protocol." | 9.10 | Assessing the efficacy of chloroquine and sulfadoxine-pyrimethamine for treatment of uncomplicated Plasmodium falciparum malaria in the Democratic Republic of Congo. ( Kabuya, W; Kazadi, WM; Kebela, BI; Makina, BN; Mantshumba, JC; Ngimbi, NP; Vong, S, 2003) |
| "The in vivo efficacies of the Lao People's Democratic Republic (Laos) nationally recommended antimalarial agents--chloroquine and sulfadoxine-pyrimethamine-were assessed in a randomized, comparative trial that involved 100 patients with uncomplicated Plasmodium falciparum malaria who were followed for 42 days after starting treatment." | 9.10 | Chloroquine versus sulfadoxine-pyrimethamine for treatment of Plasmodium falciparum malaria in Savannakhet Province, Lao People's Democratic Republic: an assessment of national antimalarial drug recommendations. ( Brockman, A; Khanthavong, M; Mayxay, M; Newton, PN; Phetsouvanh, R; Phompida, S; Tiengkham, P; White, NJ, 2003) |
| " In the present study, the efficacies of chloroquine (CQ) or amodiaquine (AQ) in the oral treatment of acute, symptomatic, uncomplicated, Plasmodium falciparum malaria were compared with those of oral treatments with the combination of CQ or AQ with pyrimethamine-sulfadoxine (PS)." | 9.10 | A randomized comparison of chloroquine, amodiaquine and their combination with pyrimethamine-sulfadoxine in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children. ( Sowunmi, A, 2002) |
| "The efficacy and kinetics of the combination chloroquine plus sulfadoxine-pyrimethamine (CQ + SP), given sequentially and simultaneously, were investigated in 32 patients with acute uncomplicated Plasmodium falciparum malaria in Palawan Island, the Philippines." | 9.10 | Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ( Bustos, DG; Diquet, B; Gay, F; Laracas, CJ; Lazaro, JE; Pottier, A; Traore, B, 2002) |
| "A study was conducted to evaluate the effectiveness of a 3-day course of therapy with quinine sulphate (10 mg/kg 8-hourly) followed by a single dose of sulfadoxine-pyrimethamine (SP) according to weight category, before discharge, for 133 hospitalised patients with uncomplicated Plasmodium falciparum malaria at Shongwe Hospital, Mpumalanga province, between February and July 1998." | 9.09 | Effectiveness of short-course quinine and single-dose sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malaria in Mpumalanga Province, South Africa. ( Athan, E; Barnes, K; Dürrheim, DN; Govere, J; Mabuza, A; Mngomezulu, NM, 2001) |
| "To assess therapeutic efficacy of sulfadoxine-pyrimethamine (SP) in treatment of uncomplicated Plasmodium falciparum malaria 3 years after introduction in Mpumalanga, South Africa." | 9.09 | Therapeutic efficacy of sulfadoxine-pyrimethamine in uncomplicated Plasmodium falciparum malaria 3 years after introduction in Mpumalanga. ( Barnes, K; Bredenkamp, B; Durrheim, D; Govere, J; Mabuza, A; Mngomezulu, N; Sharp, B, 2001) |
| "We did a systematic review of interventional or observational cohort studies assessing the efficacy of artemisinin-based or quinine-based treatments in pregnancy." | 9.05 | Efficacy and tolerability of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a systematic review and individual patient data meta-analysis. ( Anvikar, AR; Ashley, EA; Chandramohan, D; Cohee, LM; D'Alessandro, U; Genton, B; Gilder, ME; Guérin, PJ; Juma, E; Kalilani-Phiri, L; Kennon, K; Kuepfer, I; Laufer, MK; Lwin, KM; Mansoor, R; McGready, R; Meshnick, SR; Mosha, D; Mwapasa, V; Mwebaza, N; Nambozi, M; Ndiaye, JA; Nosten, F; Nyunt, M; Ogutu, B; Parikh, S; Paw, MK; Phyo, AP; Pimanpanarak, M; Piola, P; Rijken, MJ; Saito, M; Sriprawat, K; Stepniewska, K; Tagbor, HK; Tarning, J; Tinto, H; Valéa, I; Valecha, N; White, NJ; Wiladphaingern, J, 2020) |
| "Resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine threatens the antimalarial effectiveness of intermittent preventive treatment during pregnancy (IPTp) in sub-Saharan Africa." | 9.01 | Effect of Plasmodium falciparum sulfadoxine-pyrimethamine resistance on the effectiveness of intermittent preventive therapy for malaria in pregnancy in Africa: a systematic review and meta-analysis. ( Desai, M; Gutman, J; Hopkins Sibley, C; Kayentao, K; Khairallah, C; Koshy, G; Larsen, DA; Meshnick, SR; Okell, LC; Rogerson, SJ; Roper, C; Slaughter, DEC; Taylor, SM; Ter Kuile, FO; van Eijk, AM, 2019) |
| "The World Health Organization currently recommends quinine+clindamycin for use against malaria in the first trimester." | 8.95 | Animal Embryotoxicity Studies of Key Non-Artemisinin Antimalarials and Use in Women in the First Trimester. ( Clark, RL, 2017) |
| "The antifolate sulphadoxine-pyrimethamine (SP) has been used in the intermittent prevention of malaria in pregnancy (IPTp)." | 8.88 | Combination of probenecid-sulphadoxine-pyrimethamine for intermittent preventive treatment in pregnancy. ( Gutman, J; Kachur, SP; Mutabingwa, T; Nzila, A; Slutsker, L, 2012) |
| " falciparum malaria is treated using Artemisinin-based Combination Therapy (ACT)." | 8.85 | Artemisinin-based combination therapy for treating uncomplicated malaria. ( Donegan, S; Garner, P; Olliaro, P; Sinclair, D; Zani, B, 2009) |
| "Amodiaquine and chloroquine give fast relief from malaria symptoms, particularly fever." | 8.81 | Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria. ( McIntosh, HM, 2001) |
| "Amodiaquine and chloroquine give fast relief from malaria symptoms, particularly fever." | 8.80 | Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria. ( McIntosh, HM, 2000) |
| "Between December, 2015, and March, 2016, and between December, 2017, and March, 2018, immediately following the 2015 and 2017 malaria transmission seasons, community surveys were done among children younger than 5 years and individuals aged 10-30 years in districts implementing seasonal malaria chemoprevention with sulfadoxine-pyrimethamine and amodiaquine in Burkina Faso, Chad, Guinea, Mali, Nigeria, Niger and The Gambia." | 8.31 | Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine-pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study. ( Bazie, T; Beshir, KB; Bojang, K; Cairns, M; Ceesay, S; Diallo, A; Dicko, A; Doumagoum, D; Eloike, T; Gamougam, K; Kessely, H; Kolie, F; Lamine, MM; Laminou, IM; Loua, K; Maiga, H; Mansukhani, R; Merle, CS; Milligan, P; Moroso, D; Muwanguzi, J; Nader, J; NDiaye, JL; Ogboi, SJ; Ouedraogo, JB; Razafindralambo, L; Sagara, I; Scott, S; Snell, P; Sutherland, CJ; Traore, A; Zongo, I, 2023) |
| "The effectiveness of community delivery of intermittent preventive treatment (C-IPT) of malaria in pregnancy (IPTp) with sulfadoxine-pyrimethamine has been evaluated in selected areas of the Democratic Republic of the Congo, Madagascar, Mozambique, and Nigeria." | 8.31 | Prevalence of molecular markers of resistance to sulfadoxine-pyrimethamine before and after community delivery of intermittent preventive treatment of malaria in pregnancy in sub-Saharan Africa: a multi-country evaluation. ( Arikpo, I; Bissombolo, D; Doderer-Lang, C; Figueroa-Romero, A; González, R; Lemba, E; Llach, M; Ma, L; Maly, C; Mayor, A; Menard, D; Menéndez, C; Meremikwu, M; Nhama, A; Pagnoni, F; Pons-Duran, C; Rakotosaona, R; Ratsimbasoa, A; Roman, E; Sacoor, C; Sanz, S, 2023) |
| "In Tanzania, the uptake of optimal doses (≥ 3) of sulfadoxine-pyrimethamine for intermittent preventive treatment of malaria (IPTp-SP) during pregnancy has remained below the recommended target of 80%." | 8.02 | Predictors for the uptake of optimal doses of sulfadoxine-pyrimethamine for intermittent preventive treatment of malaria during pregnancy in Tanzania: further analysis of the data of the 2015-2016 Tanzania demographic and health survey and malaria indicat ( Ambrose, T; Mbotwa, CH; Moshi, FV; Mushi, V; Zacharia, A, 2021) |
| "In 2012 the World Health Organisation (WHO) revised the policy on Intermittent Preventive Treatment with Sulphadoxine Pyrimethamine (IPTp-SP) to at least three doses for improved protection against malaria parasitaemia and its associated effects such as anaemia during pregnancy." | 8.02 | Intermittent preventive treatment comparing two versus three doses of sulphadoxine pyrimethamine (IPTp-SP) in the prevention of anaemia in pregnancy in Ghana: A cross-sectional study. ( Agyeman, YN; Annor, RB; Newton, S; Owusu-Dabo, E, 2021) |
| "Increasing resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine (SP) threatens its usefulness for intermittent preventive treatment in pregnancy (IPTp-SP)." | 8.02 | Evaluation of the usefulness of intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine in a context with increased resistance of Plasmodium falciparum in Kingasani Hospital, Kinshasa in the Democratic Republic of Congo. ( DeMol, P; Devleesschauwer, B; Hayette, MP; Kabututu, PZ; Kayiba, NK; Lusamba, PD; Mukomena, ES; Mvumbi, DM; Mvumbi, GL; Rosas-Aguirre, A; Speybroeck, N; Tchakounang, VRK; Yobi, DM, 2021) |
| "Plasmodium falciparum dihydrofolate reductase (Pfdhfr) and dihydropteroate synthetase (Pfdhps) mutations compromise the effectiveness of sulfadoxine-pyrimethamine (SP) for treatment of uncomplicated malaria, and are likely to impair the efficiency of intermittent preventive treatment during pregnancy (IPTp)." | 7.96 | Occurrence of septuple and elevated Pfdhfr-Pfdhps quintuple mutations in a general population threatens the use of sulfadoxine-pyrimethamine for malaria prevention during pregnancy in eastern-coast of Tanzania. ( Bwire, GM; Kilonzi, M; Mikomangwa, WP, 2020) |
| " Intermittent preventive treatment with sulfadoxine-pyrimethamine during pregnancy (IPTp-SP) is widely implemented to prevent these negative effects of malaria." | 7.85 | Increase in the prevalence of mutations associated with sulfadoxine-pyrimethamine resistance in Plasmodium falciparum isolates collected from early to late pregnancy in Nanoro, Burkina Faso. ( d'Alessandro, U; de Jong, MD; Derra, K; Geskus, RB; Lompo, P; Mens, PF; Ruizendaal, E; Schallig, HDFH; Scott, S; Tahita, MC; Tinto, H; Traore-Coulibaly, M; Versteeg, I, 2017) |
| "The impact of sulfadoxine-pyrimethamine (SP) used as intermittent preventive treatment during pregnancy (IPTp-SP) on mutant parasite selection has been poorly documented in Burkina Faso." | 7.85 | Recent uptake of intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine is associated with increased prevalence of Pfdhfr mutations in Bobo-Dioulasso, Burkina Faso. ( Awandare, GA; Cisse, M; Guiguemdé, RT; Hayette, MP; Soulama, A; Tinto, H, 2017) |
| "Faced with intense levels of chloroquine (CQ) resistance in Plasmodium falciparum malaria, Rwanda replaced CQ with amodiaquine (AQ)+sulfadoxine-pyrimethamine (SP) in 2001, and subsequently with artemether-lumefantrine (AL) in 2006, as first-line treatments for uncomplicated malaria." | 7.83 | Molecular surveillance of Plasmodium falciparum drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda. ( Grobusch, MP; Hakizimana, E; Kateera, F; Kumar, N; Mens, PF; Mutesa, L; Nsobya, SL; Tukwasibwe, S; van Vugt, M, 2016) |
| "Intermittent preventive treatment of malaria in pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) decreases placental parasitaemia, thus improving birth outcomes." | 7.81 | Evaluation of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy: a retrospective birth outcomes study in Mansa, Zambia. ( Chalwe, V; Craig, AS; Filler, SJ; Kamuliwo, M; Katalenich, BL; Mace, KE; Mubikayi, L; Mulele, CK; Nambozi, M; Tan, KR; Wiegand, RE, 2015) |
| "Intermittent preventive treatment of malaria in pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) decreases adverse effects of malaria during pregnancy." | 7.80 | Efficacy of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy, Mansa, Zambia. ( Chalwe, V; Craig, AS; Filler, SJ; Kamuliwo, M; Katalenich, BL; Mace, KE; Meshnick, SR; Nambozi, M; Tan, KR; Taylor, SM; Wiegand, RE, 2014) |
| "The World Health Organization (WHO) recommends for sub-Saharan Africa a package of prompt and effective case-management combined with the delivery of insecticide-treated nets (ITN) and intermittent preventive treatment during pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) through the national antenatal care (ANC) programs." | 7.80 | Coverage and efficacy of intermittent preventive treatment with sulphadoxine pyrimethamine against malaria in pregnancy in Côte d'Ivoire five years after its implementation. ( Ako, BA; Bassinka, I; Beourou, S; Bokossa, EM; Coulibaly, B; Coulibaly, MA; Esmel, B; Gba, B; Gbessi, EA; Koffi, D; Kone, PL; N' Guessan, LT; Nogbou, M; Soumahoro, A; Swa, T; Toure, OA, 2014) |
| "Despite widespread parasite resistance to sulphadoxine-pyrimethamine (SP) its use for intermittent preventative treatment during pregnancy remains the policy in Benin and throughout most of sub-Saharan Africa." | 7.79 | High rates of parasite recrudescence following intermittent preventive treatment with sulphadoxine-pyrimethamine during pregnancy in Benin. ( Alifrangis, M; De Tove, YS; Deloron, P; Doritchamou, J; Luty, AJ; Massougbodji, A; Moussiliou, A; Ndam, NT, 2013) |
| "Antenatal intermittent preventive therapy with 2 doses of sulfadoxine-pyrimethamine (IPTp-SP) is the mainstay of efforts in sub-Saharan Africa to prevent pregnancy-associated malaria (PAM)." | 7.78 | Antenatal receipt of sulfadoxine-pyrimethamine does not exacerbate pregnancy-associated malaria despite the expansion of drug-resistant Plasmodium falciparum: clinical outcomes from the QuEERPAM study. ( Antonia, AL; Chaluluka, E; Feng, G; Meshnick, SR; Molyneux, ME; Mwapasa, V; Rogerson, SJ; Taylor, SM; ter Kuile, FO, 2012) |
| "Intermittent preventive treatment with sulphadoxine-pyrimethamine (SP) is recommended for reducing the risk of malaria in pregnancy and its consequences on mothers and babies (IPTp-SP)." | 7.74 | Implementation of intermittent preventive treatment in pregnancy with sulphadoxine/pyrimethamine (IPTp-SP) at a district health centre in rural Senegal. ( Badiane, M; Brasseur, P; Cisse, M; Delenne, H; Olliaro, A; Olliaro, PL; Vaillant, M, 2008) |
| " day, on days 0-2) plus sulfadoxine-pyrimethamine (25 mg/kg, on day 0) for the treatment of uncomplicated Plasmodium falciparum malaria was investigated in four sentinel areas in Sudan, with different malaria transmission (Damazin, Kassala, Kosti, and Malakal)." | 7.73 | Artesunate plus sulfadoxine-pyrimethamine for treatment of uncomplicated Plasmodium falciparum malaria in Sudan. ( Abdelgadir, T; Adam, I; Ahmed, ES; Elamin, SB; Khamiss, AH; Malik, EM; Mohammed, MM, 2005) |
| "In an efficacy trial of artemisinin-based combination treatments (ACT) in central Sudan, cases of uncomplicated, Plasmodium falciparum malaria were given artesunate-sulfadoxine-pyrimethamine (ASP) or artemether-lumefantrine (AL) as first-line treatment." | 7.73 | The efficacies of artesunate-sulfadoxine-pyrimethamine and artemether-lumefantrine in the treatment of uncomplicated, Plasmodium falciparum malaria, in an area of low transmission in central Sudan. ( Ahmed, OA; Elamin, SB; Eltaib, EH; Malik, EM; Mohamed, AO, 2006) |
| "A 28-day in vivo treatment trial to evaluate the efficacy of pyrimethamine/sulfadoxine (Fansidar, PS) was conducted in 21 Lao patients with uncomplicated Plasmodium falciparum malaria." | 7.73 | Pyrimethamine-sulfadoxine treatment of uncomplicated Plasmodium falciparum malaria in Lao PDR. ( Hatabu, T; Hongvangthong, B; Kano, S; Keokhamphavanh, B; Kobayashi, J; Mannoor, MK; Phetsouvanh, R; Phompida, S; Sato, Y; Taguchi, N; Toma, H; Vanisaveth, V; Watanabe, H, 2005) |
| "Sulphadoxine-pyrimethamine (SP) has been and is currently used for treatment of uncomplicated Plasmodium falciparum malaria in many African countries." | 7.73 | Drug resistance to sulphadoxine-pyrimethamine in Plasmodium falciparum malaria in Mlimba, Tanzania. ( Balthazary, ST; Malisa, AL; Mbugi, EV; Mshinda, H; Mutayoba, BM; Nyambo, TB, 2006) |
| "In 1998, the Kenyan Ministry of Health introduced intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine (SP), one treatment dose in the second trimester (16-27 weeks) and one treatment dose between 28 and 34 weeks of gestational age, for the control of malaria in pregnancy." | 7.72 | Implementation of intermittent preventive treatment with sulphadoxine-pyrimethamine for control of malaria in pregnancy in Kisumu, western Kenya. ( Ayisi, JG; Kager, PA; Misore, AO; Nahlen, BL; Odondi, JO; Otieno, JA; Rosen, DH; Slutsker, L; Steketee, RW; ter Kuile, FO; van Eijk, AM, 2004) |
| "The prevalence of infection with malarial parasites and the incidence of anaemia and delivery of infants with low birthweight (LBW) were investigated in 575 Malawian mothers who received one, two or three doses of sulfadoxine-pyrimethamine (SP) during pregnancy." | 7.70 | An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi. ( Brabin, BJ; Broadhead, RL; Chimsuku, L; Kazembe, P; Russell, WB; Verhoeff, FH, 1998) |
| "In 1993, Malawi introduced sulphadoxine-pyrimethamine (SP) for the treatment of uncomplicated, Plasmodium falciparum malaria and became the first country in Africa to abandon chloroquine for first-time therapy." | 7.69 | Parasitological and haematological responses to treatment of Plasmodium falciparum malaria with sulphadoxine-pyrimethamine in southern Malawi. ( Brabin, BJ; Kachale, B; Kazembe, P; Masache, P; Van der Kaay, HJ; Verhoeff, FH, 1997) |
| "Chlorproguanil is one of the antimalarial drugs developed in recent years which have shown promise for field use in malaria eradication campaigns." | 7.64 | Field trials with chlorproguanil in the prophylaxis of malaria in Ghana. ( CHARLES, LJ, 1961) |
| "The authors describe a two-year investigation carried out on a group of Nigerian schoolchildren with the object of assessing the effect of suppressing malaria infection with pyrimethamine on the physical development of the African child." | 7.63 | Suppression of malaria with pyrimethamine in Nigerian schoolchildren. ( ARCHIBALD, HM; BRUCE-CHWATT, LJ, 1956) |
| "Intermittent preventive treatment of malaria among schoolchildren (IPTsc) reduces clinical malaria, asymptomatic parasitemia, and anemia." | 7.11 | Overall and Gender-Specific Effects of Intermittent Preventive Treatment of Malaria with Artemisinin-Based Combination Therapies among Schoolchildren in Mali: A Three-Group Open Label Randomized Controlled Trial. ( Bamadio, A; Chico, RM; Cohee, LM; Coumare, S; Dara, A; Diarra, M; Djimde, AA; Doumbo, OK; Kodio, A; Maiga, H; Opondo, C; Sagara, I; Sidibe, B; Tekete, M; Traore, OB; Traore, ZI, 2022) |
| "Children with sickle cell anemia (SCA) in areas of Africa with endemic malaria transmission are commonly prescribed malaria chemoprevention." | 7.11 | Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial. ( Clapp, S; Freedman, B; Green, CL; Kirui, JK; Korwa, S; Njuguna, FM; O'Meara, WP; Taylor, SM; Wu, A, 2022) |
| "Malaria is one of the most serious global problems." | 6.82 | The efficacy and safety of intermittent preventive treatment with sulphadoxine-pyrimethamine vs artemisinin-based drugs for malaria: a systematic review and meta-analysis. ( Chen, N; Chu, X; Feng, L; Li, M; Liu, Y; Wang, Q; Wang, S; Yan, P; Yang, K; Zhang, N; Zhang, Z, 2022) |
| " SP pharmacokinetic parameters differed significantly among the study sites." | 6.75 | Pharmacokinetics of sulfadoxine and pyrimethamine in intermittent preventive treatment of malaria in pregnancy. ( Adam, I; Barnes, KI; Cassam, Y; Doumbo, O; Guirou, E; Kayentao, K; Little, F; Mauff, K; Nyunt, MM; Smith, P; Sullivan, D; Thuma, P; Traore, B; van Dijk, J, 2010) |
| "Quinine remains the treatment of choice in hospitalized malaria cases; however, adverse reactions and the long treatment duration of 7 days often hamper its adequate use." | 6.72 | Short course of quinine plus a single dose of sulfadoxine/pyrimethamine for Plasmodium falciparum malaria. ( Issifou, S; Kremsner, PG; Matsiegui, PB; Missinou, MA; Necek, M, 2006) |
| " The findings indicate that - at least at the dosing regimen used in the present study and among children with acute, uncomplicated, P." | 6.71 | A randomized comparison of chloroquine and chloroquine plus ketotifen in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children. ( Sowunmi, A, 2003) |
| "Congo is facing frequent failures of treatment of Plasmodium falciparum malaria with chloroquine (CQ), which is still recommended and used as a first-line drug." | 6.71 | Efficacy of sulfadoxine/pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria in Republic of Congo. ( Ebata-Mongo, S; Kiori, J; Le Bras, J; Louya, F; Malanda, M; Malonga, DA; Mouata, AM; Nsimba, B; Oko-Ossho, J; Yocka, D, 2004) |
| "Atovaquone-proguanil was well tolerated and more effective than chloroquine or chloroquine-sulfadoxine-pyrimethamine for treatment of multidrug-resistant falciparum malaria in the Philippines." | 6.69 | Atovaquone-proguanil compared with chloroquine and chloroquine-sulfadoxine-pyrimethamine for treatment of acute Plasmodium falciparum malaria in the Philippines. ( Bustos, DG; Canete-Miguel, E; Canfield, CJ; Hutchinson, DB, 1999) |
| "Artemether was well tolerated." | 6.67 | Artemether in moderately severe and cerebral malaria in Nigerian children. ( Adio, R; Oduola, AM; Omokhodion, SJ; Salako, LA; Sowunmi, A; Walker, O, 1994) |
| " This review evaluates the toxicity data of sulfadoxine/pyrimethamine, including severe cutaneous adverse reactions, teratogenicity and alterations in bilirubin metabolism." | 6.44 | Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment. ( Newman, RD; Parise, ME; Peters, PJ; Thigpen, MC, 2007) |
| "Despite extensive use and accumulated evidence of safety, there have been few pharmacokinetic studies from which appropriate chloroquine (CQ) dosing regimens could be developed specifically for pregnant women." | 5.46 | Optimal antimalarial dose regimens for chloroquine in pregnancy based on population pharmacokinetic modelling. ( Baiwog, F; Davis, TME; Ilett, KF; Karunajeewa, HA; Kose, K; Mueller, I; Page-Sharp, M; Rogerson, SJ; Salman, S; Siba, PM, 2017) |
| "Chloroquine failure rate was high which was well above the WHO recommended cut off threshold for drug policy change (> 10%), Sulfadoxine- Pyrimethamine can be used in place of Chloroquine as the first line drug in uncomplicated P." | 5.42 | Comparative Study of Effectiveness and Resistance Profile of Chloroquine and Sulfadoxine-Pyrimethamine in Uncomplicated Plasmodium falciparum Malaria in Kolkata. ( Basu, A; Guha, SK; Saha, S, 2015) |
| "Malaria during pregnancy is associated with low birth weight and increased perinatal mortality, especially among primigravidae." | 5.39 | Effectiveness of intermittent preventive treatment with sulfadoxine-pyrimethamine during pregnancy on maternal and birth outcomes in Machinga district, Malawi. ( Ali, D; Gutman, J; Mathanga, DP; Mwandama, D; Skarbinski, J; Wiegand, RE, 2013) |
| " There was significant association between gravidity and SP dosage taken (Pearson χ2 = 18." | 5.37 | The effectiveness and perception of the use of sulphadoxine-pyrimethamine in intermittent preventive treatment of malaria in pregnancy programme in Offinso district of Ashanti region, Ghana. ( Browne, E; Lawson, B; Tutu, EO, 2011) |
| "Sulfadoxine-pyrimethamine (SP) is used as intermittent preventive therapy in pregnancy (IPTp) for malaria in sub-Saharan Africa." | 5.34 | Interactions Between Antenatal Sulfadoxine-Pyrimethamine, Drug-Resistant Plasmodium falciparum Parasites, and Delivery Outcomes in Malawi. ( Freedman, B; Kalilani-Phiri, L; Khairallah, C; Levitt, B; Madanitsa, M; Meshnick, SR; Mwapasa, V; Taylor, SM; Ter Kuile, FO; Thwai, KL, 2020) |
| "Malaria during pregnancy is associated with serious adverse effects; these could be avoided with effective treatment." | 5.33 | Artesunate plus sulfadoxine-pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria during pregnancy in eastern Sudan. ( Abdalla, MA; Adam, I; Ali, DM, 2006) |
| "Chloroquine was thus an ineffective therapy for P." | 5.31 | Chloroquine or sulfadoxine-pyrimethamine for the treatment of uncomplicated, Plasmodium falciparum malaria during an epidemic in Central Java, Indonesia. ( Baird, JK; Bangs, MJ; Barcus, MJ; Basuki, W; Edstein, MD; Lacy, MD; Laksana, B; Maguire, JD; Marwoto, H; Masbar, S; Sismadi, P; Susanti, I; Tjokrosonto, S; Wiady, I, 2002) |
| "Amodiaquine has several advantages over sulfadoxine-pyrimethamine combination and may be considered to be an effective drug in an endemic zone with a moderate level of chloroquine resistance." | 5.31 | Chemoresistance of Plasmodium falciparum in the urban region of Yaounde, Cameroon. Part 2: Evaluation of the efficacy of amodiaquine and sulfadoxine-pyrimethamine combination in the treatment of uncomplicated Plasmodium falciparum malaria in Yaounde, Came ( Basco, LK; Keundjian, A; Ringwald, P; Same Ekobo, A, 2000) |
| "Emerging malaria parasite sulfadoxine-pyrimethamine (SP) resistance has prompted assessment of alternatives for intermittent preventive treatment in pregnancy (IPTp)." | 5.30 | A Randomized Open-Label Evaluation of the Antimalarial Prophylactic Efficacy of Azithromycin-Piperaquine versus Sulfadoxine-Pyrimethamine in Pregnant Papua New Guinean Women. ( Benjamin, JM; Davis, TME; Kasian, B; Kong, C; Laman, M; Moore, BR; Mueller, I; Ome-Kaius, M; Robinson, LJ; Rogerson, S; Tobe, R; Yadi, G, 2019) |
| " HIV-uninfected pregnant women between 12 and 20 weeks gestation were randomly assigned (1:1) to monthly intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine or dihydroartemisinin-piperaquine." | 5.30 | Monthly sulfadoxine-pyrimethamine versus dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomised, controlled, superiority trial. ( Ategeka, J; Clark, TD; Dorsey, G; Havlir, DV; Jagannathan, P; Kajubi, R; Kakuru, A; Kamya, MR; Nakalembe, M; Nayebare, P; Ochieng, T; Ochokoru, H; Opira, B; Ruel, T, 2019) |
| "In a randomised trial comparing intermittent screening and treatment (IST) with dihydroartemisinin-piperaquine (DP) and intermittent preventive therapy against malaria in pregnancy (IPT) with sulfadoxine-pyrimethamine (SP) in Malawi, the impacts of IST-DP and IPT-SP on the development and maintenance of malaria antibody immunity were compared." | 5.30 | Intermittent screening and treatment with dihydroartemisinin-piperaquine and intermittent preventive therapy with sulfadoxine-pyrimethamine have similar effects on malaria antibody in pregnant Malawian women. ( Buffet, C; Karahalios, A; Khairallah, C; Kuile, FOT; Madanitsa, M; Mwapasa, V; Narum, DL; Phiri, LK; Randall, LM; Rogerson, SJ; Teo, A, 2019) |
| "In India, the recommended first-line treatment for malaria in the second and third trimester of pregnancy is artesunate + sulfadoxine-pyrimethamine (AS+SP)." | 5.27 | Efficacy of two artemisinin-based combinations for the treatment of malaria in pregnancy in India: a randomized controlled trial. ( Anvikar, AR; Arya, T; Bruce, J; Chandramohan, D; Greenwood, B; Kuepfer, I; Mishra, DR; Mishra, N; Mishra, V; Mohanty, R; Mohanty, S; Sharma, S; Srivastava, B; Valecha, N, 2018) |
| "The spread of SP resistance may compromise the effectiveness of intermittent preventive treatment of malaria in pregnancy (MiP) with sulfadoxine-pyrimethamine (IPTp-SP) across Africa." | 5.27 | Intermittent screening and treatment with artemether-lumefantrine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in pregnancy: a facility-based, open-label, non-inferiority trial in Nigeria. ( Berens-Riha, N; Esu, E; Loescher, T; Meremikwu, M; Nwachuku, N; Pritsch, M, 2018) |
| "Intermittent preventive treatment of malaria in pregnancy (IPTp) with dihydroartemisinin-piperaquine (IPTp-DP) has been shown to reduce the burden of malaria during pregnancy compared to sulfadoxine-pyrimethamine (IPTp-SP)." | 5.27 | Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial. ( Aweeka, F; Beeson, J; Charlebois, ED; Clark, TD; Dorsey, G; Drakeley, C; Feeney, ME; Greenhouse, B; Havlir, DV; Jagannathan, P; Kakuru, A; Kamya, MR; Muhindo, MK; Nakalembe, M; Nankya, F; Natureeba, P; Okiring, J; Olwoch, P; Opira, B; Prahl, M; Reiling, L; Rodriguez-Barraquer, I; Ssewanyana, I; Tetteh, K; Wallender, E, 2018) |
| "The World Health Organization recommends intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) in African regions with moderate to high malaria transmission." | 5.22 | Efficacy and Safety of Azithromycin-Chloroquine versus Sulfadoxine-Pyrimethamine for Intermittent Preventive Treatment of Plasmodium falciparum Malaria Infection in Pregnant Women in Africa: An Open-Label, Randomized Trial. ( Ayoub, A; Duparc, S; Kamiza, S; Kimani, J; Orrico, R; Phiri, K; Robbins, J; Rojo, R; Vandenbroucke, P, 2016) |
| "The effectiveness of sulphadoxine-pyrimethamine (SP) intermittent preventive treatment of malaria in pregnancy (IPTp) might be compromised by high prevalence of resistance-associated Plasmodium falciparum dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutations." | 5.20 | In vivo efficacy of sulphadoxine-pyrimethamine for the treatment of asymptomatic parasitaemia in pregnant women in Machinga District, Malawi. ( Abdallah, J; Gutman, J; Iriemenam, NC; Mathanga, DP; Mwandama, D; Shi, YP; Skarbinski, J; Wiegand, RE, 2015) |
| "Artesunate (AS) in combination with sulfadoxine/pyrimethamine (SP) is the first-line therapy for management of uncomplicated Plasmodium falciparum malaria in Sudan." | 5.19 | Pharmacokinetics of artesunate alone and in combination with sulfadoxine/pyrimethamine in healthy Sudanese volunteers. ( Awad, AI; Elamin, SB; Matar, KM, 2014) |
| "To examine the potential to reduce foetal and neonatal growth faltering through intermittent preventive treatment in pregnancy (IPTp) of malaria and reproductive tract infections with monthly sulphadoxine-pyrimethamine (SP), alone or with two doses of azithromycin." | 5.17 | The effect of antenatal monthly sulphadoxine-pyrimethamine, alone or with azithromycin, on foetal and neonatal growth faltering in Malawi: a randomised controlled trial. ( Ashorn, P; Cheung, YB; Kulmala, T; Luntamo, M; Maleta, K, 2013) |
| "Factors involved in the development of resistance to sulphadoxine-pyrimethamine (SP) by Plasmodium falciparum, particularly in the context of intermittent preventive treatment during pregnancy (IPTp), are not well known." | 5.15 | HIV and placental infection modulate the appearance of drug-resistant Plasmodium falciparum in pregnant women who receive intermittent preventive treatment. ( Alonso, PL; Bardají, A; Cisteró, P; Dobaño, C; Mandomando, I; Mayor, A; Menéndez, C; Nhabomba, A; Sanz, S; Scahill, MD; Serra-Casas, E; Sigauque, B, 2011) |
| "In India, till recently, Chloroquine was used as first-line therapy in areas with Chloroquine sensitive Plasmodium falciparum malaria cases." | 5.15 | Efficacy of chloroquine and sulphadoxine-pyrimethamine either alone or in combination before introduction of ACT as first-line therapy in uncomplicated Plasmodium falciparum malaria in Jalpaiguri District, West Bengal, India. ( Bera, DK; Biswas, A; Das, M; Das, S; Guha, SK; Kundu, PK; Maji, AK; Mullick, S; Ray, K; Roy, D; Saha, P; Sengupta, S, 2011) |
| "The weekly chemoprophylaxis of malaria during pregnancy with chloroquine (CQ) has become problematic with the increasing resistance of Plasmodium falciparum to this drug." | 5.14 | Placental malaria and low birth weight in pregnant women living in a rural area of Burkina Faso following the use of three preventive treatment regimens. ( Bougouma, EC; Diarra, A; Konaté, AT; Nébié, I; Ouedraogo, A; Sirima, SB; Tiono, AB, 2009) |
| "Intermittent preventive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended for malaria prevention in sub-Saharan Africa." | 5.14 | The effect of intermittent preventive treatment during pregnancy on malarial antibodies depends on HIV status and is not associated with poor delivery outcomes. ( Alonso, PL; Bardají, A; Chauhan, VS; Chitnis, CE; Dobaño, C; Jiménez, A; Mandomando, I; Mayor, A; Menéndez, C; Quintó, L; Serra-Casas, E; Sigauque, B, 2010) |
| "The activities of artemether-lumefantrine and amodiaquine-sulfalene-pyrimethamine against sexual-stage parasites were evaluated in 42 of 181 Nigerian children with uncomplicated Plasmodium falciparum malaria who had gametocytaemia before, during or after treatment with the two combination therapies." | 5.13 | Activities of artemether-lumefantrine and amodiaquine-sulfalene-pyrimethamine against sexual-stage parasites in falciparum malaria in children. ( Adedeji, AA; Balogun, T; Bolaji, OM; Fehintola, FA; Folarin, OA; Gbotosho, GO; Happi, CT; Sowunmi, A, 2008) |
| "The use of sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment in pregnancy (IPTp) is threatened by the spread of resistance to SP." | 5.13 | A randomized, controlled trial of intermittent preventive treatment with sulfadoxine-pyrimethamine, amodiaquine, or the combination in pregnant women in Ghana. ( Affipunguh, PK; Bruce, J; Chandramohan, D; Clerk, CA; Greenwood, B; Hodgson, A; Mensah, N, 2008) |
| "The main objective of the study was to assess the impact of a community-based delivery system of intermittent preventive treatment (IPT) for malaria in pregnancy with sulfadoxine-pyrimethamine (SP) on access, parasitemia, anemia and low birth weight as primary outcome measures." | 5.13 | Intermittent preventive treatment of malaria in pregnancy: a community-based delivery system and its effect on parasitemia, anemia and low birth weight in Uganda. ( Bygbjerg, I; Magnussen, P; Mbonye, AK, 2008) |
| " In a small study in eastern Sudan, the effects of the treatment of uncomplicated, Plasmodium falciparum malaria with artesunate-sulfamethoxypyrazine-pyrimethamine (AS-SMP) and artemether-lumefantrine (AT-LU) on co-infections with Schistosoma mansoni were therefore investigated." | 5.13 | The antischistosomal efficacies of artesunate-sulfamethoxypyrazine-pyrimethamine and artemether-lumefantrine administered as treatment for uncomplicated, Plasmodium falciparum malaria. ( Abdalla, E; Adam, I; Elhadi, MO; Elhardello, OA; Elmardi, KA; Jansen, FH, 2008) |
| " This study tested the hypothesis that the co-formulated fixed dose combination (FDC) artesunate/sulfamethoxypyrazine/pyrimethamine (As/SMP) administered as a 24-hour therapy with a dose interval of 12 hours is as efficacious and safe as the administration of the same drug over 3 days given with a dose interval of 24 hours, for the treatment of uncomplicated Plasmodium falciparum malaria in Ivory Coast." | 5.13 | Single-day, three-dose treatment with fixed dose combination artesunate/sulfamethoxypyrazine/pyrimethamine to cure Plasmodium falciparum malaria. ( Jansen, FH; Penali, LK, 2008) |
| "The prevalence of pyrimethamine-sulfadoxine (PS)-resistant Plasmodium falciparum malaria has been increasing in sub-Saharan Africa or other parts of the world in the last one or two decades." | 5.12 | Predictors of the failure of treatment with pyrimethamine-sulfadoxine in children with uncomplicated falciparum malaria. ( Adedeji, AA; Bamgboye, AE; Bolaji, OM; Fateye, BA; Gbotosho, GO; Happi, TC; Oduola, AM; Sowunmi, A, 2006) |
| "Amodiaquine+SP is not well tolerated and a substantial proportion of patients experienced pruritus and fatigue, thus decreasing their compliance and compromising the first line treatment implementation at national level." | 5.12 | Tolerability of amodiaquine and sulphadoxine-pyrimethamine, alone or in combination for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan adults. ( D'Alessandro, U; Fanello, CI; Karema, C; Rwagacondo, CE; van Doren, W, 2006) |
| "Whether administration of folic acid to children with malaria anemia is helpful is controversial." | 5.12 | Folic acid treatment of Zambian children with moderate to severe malaria anemia. ( Bennett, S; Fielding, K; Greenwood, B; Malunga, P; Mulenga, M; Shulman, C; Thuma, P, 2006) |
| " We recommend the use of artemisinin-based combination therapy as first-line treatment for uncomplicated Plasmodium falciparum malaria in Koumantou." | 5.12 | Efficacy of chloroquine and sulfadoxine/pyrimethamine for the treatment of uncomplicated falciparum malaria in Koumantou, Mali. ( de Radiguès, X; Diallo, KI; Diallo, M; Djimdé, A; Doumbo, O; Guthmann, JP; Maiga, H; Ngwakum, PA; Sacko, M, 2006) |
| "Intermittent preventive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) decreases placental malaria parasitemia and associated maternal anemia, premature delivery, and low birth weight." | 5.12 | Randomized trial of 2-dose versus monthly sulfadoxine-pyrimethamine intermittent preventive treatment for malaria in HIV-positive and HIV-negative pregnant women in Malawi. ( Filler, SJ; Hamel, M; Kazembe, P; Macheso, A; Newman, RD; Parise, ME; Steketee, RW; Thigpen, M, 2006) |
| "We investigated the ability of intermittent preventive treatment in pregnancy (IPTp) with sulphadoxine/pyrimethamine to prevent anaemia and low birthweight in Gambian multigravidae." | 5.12 | A randomized, placebo-controlled trial of intermittent preventive treatment with sulphadoxine-pyrimethamine in Gambian multigravidae. ( Balajo, B; Dunyo, S; Greenwood, B; Mbaye, A; Milligan, P; Richardson, K; Shulman, C; Walraven, G, 2006) |
| "In Zambia, unacceptably high resistance to commonly used antimalarial drugs prompted the choice of artemether-lumefantrine (AL) as first line treatment for uncomplicated Plasmodium falciparum malaria." | 5.12 | Safety and efficacy of lumefantrine-artemether (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Zambian adults. ( Chalwe, V; Chilengi, R; D'Alessandro, U; Dujardin, JC; Moerman, F; Mulenga, M; Mwananyanda, L; Van Overmeir, C; VangGeertruyden, JP, 2006) |
| "the efficacy of fixed co-formulated (f) artesunate-sulfamethoxypyrazine-pyrimethamine (AS+SMP f) administered at time intervals of 12 hours for a 24-hour therapy was compared with the efficacy of the same drug given as a loose combination (AS+SMP l) with a dose interval of 24 hours for 3 days for the treatment of uncomplicated Plasmodium falciparum malaria in eastern Sudan." | 5.12 | A fixed-dose 24-hour regimen of artesunate plus sulfamethoxypyrazine-pyrimethamine for the treatment of uncomplicated Plasmodium falciparum malaria in eastern Sudan. ( Adam, I; Alifrangis, M; Elmardi, KA; Khalil, IF; Magzoub, M; Osman, ME, 2006) |
| "We undertook a trial of artesunate + amodiaquine (AS + AQ) and artesunate + sulphadoxine-pyrimethamine (AS + SP) in 180 children of age 6-59 months with uncomplicated malaria in Democratic Republic of Congo." | 5.12 | Artesunate + amodiaquine and artesunate + sulphadoxine-pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulphadoxine and pyrimethamine-resistant haplotypes. ( Kayembe, G; Montgomery, J; Pota, H; Roper, C; Swarthout, TD; van den Broek, IV, 2006) |
| "An open randomized controlled study of artemether-lumefantrine (AL) and amodiaquine-sulfalene-pyrimethamine (ASP) for the treatment of uncomplicated Plasmodium falciparum malaria was carried out in 181 children." | 5.12 | The effects of artemether-lumefantrine vs amodiaquine-sulfalene-pyrimethamine on the hepatomegaly associated with Plasmodium falciparum malaria in children. ( Adedeji, AA; Amoo, AO; Fateye, BA; Gbotosho, GO; Happi, CT; Sowunmi, A; Tambo, E, 2007) |
| " We tested the hypothesis that artesunate-sulfamethoxypyrazine-pyrimethamine is as efficacious as the four-dose regimen of artemether-lumefantrine for treatment of Plasmodium falciparum malaria." | 5.12 | A randomized trial of artesunate-sulfamethoxypyrazine-pyrimethamine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali. ( Dicko, A; Djimde, A; Doumbo, OK; Fofana, M; Guindo, O; Jansen, HF; Kone, M; Ouattara, A; Sagara, I; Sissoko, M; Sogoba, M; Thera, MA; Tolo, Y, 2006) |
| "Amodiaquine alone or in combination with sulphadoxine-pyrimethamine, although associated with minor side-effects, is effective when used to treat malaria in pregnancy." | 5.12 | Efficacy, safety, and tolerability of amodiaquine plus sulphadoxine-pyrimethamine used alone or in combination for malaria treatment in pregnancy: a randomised trial. ( Browne, E; Bruce, J; Chandramohan, D; Greenwood, B; Randal, A; Tagbor, H, 2006) |
| "Few studies have documented the effectiveness in west Africa of intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine (SP) in pregnancy." | 5.12 | A comparison of sulfadoxine-pyrimethamine with chloroquine and pyrimethamine for prevention of malaria in pregnant Nigerian women. ( Madaki, JK; Sagay, AS; Thacher, TD; Tukur, IU, 2007) |
| "Chloroquine should no longer be used to treat children presenting with Plasmodium falciparum malaria in Benin." | 5.12 | Dramatically decreased therapeutic efficacy of chloroquine and sulfadoxine-pyrimethamine, but not mefloquine, in southern Benin. ( Aubouy, A; Bertin, G; Deloron, P; Fievet, N; Kinde-Gazard, D; Kiniffo, R; Kossou, H; Massougbodji, A; Sagbo, JC, 2007) |
| "The treatment efficacy and effects of artemether-lumefantrine (AL) and amodiaquine-sulfalene-pyrimethamine (ASP) on gametocyte carriage were evaluated in 181 children < or = 10 years of age with uncomplicated Plasmodium falciparum malaria randomized to receive either drug combination." | 5.12 | Therapeutic efficacy and effects of artemether-lumefantrine and amodiaquine-sulfalene-pyrimethamine on gametocyte carriage in children with uncomplicated Plasmodium falciparum malaria in southwestern Nigeria. ( Adedeji, AA; Fateye, BA; Fehintola, FA; Folarin, OA; Gbotosho, GO; Happi, CT; Sowunmi, A; Tambo, E, 2007) |
| " falciparum gametocytes may persist after treatment with sulphadoxine-pyrimethamine (SP) plus artesunate (AS) and contribute considerably to malaria transmission." | 5.12 | Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate. ( Alifrangis, M; Bousema, T; Drakeley, C; Enevold, A; Gosling, R; Mosha, F; Ndaro, A; Sauerwein, R; Shekalaghe, S; van Meegeren, M, 2007) |
| "We assessed the ability of ibuprofen to modulate tumor necrosis factor alpha (TNF-alpha), soluble tumor necrosis factor receptor type I (sTNFR-I), and soluble tumor necrosis factor receptor type II (sTNFR-II) responses during the treatment of fever in uncomplicated Plasmodium falciparum malaria, in a placebo-controlled, randomized, double-blind study of 50 pediatric patients in Lambaréné, Gabon." | 5.12 | Ibuprofen does not affect levels of tumor necrosis factor alpha and soluble tumor necrosis factor receptor types I and II in Gabonese children with uncomplicated Plasmodium falciparum malaria. ( Issifou, S; Matsiegui, PB; Mavoungou, E; Missinou, MA; Necek, M, 2007) |
| " The purpose was to compare the efficacy of two regimens using chloroquine (CQ) or sulfadoxine-pyrimethamine (SP) during pregnancy and delivery in a village located in an endemic area of Mali." | 5.12 | [Randomized clinical trial of two malaria prophylaxis regimens for pregnant women in Faladie, Mali]. ( Dabo, CA; Diallo, M; Diarra, MA; Doumbo, O; Kayentao, K; Ongoiba, A; Sangho, H; Saye, R; Yattara, O, 2007) |
| "A study of the therapeutic efficacy of combined chloroquine and sulfadoxine-pyrimethamine (SP) for the treatment of uncomplicated Plasmodium falciparum malaria was carried out from June to November 2002, using the standard protocol recommended by the WHO for a low-to-moderate transmission area, in two sentinel sites in Bangladesh: Alikadam Upazilla in Bandarban district and Matiranga Upazilla in Khagrachari district." | 5.11 | Efficacy of combined chloroquine and sulfadoxine-pyrimethamine in uncomplicated Plasmodium falciparum malaria in Bangladesh. ( Bangali, M; Das, S; Rahman, M; Rahman, R; Ringwald, P; Talukder, MR, 2004) |
| "Recent clinical trials in the Lao People's Democratic Republic have demonstrated that chloroquine and sulfadoxine-pyrimethamine, which are national malaria treatment policy, are no longer effective in the treatment of uncomplicated Plasmodium falciparum malaria." | 5.11 | Randomized comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People's Democratic Republic. ( Annerberg, A; Barends, M; Keola, S; Khanthavong, M; Lindegårdh, N; Mayxay, M; Newton, PN; Phetsouvanh, R; Phompida, S; Pongvongsa, T; White, NJ; Yapom, R, 2004) |
| "The efficacy of amodiaquine (AQ) and sulfadoxine-pyrimethamine (SP) was assessed in 310 symptomatic children from western Kenya with uncomplicated Plasmodium falciparum malaria." | 5.11 | Comparison of the parasitologic efficacy of amodiaquine and sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malaria in the Bungoma District of western Kenya. ( Cobelens, FG; Gikunda, S; Hoogstraatte, SR; Kager, PA; Scheper, FY; Smolders, M; Vreugdenhil, CJ, 2004) |
| "The study examined the efficacy of chloroquine (CQ), amodiaquine (AQ) and sulphadoxine-pyrimethamine (SP) for the treatment of uncomplicated Plasmodium falciparum malaria in Ghana." | 5.11 | A randomized comparative study of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Ghana. ( Amankwa, J; Ansah, NA; Ansah, P; Anto, F; Anyorigiya, T; Atuguba, F; Hodgson, A; Mumuni, G; Oduro, AR, 2005) |
| " The efficacy of chloroquine was tested in India among 91 subjects and of sulfadoxine-pyrimethamine in Nepal among 107 subjects with laboratory-confirmed Plasmodium falciparum malaria." | 5.11 | Therapeutic efficacy of antimalarial drugs along the eastern Indo-Nepal border: a cross-border collaborative study. ( Adak, T; Ansari, MA; Bannerjee, S; Bista, MB; Chand, PB; Jha, J; Pandey, S; Shahi, B; Valecha, N; Wijeyaratne, PM, 2005) |
| "Both northern and southern Sudan are deploying artemisinin-based combinations against uncomplicated Plasmodium falciparum malaria (artesunate+sulfadoxine-pyrimethamine [AS+SP] in the north, artesunate+amodiaquine [AS+AQ] in the south)." | 5.11 | Malaria in the Nuba Mountains of Sudan: baseline genotypic resistance and efficacy of the artesunate plus sulfadoxine-pyrimethamine and artesunate plus amodiaquine combinations. ( Atkin, S; Checchi, F; Ford, N; Hamour, S; Hook, C; Keus, K; Melaku, Y; Montgomery, J; Wambugu, J, 2005) |
| "To assess the therapeutic efficacy of sulfadoxinepyrimethamine (SP) after 5 years of use as first-line treatment of uncomplicated Plasmodium falciparum malaria, and thus guide the selection of artemisinin-based combination therapy in Mpumalanga, South Africa." | 5.11 | Therapeutic efficacy of sulfadoxine-pyrimethamine for Plasmodium falciparum malaria. ( Allen, E; Barnes, K; Durrheim, D; Govere, J; La Grange, K; Mabuza, A; Mbokazi, F; Mngomezulu, N; Zitha, A, 2005) |
| "The therapeutic efficacy of sulfadoxine-pyrimethamine (SP) alone, SP plus amodiaquine (AQ), and SP plus artesunate (AS) was assessed in a randomized, placebo-controlled, and double-blind trial among 438 children with uncomplicated Plasmodium falciparum malaria in northern Ghana." | 5.11 | A randomized, placebo-controlled, double-blind trial on sulfadoxine-pyrimethamine alone or combined with artesunate or amodiaquine in uncomplicated malaria. ( Anemana, SD; Bienzle, U; Cramer, JP; Dzisi, SY; Eggelte, TA; Ehrhardt, S; Mockenhaupt, FP; Otchwemah, RN; Sauerwein, RW; Schreiber, J; Teun Bousema, J; Wassilew, N, 2005) |
| "In an open, randomized, clinical trial, conducted in New Halfa, eastern Sudan, in September-October 2004, the efficacies and adverse effects of artesunate plus sulfadoxine-pyrimethamine (SP), in the treatment of uncomplicated, Plasmodium falciparum malaria, were compared with those of SP alone." | 5.11 | A comparison of the efficacy of artesunate plus sulfadoxine-pyrimethamine with that of sulfadoxine-pyrimethamine alone, in the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan. ( A-Elbasit, IE; Adam, I; Elbashir, MI; Idris, SM; Malik, EM, 2005) |
| "A prospective clinical trial was carried out to determine in vivo efficacy of sulfadoxine/pyrimethamine for the treatment of uncomplicated Plasmodium falciparum malaria in children in New Halfa." | 5.11 | Efficacy of sulfadoxin pyrimethamine for uncomplicated Plasmodium falciparum malaria in a small sample of Sudanese children. ( A/elbasit, IA; Adam, I; Elbashir, MI; Ibrahim, MH, 2004) |
| " The authors recommend that the treatment to be used in Abie must be firstly amodiaquine followed by sulfadoxine-pyrimethamine in cases where there is persistent asymptomatic parasitemia." | 5.11 | [Evaluation of the therapeutic efficacy of amodiaquine versus chloroquine in the treatment of uncomplicated malaria in Abie, Côte-d'Ivoire]. ( Adjetey, TA; Affoumou, GB; Barro-Kiki, P; Kone, M; Loukou, DD; Menan, EI; Nebavi, NG; Yavo, W, 2005) |
| "To evaluate the therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine, and the sulfadoxine-pyrimethamine-amodiaquine combination for the treatment of uncomplicated Plasmodium falciparum malaria in young children in Cameroon." | 5.10 | Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxine-pyrimethamine-amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon. ( Basco, LK; Metoh, T; Ndounga, M; Ngane, VF; Ringwald, P; Same-Ekobo, A; Soula, G, 2002) |
| "The safety and efficacy of amodiaquine (AQ), sulfadoxine-pyrimethamine (SP), and coadministered AQ+SP was assessed in 351 Tanzanian children (age range, 6-59 months) with uncomplicated Plasmodium falciparum malaria." | 5.10 | The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine, and their combination in the treatment of uncomplicated Plasmodium falciparum malaria. ( Alonso, PL; Aponte, JJ; Drakeley, C; Kahigwa, E; Malende, A; Menendez, C; Mshinda, H; Msokame, C; Schellenberg, D; Tanner, M; Wigayi, J, 2002) |
| "Many African countries currently use a sulfadoxine-pyrimethamine combination (SP) or amodiaquine (AQ) to treat uncomplicated Plasmodium falciparum malaria." | 5.10 | Combination of drug level measurement and parasite genotyping data for improved assessment of amodiaquine and sulfadoxine-pyrimethamine efficacies in treating Plasmodium falciparum malaria in Gabonese children. ( Aubouy, A; Bakary, M; Cot, M; Deloron, P; Keundjian, A; Le Bras, J; Makita, JR; Mbomat, B; Migot-Nabias, F, 2003) |
| "In a southern border province of Lao PDR, we compared the efficacy of antimalarial drug combinations in patients aged >or=1 year with uncomplicated Plasmodium falciparum malaria: monotherapy with either mefloquine (MQ), chloroquine (CQ), or sulphadoxine/pyrimethamine (SP) vs." | 5.10 | Therapeutic efficacy of chloroquine plus sulphadoxine/ pyrimethamine compared with monotherapy with either chloroquine or sulphadoxine/pyrimethamine in uncomplicated Plasmodium falciparum malaria in Laos. ( Christophel, EM; Jelinek, T; Jordan, S; Phetsouvanh, R; Phompida, S; Schwöbel, B; Vanisaveth, V; von Sonnenburg, F, 2003) |
| " In order to further understand this relationship, we determined the proportion of gametocyte carriers over time post-treatment in patients with uncomplicated Plasmodium falciparum malaria who were treated with either chloroquine (CQ) or sulfadoxine/pyrimethamine (SP)." | 5.10 | Effects of chloroquine and sulfadoxine/pyrimethamine on gametocytes in patients with uncomplicated Plasmodium falciparum malaria in Colombia. ( Castillo, CM; Ferro, BE; Osorio, L, 2002) |
| "We evaluated gametocyte carriage and intensities of gametocytaemia in 710 children presenting with acute, symptomatic, uncomplicated Plasmodium falciparum malaria who were treated with various antimalarial drug regimens: chloroquine (CQ); chloroquine plus chlorpheniramine, a histamine H1 receptor antagonist that reverses CQ resistance in P." | 5.10 | Plasmodium falciparum gametocytaemia in Nigerian children: before, during and after treatment with antimalarial drugs. ( Fateye, BA; Sowunmi, A, 2003) |
| "We evaluated the in vivo responses to chloroquine (CQ), the first line antimalarial, and to sulfadoxine-pyrimethamine (SP), the most readily available and affordable alternative treatment, in children under 5 with acute uncomplicated Plasmodium falciparum malaria in seven sites of Democratic Republic of Congo (DRC) between May 2000 and November 2001, using the standard 14-day WHO protocol." | 5.10 | Assessing the efficacy of chloroquine and sulfadoxine-pyrimethamine for treatment of uncomplicated Plasmodium falciparum malaria in the Democratic Republic of Congo. ( Kabuya, W; Kazadi, WM; Kebela, BI; Makina, BN; Mantshumba, JC; Ngimbi, NP; Vong, S, 2003) |
| "The in vivo efficacies of the Lao People's Democratic Republic (Laos) nationally recommended antimalarial agents--chloroquine and sulfadoxine-pyrimethamine-were assessed in a randomized, comparative trial that involved 100 patients with uncomplicated Plasmodium falciparum malaria who were followed for 42 days after starting treatment." | 5.10 | Chloroquine versus sulfadoxine-pyrimethamine for treatment of Plasmodium falciparum malaria in Savannakhet Province, Lao People's Democratic Republic: an assessment of national antimalarial drug recommendations. ( Brockman, A; Khanthavong, M; Mayxay, M; Newton, PN; Phetsouvanh, R; Phompida, S; Tiengkham, P; White, NJ, 2003) |
| " In the present study, the efficacies of chloroquine (CQ) or amodiaquine (AQ) in the oral treatment of acute, symptomatic, uncomplicated, Plasmodium falciparum malaria were compared with those of oral treatments with the combination of CQ or AQ with pyrimethamine-sulfadoxine (PS)." | 5.10 | A randomized comparison of chloroquine, amodiaquine and their combination with pyrimethamine-sulfadoxine in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children. ( Sowunmi, A, 2002) |
| "The efficacy and kinetics of the combination chloroquine plus sulfadoxine-pyrimethamine (CQ + SP), given sequentially and simultaneously, were investigated in 32 patients with acute uncomplicated Plasmodium falciparum malaria in Palawan Island, the Philippines." | 5.10 | Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ( Bustos, DG; Diquet, B; Gay, F; Laracas, CJ; Lazaro, JE; Pottier, A; Traore, B, 2002) |
| " 600 children with acute uncomplicated Plasmodium falciparum malaria, aged 6 months to 10 years, at five health centres were randomly assigned pyrimethaminesulphadoxine (25 mg/500 mg) with placebo; pyrimethamine-sulphadoxine plus one dose of artesunate (4mg/kg bodyweight); or pyrimethamine-sulphadoxine plus one dose 4 mg/kg bodyweight artesunate daily for 3 days." | 5.09 | Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial. ( Alloueche, A; Anyalebechi, C; Bojang, K; Coleman, R; Doherty, T; Duraisingh, M; Gosling, R; Greenwood, B; McAdam, K; Milligan, P; Olliaro, P; Pinder, M; Sadiq, A; Targett, G; Ude, JI; von Seidlein, L; Walraven, G; Warhurst, D, 2000) |
| "We conducted two randomized clinical trials to determine the in vivo efficacy of amodiaquine and sulfadoxine/pyrimethamine in treating Plasmodium falciparum malaria." | 5.09 | In vivo efficacy study of amodiaquine and sulfadoxine/ pyrimethamine in Kibwezi, Kenya and Kigoma, Tanzania. ( Ashruf, G; Bennebroek, J; Gikunda, S; Gorissen, E; Kager, PA; Lamboo, M; Mbaruku, G, 2000) |
| " To examine the effect of such therapy on transmission, Gambian children with Plasmodium falciparum malaria were treated with standard regimens of chloroquine or pyrimethamine-sulfadoxine alone or in combination with 1 or 3 doses of artesunate." | 5.09 | Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. ( Coleman, R; Deen, J; Doherty, T; Drakeley, C; Jawara, M; Milligan, P; Pinder, M; Sutherland, C; Targett, G; von Seidlein, L; Walraven, G, 2001) |
| "A study was conducted to evaluate the effectiveness of a 3-day course of therapy with quinine sulphate (10 mg/kg 8-hourly) followed by a single dose of sulfadoxine-pyrimethamine (SP) according to weight category, before discharge, for 133 hospitalised patients with uncomplicated Plasmodium falciparum malaria at Shongwe Hospital, Mpumalanga province, between February and July 1998." | 5.09 | Effectiveness of short-course quinine and single-dose sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malaria in Mpumalanga Province, South Africa. ( Athan, E; Barnes, K; Dürrheim, DN; Govere, J; Mabuza, A; Mngomezulu, NM, 2001) |
| "The cardiac effect of amodiaquine and sulfadoxine-pyrimethamine was studied in adult Cameroonian patients with acute uncomplicated Plasmodium falciparum malaria by electrocardiographic monitoring over the course of 7 days." | 5.09 | Cardiac effects of amodiaquine and sulfadoxine-pyrimethamine in malaria-infected African patients. ( Basco, LK; Blackett, KN; Keundjian, A; Ngouesse, B; Ringwald, P, 2001) |
| "To assess therapeutic efficacy of sulfadoxine-pyrimethamine (SP) in treatment of uncomplicated Plasmodium falciparum malaria 3 years after introduction in Mpumalanga, South Africa." | 5.09 | Therapeutic efficacy of sulfadoxine-pyrimethamine in uncomplicated Plasmodium falciparum malaria 3 years after introduction in Mpumalanga. ( Barnes, K; Bredenkamp, B; Durrheim, D; Govere, J; Mabuza, A; Mngomezulu, N; Sharp, B, 2001) |
| "In a randomized trial, a high dosage chloroquine monotherapy (45 mg/kg over 3 days) was compared with combination regimens of sulfadoxine/pyrimethamine and chloroquine/clindamycin for treating Gabonese school children with Plasmodium falciparum malaria." | 5.08 | Sulfadoxine/pyrimethamine or chloroquine/clindamycin treatment of Gabonese school children infected with chloroquine resistant malaria. ( Bienzle, U; Graninger, W; Kremsner, PG; Metzger, W; Mordmüller, B, 1995) |
| "Ninety-two children with complicated, but not cerebral, Plasmodium falciparum malaria, aged 1-9 years, were recruited between August 1992 and December 1994 to an open, randomized trial of parenteral chloroquine (28), pyrimethamine-sulfadoxine (P-S) (36) and quinine (28)." | 5.08 | A comparative study of parenteral chloroquine, quinine and pyrimethamine-sulfadoxine in the treatment of Gambian children with complicated, non-cerebral malaria. ( Corrah, PT; de Veer, GE; Giadom, B; Greenwood, BM; Jaffar, S; van Hensbroek, MB, 1996) |
| " Since prophylaxis with amodiaquine at 5 mg/kg weekly had failed, amodiaquine at a dose of 10mg/kg weekly and Maloprim (half a tablet or one tablet depending on body weight, which gave ranges of dapsone of 1." | 5.07 | Chemoprophylaxis against malaria in Papua New Guinea: a trial of amodiaquine and a combination of dapsone and pyrimethamine. ( Alpers, MP; Gibney, S; Gibson, FD; Heywood, PF; Jolley, D; Stace, J; Trenholme, KR; Vrbova, H, 1992) |
| "To define an effective and deliverable antimalarial regimen for use during pregnancy, pregnant women at highest risk of malaria (those in their first or second pregnancy) in an area of Malawi with high transmission of chloroquine (CQ)-resistant Plasmodium falciparum were placed on CQ and/or sulfadoxine-pyrimethamine (SP)." | 5.07 | The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. ( Chitsulo, L; Kazembe, P; Macheso, A; Schultz, LJ; Steketee, RW; Wirima, JJ, 1994) |
| "Mefloquine levels were compared between Plasmodium falciparum malaria patients with sensitive response and those with treatment failure who received 3 drug regimens of mefloquine (46 patients with MSP 3 tablets (Fansimef), 38 and 34 with mefloquine (Lariam) 750 mg and 1,250 mg)." | 5.07 | Mefloquine monitoring in acute uncomplicated malaria treated with Fansimef and Lariam. ( Banmairuroi, V; Bunnag, D; Harinasuta, T; Karbwang, J; Na Bangchang, K, 1993) |
| " One case of mefloquine-resistant and chloroquine-sensitive Plasmodium falciparum malaria acquired in West Africa was reported, another patient took pyrimethamine/sulfadoxine because of suspected malarial fever." | 5.07 | [Self-medication of 193 travelers in the tropics. Recommendations for clinical counseling of tropical travelers and organization of a tropical travel pharmacy]. ( Reisinger, EC, 1992) |
| "We did a systematic review of interventional or observational cohort studies assessing the efficacy of artemisinin-based or quinine-based treatments in pregnancy." | 5.05 | Efficacy and tolerability of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a systematic review and individual patient data meta-analysis. ( Anvikar, AR; Ashley, EA; Chandramohan, D; Cohee, LM; D'Alessandro, U; Genton, B; Gilder, ME; Guérin, PJ; Juma, E; Kalilani-Phiri, L; Kennon, K; Kuepfer, I; Laufer, MK; Lwin, KM; Mansoor, R; McGready, R; Meshnick, SR; Mosha, D; Mwapasa, V; Mwebaza, N; Nambozi, M; Ndiaye, JA; Nosten, F; Nyunt, M; Ogutu, B; Parikh, S; Paw, MK; Phyo, AP; Pimanpanarak, M; Piola, P; Rijken, MJ; Saito, M; Sriprawat, K; Stepniewska, K; Tagbor, HK; Tarning, J; Tinto, H; Valéa, I; Valecha, N; White, NJ; Wiladphaingern, J, 2020) |
| "Resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine threatens the antimalarial effectiveness of intermittent preventive treatment during pregnancy (IPTp) in sub-Saharan Africa." | 5.01 | Effect of Plasmodium falciparum sulfadoxine-pyrimethamine resistance on the effectiveness of intermittent preventive therapy for malaria in pregnancy in Africa: a systematic review and meta-analysis. ( Desai, M; Gutman, J; Hopkins Sibley, C; Kayentao, K; Khairallah, C; Koshy, G; Larsen, DA; Meshnick, SR; Okell, LC; Rogerson, SJ; Roper, C; Slaughter, DEC; Taylor, SM; Ter Kuile, FO; van Eijk, AM, 2019) |
| "The World Health Organization currently recommends quinine+clindamycin for use against malaria in the first trimester." | 4.95 | Animal Embryotoxicity Studies of Key Non-Artemisinin Antimalarials and Use in Women in the First Trimester. ( Clark, RL, 2017) |
| " Chemopreventive strategies have been increasingly deployed in Africa, notably intermittent sulfadoxine-pyrimethamine treatment in pregnancy, and monthly amodiaquine-sulfadoxine-pyrimethamine during the rainy season months in children aged between 3 months and 5 years across the sub-Sahel." | 4.90 | Malaria. ( Dondorp, AM; Faiz, MA; Hien, TT; Mokuolu, OA; Pukrittayakamee, S; White, NJ, 2014) |
| "The antifolate sulphadoxine-pyrimethamine (SP) has been used in the intermittent prevention of malaria in pregnancy (IPTp)." | 4.88 | Combination of probenecid-sulphadoxine-pyrimethamine for intermittent preventive treatment in pregnancy. ( Gutman, J; Kachur, SP; Mutabingwa, T; Nzila, A; Slutsker, L, 2012) |
| " We tried to limit confounding bias through exact matching on potential confounding factors associated with both exposure to malaria prevention (ITNs or IPTp with sulfadoxine-pyrimethamine) in pregnancy and birth outcomes, including local malaria transmission, neonatal tetanus vaccination, maternal age and education, and household wealth." | 4.88 | Malaria prevention in pregnancy, birthweight, and neonatal mortality: a meta-analysis of 32 national cross-sectional datasets in Africa. ( Anglewicz, PA; Bennett, A; Eisele, TP; Hutchinson, P; Keating, J; Larsen, DA; Steketee, RW; Yukich, J, 2012) |
| " falciparum malaria is treated using Artemisinin-based Combination Therapy (ACT)." | 4.85 | Artemisinin-based combination therapy for treating uncomplicated malaria. ( Donegan, S; Garner, P; Olliaro, P; Sinclair, D; Zani, B, 2009) |
| "Plasmodium falciparum resistance to chloroquine and sulphadoxine-pyrimethamine has led to the recent adoption of artemisinin-based combination therapies (ACTs) as the first line of treatment against malaria." | 4.85 | Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. ( Eastman, RT; Fidock, DA, 2009) |
| "To compare sulfadoxine-pyrimethamine plus amodiaquine (SP plus AQ) with sulfadoxine-pyrimethamine plus artesunate (SP plus AS) for treating uncomplicated Plasmodium falciparum malaria." | 4.83 | Sulfadoxine-pyrimethamine plus artesunate versus sulfadoxine-pyrimethamine plus amodiaquine for treating uncomplicated malaria. ( Bukirwa, H; Critchley, J, 2006) |
| "To compare amodiaquine with chloroquine or sulfadoxine-pyrimethamine for treating uncomplicated Plasmodium falciparum malaria." | 4.82 | Amodiaquine for treating malaria. ( Mussano, P; Olliaro, P, 2003) |
| "Drug resistance is one of the major factors contributing to the resurgence of malaria, especially resistance to the most affordable drugs such as chloroquine and Fansidar, a combination drug of pyrimethamine and sulfadoxine." | 4.82 | Genetic and biochemical aspects of drug resistance in malaria parasites. ( Hayton, K; Su, XZ, 2004) |
| "Amodiaquine and chloroquine give fast relief from malaria symptoms, particularly fever." | 4.81 | Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria. ( McIntosh, HM, 2001) |
| "Amodiaquine and chloroquine give fast relief from malaria symptoms, particularly fever." | 4.80 | Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria. ( McIntosh, HM, 2000) |
| "Between December, 2015, and March, 2016, and between December, 2017, and March, 2018, immediately following the 2015 and 2017 malaria transmission seasons, community surveys were done among children younger than 5 years and individuals aged 10-30 years in districts implementing seasonal malaria chemoprevention with sulfadoxine-pyrimethamine and amodiaquine in Burkina Faso, Chad, Guinea, Mali, Nigeria, Niger and The Gambia." | 4.31 | Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine-pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study. ( Bazie, T; Beshir, KB; Bojang, K; Cairns, M; Ceesay, S; Diallo, A; Dicko, A; Doumagoum, D; Eloike, T; Gamougam, K; Kessely, H; Kolie, F; Lamine, MM; Laminou, IM; Loua, K; Maiga, H; Mansukhani, R; Merle, CS; Milligan, P; Moroso, D; Muwanguzi, J; Nader, J; NDiaye, JL; Ogboi, SJ; Ouedraogo, JB; Razafindralambo, L; Sagara, I; Scott, S; Snell, P; Sutherland, CJ; Traore, A; Zongo, I, 2023) |
| "Intermittent preventive therapy during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended in areas of moderate to high malaria transmission intensity." | 4.31 | Peripheral and Placental Prevalence of Sulfadoxine-Pyrimethamine Resistance Markers in Plasmodium falciparum among Pregnant Women in Southern Province, Rwanda. ( Abram, A; Alruwaili, M; Eckert, E; Gutman, JR; Mbituyumuremyi, A; Munguti, K; Murindahabi, M; Piercefield, E; Sethi, R; Sullivan, DJ; Umulisa, N; Uwimana, A, 2023) |
| "The effectiveness of community delivery of intermittent preventive treatment (C-IPT) of malaria in pregnancy (IPTp) with sulfadoxine-pyrimethamine has been evaluated in selected areas of the Democratic Republic of the Congo, Madagascar, Mozambique, and Nigeria." | 4.31 | Prevalence of molecular markers of resistance to sulfadoxine-pyrimethamine before and after community delivery of intermittent preventive treatment of malaria in pregnancy in sub-Saharan Africa: a multi-country evaluation. ( Arikpo, I; Bissombolo, D; Doderer-Lang, C; Figueroa-Romero, A; González, R; Lemba, E; Llach, M; Ma, L; Maly, C; Mayor, A; Menard, D; Menéndez, C; Meremikwu, M; Nhama, A; Pagnoni, F; Pons-Duran, C; Rakotosaona, R; Ratsimbasoa, A; Roman, E; Sacoor, C; Sanz, S, 2023) |
| "Intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) is used to prevent malaria and associated unfavorable maternal and foetal outcomes in pregnancy in moderate to high malaria transmission areas." | 4.12 | The prevalence of molecular markers of resistance to sulfadoxine-pyrimethamine among pregnant women at first antenatal clinic attendance and delivery in the forest-savannah area of Ghana. ( Asante, KP; Bailey, JA; Chandramohan, D; Dosoo, DK; Greenwood, B; Niaré, K; Opoku-Mensah, J; Oppong, FB; Owusu-Agyei, S, 2022) |
| "Sulfadoxine-pyrimethamine (SP) is recommended in Africa in several antimalarial preventive regimens including Intermittent Preventive Treatment in pregnant women (IPTp), Intermittent Preventive Treatment in infants (IPTi) and Seasonal Malaria Chemoprevention (SMC)." | 4.12 | Spatiotemporal spread of Plasmodium falciparum mutations for resistance to sulfadoxine-pyrimethamine across Africa, 1990-2020. ( Barnes, KI; Dahlström Otienoburu, S; Flegg, JA; Guerin, PJ; Hopkins Sibley, C; Humphreys, GS; Jacome-Meza, ZJ; Montanez, B; Raman, J; Strickland, T, 2022) |
| " Artesunate plus sulfadoxine-pyrimethamine (AS + SP) has been introduced since 2010 as first-line treatment for uncomplicated Plasmodium falciparum malaria." | 4.12 | Molecular surveillance of anti-malarial drug resistance genes in Plasmodium falciparum isolates in Odisha, India. ( Bal, M; Das, A; Khan, N; Pati, S; Rana, R; Ranjit, M; Sandeepta, S, 2022) |
| " The mean number of doses of sulfadoxine-pyrimethamine for Intermittent Preventive Treatment in pregnancy (IPTp-SP) was 0." | 4.02 | Risk factors for Plasmodium falciparum infection in pregnant women in Burkina Faso: a community-based cross-sectional survey. ( Diarra, A; Drakeley, C; Lindsay, SW; Nébié, I; Ouedraogo, A; Ouedraogo, ZA; Sirima, SB; Sombié, S; Tiono, AB; Wilson, AL; Yaro, JB, 2021) |
| "Harmful maternal and neonatal health outcomes result from malaria in pregnancy, the prevention of which primarily relies on intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP)." | 4.02 | Suboptimal Intermittent Preventive Treatment in Pregnancy (IPTp) is Associated With an Increased Risk of Submicroscopic Plasmodium falciparum Infection in Pregnant Women: A Prospective Cohort Study in Benin. ( Accrombessi, M; Briand, V; Cot, M; Cottrell, G; Fievet, N; Hounkonnou, CPA; Mama, A; Massougbodji, A; Ndam, NT; Sossou, D; Vianou, B; Yovo, E, 2021) |
| " Taking sulphadoxine-pyrimethamine (SP) at predetermined periods during pregnancy, referred to as 'intermittent preventive treatment with SP' (IPTp-SP)' helps to curtail these problems." | 4.02 | High Prevalence of Molecular Markers of Plasmodium falciparum Resistance to Sulphadoxine-Pyrimethamine in Parts of Ghana: A Threat to ITPTp-SP? ( Afutu, LL; Boampong, JN; Quashie, NB, 2021) |
| "The World Health Organization recommends the provision of intermittent preventive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) at 4-week intervals from gestational week 13 to delivery in areas of moderate to high malaria transmission intensity." | 4.02 | Sulfadoxine-pyrimethamine parasitological efficacy against Plasmodium falciparum among pregnant women and molecular markers of resistance in Zambia: an observational cohort study. ( Bruce, J; Chandramoha, D; Chaponda, EB; Matthew Chico, R; Mharakurwa, S; Michelo, C, 2021) |
| "In 2004, in response to high levels of treatment failure associated with sulfadoxine-pyrimethamine (SP) resistance, Benin changed its first-line malaria treatment from SP to artemisinin-based combination therapy for treatment of uncomplicated Plasmodium falciparum malaria." | 4.02 | Low prevalence of highly sulfadoxine-resistant dihydropteroate synthase alleles in Plasmodium falciparum isolates in Benin. ( Adeothy, A; Dagnon, F; Halsey, ES; Houngbo, E; Kpemasse, A; Lucchi, NW; Patton, ME; Saliou, R; Sianou, A; Svigel, SS; Tchevoede, A; Udhayakumar, V, 2021) |
| "In Tanzania, the uptake of optimal doses (≥ 3) of sulfadoxine-pyrimethamine for intermittent preventive treatment of malaria (IPTp-SP) during pregnancy has remained below the recommended target of 80%." | 4.02 | Predictors for the uptake of optimal doses of sulfadoxine-pyrimethamine for intermittent preventive treatment of malaria during pregnancy in Tanzania: further analysis of the data of the 2015-2016 Tanzania demographic and health survey and malaria indicat ( Ambrose, T; Mbotwa, CH; Moshi, FV; Mushi, V; Zacharia, A, 2021) |
| "Mutations in the Plasmodium falciparum genes Pfdhfr and Pfdhps, particularly the sextuple mutant haplotype threatens the antimalarial effectiveness of sulfadoxine-pyrimethamine (SP) as intermittent preventive treatment during pregnancy (IPTp)." | 4.02 | Reduced Birth Weight Caused by Sextuple Drug-Resistant Plasmodium falciparum Infection in Early Second Trimester. ( Alifrangis, M; Bygbjerg, IC; Hansson, H; Jensen, RW; Lusingu, JPA; Minja, DTR; Moeller, SL; Msemo, OA; Nag, S; Schmiegelow, C; Theander, TG; Yde, AM, 2021) |
| "In 2012 the World Health Organisation (WHO) revised the policy on Intermittent Preventive Treatment with Sulphadoxine Pyrimethamine (IPTp-SP) to at least three doses for improved protection against malaria parasitaemia and its associated effects such as anaemia during pregnancy." | 4.02 | Intermittent preventive treatment comparing two versus three doses of sulphadoxine pyrimethamine (IPTp-SP) in the prevention of anaemia in pregnancy in Ghana: A cross-sectional study. ( Agyeman, YN; Annor, RB; Newton, S; Owusu-Dabo, E, 2021) |
| "Artemisinin is the frontline fast-acting anti-malarial against P." | 4.02 | Artemisinin combination therapy fails even in the absence of Plasmodium falciparum kelch13 gene polymorphism in Central India. ( Das, S; Hati, AK; Kar, A; Mandal, S; Manna, S; Saha, B, 2021) |
| "Increasing resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine (SP) threatens its usefulness for intermittent preventive treatment in pregnancy (IPTp-SP)." | 4.02 | Evaluation of the usefulness of intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine in a context with increased resistance of Plasmodium falciparum in Kingasani Hospital, Kinshasa in the Democratic Republic of Congo. ( DeMol, P; Devleesschauwer, B; Hayette, MP; Kabututu, PZ; Kayiba, NK; Lusamba, PD; Mukomena, ES; Mvumbi, DM; Mvumbi, GL; Rosas-Aguirre, A; Speybroeck, N; Tchakounang, VRK; Yobi, DM, 2021) |
| "Plasmodium falciparum dihydrofolate reductase (Pfdhfr) and dihydropteroate synthetase (Pfdhps) mutations compromise the effectiveness of sulfadoxine-pyrimethamine (SP) for treatment of uncomplicated malaria, and are likely to impair the efficiency of intermittent preventive treatment during pregnancy (IPTp)." | 3.96 | Occurrence of septuple and elevated Pfdhfr-Pfdhps quintuple mutations in a general population threatens the use of sulfadoxine-pyrimethamine for malaria prevention during pregnancy in eastern-coast of Tanzania. ( Bwire, GM; Kilonzi, M; Mikomangwa, WP, 2020) |
| "Artesunate plus sulfadoxine-pyrimethamine (ASP) is first-line treatment for uncomplicated Plasmodium falciparum malaria in most of India, except for six North-eastern provinces where treatment failure rates were high." | 3.96 | Stable high frequencies of sulfadoxine-pyrimethamine resistance associated mutations and absence of K13 mutations in Plasmodium falciparum 3 and 4 years after the introduction of artesunate plus sulfadoxine-pyrimethamine in Ujjain, Madhya Pradesh, India. ( Diwan, V; Gawariker, S; Mårtensson, A; Pathak, A; Purohit, M; Sharma, A; Ursing, J, 2020) |
| "In high malaria transmission settings, the use of sulfadoxine-pyrimethamine-based intermittent preventive treatment during pregnancy (IPTp-SP) has resulted in decreased antibody (Ab) levels to VAR2CSA." | 3.96 | Antibodies to full-length and the DBL5 domain of VAR2CSA in pregnant women after long-term implementation of intermittent preventive treatment in Etoudi, Cameroon. ( Djontu, JC; Leke, RGF; Lloyd, YM; Megnekou, R; Salanti, A; Seumko'o, RMN; Taylor, DW, 2020) |
| "Intermittent preventive treatment in pregnancy with sulphadoxine-pyrimethamine (IPTp-SP) is one of the main strategies for protecting pregnant women, fetus, and their new-born against adverse effects of P." | 3.96 | Analysis of sulphadoxine-pyrimethamine resistance-associated mutations in Plasmodium falciparum isolates obtained from asymptomatic pregnant women in Ogun State, Southwest Nigeria. ( Adebusuyi, SA; Adedokun, SA; Amoo, AOJ; Fagbemi, KA; Nderu, D; Ojurongbe, O; Pallerla, SR; Thomas, BN; Velavan, TP, 2020) |
| " Artesunate plus sulfadoxine-pyrimethamine (AS + SP) has been used in Saudi Arabia since 2007 as a first-line treatment for uncomplicated Plasmodium falciparum malaria." | 3.96 | Increased prevalence of pfdhfr and pfdhps mutations associated with sulfadoxine-pyrimethamine resistance in Plasmodium falciparum isolates from Jazan Region, Southwestern Saudi Arabia: important implications for malaria treatment policy. ( Abdulhaq, AA; Al-Mekhlafi, HM; Anwar, AA; Atroosh, WM; Eisa, ZM; Ghailan, KY; Ghzwani, AH; Madkhali, AM; Zain, KA, 2020) |
| "Sulfadoxine-pyrimethamine (SP) is the recommended drug for intermittent preventive treatment of malaria in pregnancy in most of sub-Saharan Africa." | 3.88 | Prevalence of the Pfdhfr and Pfdhps mutations among asymptomatic pregnant women in Southeast Nigeria. ( Berens-Riha, N; Esu, E; Gai, P; Loescher, T; Meremikwu, M; Pritsch, M; Tacoli, C, 2018) |
| "In 2005, Nigeria changed its policy on prevention of malaria in pregnancy to intermittent preventive treatment with sulphadoxine-pyrimethamine (IPTp-SP)." | 3.88 | Prevalence of Low Birth Weight before and after Policy Change to IPTp-SP in Two Selected Hospitals in Southern Nigeria: Eleven-Year Retrospective Analyses. ( Adibe, MO; Aguwa, NC; Igboeli, NU; Ukwe, CV, 2018) |
| "Despite the development of resistance to Plasmodium falciparum malaria, sulfadoxine-pyrimethamine is still effective for intermittent preventive treatment of malaria in pregnancy (IPTp)." | 3.88 | A decade since sulfonamide-based anti-malarial medicines were limited for intermittent preventive treatment of malaria among pregnant women in Tanzania. ( Kilonzi, M; Marealle, AI; Mbwambo, DP; Mikomangwa, WP; Mlyuka, HJ; Mutagonda, RF, 2018) |
| " Intermittent preventive treatment with sulfadoxine-pyrimethamine during pregnancy (IPTp-SP) is widely implemented to prevent these negative effects of malaria." | 3.85 | Increase in the prevalence of mutations associated with sulfadoxine-pyrimethamine resistance in Plasmodium falciparum isolates collected from early to late pregnancy in Nanoro, Burkina Faso. ( d'Alessandro, U; de Jong, MD; Derra, K; Geskus, RB; Lompo, P; Mens, PF; Ruizendaal, E; Schallig, HDFH; Scott, S; Tahita, MC; Tinto, H; Traore-Coulibaly, M; Versteeg, I, 2017) |
| "Sulphadoxine-pyrimethamine (SP) is only used for intermittent preventive treatment during pregnancy (IPTp) in most Sub-Saharan African countries." | 3.85 | Presence of quintuple dhfr N51, C59, S108 - dhps A437, K540 mutations in Plasmodium falciparum isolates from pregnant women and the general population in Nanoro, Burkina Faso. ( Mens, PF; Ruizendaal, E; Schallig, HDFH; Tahita, MC; Tinto, H; Traoré-Coulibaly, M, 2017) |
| "In a recent trial of intermittent preventive treatment in pregnancy (IPTp) in Uganda, dihydroartemisinin-piperaquine (DP) was superior to sulfadoxine-pyrimethamine (SP) in preventing maternal and placental malaria." | 3.85 | Impact of Intermittent Preventive Treatment During Pregnancy on Plasmodium falciparum Drug Resistance-Mediating Polymorphisms in Uganda. ( Aweeka, F; Conrad, MD; Dorsey, G; Foster, M; Havlir, DV; Huang, L; Jagannathan, P; Kakuru, A; Kamya, MR; Legac, J; Mota, D; Nayebare, P; Rosenthal, PJ; Tukwasibwe, S; Tumwebaze, P; Wallender, E; Whalen, M, 2017) |
| "The impact of sulfadoxine-pyrimethamine (SP) used as intermittent preventive treatment during pregnancy (IPTp-SP) on mutant parasite selection has been poorly documented in Burkina Faso." | 3.85 | Recent uptake of intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine is associated with increased prevalence of Pfdhfr mutations in Bobo-Dioulasso, Burkina Faso. ( Awandare, GA; Cisse, M; Guiguemdé, RT; Hayette, MP; Soulama, A; Tinto, H, 2017) |
| " Age, parity and intermittent preventive treatment during pregnancy with sulphadoxine-pyrimethamine (IPTp-SP) usage were considered during analysis." | 3.83 | IgG isotypic antibodies to crude Plasmodium falciparum blood-stage antigen associated with placental malaria infection in parturient Cameroonian women. ( Achidi, EA; Anchang-Kimbi, JK; Mendimi, JN; Nkegoum, B; Sverremark-Ekström, E; Troye-Blomberg, M, 2016) |
| "The efficacy of Sulphadoxine/Pyrimethamine (SP) in Plasmodium falciparum malaria treatment was increasingly compromised by development of parasites' resistance." | 3.83 | RETROSPECTIVE INVESTIGATION OF PYRIMETHAMINE-SULFADOXINE RESISTANCE INDICATORS IN FALCIPARUM-MALARIA POSITIVE BLOOD SAMPLES FROM SOUTH-WESTERN SAUDI ARABIA. ( Al-Harthi, SA, 2016) |
| "In 1993, Malawi changed its first-line anti-malarial treatment for uncomplicated malaria from chloroquine to sulfadoxine-pyrimethamine (SP), and in 2007, it changed from SP to lumefantrine-artemether." | 3.83 | Malaria research and its influence on anti-malarial drug policy in Malawi: a case study. ( de Jager, C; Hongoro, C; Longwe, H; Mutero, CM; Mwendera, C; Phiri, K, 2016) |
| "Six years after the implementation of intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) in Gabon, its impact on placental malaria and pregnancy outcomes remains unknown." | 3.83 | Decrease of microscopic Plasmodium falciparum infection prevalence during pregnancy following IPTp-SP implementation in urban cities of Gabon. ( Ambounda, N; Bouyou-Akotet, MK; Kendjo, E; Kombila, M; Mawili-Mboumba, DP; Moutandou Chiesa, S; Tshibola Mbuyi, ML; Tsoumbou-Bakana, G; Zong, J, 2016) |
| "Insecticides treated nets (ITNs) and intermittent preventive therapy with two doses of sulfadoxine-pyrimethamine (SP IPTp) are the cornerstone for malaria control in pregnancy." | 3.83 | Determinants of timely uptake of ITN and SP (IPT) and pregnancy time protected against malaria in Bukoba, Tanzania. ( Moshiro, C; Protas, J; Tarimo, D, 2016) |
| "Faced with intense levels of chloroquine (CQ) resistance in Plasmodium falciparum malaria, Rwanda replaced CQ with amodiaquine (AQ)+sulfadoxine-pyrimethamine (SP) in 2001, and subsequently with artemether-lumefantrine (AL) in 2006, as first-line treatments for uncomplicated malaria." | 3.83 | Molecular surveillance of Plasmodium falciparum drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda. ( Grobusch, MP; Hakizimana, E; Kateera, F; Kumar, N; Mens, PF; Mutesa, L; Nsobya, SL; Tukwasibwe, S; van Vugt, M, 2016) |
| "The A581 G: mutation in the gene encoding Plasmodium falciparum dihydropteroate synthase (dhps), in combination with the quintuple mutant involving mutations in both dhps and the gene encoding dihydrofolate reductase (dhfr), the so-called sextuple mutant, has been associated with increased placental inflammation and decreased infant birth weight among women receiving intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) during pregnancy." | 3.81 | The A581G Mutation in the Gene Encoding Plasmodium falciparum Dihydropteroate Synthetase Reduces the Effectiveness of Sulfadoxine-Pyrimethamine Preventive Therapy in Malawian Pregnant Women. ( Ali, D; Chaluluka, E; Dzinjalamala, F; Gutman, J; Kalilani, L; Khairallah, C; Madanitsa, M; Mathanga, DP; Meshnick, S; Mwandama, D; Shi, YP; Skarbinski, J; Taylor, S; ter Kuile, FO; Thwai, KL; Wiegand, RE; Zhou, Z, 2015) |
| "In 2007, Malawi replaced sulfadoxine-pyrimethamine (SP) with an artemisinin-based combination therapy as the first-line treatment for uncomplicated Plasmodium falciparum malaria in response to failing SP efficacy." | 3.81 | Persistence of Sulfadoxine-Pyrimethamine Resistance Despite Reduction of Drug Pressure in Malawi. ( Artimovich, E; Dzinjalamala, FK; Escalante, AA; Kublin, JG; Laufer, MK; Plowe, CV; Schneider, K; Takala-Harrison, S; Taylor, TE, 2015) |
| "Intermittent preventive treatment of malaria in pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) decreases placental parasitaemia, thus improving birth outcomes." | 3.81 | Evaluation of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy: a retrospective birth outcomes study in Mansa, Zambia. ( Chalwe, V; Craig, AS; Filler, SJ; Kamuliwo, M; Katalenich, BL; Mace, KE; Mubikayi, L; Mulele, CK; Nambozi, M; Tan, KR; Wiegand, RE, 2015) |
| "Intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) has not been evaluated in the Republic of Congo since its implementation in 2006 and there is no published data on molecular markers of SP resistance among Plasmodium falciparum isolates from pregnant women." | 3.81 | High prevalence of sulphadoxine-pyrimethamine resistance-associated mutations in Plasmodium falciparum field isolates from pregnant women in Brazzaville, Republic of Congo. ( Bakoua, D; Fesser, A; Koukouikila-Koussounda, F; Nkombo, M; Ntoumi, F; Vouvoungui, C, 2015) |
| "Sulphadoxine-pyrimethamine (SP) is the recommended drug for intermittent preventive treatment in pregnancy (IPTp) in most African countries, including Zambia." | 3.81 | High prevalence of dhfr and dhps molecular markers in Plasmodium falciparum in pregnant women of Nchelenge district, Northern Zambia. ( Chipeta, J; Mharakurwa, S; Michelo, C; Siame, MN; Thuma, P, 2015) |
| " Sulfadoxine-pyrimethamine (SP) is currently deployed as intermittent preventive treatment in pregnancy (IPTp) to prevent the adverse effects of malaria on the mother and her offspring." | 3.81 | Prevalence of the dhfr and dhps Mutations among Pregnant Women in Rural Burkina Faso Five Years after the Introduction of Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine. ( D'Alessandro, U; Erhart, A; Fitzhenry, R; Guiguemde, RT; Kazienga, A; Ouedraogo, JB; Rosanas-Urgell, A; Tahita, MC; Tinto, H; Van Geertruyden, JP; VanOvermeir, C, 2015) |
| "Chloroquine (CQ) is used as a first-line therapy for the treatment of Plasmodium falciparum malaria in Nicaragua." | 3.80 | Molecular analysis of chloroquine and sulfadoxine-pyrimethamine resistance-associated alleles in Plasmodium falciparum isolates from Nicaragua. ( Macedo De Oliveira, A; Rodriguez, B; Soto, AM; Sridaran, S; Udhayakumar, V, 2014) |
| "In 2006, the first-line anti-malarial drug treatment in Tanzania was changed from sulphadoxine-pyrimethamine (SP) to artemether-lumefantrine (ALu), an artemisinin-based combination (ACT), since when the use of SP has been restricted for intermittent preventive treatment in pregnancy (IPTp)." | 3.80 | High levels of sulphadoxine-pyrimethamine resistance Pfdhfr-Pfdhps quintuple mutations: a cross sectional survey of six regions in Tanzania. ( Kalinga, A; Kauki, JS; Kavishe, AA; Kavishe, RA; Matondo, SI; Reyburn, H; Temba, GS; van Zwetselaar, M, 2014) |
| "To use ultrasound to explore the impact of malaria in pregnancy on fetal growth and newborn outcomes among a cohort of women enrolled in an intermittent presumptive treatment in pregnancy (IPTp) with sulfadoxine/pyrimethamine (SP) program in coastal Kenya." | 3.80 | A cohort study of Plasmodium falciparum malaria in pregnancy and associations with uteroplacental blood flow and fetal anthropometrics in Kenya. ( Dent, AE; Goldenberg, RL; Hudgens, M; King, CL; Lazebnik, N; McClure, EM; Meshnick, SR; Mungai, P; Siega-Riz, AM, 2014) |
| "Intermittent preventive treatment of malaria in pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) decreases adverse effects of malaria during pregnancy." | 3.80 | Efficacy of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy, Mansa, Zambia. ( Chalwe, V; Craig, AS; Filler, SJ; Kamuliwo, M; Katalenich, BL; Mace, KE; Meshnick, SR; Nambozi, M; Tan, KR; Taylor, SM; Wiegand, RE, 2014) |
| "The World Health Organization (WHO) recommends for sub-Saharan Africa a package of prompt and effective case-management combined with the delivery of insecticide-treated nets (ITN) and intermittent preventive treatment during pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) through the national antenatal care (ANC) programs." | 3.80 | Coverage and efficacy of intermittent preventive treatment with sulphadoxine pyrimethamine against malaria in pregnancy in Côte d'Ivoire five years after its implementation. ( Ako, BA; Bassinka, I; Beourou, S; Bokossa, EM; Coulibaly, B; Coulibaly, MA; Esmel, B; Gba, B; Gbessi, EA; Koffi, D; Kone, PL; N' Guessan, LT; Nogbou, M; Soumahoro, A; Swa, T; Toure, OA, 2014) |
| "Despite widespread parasite resistance to sulphadoxine-pyrimethamine (SP) its use for intermittent preventative treatment during pregnancy remains the policy in Benin and throughout most of sub-Saharan Africa." | 3.79 | High rates of parasite recrudescence following intermittent preventive treatment with sulphadoxine-pyrimethamine during pregnancy in Benin. ( Alifrangis, M; De Tove, YS; Deloron, P; Doritchamou, J; Luty, AJ; Massougbodji, A; Moussiliou, A; Ndam, NT, 2013) |
| "Ethiopia changed the first-line anti-malarial drug for uncomplicated Plasmodium falciparum malaria from sulfadoxine-pyrimethamine (SP) to Coartem(®) in 2004 following nation-wide assessment of the efficacy of both drugs in 2003." | 3.79 | Prevalence of sulfadoxine-pyrimethamine resistance-associated mutations in dhfr and dhps genes of Plasmodium falciparum three years after SP withdrawal in Bahir Dar, Northwest Ethiopia. ( Hailemeskel, E; Kassa, M; Kebede, A; Mohammed, H; Petros, B; Sleshi, M; Taddesse, G; Tasew, G; Woyessa, A, 2013) |
| " In addition, the National Malaria Control Programmes of these countries have virtually identical policies: (1) Artemisinin Combination Therapies (ACTs) for the treatment of symptomatic Plasmodium falciparum infection, (2) Long-Lasting Insecticide-treated bed Nets (LLINs) to reduce the Entomololgic Inoculation Rate (EIR), and (3) sulfadoxine-pyrimethamine for the Intermittent Preventive Treatment of malaria during pregnancy (IPTp)." | 3.78 | Sahel, savana, riverine and urban malaria in West Africa: Similar control policies with different outcomes. ( Abubakar, I; Bojang, KA; Ceesay, SJ; Conway, DJ; Coulibaly, M; Coulibaly, TF; Dao, A; Diakité, M; Diarra, A; Diawara, S; Doumbia, SO; Duraisingh, M; Fairhurst, RM; Faye, B; Faye, O; Gaye, O; Jawara, M; Kandeh, B; Kéita, M; Koita, OA; Konaté, L; Krogstad, DJ; Long, CA; Muskavitch, MA; Ndiaye, D; Ndiaye, JL; Nwakanma, D; Okebe, J; Perry, R; Poudiougou, B; Sangaré, L; Sarr, O; Sissako, A; Sogoba, N; Sy, N; Traoré, SF; Valim, C; Volkman, SK; Wirth, DF, 2012) |
| "Antenatal intermittent preventive therapy with 2 doses of sulfadoxine-pyrimethamine (IPTp-SP) is the mainstay of efforts in sub-Saharan Africa to prevent pregnancy-associated malaria (PAM)." | 3.78 | Antenatal receipt of sulfadoxine-pyrimethamine does not exacerbate pregnancy-associated malaria despite the expansion of drug-resistant Plasmodium falciparum: clinical outcomes from the QuEERPAM study. ( Antonia, AL; Chaluluka, E; Feng, G; Meshnick, SR; Molyneux, ME; Mwapasa, V; Rogerson, SJ; Taylor, SM; ter Kuile, FO, 2012) |
| "Previous history of malaria during pregnancy represents a risk factor for current infection and anemia was an important complication associated with malaria, even in women who were treated with sulfadoxine-pyrimethamine during pregnancy." | 3.78 | Plasmodium falciparum infection in pregnant women attending antenatal care in Luanda, Angola. ( Campos, PA; Campos, RB; Gonçalves, L; Rosário, VE; Silveira, H; Valente, B; Varandas, L, 2012) |
| "In 2005, sulphadoxine-pyrimethamine (SP) became the drug of choice for intermittent preventive treatment of Plasmodium falciparum malaria in pregnancy (IPTp) in Ghana." | 3.78 | Surveillance of molecular markers of Plasmodium falciparum resistance to sulphadoxine-pyrimethamine 5 years after the change of malaria treatment policy in Ghana. ( Abuaku, BK; Duah, NO; Koram, KA; Kronmann, KC; Quashie, NB; Sebeny, PJ, 2012) |
| "Drug resistance against dihydrofolate reductase (DHFR) inhibitors-such as pyrimethamine (PM)-has now spread to almost all regions where malaria is endemic, rendering antifolate-based malaria treatments highly ineffective." | 3.76 | Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate. ( Brun, R; Chitnumsub, P; Dartois, V; Diagana, TT; Goh, A; Kamchonwongpaisan, S; Keller, TH; Kiara, SM; Lakshminarayana, SB; Ma, NL; Maneeruttanarungroj, C; Nzila, A; Rottmann, M; Taweechai, S; Weaver, M; Wittlin, S; Wong, J; Yeung, BK; Yuthavong, Y; Zou, B, 2010) |
| " We tested whether chloroquine- and antifolate drug-resistant genotypes would be more commonly associated with cases of cerebral malaria than with cases of mild malaria in the province of Jabalpur, India, by genotyping the dhps, dhfr, pfmdr-1, and pfcrt genes using pyrosequencing, direct sequencing, and real-time PCR." | 3.76 | Evidence of selective sweeps in genes conferring resistance to chloroquine and pyrimethamine in Plasmodium falciparum isolates in India. ( Dash, AP; Jain, V; McCollum, AM; Mixson-Hayden, T; Nagpal, AC; Poe, A; Singh, N; Stiles, JK; Udhayakumar, V, 2010) |
| "The therapeutic efficacy of sulfadoxine-pyrimethamine (SP) in treating uncomplicated Plasmodium falciparum malaria is unevenly distributed in Colombia." | 3.76 | Origin and dissemination across the Colombian Andes mountain range of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum. ( Benavides, J; Corredor, V; Echeverry, DF; Guerra, AP; Murillo, C; Osorio, L; Pearce, RJ; Roper, C, 2010) |
| " A three-arm, three-centre trial of Amodiaquine (AQ), sulfadoxine-pyrimethamine (SP) and their combination (AQ + SP), conducted by OCEAC-IRD in 2003, in 538 children with uncomplicated Plasmodium falciparum malaria, is used as an illustration." | 3.76 | Analysis of an ordinal outcome in a multicentric randomized controlled trial: application to a 3- arm anti- malarial drug trial in Cameroon. ( Basco, LK; Gwét, H; Thalabard, JC; Whegang, SY, 2010) |
| " They were monitored for development of Plasmodium falciparum malaria, which was treated with chloroquine (CQ) + sulfadoxine-pyrimethamine (SP) and the children followed up for 28 days." | 3.76 | Prolonged elevation of viral loads in HIV-1-infected children in a region of intense malaria transmission in Northern Uganda: a prospective cohort study. ( Egwang, TG; Kiyingi, HS; Nannyonga, M, 2010) |
| "In 2003, the high level of chloroquine (CQ) treatment failure for uncomplicated Plasmodium falciparum malaria cases has led Senegal to adopt a new combination therapy with sulfadoxine-pyrimethamine and amodiaquine (SP-AQ)." | 3.74 | Mutations in PFCRT K76T do not correlate with sulfadoxine-pyrimethamine-amodiaquine failure in Pikine, Senegal. ( Ahouidi, AD; Daily, JP; Ly, O; Mboup, S; Ndiaye, D; Ndir, O; Sarr, O; Wirth, DF, 2008) |
| "In 2001, Peru changed its treatment policy for uncomplicated Plasmodium falciparum malaria on the northern Pacific Coast to sulfadoxine-pyrimethamine with atresunate (SP-AS)." | 3.74 | Surveillance for adverse drug reactions to combination antimalarial therapy with sulfadoxine-pyrimethamine plus artesunate in Peru. ( Bacon, DJ; Cabezas, C; Cairo, J; Durand, S; Lachira, A; Marquiño, W; Quintana, F; Ruebush, TK; Utz, G; Vegas, W, 2008) |
| "Use of intermittent preventive treatment with sulfadoxine-pyrimethamine (SP) during pregnancy (IPTp-SP) has become policy in much of sub-Saharan Africa but crucially depends on the efficacy of SP." | 3.74 | Rapid increase in the prevalence of sulfadoxine-pyrimethamine resistance among Plasmodium falciparum isolated from pregnant women in Ghana. ( Bedu-Addo, G; Bienzle, U; Eggelte, TA; Holmberg, V; Hommerich, L; Mockenhaupt, FP; von Oertzen, C, 2008) |
| "Intermittent preventive treatment with sulphadoxine-pyrimethamine (SP) is recommended for reducing the risk of malaria in pregnancy and its consequences on mothers and babies (IPTp-SP)." | 3.74 | Implementation of intermittent preventive treatment in pregnancy with sulphadoxine/pyrimethamine (IPTp-SP) at a district health centre in rural Senegal. ( Badiane, M; Brasseur, P; Cisse, M; Delenne, H; Olliaro, A; Olliaro, PL; Vaillant, M, 2008) |
| "Placental sequestration of Plasmodium falciparum in pregnancy may impair the usefulness of molecular markers of sulfadoxine-pyrimethamine resistance." | 3.74 | Markers of sulfadoxine-pyrimethamine-resistant Plasmodium falciparum in placenta and circulation of pregnant women. ( Bedu-Addo, G; Bienzle, U; Eggelte, TA; Hommerich, L; Junge, C; Mockenhaupt, FP, 2007) |
| "Usefulness of sulfadoxine-pyrimethamine as first-line therapy for uncomplicated Plasmodium falciparum malaria and intermittent preventive treatment in pregnancy throughout sub-Saharan Africa is compromised by the spread of dhfr alleles associated with pyrimethamine resistance." | 3.74 | A shared Asian origin of the triple-mutant dhfr allele in Plasmodium falciparum from sites across Africa. ( Aubouy, A; Clain, J; Djimdé, AA; Doumbo, OK; Hubert, V; Kironde, F; Koram, K; Le Bras, J; Maïga, O; Nsimba, B; Renard, E, 2007) |
| "The therapeutic efficacy of three monotherapies was assessed: amodiaquine and sulfadoxine/pyrimethamine for uncomplicated Plasmodium falciparum malaria, and chloroquine for Plasmodium vivax malaria in the municipality of Tarapacá, located in the Colombian province of Amazonas." | 3.74 | [Assessment of the efficacy of antimalarial drugs in Tarapacá, in the Colombian Amazon basin]. ( González, IJ; Osorio, L; Pérez, Ldel P, 2007) |
| "In 1998, Kenya adopted intermittent preventive treatment (IPTp) with sulphadoxine-pyrimethamine (SP) for malaria prevention during pregnancy." | 3.74 | The effect of health care worker training on the use of intermittent preventive treatment for malaria in pregnancy in rural western Kenya. ( Ayisi, JG; Hamel, MJ; Kager, PA; Munguti, K; Odhiambo, F; Ouma, PO; Sikuku, E; Slutsker, L; Van Eijk, AM, 2007) |
| "Intermittent preventive treatment in pregnancy with sulphadoxine-pyrimethamine (IPTp-SP) has been adopted as policy by many countries in sub-Saharan Africa." | 3.74 | Decline of placental malaria in southern Ghana after the implementation of intermittent preventive treatment in pregnancy. ( Acquah, PA; Bedu-Addo, G; Bienzle, U; Eggelte, TA; Holmberg, V; Hommerich, L; Mockenhaupt, FP; von Oertzen, C, 2007) |
| " Women pregnant in the last 12 months were asked about their age, parity, education, use of nets, ITN, antenatal care (ANC) services and sulphadoxine-pyrimethamine (SP) (overall and for IPT) during pregnancy." | 3.74 | Access and barriers to measures targeted to prevent malaria in pregnancy in rural Kenya. ( Ajanga, AA; Gikandi, PW; Gitonga, CW; Noor, AM; Snow, RW, 2008) |
| "Sulfadoxine-pyrimethamine (SP) has been widely used in recent years to treat acute uncomplicated Plasmodium falciparum malaria." | 3.73 | Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian children. ( Barnes, KI; Dzinjalamala, FK; Kublin, JG; Macheso, A; Molyneux, ME; Plowe, CV; Smith, PJ; Taylor, TE, 2005) |
| " day, on days 0-2) plus sulfadoxine-pyrimethamine (25 mg/kg, on day 0) for the treatment of uncomplicated Plasmodium falciparum malaria was investigated in four sentinel areas in Sudan, with different malaria transmission (Damazin, Kassala, Kosti, and Malakal)." | 3.73 | Artesunate plus sulfadoxine-pyrimethamine for treatment of uncomplicated Plasmodium falciparum malaria in Sudan. ( Abdelgadir, T; Adam, I; Ahmed, ES; Elamin, SB; Khamiss, AH; Malik, EM; Mohammed, MM, 2005) |
| " Despite its high resistance level, chloroquine (CQ) is still extensively used as the first-line treatment for uncomplicated Plasmodium falciparum malaria." | 3.73 | Epidemiology of drug-resistant malaria in Republic of Congo: using molecular evidence for monitoring antimalarial drug resistance combined with assessment of antimalarial drug use. ( Durand, R; Jafari-Guemouri, S; Kiori, J; Le Bras, J; Louya, F; Malanda, M; Malonga, DA; Mouata, AM; Nsimba, B; Yocka, D, 2005) |
| "Kenya established intermittent preventive treatment (IPT) with sulfadoxine-pyrimethamine (SP) for malaria in pregnancy as national policy in 1998." | 3.73 | Use of intermittent preventive treatment for malaria in pregnancy in a rural area of western Kenya with high coverage of insecticide-treated bed nets. ( Adazu, K; Ayisi, JG; Bles, HM; Blokland, IE; Lindblade, KA; Odhiambo, F; Rosen, DH; Slutsker, L; van Eijk, AM, 2005) |
| "In an efficacy trial of artemisinin-based combination treatments (ACT) in central Sudan, cases of uncomplicated, Plasmodium falciparum malaria were given artesunate-sulfadoxine-pyrimethamine (ASP) or artemether-lumefantrine (AL) as first-line treatment." | 3.73 | The efficacies of artesunate-sulfadoxine-pyrimethamine and artemether-lumefantrine in the treatment of uncomplicated, Plasmodium falciparum malaria, in an area of low transmission in central Sudan. ( Ahmed, OA; Elamin, SB; Eltaib, EH; Malik, EM; Mohamed, AO, 2006) |
| "A 28-day in vivo treatment trial to evaluate the efficacy of pyrimethamine/sulfadoxine (Fansidar, PS) was conducted in 21 Lao patients with uncomplicated Plasmodium falciparum malaria." | 3.73 | Pyrimethamine-sulfadoxine treatment of uncomplicated Plasmodium falciparum malaria in Lao PDR. ( Hatabu, T; Hongvangthong, B; Kano, S; Keokhamphavanh, B; Kobayashi, J; Mannoor, MK; Phetsouvanh, R; Phompida, S; Sato, Y; Taguchi, N; Toma, H; Vanisaveth, V; Watanabe, H, 2005) |
| "Sulfadoxine-pyrimethamine (SP) is the second-line treatment for Plasmodium falciparum malaria in Sri Lanka." | 3.73 | Point mutations in the dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum and resistance to sulfadoxine-pyrimethamine in Sri Lanka. ( Abeyewickreme, W; Abeysundara, S; Bandara, KB; Dayanath, MY; de Silva, NR; Hapuarachchi, HC; Hunt, SY; Sibley, CH, 2006) |
| "Several factors appear to have accelerated the process: (1) recognition of the extent of the problem of malaria during pregnancy and its adverse consequences; (2) a clear, evidence-based program strategy strongly articulated by an important multilateral organization (World Health Organization); (3) subregionally generated evidence to support the proposed strategy; (4) a subregional forum for dissemination of data and discussion regarding the proposed policy changes; (5) widespread availability of the proposed intervention drug (sulfadoxine-pyrimethamine); (6) technical support from reputable and respected institutions in drafting new policies and planning for implementation; (7) donor support for pilot experiences in integrating proposed policy change into a package of preventive services; and (8) financial support for scaling up the proposed interventions." | 3.73 | Prevention of malaria during pregnancy in West Africa: policy change and the power of subregional action. ( Benga-De, E; Doumbo, O; Faye, O; Gaye, O; Kayentao, K; Lo, Y; Moran, AC; Moreira, PM; Newman, RD; Parise, ME; Steketee, RW; Yameogo, M, 2006) |
| "We have previously shown that both chloroquine and paracetamol (acetaminophen) have antipyretic activity during treatment of acute uncomplicated Plasmodium falciparum malaria in children 1-4 years old." | 3.73 | Relationship between antipyretic effects and cytokine levels in uncomplicated falciparum malaria during different treatment regimes. ( Björkman, A; Hugosson, E; Montgomery, SM; Premji, Z; Troye-Blomberg, M, 2006) |
| "Sulphadoxine-pyrimethamine (SP) has been and is currently used for treatment of uncomplicated Plasmodium falciparum malaria in many African countries." | 3.73 | Drug resistance to sulphadoxine-pyrimethamine in Plasmodium falciparum malaria in Mlimba, Tanzania. ( Balthazary, ST; Malisa, AL; Mbugi, EV; Mshinda, H; Mutayoba, BM; Nyambo, TB, 2006) |
| "Febrile adults with Plasmodium falciparum parasitemia were treated with sulfadoxine-pyrimethamine and were monitored for 28 days." | 3.73 | HIV immunosuppression and antimalarial efficacy: sulfadoxine-pyrimethamine for the treatment of uncomplicated malaria in HIV-infected adults in Siaya, Kenya. ( Bloland, PB; Hamel, MJ; Kain, KC; Obonyo, CO; Shah, SN; Slutsker, L; Smith, EE, 2006) |
| "The safety and the efficacy of amodiaquine (AQ) alone, AQ plus sulfadoxine-pyrimethamine (SP) (AQ plus SP), and artesunate (ART) plus SP (ART plus SP), three possible alternatives to chloroquine (CQ), were investigated in 379 Rwandan children 6-59 months old with uncomplicated Plasmodium falciparum malaria who visited one urban/peri-urban health center and two rural health centers." | 3.72 | Efficacy of amodiaquine alone and combined with sulfadoxine-pyrimethamine and of sulfadoxine pyrimethamine combined with artesunate. ( D'Alessandro, U; Dujardin, JC; Karema, C; Mugisha, V; Niyitegeka, F; Rwagacondo, CE; Sarushi, J; van den Ende, J; Van Overmeir, C, 2003) |
| "Increasing resistance, recrudescences, and treatment failure have led to the replacement of chloroquine with the combination of pyrimethamine (PYR) and sulfadoxine (SDX) as the first-line antimalarial drugs for treatment of uncomplicated Plasmodium falciparum malaria in several areas where this disease is endemic." | 3.72 | Genotyping of Plasmodium falciparum pyrimethamine resistance by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry. ( Evans, J; Horstmann, RD; Marks, F; May, J; Meyer, CG; Sievertsen, J; Timmann, C, 2004) |
| "The combination of sulfadoxine-pyrimethamine (SP) is used as a second line of therapy for the treatment of uncomplicated chloroquine-resistant Plasmodium falciparum malaria." | 3.72 | Plasmodium falciparum isolates in India exhibit a progressive increase in mutations associated with sulfadoxine-pyrimethamine resistance. ( Ahmed, A; Ansari, MA; Bararia, D; Biswas, S; Dev, V; Kumar, A; Sharma, YD; Vinayak, S; Yameen, M, 2004) |
| "In 1998, the Kenyan Ministry of Health introduced intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine (SP), one treatment dose in the second trimester (16-27 weeks) and one treatment dose between 28 and 34 weeks of gestational age, for the control of malaria in pregnancy." | 3.72 | Implementation of intermittent preventive treatment with sulphadoxine-pyrimethamine for control of malaria in pregnancy in Kisumu, western Kenya. ( Ayisi, JG; Kager, PA; Misore, AO; Nahlen, BL; Odondi, JO; Otieno, JA; Rosen, DH; Slutsker, L; Steketee, RW; ter Kuile, FO; van Eijk, AM, 2004) |
| "To reduce the intolerable burden of malaria in pregnancy, the Ministry of Health in Tanzania has recently adopted a policy of intermittent presumptive treatment for pregnant women using sulphadoxine-pyrimethamine (IPTp-SP)." | 3.72 | Knowledge of malaria influences the use of insecticide treated nets but not intermittent presumptive treatment by pregnant women in Tanzania. ( Drakeley, C; Marchant, T; Nganda, RY; Reyburn, H, 2004) |
| "Nias Island, off the north-western coast of Sumatra, Indonesia, was one of the first locations in which chloroquine-resistant Plasmodium vivax malaria was reported." | 3.71 | The drug sensitivity and transmission dynamics of human malaria on Nias Island, North Sumatra, Indonesia. ( Atmosoedjono, S; Baird, JK; Bangs, MJ; Fryauff, DJ; Leksana, B; Masbar, S; Nagesha, HS; Sismadi, P; Susanti, AI; Wiady, I, 2002) |
| "Since 1993 sulphadoxine/pyrimethamine (SP) has been used as the first-line drug for uncomplicated Plasmodium falciparum malaria in Malawi." | 3.71 | Therapeutic efficacy of sulphadoxine/pyrimethamine and susceptibility in vitro of P. falciparum isolates to sulphadoxine-pyremethamine and other antimalarial drugs in Malawian children. ( Bustos, MD; Butao, D; Chakanika, I; MacHeso, A; Matsuo, M; Takechi, M; Ziba, C; Zungu, IL, 2001) |
| "The prevalence of infection with malarial parasites and the incidence of anaemia and delivery of infants with low birthweight (LBW) were investigated in 575 Malawian mothers who received one, two or three doses of sulfadoxine-pyrimethamine (SP) during pregnancy." | 3.70 | An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi. ( Brabin, BJ; Broadhead, RL; Chimsuku, L; Kazembe, P; Russell, WB; Verhoeff, FH, 1998) |
| " Malaria prevalence at delivery remained high in HIV-infected women despite prior routine treatment with sulphadoxine-pyrimethamine in pregnancy There was no significant difference in parasite prevalence at delivery between women who did or did not use sulphadoxine-pyrimethamine." | 3.70 | Increased prevalence of malaria in HIV-infected pregnant women and its implications for malaria control. ( Brabin, BJ; Broadhead, RL; Chimsuku, L; Hart, CA; Kazembe, P; Verhoeff, FH, 1999) |
| " Seventy patients with Plasmodium falciparum malaria were included in a study of resistance to chloroquine and sulfadoxine-pyrimethamine therapy." | 3.70 | Chemotherapy of malaria and resistance to antimalarial drugs in Guayana area, Venezuela. ( Caraballo, A; Rodriguez-Acosta, A, 1999) |
| "Pyrimethamine, in combination with sulfadoxine, is currently one of the major alternative drugs used for the treatment of chloroquine-resistant Plasmodium falciparum malaria infections in Africa." | 3.70 | Molecular epidemiology of malaria in Yaounde, Cameroon IV. Evolution of pyrimethamine resistance between 1994 and 1998. ( Basco, LK; Ringwald, P, 1999) |
| "As chloroquine resistance spreads across Africa, the dihydrofolate reductase (DHFR) inhibitors pyrimethamine and proguanil are being used as alternative first-line drugs for the treatment and prevention of Plasmodium falciparum malaria." | 3.69 | Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. ( Bouare, M; Djimde, A; Doumbo, O; Plowe, CV; Wellems, TE, 1995) |
| "United States military personnel deployed to Somalia were at risk for malaria, including chloroquine-resistant Plasmodium falciparum malaria." | 3.69 | Malaria among United States troops in Somalia. ( Batchelor, R; Burans, JP; Iriye, C; Lobel, HO; Longer, CF; Magill, AJ; Rozmajzl, P; Sharp, TW; Smoak, B; Thornton, SA; Wallace, MR, 1996) |
| "Several reports have confirmed the existence of chloroquine resistant Plasmodium falciparum malaria in Bombay." | 3.69 | Efficacy of sulfadoxine-pyrimethamine in chloroquine resistant falciparum malaria in Bombay. ( Garg, MR; Gogtay, NJ; Kshirsagar, NA, 1996) |
| "In 1993, Malawi introduced sulphadoxine-pyrimethamine (SP) for the treatment of uncomplicated, Plasmodium falciparum malaria and became the first country in Africa to abandon chloroquine for first-time therapy." | 3.69 | Parasitological and haematological responses to treatment of Plasmodium falciparum malaria with sulphadoxine-pyrimethamine in southern Malawi. ( Brabin, BJ; Kachale, B; Kazembe, P; Masache, P; Van der Kaay, HJ; Verhoeff, FH, 1997) |
| " Chloroquine, quinine and pyrimethamine, administered after macrogametocytes of Plasmodium falciparum had been found in the blood smear, eliminated the parasites from the peripheral blood, but respiratory failure and treatment-resistant pneumonia occurred, leading to the adult respiratory distress syndrome (Morel stage 4)." | 3.68 | [Acute respiratory failure in tropical malaria during pregnancy. Successful treatment using extracorporeal CO2 elimination]. ( Benzing, A; Dippold, W; Grundmann, H; Knolle, P; Meyer zum Büschenfelde, KH; Neurath, M, 1993) |
| "The clinical and parasitologic efficacies of oral chloroquine phosphate, pyrimethamine/sulphadoxine and pyrimethamine/sulphalene in treating Plasmodium falciparum malaria were assessed in selected sites of northeastern Nigeria (Zone D of the Primary Health Care (PHC) Programme) using a 14-day standard in-vivo protocol during 1988-1990." | 3.68 | Efficacies of chloroquine, pyrimethamine/sulphadoxine and pyrimethamine/sulphalene against P. falciparum in northeastern Nigeria. ( Ameh, JO; Daniel, HI; Gadzama, NM; Molta, NB; Oguche, SO; Otu, TI; Watila, IM, 1992) |
| "Chlorproguanil is one of the antimalarial drugs developed in recent years which have shown promise for field use in malaria eradication campaigns." | 3.64 | Field trials with chlorproguanil in the prophylaxis of malaria in Ghana. ( CHARLES, LJ, 1961) |
| "During the preparatory phase of the Malaria Eradication Pilot Project in Ghana, a weekly pyrimethamine regimen was instituted at two hyperendemic villages, primarily to assess the reliability of self-administration techniques under local conditions." | 3.64 | The appearance of pyrimethamine resistance in Plasmodium falciparum following self-medication by a rural community in Ghana. ( BRADY, J; CHARLES, LJ; VAN DER KAAY, HJ; VINCKE, IH, 1962) |
| " Eleven volunteers received chloroquine in usually curative doses on a three-day schedule during acute clinical malaria attacks." | 3.64 | STUDIES ON A STRAIN OF CHLOROQUINE-RESISTANT PLASMODIUM FALCIPARUM FROM THAILAND. ( ALVING, AS; BREWER, GJ; MILLAR, JW; POWELL, RD, 1964) |
| "The authors describe a two-year investigation carried out on a group of Nigerian schoolchildren with the object of assessing the effect of suppressing malaria infection with pyrimethamine on the physical development of the African child." | 3.63 | Suppression of malaria with pyrimethamine in Nigerian schoolchildren. ( ARCHIBALD, HM; BRUCE-CHWATT, LJ, 1956) |
| "Intermittent preventive treatment of malaria among schoolchildren (IPTsc) reduces clinical malaria, asymptomatic parasitemia, and anemia." | 3.11 | Overall and Gender-Specific Effects of Intermittent Preventive Treatment of Malaria with Artemisinin-Based Combination Therapies among Schoolchildren in Mali: A Three-Group Open Label Randomized Controlled Trial. ( Bamadio, A; Chico, RM; Cohee, LM; Coumare, S; Dara, A; Diarra, M; Djimde, AA; Doumbo, OK; Kodio, A; Maiga, H; Opondo, C; Sagara, I; Sidibe, B; Tekete, M; Traore, OB; Traore, ZI, 2022) |
| "Children with sickle cell anemia (SCA) in areas of Africa with endemic malaria transmission are commonly prescribed malaria chemoprevention." | 3.11 | Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial. ( Clapp, S; Freedman, B; Green, CL; Kirui, JK; Korwa, S; Njuguna, FM; O'Meara, WP; Taylor, SM; Wu, A, 2022) |
| " After exclusion of blue urine, adverse events were similar across all groups (59 [74%] of 80 participants had 162 adverse events overall, 145 [90%] of which were mild)." | 2.87 | Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind, randomised controlled trial. ( Bousema, T; Bradley, J; Brown, JM; Chen, I; Diarra, K; Diawara, H; Dicko, A; Drakeley, C; Gosling, R; Hwang, J; Issiaka, D; Keita, S; Kone, DT; Lanke, K; Mahamar, A; McCulloch, C; Müller, O; Roh, ME; Sanogo, K; Soumare, HM; Srinivasan, V; Stone, WJR; Traore, SF, 2018) |
| "vivax malaria were treated with AS/SP." | 2.87 | Low risk of recurrence following artesunate-Sulphadoxine-pyrimethamine plus primaquine for uncomplicated Plasmodium falciparum and Plasmodium vivax infections in the Republic of the Sudan. ( Abdelbagi, H; Basheir, HM; Boshara, SA; Chen, I; Elobied, ME; Elsafi, HMH; Gosling, R; Gumaa, SA; Hamid, MMA; Hamid, T; Ley, B; Mahgoub, NS; Marfurt, J; Price, RN; Thriemer, K, 2018) |
| "Malaria is one of the most serious global problems." | 2.82 | The efficacy and safety of intermittent preventive treatment with sulphadoxine-pyrimethamine vs artemisinin-based drugs for malaria: a systematic review and meta-analysis. ( Chen, N; Chu, X; Feng, L; Li, M; Liu, Y; Wang, Q; Wang, S; Yan, P; Yang, K; Zhang, N; Zhang, Z, 2022) |
| "Asymptomatic falciparum malaria is associated with poorer cognitive performance in African schoolchildren and intermittent preventive treatment of malaria improves cognitive outcomes." | 2.82 | Malaria illness mediated by anaemia lessens cognitive development in younger Ugandan children. ( Bass, JK; Bigira, V; Boivin, MJ; Dorsey, G; Familiar-Lopez, I; Kamya, M; Kapisi, J; Muhindo, M; Nakasujja, N; Opoka, RO; Ruiseñor-Escudero, H; Sikorskii, A, 2016) |
| "falciparum malaria were recruited." | 2.80 | Efficacy of sulphadoxine-pyrimethamine + artesunate, sulphadoxine-pyrimethamine + amodiaquine, and sulphadoxine-pyrimethamine alone in uncomplicated falciparum malaria in Mali. ( Beavogui, AH; Dama, S; Dara, A; Dembele, D; Diallo, N; Djimde, AA; Doumbo, OK; Maiga, H; N'Dong, C; Niangaly, H; Sagara, I; Sangare, CP; Tekete, M; Toure, O; Traore, OB; Traore, ZI, 2015) |
| "Primaquine was well tolerated and could be administered along with an artemisinin combination therapy as the first-line therapy." | 2.78 | Nonrandomized controlled trial of artesunate plus sulfadoxine-pyrimethamine with or without primaquine for preventing posttreatment circulation of Plasmodium falciparum gametocytes. ( Anvikar, A; Juliano, JJ; MacDonald, PD; Meshnick, SR; Mishra, N; Poole, C; Schapira, A; Shah, NK; Srivastava, B; Valecha, N, 2013) |
| " Because of limited pharmacokinetic data and suggestions that higher milligram/kilogram pediatric doses than recommended should be considered, we assessed SDX/PYR disposition, randomized to conventional (25/1." | 2.76 | Pharmacokinetic properties of conventional and double-dose sulfadoxine-pyrimethamine given as intermittent preventive treatment in infancy. ( Davis, TM; Griffin, S; Ilett, KF; Kose, K; Moore, B; Mueller, I; Pitus, N; Salman, S; Siba, P; Winmai, J, 2011) |
| " SP pharmacokinetic parameters differed significantly among the study sites." | 2.75 | Pharmacokinetics of sulfadoxine and pyrimethamine in intermittent preventive treatment of malaria in pregnancy. ( Adam, I; Barnes, KI; Cassam, Y; Doumbo, O; Guirou, E; Kayentao, K; Little, F; Mauff, K; Nyunt, MM; Smith, P; Sullivan, D; Thuma, P; Traore, B; van Dijk, J, 2010) |
| "falciparum malaria were enrolled." | 2.75 | Therapeutic efficacy and effect on gametocyte carriage of an artemisinin and a non-based combination treatment in children with uncomplicated P. falciparum malaria, living in an area with high-level chloroquine resistance. ( Oguonu, T; Okafor, HU; Shu, EN, 2010) |
| "Amodiaquine was the most effective on fever." | 2.74 | Efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria: revisiting molecular markers in an area of emerging AQ and SP resistance in Mali. ( Beavogui, AH; Dama, S; Dembele, D; Dicko, A; Djimde, AA; Doumbo, OK; Fofana, B; Kone, A; Maiga, H; Ouologuem, D; Sagara, I; Tekete, M; Wele, M, 2009) |
| " Most common drug-related adverse events were gastrointestinal symptoms (such as vomiting and diarrhea) which were slightly higher in the AS-SMP 24-hour group." | 2.74 | Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial. ( Adam, I; Dara, N; Dicko, A; Dicko, YT; Djimdé, A; Doumbo, OK; Jansen, FH; Maiga, H; Mbacham, W; Rulisa, S; Sagara, I; Sissoko, K; Traore, OB, 2009) |
| " The main outcome measures for safety were incidences of post-treatment clinical and laboratory adverse events." | 2.74 | Artemisinin-naphthoquine combination (ARCO) therapy for uncomplicated falciparum malaria in adults of Papua New Guinea: a preliminary report on safety and efficacy. ( Geita, J; Hiawalyer, G; Hombhanje, FW; Jones, R; Kevau, I; Kuanch, C; Linge, D; Masta, A; Sapuri, M; Saweri, A; Toraso, S, 2009) |
| " Participants were actively monitored for adverse events for the first 14 days after each treatment, and then passively followed until their next study medication treatment, or withdrawal from study." | 2.73 | Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children. ( Clark, TD; Dorsey, G; Jagannathan, P; Kamya, MR; Maiteki-Sebuguzi, C; Njama-Meya, D; Nzarubara, B; Rosenthal, PJ; Staedke, SG; Talisuna, AO; Yau, VM, 2008) |
| "falciparum malaria was evaluated according to G6PD deficiency in a secondary analysis of an open-label, randomized clinical trial." | 2.73 | High risk of severe anaemia after chlorproguanil-dapsone+artesunate antimalarial treatment in patients with G6PD (A-) deficiency. ( Avellino, P; Bancone, G; d'Alessandro, U; Fanello, CI; Karema, C; Lee, SJ; Modiano, D; Uwimana, A, 2008) |
| " Adverse events and clinical and parasitological outcomes were recorded." | 2.73 | A randomised trial to assess the safety and efficacy of artemether-lumefantrine (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwanda. ( D'Alessandro, U; Fanello, CI; Karema, C; Ngamije, D; van Doren, W; Van Overmeir, C, 2007) |
| "Nearly all recurrences were due to new infections." | 2.73 | Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. ( Dokomajilar, C; Dorsey, G; Guiguemde, RT; Ouedraogo, JB; Rosenthal, PJ; Rouamba, N; Tinto, H; Zongo, I, 2007) |
| "Treatment with sulfadoxine-pyrimethamine was associated with an increase of gametocyte charge." | 2.73 | Efficacy of sulfadoxine-pyrimethamine, amodiaquine, and sulfadoxine-pyrimethamine-amodiaquine combination for the treatment of uncomplicated falciparum malaria in the urban and suburban areas of Brazzaville (Congo). ( Basco, LK; Casimiro, PN; Mallanda, G; Malonga, DA; Matondo Maya, DW; Mayengue, PI; Miakassissa-Mpassi, V; Ndounga, M; Nsonde-Ntandou, F; Ntoumi, F; Ringwald, P; Tahar, R, 2007) |
| "Chloroquine (CQ) is an effective treatment of choice for vivax malaria in most settings, but with the spread of CQ-resistant Plasmodium falciparum, many countries now use artemisinin-based combination therapy for treatment of falciparum malaria." | 2.73 | Sulfadoxine-pyrimethamine plus artesunate compared with chloroquine for the treatment of vivax malaria in areas co-endemic for Plasmodium falciparum and P. vivax: a randomised non-inferiority trial in eastern Afghanistan. ( Durrani, N; Kolaczinski, K; Rahim, S; Rowland, M, 2007) |
| "06 liters/h/kg), the median distribution half-life (t 1/2 alpha) was 0." | 2.73 | Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. ( Batty, KT; Davis, TM; Ilett, KF; Karunajeewa, HA; Lammey, J; Law, I; Lin, E; Mueller, I; Page-Sharp, M; Siba, P, 2008) |
| "vivax malaria were treated according to the new policy guidelines (i." | 2.73 | Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against Plasmodium falciparum and P. vivax malaria in Papua New Guinea. ( Beck, HP; Genton, B; Goroti, M; Maku, P; Marfurt, J; Müeller, I; Reeder, JC; Sie, A, 2007) |
| " However, the optimal dosing regimen in settings in which human immunodeficiency virus (HIV) is highly prevalent among pregnant women remains controversial." | 2.73 | Two-dose versus monthly intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine in HIV-seropositive pregnant Zambian women. ( Chalwe, V; Champo, D; Chilengi, R; Gill, CJ; Hamer, DH; Macleod, WB; Mubikayi, L; Mukwamataba, D; Mulele, CK; Mulenga, M; Mwanakasale, V; Mwananyanda, L; Thea, DM, 2007) |
| " No significant adverse event attributable to any of the study drugs was found." | 2.73 | Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. ( Dama, S; Dembele, D; Dicko, A; Djimdé, AA; Doumbo, OK; Fofana, B; Ouologuem, D; Sagara, I; Sidibe, B; Toure, S, 2008) |
| "The main objective of this work was to assess the relative bioavailability of two tablet formulations containing sulfadoxine/pyrimethamine (SP) and marketed in Tanzania." | 2.72 | Existence of antimalarial formulations with low bioavailability in Tanzania. ( Ericsson, O; Gustafsson, LL; Justin-Temu, M; Massele, A; Minzi, OM, 2006) |
| "36), there was a significant reduction in hospital admissions for anemia during the month after dosing for both the first and second dose." | 2.72 | Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial. ( Aide, P; Alonso, P; Aponte, JJ; DgeDge, M; Dobaño, C; Espasa, M; Mabunda, S; Macete, E; Mandomando, I; Menendez, C; Sanz, S; Sigauque, B, 2006) |
| "Amodiaquine (AQ) is an affordable compound, chemically related to chloroquine (CQ) but often effective against CQ resistant Plasmodium falciparum." | 2.72 | Improved efficacy with amodiaquine instead of chloroquine in sulfadoxine/pyrimethamine combination treatment of falciparum malaria in Uganda: experience with fixed-dose formulation. ( Aguttu, C; Anokbonggo, WW; Chiria, J; Gustafsson, LL; Hellgren, U; Obua, C; Ogwal-Okeng, JW, 2006) |
| "Quinine remains the treatment of choice in hospitalized malaria cases; however, adverse reactions and the long treatment duration of 7 days often hamper its adequate use." | 2.72 | Short course of quinine plus a single dose of sulfadoxine/pyrimethamine for Plasmodium falciparum malaria. ( Issifou, S; Kremsner, PG; Matsiegui, PB; Missinou, MA; Necek, M, 2006) |
| " The findings indicate that - at least at the dosing regimen used in the present study and among children with acute, uncomplicated, P." | 2.71 | A randomized comparison of chloroquine and chloroquine plus ketotifen in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children. ( Sowunmi, A, 2003) |
| "The effectiveness of chloroquine or sulfadoxine-pyrimethamine administered with artesunate for treating uncomplicated falciparum malaria was assessed in 2 Vietnamese provinces where the sensitivity of parasites in vitro to conventional therapies had increased with the removal of drug pressure." | 2.71 | Treatment of uncomplicated falciparum malaria in southern Vietnam: can chloroquine or sulfadoxine-pyrimethamine be reintroduced in combination with artesunate? ( Cox-Singh, J; Davis, TM; Doan, HN; Hewitt, S; Le, DC; Nguyen, MH; Nguyen, TH; Tran, BK; Tran, QT; Vo, NP, 2003) |
| "Congo is facing frequent failures of treatment of Plasmodium falciparum malaria with chloroquine (CQ), which is still recommended and used as a first-line drug." | 2.71 | Efficacy of sulfadoxine/pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria in Republic of Congo. ( Ebata-Mongo, S; Kiori, J; Le Bras, J; Louya, F; Malanda, M; Malonga, DA; Mouata, AM; Nsimba, B; Oko-Ossho, J; Yocka, D, 2004) |
| " In 2002, we assessed the efficacy of SP alone and combined with amodiaquine (AQ/SP) or chloroquine (CQ/SP) in Ugandan children with uncomplicated falciparum malaria." | 2.71 | Efficacy of sulphadoxine-pyrimethamine alone or combined with amodiaquine or chloroquine for the treatment of uncomplicated falciparum malaria in Ugandan children. ( Bakyaita, N; D'Alessandro, U; Egwang, TG; Langi, P; Mutabingwa, TK; Nalunkuma-Kazibwe, A; Talisuna, AO; Van Marck, E; Watkins, WW, 2004) |
| "Chloroquine resistance was detected at the RI level in 29 cases (13%) and RII level in 8 cases (4%)." | 2.71 | The drug sensitivities of Plasmodium falciparum in the Sonitpur district, Assam, India. ( Baruah, I; Das, SC; Talukdar, PK, 2005) |
| "Quinine (30 mg/kg) was totally effective in curing patients in all three areas." | 2.70 | In vivo drug resistance of falciparum malaria in mining areas of Venezuela. ( Aché, A; Díaz, O; Escorihuela, M; Izarra, E; Matos, A; Miranda, L; Páez, E; Pérez, W; Vivas, E, 2002) |
| " In a pilot study carried out in Gabon, a reduced dosage of the triple combination with a mean of 1 mg/kg of mefloquine/2 mg/kg of sulfadoxine/0." | 2.69 | Malaria chemotherapy trial at a minimal effective dose of mefloquine/sulfadoxine/pyrimethamine compared with equivalent doses of sulfadoxine/pyrimethamine or mefloquine alone. ( Handschin, J; Kremsner, PG; Lehman, LG; Lell, B; Schmidt-Ott, JR; Sturchler, D, 1998) |
| "Atovaquone-proguanil was well tolerated and more effective than chloroquine or chloroquine-sulfadoxine-pyrimethamine for treatment of multidrug-resistant falciparum malaria in the Philippines." | 2.69 | Atovaquone-proguanil compared with chloroquine and chloroquine-sulfadoxine-pyrimethamine for treatment of acute Plasmodium falciparum malaria in the Philippines. ( Bustos, DG; Canete-Miguel, E; Canfield, CJ; Hutchinson, DB, 1999) |
| "Halofantrine is a viable drug in the treatment of uncomplicated P." | 2.68 | Efficacy of halofantrine in the treatment of uncomplicated falciparum malaria. ( Chunge, C; Luta, M; Mbori-Ngacha, DA; Muga, RO; Oloo, AJ; Onyango, FE, 1995) |
| "Halofantrine was the most efficacious drug with 82% of the cases cured followed by fansidar(R)(62%), amodiaquine (55%) and chloroquine (29%)." | 2.68 | A randomised controlled trial to assess the relative efficacy of chloroquine, amodiaquine, halofantrine and Fansidar in the treatment of uncomplicated malaria in children. ( Anabwani, GM; Esamai, FO; Menya, DA, 1996) |
| " There is potential advantage of this combination therapy in reducing the dosage and treatment period of artemisinin derivative, which is therefore likely to improve complaince in clinical practice." | 2.68 | Artemether-pyrimethamine in the treatment of pyrimethamine-resistant falciparum malaria. ( Kanda, T; Karbwang, J; Na-Bangchang, K; Suprakob, K; Tan-ariya, P; Thanavibul, A; Tipwangso, P, 1996) |
| "Artemether was well tolerated." | 2.67 | Artemether in moderately severe and cerebral malaria in Nigerian children. ( Adio, R; Oduola, AM; Omokhodion, SJ; Salako, LA; Sowunmi, A; Walker, O, 1994) |
| "Treatment with chloroquine failed to produce either a durable clinical improvement or optimal hematologic recovery." | 2.67 | Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. ( Bloland, PB; Campbell, CC; Kazembe, PN; Lackritz, EM; Steketee, R; Were, JB, 1993) |
| "In a randomized controlled study of malaria prophylaxis, dapsone-pyrimethamine at a weekly dosage of dapsone 50-100 mg with pyrimethamine 6." | 2.67 | Efficacy of dapsone with pyrimethamine (Maloprim) for malaria prophylaxis in Maputo, Mozambique. ( Pividal, J; Schapira, A; Streat, E; Viktinski, V, 1992) |
| "Amodiaquine and FansidarR were fully effective in eliminating asexual parasitaemia from the blood in all the cases during the seven days of follow-up." | 2.67 | Falciparum malaria fully cleared by amodiaquine, pyrimethamine-sulfadoxine and pyrimethamine-sulfalene in areas of chloroquine resistance in Dodoma, Tanzania. ( Irare, SG; Lemnge, MM; Mhina, JI, 1991) |
| "Intermittent screening and treatment in pregnancy (ISTp) is an alternative to IPTp that could reduce unnecessary antenatal drug exposure and resistance risk, but it is not recommended with current, insensitive screening tests." | 2.55 | Prevention and control of malaria in pregnancy - new threats, new opportunities? ( Rogerson, SJ; Unger, HW, 2017) |
| " The objectives of this review are to summarize and evaluate published literature reporting the pharmacokinetic parameters of artemisinin-based combinations used to treat P." | 2.49 | Pharmacokinetic profile of artemisinin derivatives and companion drugs used in artemisinin-based combination therapies for the treatment of Plasmodium falciparum malaria in children. ( Ensom, MH; Pawluk, SA; Wilby, KJ, 2013) |
| " In the second and third trimesters, AL was not associated with increased adverse pregnancy outcomes as compared with quinine or sulphadoxine-pyrimethamine, showed improved tolerability relative to quinine, and its efficacy was non-inferior to quinine." | 2.48 | A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy. ( D'Alessandro, U; Hamed, K; Juma, E; Kayentao, K; Manyando, C; Okafor, HU, 2012) |
| "Continued use of chloroquine for treatment of P falciparum malaria in India will likely be ineffective." | 2.47 | Antimalarial drug resistance of Plasmodium falciparum in India: changes over time and space. ( Arora, U; Dash, AP; Dhillon, GP; Meshnick, SR; Shah, NK; Valecha, N, 2011) |
| " Data from the trials for incidence of clinical malaria, risk of anaemia (packed-cell volume <25% or haemoglobin <80 g/L), and incidence of hospital admissions and adverse events in infants up to 12 months of age were reanalysed by use of standard outcome definitions and time periods." | 2.45 | Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. ( Adjei, S; Alonso, P; Anemana, S; Aponte, JJ; Breckenridge, A; Carneiro, I; Chandramohan, D; Critchley, J; Danquah, I; Dodoo, A; Egan, A; Greenwood, B; Grobusch, MP; Issifou, S; Kobbe, R; Kremsner, PG; Lell, B; Macete, E; May, J; Menendez, C; Mockenhaupt, F; Mshinda, H; Newman, RD; Owusu-Agyei, S; Premji, Z; Sanz, S; Schellenberg, D; Sevene, E; Slutsker, L; Soulaymani-Becheikh, R; Tanner, M; Winstanley, P, 2009) |
| " This review evaluates the toxicity data of sulfadoxine/pyrimethamine, including severe cutaneous adverse reactions, teratogenicity and alterations in bilirubin metabolism." | 2.44 | Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment. ( Newman, RD; Parise, ME; Peters, PJ; Thigpen, MC, 2007) |
| " Chemoprophylaxis or intermittent preventive treatment (IPT) with an effective antimalarial can ameliorate the adverse effects of malaria during pregnancy." | 2.42 | Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum-endemic sub-Saharan Africa. ( Nahlen, B; Newman, RD; Parise, ME; Slutsker, L; Steketee, RW, 2003) |
| "Malaria is frequently a deadly disease, particularly in tropical countries of the world where this protozoan infection is endemic." | 2.41 | Malaria: a rising incidence in the United States. ( Broder, JS; Colletti, JE; Geroff, AJ; Grundmann, KA; Hanna, JR; Jerrard, DA; Mattu, A, 2002) |
| "Malaria is the most important emergency in people returning from tropical countries." | 2.38 | [Malaria: the most important emergency in subjects returning from the tropics]. ( Schubarth, P, 1993) |
| "007) and dosage (p = 0." | 1.72 | Intermittent preventive treatment with Sulphadoxine-Pyrimethamine (IPTp-SP) is associated with protection against sub-microscopic P. falciparum infection in pregnant women during the low transmission dry season in southwestern Cameroon: A Semi - longitudi ( Achidi, EA; Amambua-Ngwa, A; Anchang-Kimbi, JK; Apinjoh, TO; Chi, HF; Dionne-Odom, J; Kwi, PN; Mayaba, JM; Moyeh, MN; Ntui, VN; Tangi, LN; Tita, ATN; Titanji, VPK; Toussi, CT, 2022) |
| "Intermittent preventative treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) was documented and prompt treatment regardless of symptoms given upon malaria diagnosis." | 1.62 | Malaria Infection Is Common and Associated With Perinatal Mortality and Preterm Delivery Despite Widespread Use of Chemoprevention in Mali: An Observational Study 2010 to 2014. ( Andemel, N; Attaher, O; Barry, A; Dembele, AB; Diarra, BS; Dicko, A; Duffy, PE; Fried, M; Gaoussou, S; Keita, S; Mahamar, A; Sidibe, Y; Swihart, B; Traore, M, 2021) |
| " Suboptimal dosing in children may lead to treatment failure and increased resistance." | 1.48 | Population Pharmacokinetic Properties of Sulfadoxine and Pyrimethamine: a Pooled Analysis To Inform Optimal Dosing in African Children with Uncomplicated Malaria. ( Allen, EN; Barnes, KI; Bell, DJ; de Kock, M; Denti, P; Djimde, AA; Tarning, J; Tekete, MM; Ward, SA; Workman, L, 2018) |
| " Furthermore, doxycycline has anti-malarial properties and is already recommended as prophylaxis for travellers and for treatment of falciparum malaria in combination with other anti-malarial drugs." | 1.48 | Has doxycycline, in combination with anti-malarial drugs, a role to play in intermittent preventive treatment of Plasmodium falciparum malaria infection in pregnant women in Africa? ( Boxberger, M; Gaillard, T; Madamet, M; Pradines, B, 2018) |
| " It was nongenotoxic in an Ames assay, an in vitro micronucleus assay, and an in vivo rat micronucleus assay when dosed orally up to 2000 mg/kg." | 1.46 | Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate. ( Berry, P; Campo, B; Cao, J; Ciaravino, V; Easom, EE; Erve, JCL; Freund, YR; Gamo, FJ; Guo, D; Jacobs, RT; Plattner, JJ; Rosenthal, PJ; Sanz, LM; Zhang, YK, 2017) |
| "The burden of falciparum malaria is especially high in sub-Saharan Africa." | 1.46 | Pooled-DNA sequencing identifies genomic regions of selection in Nigerian isolates of Plasmodium falciparum. ( Amambua-Ngwa, A; Awolola, TS; Idowu, ET; Olukosi, YA; Oyebola, KM, 2017) |
| "Despite extensive use and accumulated evidence of safety, there have been few pharmacokinetic studies from which appropriate chloroquine (CQ) dosing regimens could be developed specifically for pregnant women." | 1.46 | Optimal antimalarial dose regimens for chloroquine in pregnancy based on population pharmacokinetic modelling. ( Baiwog, F; Davis, TME; Ilett, KF; Karunajeewa, HA; Kose, K; Mueller, I; Page-Sharp, M; Rogerson, SJ; Salman, S; Siba, PM, 2017) |
| "Chloroquine treatment possibly resulted in the development of pfcrt 72-76 CVIET." | 1.46 | Unexpected selections of Plasmodium falciparum polymorphisms in previously treatment-naïve areas after monthly presumptive administration of three different anti-malarial drugs in Liberia 1976-78. ( Björkman, A; Jovel, IT; Mårtensson, A; Roper, C; Ursing, J, 2017) |
| " Median parasite clearance half-life was 1." | 1.43 | In Vivo Efficacy and Parasite Clearance of Artesunate + Sulfadoxine-Pyrimethamine Versus Artemether-Lumefantrine in Mali. ( Benoit-Vical, F; Berry, A; Cissé, NH; Coulibaly, CO; Dara, A; Djimdé, AA; Doumbo, OK; Guindo, CO; Niaré, K; Ringwald, P; Sagara, I; Sissoko, MS, 2016) |
| " Compartmental pharmacokinetic models were developed using a population-based approach." | 1.42 | Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women. ( Batty, KT; Benjamin, JM; Davis, TM; Lorry, L; Moore, BR; Mueller, I; Page-Sharp, M; Robinson, LJ; Salman, S; Siba, PM; Tawat, S; Yadi, G, 2015) |
| "Chloroquine failure rate was high which was well above the WHO recommended cut off threshold for drug policy change (> 10%), Sulfadoxine- Pyrimethamine can be used in place of Chloroquine as the first line drug in uncomplicated P." | 1.42 | Comparative Study of Effectiveness and Resistance Profile of Chloroquine and Sulfadoxine-Pyrimethamine in Uncomplicated Plasmodium falciparum Malaria in Kolkata. ( Basu, A; Guha, SK; Saha, S, 2015) |
| "falciparum malaria were obtained in four provinces of Afghanistan." | 1.39 | Prevalence of antifolate resistance mutations in Plasmodium falciparum isolates in Afghanistan. ( Awab, GR; Day, NP; Dondorp, AM; Imwong, M; Jamornthanyawat, N; Pukrittayakamee, S; White, NJ; Woodrow, CJ; Yamin, F, 2013) |
| "falciparum malaria were collected: 135 from Tumaco and 206 from Tierralta." | 1.39 | Haplotypes associated with resistance to sulfadoxine-pyrimethamine in Plasmodium falciparum in two malaria endemic locations in Colombia. ( Barrera, SM; Cucunubá, ZM; Guerra, AP; Hernández, DC; Nicholls, RS, 2013) |
| "Malaria during pregnancy is associated with low birth weight and increased perinatal mortality, especially among primigravidae." | 1.39 | Effectiveness of intermittent preventive treatment with sulfadoxine-pyrimethamine during pregnancy on maternal and birth outcomes in Machinga district, Malawi. ( Ali, D; Gutman, J; Mathanga, DP; Mwandama, D; Skarbinski, J; Wiegand, RE, 2013) |
| " However, information on pharmacokinetic disposition of SDX-pyrimethamine in children is limited." | 1.38 | Pharmacokinetic disposition of sulfadoxine in children with acute uncomplicated falciparum malaria treated with sulfadoxine-pyrimethamine in South West Nigeria. ( Gbotosho, GO; Happi, CT; Oduola, A; Sijuade, A; Sowunmi, A, 2012) |
| " The treatment of malaria in young children and the relative benefits of age- and weight-based dosing need further exploration." | 1.38 | Monitoring antimalarial drug resistance in India via sentinel sites: outcomes and risk factors for treatment failure, 2009-2010. ( Anvikar, AR; Arora, U; Bhatt, RM; Das, MK; Dhariwal, AC; Ghosh, SK; Gupta, R; Kaitholia, K; Kumar, A; Mishra, N; Shah, NK; Sharma, SK; Singh, JP; Sonal, GS; Srivastava, B; Valecha, N, 2012) |
| " There was significant association between gravidity and SP dosage taken (Pearson χ2 = 18." | 1.37 | The effectiveness and perception of the use of sulphadoxine-pyrimethamine in intermittent preventive treatment of malaria in pregnancy programme in Offinso district of Ashanti region, Ghana. ( Browne, E; Lawson, B; Tutu, EO, 2011) |
| "falciparum malaria were recruited and treated with CQ+SP." | 1.36 | Monitoring of malaria parasite resistance to chloroquine and sulphadoxine-pyrimethamine in the Solomon Islands by DNA microarray technology. ( Ballif, M; Beck, HP; Crameri, A; Fafale, A; Felger, I; Genton, B; Hii, J; Marfurt, J, 2010) |
| "1%) were the three main molecules which account for antimalarial self-treatment However the use of these molecules was inappropriate regarding the dosage (41." | 1.35 | [Self-medication in the treatment of acute malaria: study based on users of private health drug stores in Ouagadougou, Burkina Faso]. ( Diarra, M; Guissou, IP; Ouédraogo, LT; Somé, IT, 2008) |
| "Parasite recrudescences in 33 consecutive paired episodes during the same pregnancy were identified by msp1 and msp2 genotyping." | 1.35 | Sub-microscopic infections and long-term recrudescence of Plasmodium falciparum in Mozambican pregnant women. ( Alonso, PL; Aponte, JJ; Bardají, A; Cisteró, P; Mandomando, I; Mayor, A; Menéndez, C; Puyol, L; Sanz, S; Serra-Casas, E; Sigauque, B, 2009) |
| "Intermittent preventive treatment in pregnancy (IPTp) is used to prevent Plasmodium falciparum malaria." | 1.35 | Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment. ( Bolla, MC; Duffy, PE; Fried, M; Harrington, WE; Muehlenbachs, A; Mutabingwa, TK; Sorensen, B, 2009) |
| " We investigated whether the in vivo efficacy of chloroquine (CQ) in children aged 6-59 months with uncomplicated malaria differed in 9 villages that had benefited from long-term use of insecticide-treated curtains (ITCs) and in 9 nearby non-ITC villages." | 1.34 | Sustained use of insecticide-treated curtains is not associated with greater circulation of drug-resistant malaria parasites, or with higher risk of treatment failure among children with uncomplicated malaria in Burkina Faso. ( Cousens, SN; Diallo, DA; Greenwood, BM; Ilboudo-Sanogo, E; Konaté, AT; Nebié, I; Ord, R; Pota, H; Roper, C; Sutherland, C, 2007) |
| "Chloroquine has been the first line drug of treatment for malaria in Zimbabwe until a recent adoption of an interim policy to treat using a combination of chloroquine (CQ) and sulfadoxine/pyrimethamine (SP)." | 1.34 | High prevalence of molecular markers for resistance to chloroquine and pyrimethamine in Plasmodium falciparum from Zimbabwe. ( Chivenga, J; Gemperli, A; Kumar, N; Mbedzi, J; Mlambo, G; Mutambu, SL; Soko, W; Sullivan, D, 2007) |
| "Falciparum Malaria is hyperendemic in southern Nigeria and chloroquine resistance is an increasing problem." | 1.33 | Efficacy of amodiaquine in uncomplicated falciparum malaria in Nigeria in an area with high-level resistance to chloroquine and sulphadoxine/pyrimethamine. ( Göbels, K; Graupner, J; Grobusch, MP; Häussinger, D; Lund, A; Richter, J, 2005) |
| "Malaria during pregnancy is associated with serious adverse effects; these could be avoided with effective treatment." | 1.33 | Artesunate plus sulfadoxine-pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria during pregnancy in eastern Sudan. ( Abdalla, MA; Adam, I; Ali, DM, 2006) |
| "To overcome the declining efficacy of the 4-aminoquinolines in Papua New Guinea, sulfadoxine/pyrimethamine (SP) was combined with the 4-aminoquinolines as the first line treatment for falciparum malaria since 2000." | 1.33 | Rapid selection of dhfr mutant allele in Plasmodium falciparum isolates after the introduction of sulfadoxine/pyrimethamine in combination with 4-aminoquinolines in Papua New Guinea. ( Björkman, A; Hwaihwanje, I; Kaneko, A; Kobayakawa, T; Mita, T; Osawa, H; Takahashi, N; Tanabe, K; Tsukahara, T, 2006) |
| "Sulfadoxine-pyremethamine treatment alone cured 68." | 1.33 | The efficacy of sulfadoxine-pyrimethamine alone and in combination with chloroquine for malaria treatment in rural Eastern Sudan: the interrelation between resistance, age and gametocytogenesis. ( A-Elbasit, IE; Alifrangis, M; Elbashir, MI; Giha, HA; Khalil, IF, 2006) |
| "Sulfadoxine-pyrimethamine has been widely used as first-line therapy for uncomplicated malaria throughout sub-Saharan Africa." | 1.33 | Antifolate resistance in Plasmodium falciparum: multiple origins and identification of novel dhfr alleles. ( Barnwell, JW; Bloland, P; Escalante, AA; Hamel, M; Huber, C; McCollum, AM; Ouma, P; Poe, AC; Shi, YP; Slutsker, L; Udhayakumar, V; Vulule, J; Zhou, Z, 2006) |
| "Amodiaquine was effective at all study sites (proportion of failures, 7." | 1.33 | Molecular epidemiology of malaria in Cameroon. XXI. Baseline therapeutic efficacy of chloroquine, amodiaquine, and sulfadoxine-pyrimethamine monotherapies in children before national drug policy change. ( Abodo, RT; Basco, LK; Ndounga, M; Ngane, VF; Same-Ekobo, A; Soula, G; Youmba, JC, 2006) |
| "Our objective was to characterize the pharmacokinetic properties of sulfadoxine-pyrimethamine in African adults and children with acute falciparum malaria." | 1.33 | Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. ( Barnes, KI; Evans, A; Little, F; Smith, PJ; Watkins, WM; White, NJ, 2006) |
| " Severe malaria in rural areas of Sudan, where facilities for the safe and effective use of parenteral quinine are lacking, is a frequent problem." | 1.32 | Descriptive study on the efficacy and safety of artesunate suppository in combination with other antimalarials in the treatment of severe malaria in Sudan. ( Alkadru, AM; Awad, MI; Baraka, OZ; Behrens, RH; Eltayeb, IB, 2003) |
| "When pyrimethamine was combined with sulfadoxine, the mean EC(50) value decreased to less than one tenth of the pyrimethamine alone level." | 1.32 | High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi. ( Bergqvist, Y; Björkman, A; Bwijo, B; Kaneko, A; Kobayakawa, T; Lum, JK; Mita, T; Moriyama, Y; Takahashi, N; Takechi, M; Tsukahara, T; Zungu, IL, 2003) |
| "Sulfadoxine-pyrimethamine was first introduced for treatment of malaria in Africa during the early 1980s for cases when chloroquine treatment failed, and has since become the first-line treatment in many countries." | 1.32 | Antifolate antimalarial resistance in southeast Africa: a population-based analysis. ( Bredenkamp, B; Chandramohan, D; Drakeley, C; Gumede, J; Mosha, F; Pearce, R; Roper, C; Sharp, B, 2003) |
| "falciparum malaria were initially treated with chloroquine (CQ)." | 1.32 | Therapeutic efficacies of antimalarial drugs in the treatment of uncomplicated, Plasmodium falciparum malaria in Assam, north-eastern India. ( Barman, K; Dev, V; Phookan, S, 2003) |
| "Atovaquone-proguanil has recently been introduced for the treatment and prophylaxis of malaria." | 1.32 | Short communication: Prevalence of mutations associated with resistance to atovaquone and to the antifolate effect of proguanil in Plasmodium falciparum isolates from northern Ghana. ( Bienzle, U; Ehrhardt, S; Jelinek, T; Mockenhaupt, FP; Muehlen, M; Otchwemah, R; Schreiber, J, 2004) |
| "Chloroquine treatment failed in 23 children (76." | 1.32 | Plasmodium falciparum resistant to chloroquine and to pyrimethamine in Comoros. ( Ariey, F; Bedja, SA; Mercereau-Puijalon, O; Migliani, R; Raherinjafy, RH; Randrianarivelojosia, M, 2004) |
| "Chloroquine treatment resulted in clinical failure in 33% (n = 60) and 51% (n = 49) of the patients in Merca and Gabiley respectively." | 1.31 | Therapeutic efficacy of chloroquine and sulfadoxine/pyrimethamine against Plasmodium falciparum infection in Somalia. ( Abdillahi, A; Duale, ON; Hassan, AM; Ismail, AN; Mohamed, A; Warsame, A; Warsame, M, 2002) |
| " There were no adverse effects experienced by the patients." | 1.31 | A safety and efficacy trial of artesunate, sulphadoxine-pyrimethamine and primaquine in P falciparum malaria. ( Faizal, HM; Fernando, WP; Galappaththy, G; Weerasinghe, KL; Wickremasinghe, AR; Wickremasinghe, DR, 2002) |
| "Chloroquine was thus an ineffective therapy for P." | 1.31 | Chloroquine or sulfadoxine-pyrimethamine for the treatment of uncomplicated, Plasmodium falciparum malaria during an epidemic in Central Java, Indonesia. ( Baird, JK; Bangs, MJ; Barcus, MJ; Basuki, W; Edstein, MD; Lacy, MD; Laksana, B; Maguire, JD; Marwoto, H; Masbar, S; Sismadi, P; Susanti, I; Tjokrosonto, S; Wiady, I, 2002) |
| "Amodiaquine was 3." | 1.31 | In vitro sensitivity of Plasmodium falciparum to amodiaquine compared with other major antimalarials in Madagascar. ( Ariey, F; Duchemin, JB; Harisoa, JL; Mauclere, P; Pietra, V; Rabarijaona, LP; Raharimalala, LA; Rakotomanana, F; Ranaivo, L; Randrianarivelojosia, M; Robert, V, 2002) |
| "Pyronaridine was the most effective gametocytocidal drug against P." | 1.31 | Gametocytocidal activity of pyronaridine and DNA topoisomerase II inhibitors against multidrug-resistant Plasmodium falciparum in vitro. ( Auparakkitanon, S; Chavalitshewinkoon-Petmitr, P; Pongvilairat, G; Wilairat, P, 2000) |
| "Amodiaquine has several advantages over sulfadoxine-pyrimethamine combination and may be considered to be an effective drug in an endemic zone with a moderate level of chloroquine resistance." | 1.31 | Chemoresistance of Plasmodium falciparum in the urban region of Yaounde, Cameroon. Part 2: Evaluation of the efficacy of amodiaquine and sulfadoxine-pyrimethamine combination in the treatment of uncomplicated Plasmodium falciparum malaria in Yaounde, Came ( Basco, LK; Keundjian, A; Ringwald, P; Same Ekobo, A, 2000) |
| " From September to December 1998, 598 children with uncomplicated malaria were treated; 135 received chloroquine (CQ) alone, 276 received pyrimethamine/sulfadoxine (Fansidar, PSD) alone, 113 received PSD with a single dose of artesunate (PSD + 1ART) and 74 received PSD combined with three doses of artesunate (PSD + 3ART)." | 1.31 | Parasitaemia and gametocytaemia after treatment with chloroquine, pyrimethamine/sulfadoxine, and pyrimethamine/sulfadoxine combined with artesunate in young Gambians with uncomplicated malaria. ( Coleman, R; Doherty, T; Jawara, M; Targett, G; von Seidlein, L; Walraven, G, 2001) |
| "Pyrimethamine use was associated with increased frequencies of Asn-108 and Arg-59 but not of Ile-51 or Thr-108." | 1.31 | Plasmodium falciparum dihydrofolate reductase alleles and pyrimethamine use in pregnant Ghanaian women. ( Bienzle, U; Böhme, T; Eggelte, TA; Mockenhaupt, FP; Thompson, WN, 2001) |
| " This malaria parasite was sensitive to standard dosage of either chloroquine or sulphadoxine-pyrimethamine." | 1.30 | Malaria in Mvumi, central Tanzania and the in vivo response of Plasmodium falciparum to chloroquine and sulphadoxine pyrimethamine. ( Mboera, LE; Ndawi, BT; Wakibara, JV, 1997) |
| " Chemoprophylaxis was given to both the groups at weekly intervals using age adjusted dosage of Pyrixine tablet (sulfadoxine-pyrimethamine)." | 1.30 | The use of personal protective measures in control of malaria in a defined community. ( Kyaw, MP; Lin, H; Linn, N; Lwin, M; Maung, NS; Ohn, M; Oo, T; Soe, K, 1997) |
| "falciparum malaria were treated with PS and monitored for 56 days." | 1.30 | Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali. ( Cortese, JF; Coulibaly, Y; Diakité, M; Diallo, M; Dicko, A; Diourté, Y; Djimdé, A; Doumbo, OK; Plowe, CV; Sagara, I, 1999) |
| "Chloroquine failure was found in 43% of the children." | 1.30 | Current clinical efficacy of chloroquine for the treatment of Plasmodium falciparum infections in urban Dar es Salaam, United Republic of Tanzania. ( Makwaya, C; Minjas, JN; Premji, Z, 1999) |
| "Chloroquine was prescribed at 25 mg/kg for 3 days in febrile patients with uncomplicated P." | 1.30 | [Chloroquine sensitivity of Plasmodium falciparum at the Gamkalley Clinic and the Nigerian armed forces PMI (Niamey, Niger)]. ( Ali, I; Bendavid, C; Condomines, P; Crassard, N; Djermakoye, F; Faugère, B; Parola, P, 1999) |
| "Twenty patients with severe malaria (17 cerebral malaria and 3 severe anaemia) were studied." | 1.29 | Severe malaria in children at Port Moresby General Hospital, Papua New Guinea. ( Brown, N, 1995) |
| "Fever was the only clinical manifestation attributable to parasitemia and only when the parasite density was > or = 5000/microL." | 1.29 | Impact of transmission intensity and age on Plasmodium falciparum density and associated fever: implications for malaria vaccine trial design. ( Bales, JD; Beadle, C; Beier, JC; Chumo, DK; Hoffman, SL; McElroy, PD; Oloo, AJ; Onyango, FK; Oster, CN; Sherwood, JA, 1995) |
| "Treatment with diazepam, haloperidol and thioridazine achieved relief of the severe symptoms after 4 days." | 1.29 | [Mefloquine and sulfadoxine/pyrimethamine overdose in malaria tropica]. ( Bergqvist, Y; Breyer, S; Burgmann, H; Feistauer, S; Feucht, M; Graninger, W; Hellgren, U; Uhl, F; Winkler, S, 1993) |
| " Increasing the drug dosage does not overcome the resistance." | 1.24 | The development of pyrimethamine resistance by Plasmodium falciparum. ( BURGESS, RW; YOUNG, MD, 1959) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (1.51) | 18.7374 |
| 1990's | 164 (15.49) | 18.2507 |
| 2000's | 496 (46.84) | 29.6817 |
| 2010's | 298 (28.14) | 24.3611 |
| 2020's | 85 (8.03) | 2.80 |
| Authors | Studies |
|---|---|
| Tarnchompoo, B | 1 |
| Sirichaiwat, C | 1 |
| Phupong, W | 1 |
| Intaraudom, C | 1 |
| Sirawaraporn, W | 2 |
| Kamchonwongpaisan, S | 9 |
| Vanichtanankul, J | 1 |
| Thebtaranonth, Y | 1 |
| Yuthavong, Y | 8 |
| Baniecki, ML | 1 |
| Wirth, DF | 6 |
| Clardy, J | 2 |
| Savini, H | 1 |
| Bogreau, H | 3 |
| Bertaux, L | 1 |
| Bouchiba, H | 2 |
| Kraemer, P | 1 |
| Parzy, D | 3 |
| Garnotel, E | 1 |
| Rogier, C | 6 |
| Simon, F | 1 |
| Pradines, B | 8 |
| Jiménez-Díaz, MB | 4 |
| Mulet, T | 1 |
| Viera, S | 2 |
| Gómez, V | 1 |
| Garuti, H | 1 |
| Ibáñez, J | 1 |
| Alvarez-Doval, A | 1 |
| Shultz, LD | 1 |
| Martínez, A | 1 |
| Gargallo-Viola, D | 1 |
| Angulo-Barturen, I | 3 |
| Nzila, A | 5 |
| Rottmann, M | 1 |
| Chitnumsub, P | 1 |
| Kiara, SM | 3 |
| Maneeruttanarungroj, C | 1 |
| Taweechai, S | 1 |
| Yeung, BK | 1 |
| Goh, A | 1 |
| Lakshminarayana, SB | 1 |
| Zou, B | 1 |
| Wong, J | 1 |
| Ma, NL | 1 |
| Weaver, M | 1 |
| Keller, TH | 1 |
| Dartois, V | 1 |
| Wittlin, S | 3 |
| Brun, R | 1 |
| Diagana, TT | 1 |
| Gutteridge, CE | 1 |
| Hoffman, MM | 1 |
| Bhattacharjee, AK | 1 |
| Milhous, WK | 3 |
| Gerena, L | 1 |
| Derbyshire, ER | 1 |
| Prudêncio, M | 1 |
| Mota, MM | 1 |
| Pretorius, SI | 1 |
| Breytenbach, WJ | 1 |
| de Kock, C | 1 |
| Smith, PJ | 4 |
| N'Da, DD | 1 |
| Flannery, EL | 1 |
| Fidock, DA | 4 |
| Winzeler, EA | 2 |
| Hameed P, S | 1 |
| Chinnapattu, M | 1 |
| Shanbag, G | 1 |
| Manjrekar, P | 1 |
| Koushik, K | 1 |
| Raichurkar, A | 1 |
| Patil, V | 1 |
| Jatheendranath, S | 1 |
| Rudrapatna, SS | 1 |
| Barde, SP | 1 |
| Rautela, N | 1 |
| Awasthy, D | 1 |
| Morayya, S | 1 |
| Narayan, C | 1 |
| Kavanagh, S | 1 |
| Saralaya, R | 1 |
| Bharath, S | 1 |
| Viswanath, P | 1 |
| Mukherjee, K | 1 |
| Bandodkar, B | 1 |
| Srivastava, A | 1 |
| Panduga, V | 1 |
| Reddy, J | 1 |
| Prabhakar, KR | 1 |
| Sinha, A | 1 |
| Martínez, MS | 1 |
| Ferrer, S | 2 |
| Sanz, LM | 4 |
| Gamo, FJ | 2 |
| Duffy, S | 3 |
| Avery, VM | 4 |
| Magistrado, PA | 1 |
| Lukens, AK | 1 |
| Waterson, D | 2 |
| Balasubramanian, V | 1 |
| Iyer, PS | 2 |
| Narayanan, S | 1 |
| Hosagrahara, V | 1 |
| Sambandamurthy, VK | 1 |
| Ramachandran, S | 1 |
| Kannan, M | 1 |
| Raichurkar, AV | 1 |
| Khan, FR | 1 |
| Keurulainen, L | 1 |
| Vahermo, M | 1 |
| Puente-Felipe, M | 1 |
| Sandoval-Izquierdo, E | 1 |
| Crespo-Fernández, B | 1 |
| Guijarro-López, L | 1 |
| Huertas-Valentín, L | 1 |
| de las Heras-Dueña, L | 1 |
| Leino, TO | 1 |
| Siiskonen, A | 1 |
| Ballell-Pages, L | 1 |
| Castañeda-Casado, P | 1 |
| Martínez-Martínez, MS | 1 |
| Kiuru, P | 1 |
| Calderón, F | 1 |
| Yli-Kauhaluoma, J | 1 |
| Le Manach, C | 1 |
| Paquet, T | 1 |
| Brunschwig, C | 1 |
| Njoroge, M | 1 |
| Han, Z | 1 |
| Gonzàlez Cabrera, D | 1 |
| Bashyam, S | 1 |
| Dhinakaran, R | 1 |
| Taylor, D | 1 |
| Reader, J | 1 |
| Botha, M | 1 |
| Churchyard, A | 1 |
| Lauterbach, S | 1 |
| Coetzer, TL | 1 |
| Birkholtz, LM | 1 |
| Meister, S | 1 |
| Witty, MJ | 1 |
| Santos Martínez, M | 1 |
| Street, LJ | 1 |
| Chibale, K | 1 |
| Scott, FJ | 1 |
| Khalaf, AI | 1 |
| Suckling, CJ | 1 |
| Yang, Y | 1 |
| Yu, Y | 1 |
| Li, X | 3 |
| Li, J | 4 |
| Wu, Y | 1 |
| Yu, J | 1 |
| Ge, J | 1 |
| Huang, Z | 1 |
| Jiang, L | 1 |
| Rao, Y | 1 |
| Yang, M | 1 |
| Zhang, YK | 1 |
| Plattner, JJ | 1 |
| Easom, EE | 1 |
| Jacobs, RT | 1 |
| Guo, D | 1 |
| Freund, YR | 1 |
| Berry, P | 1 |
| Ciaravino, V | 1 |
| Erve, JCL | 1 |
| Rosenthal, PJ | 28 |
| Campo, B | 1 |
| Cao, J | 1 |
| Patel, TS | 1 |
| Bhatt, JD | 1 |
| Dixit, RB | 1 |
| Chudasama, CJ | 1 |
| Patel, BD | 1 |
| Dixit, BC | 1 |
| Gaikwad, VR | 1 |
| Karale, UB | 1 |
| Govindarajalu, G | 1 |
| Adhikari, N | 1 |
| Krishna, EV | 1 |
| Krishna, VS | 1 |
| Misra, S | 1 |
| Sriram, D | 1 |
| Sijwali, PS | 1 |
| Rode, HB | 1 |
| Devine, SM | 1 |
| Challis, MP | 1 |
| Kigotho, JK | 1 |
| Siddiqui, G | 1 |
| De Paoli, A | 1 |
| MacRaild, CA | 1 |
| Creek, DJ | 1 |
| Norton, RS | 1 |
| Scammells, PJ | 1 |
| Nardella, F | 1 |
| Halby, L | 1 |
| Dobrescu, I | 1 |
| Viluma, J | 1 |
| Bon, C | 1 |
| Claes, A | 1 |
| Cadet-Daniel, V | 1 |
| Tafit, A | 1 |
| Roesch, C | 1 |
| Hammam, E | 1 |
| Erdmann, D | 1 |
| Mairet-Khedim, M | 1 |
| Peronet, R | 1 |
| Mecheri, S | 1 |
| Witkowski, B | 1 |
| Scherf, A | 1 |
| Arimondo, PB | 1 |
| Laleu, B | 1 |
| Akao, Y | 1 |
| Ochida, A | 1 |
| Lucantoni, L | 1 |
| Shackleford, DM | 1 |
| Chen, G | 1 |
| Katneni, K | 1 |
| Chiu, FCK | 1 |
| White, KL | 1 |
| Chen, X | 2 |
| Sturm, A | 1 |
| Dechering, KJ | 1 |
| Crespo, B | 1 |
| Wang, B | 1 |
| Charman, SA | 1 |
| Cho, N | 1 |
| Kamaura, M | 1 |
| Hogh, B | 3 |
| Thompson, R | 6 |
| Lobo, V | 1 |
| Dgedge, M | 4 |
| Dziegiel, M | 1 |
| Borre, M | 1 |
| Gottschau, A | 1 |
| Streat, E | 3 |
| Schapira, A | 3 |
| Barreto, J | 3 |
| Rieckmann, KH | 2 |
| Yeo, AE | 1 |
| Davis, DR | 1 |
| Hutton, DC | 1 |
| Wheatley, PF | 1 |
| Simpson, R | 1 |
| Mshinda, H | 16 |
| Font, F | 2 |
| Hirt, R | 2 |
| Mashaka, M | 1 |
| Ascaso, C | 1 |
| Menendez, C | 21 |
| Vrbova, H | 1 |
| Gibney, S | 1 |
| Gibson, FD | 1 |
| Jolley, D | 1 |
| Heywood, PF | 1 |
| Stace, J | 1 |
| Trenholme, KR | 1 |
| Alpers, MP | 2 |
| Kreutzfeld, O | 1 |
| Tumwebaze, PK | 2 |
| Byaruhanga, O | 1 |
| Katairo, T | 1 |
| Okitwi, M | 1 |
| Orena, S | 1 |
| Rasmussen, SA | 1 |
| Legac, J | 2 |
| Conrad, MD | 3 |
| Nsobya, SL | 5 |
| Aydemir, O | 4 |
| Bailey, JA | 5 |
| Duffey, M | 1 |
| Cooper, RA | 1 |
| Yaro, JB | 3 |
| Ouedraogo, A | 6 |
| Diarra, A | 7 |
| Sombié, S | 1 |
| Ouedraogo, ZA | 2 |
| Nébié, I | 6 |
| Drakeley, C | 12 |
| Sirima, SB | 5 |
| Tiono, AB | 5 |
| Lindsay, SW | 2 |
| Wilson, AL | 2 |
| Cairns, M | 5 |
| Ceesay, SJ | 2 |
| Sagara, I | 12 |
| Zongo, I | 9 |
| Kessely, H | 2 |
| Gamougam, K | 2 |
| Diallo, A | 3 |
| Ogboi, JS | 1 |
| Moroso, D | 2 |
| Van Hulle, S | 1 |
| Eloike, T | 2 |
| Snell, P | 2 |
| Scott, S | 4 |
| Merle, C | 1 |
| Bojang, K | 5 |
| Ouedraogo, JB | 13 |
| Dicko, A | 14 |
| Ndiaye, JL | 9 |
| Milligan, P | 8 |
| Yan, H | 1 |
| Feng, J | 1 |
| Yin, JH | 1 |
| Huang, F | 2 |
| Kong, XL | 1 |
| Lin, KM | 1 |
| Zhang, T | 1 |
| Feng, XY | 1 |
| Zhou, SS | 1 |
| Cao, JP | 1 |
| Xia, ZG | 1 |
| Chu, X | 1 |
| Yan, P | 1 |
| Zhang, N | 1 |
| Chen, N | 1 |
| Liu, Y | 1 |
| Feng, L | 2 |
| Li, M | 1 |
| Zhang, Z | 1 |
| Wang, Q | 1 |
| Wang, S | 2 |
| Yang, K | 1 |
| Richardson, S | 1 |
| Moukenet, A | 1 |
| Diar, MSI | 1 |
| de Cola, MA | 1 |
| Rassi, C | 1 |
| Counihan, H | 1 |
| Roca-Feltrer, A | 1 |
| Pethrak, C | 1 |
| Posayapisit, N | 3 |
| Pengon, J | 3 |
| Suwanakitti, N | 2 |
| Saeung, A | 1 |
| Shorum, M | 1 |
| Aupalee, K | 1 |
| Taai, K | 1 |
| Jupatanakul, N | 2 |
| Enato, IG | 3 |
| Sadoh, AE | 2 |
| Ibadin, OM | 2 |
| Odunvbun, ME | 2 |
| Nundu, SS | 1 |
| Culleton, R | 3 |
| Simpson, SV | 1 |
| Arima, H | 1 |
| Chitama, BA | 1 |
| Muyembe, JJ | 1 |
| Ahuka, S | 1 |
| Kaneko, O | 2 |
| Mita, T | 9 |
| Yamamoto, T | 1 |
| Lambert, B | 3 |
| Traore, A | 4 |
| Lankouande, M | 1 |
| Soulama, I | 3 |
| Sanou, A | 1 |
| Worrall, E | 1 |
| Agboraw, E | 1 |
| Sagnon, N | 2 |
| Ranson, H | 1 |
| Churcher, TS | 1 |
| Mahamar, A | 4 |
| Sumner, KM | 1 |
| Levitt, B | 2 |
| Freedman, B | 3 |
| Barry, A | 4 |
| Issiaka, D | 3 |
| Dembele, AB | 2 |
| Kanoute, MB | 2 |
| Attaher, O | 3 |
| Diarra, BN | 1 |
| Djimde, A | 12 |
| Duffy, PE | 5 |
| Fried, M | 6 |
| Taylor, SM | 11 |
| Osoti, V | 1 |
| Akinyi, M | 1 |
| Wamae, K | 1 |
| Kimenyi, KM | 1 |
| de Laurent, Z | 1 |
| Ndwiga, L | 1 |
| Gichuki, P | 1 |
| Okoyo, C | 1 |
| Kepha, S | 1 |
| Mwandawiro, C | 2 |
| Kandie, R | 1 |
| Bejon, P | 2 |
| Snow, RW | 7 |
| Ochola-Oyier, LI | 1 |
| Mama, A | 2 |
| Ahiabor, C | 1 |
| Tornyigah, B | 1 |
| Frempong, NA | 1 |
| Kusi, KA | 1 |
| Adu, B | 1 |
| Courtin, D | 2 |
| Houzé, S | 2 |
| Deloron, P | 9 |
| Ofori, MF | 2 |
| Anang, AK | 1 |
| Ariey, F | 8 |
| Ndam, NT | 7 |
| Kuesap, J | 1 |
| Suphakhonchuwong, N | 1 |
| Kalawong, L | 1 |
| Khumchum, N | 1 |
| Segala, FV | 1 |
| Di Gennaro, F | 1 |
| Ictho, J | 1 |
| L'Episcopia, M | 2 |
| Onapa, E | 1 |
| Marotta, C | 1 |
| De Vita, E | 1 |
| Amone, J | 1 |
| Iacobelli, V | 1 |
| Ogwang, J | 1 |
| Dall'Oglio, G | 1 |
| Ngole, B | 1 |
| Murri, R | 1 |
| Olal, L | 1 |
| Fantoni, M | 1 |
| Okori, S | 1 |
| Putoto, G | 1 |
| Severini, C | 3 |
| Lochoro, P | 1 |
| Saracino, A | 1 |
| Dosoo, DK | 1 |
| Asante, KP | 1 |
| Oppong, FB | 1 |
| Niaré, K | 2 |
| Opoku-Mensah, J | 1 |
| Owusu-Agyei, S | 3 |
| Greenwood, B | 21 |
| Chandramohan, D | 21 |
| Flegg, JA | 2 |
| Humphreys, GS | 1 |
| Montanez, B | 1 |
| Strickland, T | 1 |
| Jacome-Meza, ZJ | 1 |
| Barnes, KI | 16 |
| Raman, J | 3 |
| Guerin, PJ | 5 |
| Hopkins Sibley, C | 3 |
| Dahlström Otienoburu, S | 1 |
| Bhullar, S | 1 |
| Mishra, N | 8 |
| Maiga, H | 8 |
| Opondo, C | 1 |
| Chico, RM | 4 |
| Cohee, LM | 2 |
| Traore, OB | 4 |
| Tekete, M | 5 |
| Dara, A | 5 |
| Traore, ZI | 3 |
| Diarra, M | 2 |
| Coumare, S | 1 |
| Kodio, A | 1 |
| Bamadio, A | 1 |
| Sidibe, B | 2 |
| Doumbo, OK | 18 |
| Djimde, AA | 11 |
| Apinjoh, TO | 1 |
| Ntui, VN | 1 |
| Chi, HF | 1 |
| Moyeh, MN | 1 |
| Toussi, CT | 1 |
| Mayaba, JM | 1 |
| Tangi, LN | 1 |
| Kwi, PN | 1 |
| Anchang-Kimbi, JK | 3 |
| Dionne-Odom, J | 1 |
| Tita, ATN | 1 |
| Achidi, EA | 2 |
| Amambua-Ngwa, A | 3 |
| Titanji, VPK | 1 |
| Korwa, S | 1 |
| Wu, A | 1 |
| Green, CL | 1 |
| Clapp, S | 1 |
| Kirui, JK | 1 |
| O'Meara, WP | 2 |
| Njuguna, FM | 1 |
| Guerra, AP | 3 |
| Olivera, MJ | 1 |
| Cortés, LJ | 1 |
| Chenet, SM | 1 |
| Macedo de Oliveira, A | 2 |
| Lucchi, NW | 3 |
| Zhao, W | 1 |
| Yang, Q | 1 |
| Zhou, L | 1 |
| Duan, M | 1 |
| Pan, M | 1 |
| Qin, Y | 2 |
| Wang, X | 1 |
| Zeng, W | 2 |
| Zhao, H | 1 |
| Sun, K | 1 |
| Zhu, W | 1 |
| Afrane, Y | 3 |
| Amoah, LE | 1 |
| Abuaku, B | 4 |
| Duah-Quashie, NO | 2 |
| Huang, Y | 3 |
| Cui, L | 2 |
| Yang, Z | 2 |
| Beshir, KB | 2 |
| Muwanguzi, J | 1 |
| Nader, J | 1 |
| Mansukhani, R | 1 |
| Ceesay, S | 2 |
| Bazie, T | 1 |
| Kolie, F | 1 |
| Lamine, MM | 1 |
| Merle, CS | 1 |
| Razafindralambo, L | 1 |
| Doumagoum, D | 1 |
| Loua, K | 1 |
| Laminou, IM | 2 |
| Ogboi, SJ | 1 |
| Sutherland, CJ | 11 |
| Srisutham, S | 2 |
| Madmanee, W | 2 |
| Kouhathong, J | 2 |
| Sutawong, K | 2 |
| Tripura, R | 2 |
| Peto, TJ | 2 |
| van der Pluijm, RW | 2 |
| Callery, JJ | 2 |
| Dysoley, L | 3 |
| Mayxay, M | 7 |
| Newton, PN | 8 |
| Pongvongsa, T | 5 |
| Hongvanthong, B | 2 |
| Day, NPJ | 3 |
| White, NJ | 19 |
| Dondorp, AM | 6 |
| Imwong, M | 10 |
| Rana, R | 3 |
| Khan, N | 1 |
| Sandeepta, S | 1 |
| Pati, S | 1 |
| Das, A | 2 |
| Bal, M | 1 |
| Ranjit, M | 2 |
| Osaigbovo, II | 1 |
| Cohen, O | 1 |
| Guemas, E | 1 |
| Menard, S | 2 |
| Tsague Kenfack, M | 1 |
| Talom Ngassa, C | 1 |
| Iriart, X | 2 |
| Bidzogo Lebobo, M | 1 |
| Ondobo Ekae, C | 1 |
| Eboumbou, C | 1 |
| Tiyou Kenmeni, C | 1 |
| Berry, A | 3 |
| Olukosi, AY | 1 |
| Ajibaye, O | 1 |
| Omoniwa, O | 1 |
| Oresanya, O | 1 |
| Oluwagbemiga, AO | 1 |
| Ujuju, C | 1 |
| Ekholuenetale, M | 1 |
| Maxwell, K | 1 |
| Tibenderana, JK | 1 |
| Okek, EJ | 1 |
| Ocan, M | 1 |
| Obondo, SJ | 1 |
| Kiyimba, A | 1 |
| Arinaitwe, E | 3 |
| Nankabirwa, J | 1 |
| Ssewanyana, I | 2 |
| Kamya, MR | 18 |
| Akinola, O | 1 |
| Ategbero, E | 1 |
| Amusan, AI | 1 |
| Gbotosho, GO | 12 |
| Rosillo, SR | 1 |
| Dimbu, PR | 1 |
| Cândido, ALM | 1 |
| Oh, JM | 1 |
| Ferreira, CM | 1 |
| Nieto Andrade, B | 1 |
| Labuda, S | 1 |
| Horth, R | 1 |
| Kelley, J | 1 |
| Morais, JFM | 1 |
| Fortes, F | 4 |
| Martins, JF | 1 |
| Talundzic, E | 1 |
| Pluciński, MM | 1 |
| Moss, S | 1 |
| Mańko, E | 1 |
| Vasileva, H | 1 |
| Da Silva, ET | 1 |
| Goncalves, A | 1 |
| Osborne, A | 2 |
| Phelan, J | 1 |
| Rodrigues, A | 3 |
| Djata, P | 1 |
| D'Alessandro, U | 27 |
| Mabey, D | 1 |
| Krishna, S | 2 |
| Last, A | 1 |
| Clark, TG | 4 |
| Campino, S | 4 |
| Shaw, PJ | 2 |
| Uthaipibull, C | 3 |
| Kongkasuriyachai, D | 2 |
| Phyo, AP | 2 |
| Nosten, F | 9 |
| Anabire, NG | 1 |
| Aculley, B | 1 |
| Pobee, A | 1 |
| Kyei-Baafour, E | 1 |
| Awandare, GA | 3 |
| Del Pilar Quintana, M | 1 |
| Hviid, L | 2 |
| Doderer-Lang, C | 2 |
| Perrotti, E | 1 |
| Priuli, GB | 1 |
| Cavallari, S | 1 |
| Guidetti, C | 1 |
| Bernieri, F | 1 |
| Menard, D | 8 |
| Phelan, JE | 1 |
| Kaneko, A | 6 |
| Kagaya, W | 1 |
| Chan, C | 1 |
| Ngara, M | 1 |
| Kongere, J | 1 |
| Kita, K | 2 |
| Gitaka, J | 1 |
| Tarama, CW | 1 |
| Soré, H | 1 |
| Siribié, M | 1 |
| Débé, S | 1 |
| Kinda, R | 1 |
| Ganou, A | 1 |
| Nonkani, WG | 1 |
| Tiendrebeogo, F | 1 |
| Bantango, W | 1 |
| Yira, K | 1 |
| Sagnon, A | 1 |
| Ilboudo, S | 1 |
| Hien, EY | 1 |
| Guelbéogo, MW | 1 |
| Traoré, Y | 1 |
| Gansané, A | 2 |
| Alruwaili, M | 1 |
| Uwimana, A | 3 |
| Sethi, R | 1 |
| Murindahabi, M | 1 |
| Piercefield, E | 1 |
| Umulisa, N | 1 |
| Abram, A | 1 |
| Eckert, E | 2 |
| Munguti, K | 2 |
| Mbituyumuremyi, A | 1 |
| Gutman, JR | 2 |
| Sullivan, DJ | 2 |
| Tandoh, KZ | 1 |
| Figueroa-Romero, A | 1 |
| Bissombolo, D | 1 |
| Meremikwu, M | 3 |
| Ratsimbasoa, A | 5 |
| Sacoor, C | 1 |
| Arikpo, I | 1 |
| Lemba, E | 1 |
| Nhama, A | 1 |
| Rakotosaona, R | 1 |
| Llach, M | 1 |
| Pons-Duran, C | 1 |
| Sanz, S | 11 |
| Ma, L | 1 |
| Maly, C | 1 |
| Roman, E | 4 |
| Pagnoni, F | 1 |
| Mayor, A | 11 |
| González, R | 2 |
| Moore, BR | 2 |
| Benjamin, JM | 2 |
| Tobe, R | 1 |
| Ome-Kaius, M | 2 |
| Yadi, G | 2 |
| Kasian, B | 1 |
| Kong, C | 1 |
| Robinson, LJ | 3 |
| Laman, M | 1 |
| Mueller, I | 10 |
| Rogerson, S | 1 |
| Davis, TME | 2 |
| Unger, HW | 3 |
| Rosanas-Urgell, A | 3 |
| Jally, S | 1 |
| Umbers, AJ | 1 |
| Pomat, W | 1 |
| Kattenberg, E | 1 |
| Rogerson, SJ | 12 |
| Qi-Cheng, Z | 1 |
| Zaidi, I | 1 |
| Kwan, JL | 1 |
| Samassekou, MB | 1 |
| Cisse, KB | 1 |
| Coulibaly, B | 3 |
| Keita, S | 3 |
| Sissoko, S | 1 |
| Traore, T | 1 |
| Diarra, K | 2 |
| Diarra, BS | 2 |
| Dembele, A | 1 |
| Deutsch-Feldman, M | 1 |
| Carrel, M | 1 |
| Brazeau, NF | 2 |
| Bhatt, S | 1 |
| Kashamuka, M | 1 |
| Tshefu, AK | 4 |
| Juliano, JJ | 5 |
| Meshnick, SR | 22 |
| Verity, R | 2 |
| Huijben, S | 1 |
| Macete, E | 7 |
| Mombo-Ngoma, G | 3 |
| Ramharter, M | 3 |
| Kariuki, S | 6 |
| Desai, M | 4 |
| Shi, YP | 10 |
| Mwangoka, G | 1 |
| Massougbodji, A | 12 |
| Cot, M | 6 |
| Uberegui, E | 1 |
| Gupta, H | 1 |
| Cisteró, P | 6 |
| Aponte, JJ | 16 |
| Zhao, L | 1 |
| Pi, L | 1 |
| Lu, Y | 1 |
| Xiang, Z | 1 |
| Qin, P | 1 |
| Li, C | 1 |
| Zhang, Y | 1 |
| Si, Y | 1 |
| Yang, G | 1 |
| Rosenthal, BM | 1 |
| Mensah, BA | 3 |
| Myers-Hansen, JL | 3 |
| Opoku, M | 1 |
| Hathaway, NJ | 3 |
| Marsh, PW | 2 |
| Anto, F | 2 |
| Bailey, J | 1 |
| Ghansah, A | 4 |
| Sugaram, R | 1 |
| Suwannasin, K | 1 |
| Kunasol, C | 1 |
| Mathema, VB | 1 |
| Sudathip, P | 1 |
| Prempree, P | 1 |
| Madanitsa, M | 4 |
| Thwai, KL | 4 |
| Kalilani-Phiri, L | 3 |
| Khairallah, C | 6 |
| Mwapasa, V | 8 |
| Ter Kuile, FO | 10 |
| Rogier, E | 1 |
| Herman, C | 1 |
| Huber, CS | 1 |
| Hamre, KES | 2 |
| Pierre, B | 2 |
| Mace, KE | 3 |
| Présumé, J | 1 |
| Mondélus, G | 1 |
| Romilus, I | 1 |
| Elismé, T | 1 |
| Eisele, TP | 4 |
| Druetz, T | 1 |
| Existe, A | 2 |
| Boncy, J | 4 |
| Lemoine, JF | 2 |
| Udhayakumar, V | 15 |
| Chang, MA | 3 |
| Watson, OJ | 1 |
| Mwandagalirwa, MK | 1 |
| Thwai, K | 1 |
| Fulton, T | 1 |
| Denton, M | 1 |
| Morgan, AP | 1 |
| Parr, JB | 1 |
| Conrad, M | 1 |
| Ishengoma, DS | 2 |
| Ngondi, J | 1 |
| Gutman, J | 11 |
| Mulenga, M | 8 |
| Norris, DE | 1 |
| Moss, WJ | 1 |
| Ghani, AC | 3 |
| Gikunju, SW | 1 |
| Agola, EL | 1 |
| Ondondo, RO | 1 |
| Kinyua, J | 1 |
| Kimani, F | 1 |
| LaBeaud, AD | 1 |
| Malhotra, I | 1 |
| King, C | 1 |
| Thiong'o, K | 1 |
| Mutuku, F | 1 |
| Saito, M | 1 |
| Mansoor, R | 1 |
| Kennon, K | 1 |
| Anvikar, AR | 6 |
| Ashley, EA | 2 |
| Genton, B | 11 |
| Gilder, ME | 1 |
| Juma, E | 2 |
| Kuepfer, I | 2 |
| Laufer, MK | 6 |
| Lwin, KM | 1 |
| Mosha, D | 2 |
| Mwebaza, N | 1 |
| Nambozi, M | 3 |
| Ndiaye, JA | 1 |
| Nyunt, M | 2 |
| Ogutu, B | 1 |
| Parikh, S | 2 |
| Paw, MK | 1 |
| Pimanpanarak, M | 1 |
| Piola, P | 3 |
| Rijken, MJ | 1 |
| Sriprawat, K | 1 |
| Tagbor, HK | 1 |
| Tarning, J | 4 |
| Tinto, H | 13 |
| Valéa, I | 4 |
| Valecha, N | 12 |
| Wiladphaingern, J | 1 |
| Stepniewska, K | 3 |
| McGready, R | 4 |
| Bwire, GM | 1 |
| Mikomangwa, WP | 2 |
| Kilonzi, M | 2 |
| Walker, PGT | 1 |
| Slater, H | 1 |
| Kayentao, K | 8 |
| Williams, JE | 1 |
| Coulibaly, SO | 4 |
| Taylor, S | 3 |
| Hill, J | 4 |
| Tagbor, H | 4 |
| Griffin, JT | 4 |
| Ghani, ACH | 1 |
| Pathak, A | 1 |
| Mårtensson, A | 5 |
| Gawariker, S | 1 |
| Sharma, A | 1 |
| Diwan, V | 1 |
| Purohit, M | 1 |
| Ursing, J | 4 |
| Djontu, JC | 1 |
| Lloyd, YM | 1 |
| Megnekou, R | 1 |
| Seumko'o, RMN | 1 |
| Salanti, A | 2 |
| Taylor, DW | 2 |
| Leke, RGF | 1 |
| Fagbemi, KA | 1 |
| Adebusuyi, SA | 1 |
| Nderu, D | 1 |
| Adedokun, SA | 1 |
| Pallerla, SR | 1 |
| Amoo, AOJ | 1 |
| Thomas, BN | 2 |
| Velavan, TP | 2 |
| Ojurongbe, O | 3 |
| Hounkonnou, CPA | 1 |
| Fievet, N | 2 |
| Accrombessi, M | 1 |
| Yovo, E | 1 |
| Sossou, D | 1 |
| Vianou, B | 1 |
| Briand, V | 2 |
| Cottrell, G | 2 |
| Namuyinga, R | 1 |
| Mace, K | 1 |
| Rogier, EW | 1 |
| Sitali, L | 1 |
| Mwenda, MC | 1 |
| Miller, JM | 2 |
| Bridges, DJ | 1 |
| Hawela, MB | 1 |
| Hamainza, B | 1 |
| Mudenda-Chilufya, M | 1 |
| Chizema-Kawesha, E | 1 |
| Daniels, RF | 1 |
| Nerland, AH | 1 |
| Chipeta, J | 2 |
| Lindtjorn, B | 1 |
| Mohamed, NS | 1 |
| Abdelbagi, H | 2 |
| Osman, HA | 1 |
| Ahmed, AE | 1 |
| Yousif, AM | 1 |
| Edris, YB | 1 |
| Osman, EY | 1 |
| Elsadig, AR | 1 |
| Siddig, EE | 1 |
| Mustafa, M | 1 |
| Mohammed, AA | 1 |
| Ali, Y | 1 |
| Osman, MM | 1 |
| Ali, MS | 3 |
| Omer, RA | 1 |
| Ahmed, A | 3 |
| Sibley, CH | 10 |
| Natama, HM | 2 |
| Toussaint, R | 1 |
| Bazié, DLC | 1 |
| Samadoulougou, S | 1 |
| Coulibaly-Traoré, M | 1 |
| Kirakoya-Samadoulougou, F | 1 |
| Amimo, F | 2 |
| Magit, A | 2 |
| Sacarlal, J | 3 |
| Hashizume, M | 1 |
| Shibuya, K | 1 |
| Jiang, T | 3 |
| Cheng, W | 2 |
| Yao, Y | 2 |
| Tan, H | 2 |
| Wu, K | 3 |
| Madkhali, AM | 1 |
| Al-Mekhlafi, HM | 2 |
| Atroosh, WM | 2 |
| Ghzwani, AH | 1 |
| Zain, KA | 1 |
| Abdulhaq, AA | 1 |
| Ghailan, KY | 1 |
| Anwar, AA | 1 |
| Eisa, ZM | 1 |
| Kakuru, A | 4 |
| Roh, ME | 2 |
| Kajubi, R | 2 |
| Ochieng, T | 2 |
| Ategeka, J | 2 |
| Ochokoru, H | 2 |
| Nakalembe, M | 3 |
| Clark, TD | 6 |
| Ruel, T | 2 |
| Staedke, SG | 9 |
| Havlir, DV | 4 |
| Dorsey, G | 27 |
| Jagannathan, P | 6 |
| Oyebola, MK | 1 |
| Ahorlu, C | 1 |
| Wilson, MD | 2 |
| Awandare, G | 1 |
| Koram, KA | 4 |
| Ngwa, AA | 1 |
| Sun, Y | 1 |
| Wei, W | 1 |
| Shen, C | 1 |
| Fu, X | 1 |
| Dong, H | 1 |
| Mahaman Moustapha, L | 1 |
| Adamou, R | 1 |
| Ibrahim, ML | 1 |
| Abdoulaye Louis Padounou, M | 1 |
| Testa, J | 1 |
| Ndiaye, JLA | 1 |
| Afutu, LL | 1 |
| Boampong, JN | 1 |
| Quashie, NB | 2 |
| Kayode, AT | 1 |
| Ajogbasile, FV | 1 |
| Akano, K | 1 |
| Uwanibe, JN | 1 |
| Oluniyi, PE | 1 |
| Eromon, PJ | 1 |
| Folarin, OA | 4 |
| Sowunmi, A | 30 |
| Happi, CT | 7 |
| Chaponda, EB | 1 |
| Mharakurwa, S | 6 |
| Michelo, C | 2 |
| Bruce, J | 6 |
| Chandramoha, D | 1 |
| Matthew Chico, R | 1 |
| Svigel, SS | 1 |
| Adeothy, A | 2 |
| Kpemasse, A | 1 |
| Houngbo, E | 1 |
| Sianou, A | 1 |
| Saliou, R | 1 |
| Patton, ME | 1 |
| Dagnon, F | 1 |
| Halsey, ES | 1 |
| Tchevoede, A | 1 |
| Mushi, V | 1 |
| Mbotwa, CH | 1 |
| Zacharia, A | 1 |
| Ambrose, T | 1 |
| Moshi, FV | 1 |
| Hansson, H | 1 |
| Minja, DTR | 1 |
| Moeller, SL | 1 |
| Lusingu, JPA | 1 |
| Bygbjerg, IC | 13 |
| Yde, AM | 1 |
| Jensen, RW | 1 |
| Nag, S | 2 |
| Msemo, OA | 1 |
| Theander, TG | 3 |
| Alifrangis, M | 21 |
| Schmiegelow, C | 1 |
| Prommana, P | 1 |
| Shoram, M | 1 |
| Amenga-Etego, LN | 1 |
| Asoala, V | 1 |
| Agongo, G | 1 |
| Jacob, C | 1 |
| Goncalves, S | 1 |
| Rockett, KA | 1 |
| Kwiatkowski, D | 1 |
| Andemel, N | 1 |
| Swihart, B | 1 |
| Sidibe, Y | 2 |
| Gaoussou, S | 1 |
| Traore, M | 2 |
| Agyeman, YN | 1 |
| Newton, S | 1 |
| Annor, RB | 1 |
| Owusu-Dabo, E | 1 |
| Das, S | 7 |
| Kar, A | 1 |
| Manna, S | 1 |
| Mandal, S | 2 |
| Saha, B | 1 |
| Hati, AK | 1 |
| Kayiba, NK | 1 |
| Yobi, DM | 1 |
| Tchakounang, VRK | 1 |
| Mvumbi, DM | 1 |
| Kabututu, PZ | 1 |
| Devleesschauwer, B | 1 |
| Mukomena, ES | 1 |
| DeMol, P | 1 |
| Hayette, MP | 2 |
| Mvumbi, GL | 1 |
| Rosas-Aguirre, A | 1 |
| Lusamba, PD | 1 |
| Speybroeck, N | 2 |
| Yaméogo, KB | 1 |
| Yerbanga, RS | 1 |
| Ouattara, SB | 1 |
| Yao, FA | 1 |
| Lefèvre, T | 1 |
| Nikièma, F | 1 |
| Compaoré, YD | 1 |
| Belem, AMG | 1 |
| Cohuet, A | 1 |
| Corral, MG | 1 |
| Leroux, J | 1 |
| Stubbs, KA | 1 |
| Mylne, JS | 1 |
| Mohamed, AO | 3 |
| Abdel Hamid, MM | 2 |
| Mohamed, OS | 1 |
| Elkando, NS | 1 |
| Suliman, A | 1 |
| Adam, MA | 2 |
| Elnour, FAA | 1 |
| Malik, EM | 10 |
| Ruizendaal, E | 2 |
| Tahita, MC | 3 |
| Geskus, RB | 1 |
| Versteeg, I | 1 |
| Lompo, P | 1 |
| Derra, K | 1 |
| Traore-Coulibaly, M | 3 |
| de Jong, MD | 1 |
| Schallig, HDFH | 3 |
| Mens, PF | 5 |
| Nkegoum, B | 1 |
| Mendimi, JN | 1 |
| Sverremark-Ekström, E | 1 |
| Troye-Blomberg, M | 3 |
| Chatterjee, M | 1 |
| Ganguly, S | 3 |
| Saha, P | 4 |
| Guha, SK | 5 |
| Maji, AK | 4 |
| Mishra, S | 1 |
| Bharti, PK | 2 |
| Shukla, MM | 1 |
| Ali, NA | 1 |
| Kashyotia, SS | 1 |
| Kumar, A | 7 |
| Dhariwal, AC | 3 |
| Singh, N | 5 |
| Ngondi, JM | 1 |
| Doctor, SM | 1 |
| Keeler, C | 1 |
| Mkude, S | 1 |
| Munishi, OM | 1 |
| Willilo, RA | 1 |
| Lalji, S | 1 |
| Kaspar, N | 1 |
| Kitojo, C | 2 |
| Paxton, LA | 1 |
| Clark, RL | 1 |
| Oyebola, KM | 1 |
| Idowu, ET | 1 |
| Olukosi, YA | 1 |
| Awolola, TS | 1 |
| Salman, S | 4 |
| Baiwog, F | 1 |
| Page-Sharp, M | 4 |
| Kose, K | 2 |
| Karunajeewa, HA | 3 |
| Siba, PM | 3 |
| Ilett, KF | 5 |
| Gebreyohannes, EA | 1 |
| Bhagavathula, AS | 1 |
| Seid, MA | 1 |
| Tegegn, HG | 1 |
| Chhonker, YS | 1 |
| Bhosale, VV | 1 |
| Sonkar, SK | 1 |
| Chandasana, H | 1 |
| Kumar, D | 1 |
| Vaish, S | 1 |
| Choudhary, SC | 1 |
| Bhadhuria, S | 1 |
| Sharma, S | 2 |
| Singh, RK | 2 |
| Jain, GK | 1 |
| Vaish, AK | 1 |
| Gaur, SPS | 1 |
| Bhatta, RS | 1 |
| Okell, LC | 2 |
| Roper, C | 28 |
| Cañón, M | 1 |
| Diaz, H | 1 |
| Olarte, A | 1 |
| Boudová, S | 1 |
| Divala, T | 1 |
| Mungwira, R | 1 |
| Mawindo, P | 1 |
| Tomoka, T | 1 |
| Mota, D | 1 |
| Foster, M | 1 |
| Tukwasibwe, S | 3 |
| Tumwebaze, P | 1 |
| Whalen, M | 1 |
| Nayebare, P | 2 |
| Wallender, E | 2 |
| Huang, L | 1 |
| Aweeka, F | 2 |
| Sarmah, NP | 1 |
| Sarma, K | 1 |
| Bhattacharyya, DR | 3 |
| Sultan, AA | 2 |
| Bansal, D | 1 |
| Sehgal, R | 1 |
| Mohapatra, PK | 3 |
| Parida, P | 1 |
| Mahanta, J | 3 |
| Ruh, E | 1 |
| Bateko, JP | 1 |
| Imir, T | 1 |
| Taylan-Ozkan, A | 1 |
| Nguetse, CN | 1 |
| Fayemiwo, SA | 1 |
| Falade, CO | 7 |
| Ojurongbe, TA | 1 |
| Meyer, CG | 6 |
| Esu, E | 2 |
| Tacoli, C | 2 |
| Gai, P | 2 |
| Berens-Riha, N | 3 |
| Pritsch, M | 2 |
| Loescher, T | 2 |
| Graves, PM | 4 |
| Choi, L | 1 |
| Gelband, H | 4 |
| Garner, P | 8 |
| Diawara, H | 1 |
| Soumare, HM | 1 |
| Lanke, K | 1 |
| Bradley, J | 1 |
| Sanogo, K | 1 |
| Kone, DT | 1 |
| Traore, SF | 2 |
| McCulloch, C | 1 |
| Stone, WJR | 1 |
| Hwang, J | 2 |
| Müller, O | 3 |
| Brown, JM | 1 |
| Srinivasan, V | 1 |
| Gosling, R | 4 |
| Chen, I | 2 |
| Bousema, T | 6 |
| de Kock, M | 1 |
| Workman, L | 1 |
| Allen, EN | 2 |
| Tekete, MM | 1 |
| Bell, DJ | 2 |
| Ward, SA | 4 |
| Denti, P | 1 |
| Grais, RF | 1 |
| Woi-Messe, L | 1 |
| Makarimi, R | 1 |
| Bouriema, SH | 1 |
| Langendorf, C | 1 |
| Fandeur, T | 2 |
| Igboeli, NU | 1 |
| Adibe, MO | 1 |
| Ukwe, CV | 1 |
| Aguwa, NC | 1 |
| Hamid, MMA | 1 |
| Thriemer, K | 2 |
| Elobied, ME | 1 |
| Mahgoub, NS | 1 |
| Boshara, SA | 1 |
| Elsafi, HMH | 1 |
| Gumaa, SA | 1 |
| Hamid, T | 1 |
| Basheir, HM | 1 |
| Marfurt, J | 5 |
| Price, RN | 3 |
| Ley, B | 1 |
| Osarfo, J | 1 |
| Magnussen, P | 11 |
| Rovira-Vallbona, E | 1 |
| Sorgho, H | 2 |
| Somé, MA | 1 |
| Zango, SH | 1 |
| Sawadogo, O | 1 |
| Zongo, SC | 1 |
| Kestens, L | 2 |
| Awantang, GN | 1 |
| Babalola, SO | 1 |
| Koenker, H | 1 |
| Fox, KA | 1 |
| Toso, M | 1 |
| Lewicky, N | 1 |
| Goomber, S | 1 |
| Anvikar, A | 3 |
| Yadav, CP | 1 |
| Mishra, V | 1 |
| Arya, T | 1 |
| Mishra, DR | 1 |
| Mohanty, S | 1 |
| Mohanty, R | 1 |
| Srivastava, B | 6 |
| Nwachuku, N | 1 |
| Okiring, J | 1 |
| Muhindo, MK | 1 |
| Natureeba, P | 1 |
| Opira, B | 2 |
| Olwoch, P | 1 |
| Nankya, F | 2 |
| Tetteh, K | 1 |
| Beeson, J | 1 |
| Reiling, L | 1 |
| Rodriguez-Barraquer, I | 1 |
| Greenhouse, B | 3 |
| Prahl, M | 1 |
| Charlebois, ED | 2 |
| Feeney, ME | 2 |
| Nkoli Mandoko, P | 1 |
| Rouvier, F | 1 |
| Matendo Kakina, L | 1 |
| Moke Mbongi, D | 1 |
| Latour, C | 1 |
| Losimba Likwela, J | 1 |
| Ngoyi Mumba, D | 1 |
| Bi Shamamba, SK | 1 |
| Tamfum Muyembe, JJ | 1 |
| Muepu Tshilolo, L | 1 |
| Sinou, V | 1 |
| Al-Harthi, SA | 1 |
| Jafari-Guemouri, S | 2 |
| Dhiab, J | 1 |
| Tuikue, NN | 1 |
| Dobaño, C | 11 |
| Nhabomba, AJ | 2 |
| Manaca, MN | 3 |
| Berthoud, T | 1 |
| Aguilar, R | 3 |
| Quintó, L | 10 |
| Barbosa, A | 3 |
| Rodríguez, MH | 2 |
| Jiménez, A | 4 |
| Groves, PL | 1 |
| Santano, R | 1 |
| Bassat, Q | 2 |
| Guinovart, C | 3 |
| Doolan, DL | 2 |
| Alonso, PL | 15 |
| Manore, CA | 1 |
| Teboh-Ewungkem, MI | 1 |
| Prosper, O | 1 |
| Peace, A | 1 |
| Gurski, K | 1 |
| Feng, Z | 1 |
| Wedam, J | 1 |
| Gai, PP | 1 |
| Siegert, K | 1 |
| Kulkarni, SS | 1 |
| Rasalkar, R | 1 |
| Boloor, A | 1 |
| Jain, A | 1 |
| Mahabala, C | 1 |
| Baliga, S | 1 |
| Shenoy, D | 1 |
| Devi, R | 1 |
| Mockenhaupt, FP | 13 |
| Marealle, AI | 1 |
| Mbwambo, DP | 1 |
| Mlyuka, HJ | 1 |
| Mutagonda, RF | 1 |
| Gaillard, T | 1 |
| Boxberger, M | 1 |
| Madamet, M | 1 |
| Moon, TD | 1 |
| Nomura, S | 1 |
| Juma, DW | 1 |
| Muiruri, P | 1 |
| Yuhas, K | 1 |
| John-Stewart, G | 1 |
| Ottichilo, R | 1 |
| Waitumbi, J | 1 |
| Singa, B | 1 |
| Polyak, C | 1 |
| Kamau, E | 1 |
| Chen, J | 1 |
| Fu, H | 1 |
| Eyi, JUM | 1 |
| Matesa, RA | 1 |
| Obono, MMO | 1 |
| Du, W | 1 |
| Lin, M | 1 |
| van Eijk, AM | 8 |
| Larsen, DA | 3 |
| Koshy, G | 1 |
| Slaughter, DEC | 1 |
| Abdallah, WME | 1 |
| Hussien, M | 1 |
| Mohammed, NM | 1 |
| Ahmed, ME | 1 |
| Teo, A | 2 |
| Randall, LM | 2 |
| Phiri, LK | 1 |
| Buffet, C | 1 |
| Karahalios, A | 1 |
| Narum, DL | 1 |
| Kuile, FOT | 1 |
| Ravenhall, M | 2 |
| Benavente, ED | 2 |
| Baker, DA | 1 |
| Bakhiet, AMA | 1 |
| Abdelraheem, MH | 1 |
| Kheir, A | 2 |
| Omer, S | 1 |
| Gismelseed, L | 1 |
| Abdel-Muhsin, AA | 2 |
| Naiem, A | 1 |
| Al Hosni, A | 1 |
| Al Dhuhli, A | 1 |
| Al Rubkhi, M | 1 |
| Al-Hamidhi, S | 1 |
| Gadalla, A | 1 |
| Mukhtar, M | 1 |
| Babiker, HA | 8 |
| Biswas, A | 3 |
| Kundu, PK | 3 |
| Luntamo, M | 3 |
| Kulmala, T | 2 |
| Cheung, YB | 1 |
| Maleta, K | 2 |
| Ashorn, P | 3 |
| Tsoka-Gwegweni, JM | 1 |
| Kleinschmidt, I | 2 |
| Awab, GR | 2 |
| Pukrittayakamee, S | 3 |
| Jamornthanyawat, N | 1 |
| Yamin, F | 1 |
| Day, NP | 3 |
| Woodrow, CJ | 2 |
| Charle, P | 1 |
| Berzosa, P | 4 |
| de Lucio, A | 1 |
| Raso, J | 2 |
| Nseng Nchama, G | 1 |
| Benito, A | 7 |
| Anglewicz, PA | 2 |
| Keating, J | 2 |
| Yukich, J | 2 |
| Bennett, A | 2 |
| Steketee, RW | 9 |
| Mangiaterra, V | 2 |
| Bardají, A | 8 |
| Nahlen, B | 4 |
| Slutsker, L | 14 |
| Shah, NK | 5 |
| MacDonald, PD | 1 |
| Poole, C | 1 |
| Ndiaye, M | 5 |
| Tine, R | 2 |
| Faye, B | 7 |
| Lo, AC | 3 |
| Sylla, K | 3 |
| Abiola, A | 2 |
| Dieng, Y | 4 |
| Ndiaye, D | 5 |
| Hallett, R | 5 |
| Gaye, O | 10 |
| Ba, el-H | 2 |
| Cisse, B | 3 |
| Sokhna, C | 3 |
| Gomis, JF | 1 |
| Faye, O | 5 |
| Ndir, O | 2 |
| Sutherland, C | 5 |
| Ogouyèmi-Hounto, A | 2 |
| Kinde Gazard, D | 2 |
| d'Almeida, S | 2 |
| Koussihoude, L | 1 |
| Ollo, E | 1 |
| Azagnandji, C | 2 |
| Bello, M | 2 |
| Chippaux, JP | 2 |
| Martins, JS | 1 |
| Zwi, AB | 1 |
| Hobday, K | 1 |
| Bonaparte, F | 1 |
| Kelly, PM | 1 |
| Hernández, DC | 1 |
| Cucunubá, ZM | 1 |
| Nicholls, RS | 1 |
| Barrera, SM | 1 |
| Augagneur, Y | 1 |
| Jaubert, L | 1 |
| Schiavoni, M | 1 |
| Pachikara, N | 1 |
| Garg, A | 1 |
| Usmani-Brown, S | 1 |
| Wesolowski, D | 1 |
| Zeller, S | 1 |
| Ghosal, A | 1 |
| Cornillot, E | 1 |
| Said, HM | 1 |
| Kumar, P | 1 |
| Altman, S | 1 |
| Ben Mamoun, C | 1 |
| Moussiliou, A | 2 |
| De Tove, YS | 1 |
| Doritchamou, J | 2 |
| Luty, AJ | 3 |
| Khaireh, BA | 1 |
| Assefa, A | 1 |
| Guessod, HH | 1 |
| Basco, LK | 25 |
| Khaireh, MA | 1 |
| Pascual, A | 2 |
| Briolant, S | 3 |
| Bouh, SM | 1 |
| Farah, IH | 1 |
| Ali, HM | 1 |
| Abdi, AI | 1 |
| Aden, MO | 1 |
| Abdillahi, Z | 1 |
| Ayeh, SN | 1 |
| Darar, HY | 1 |
| Koeck, JL | 1 |
| Tonga, C | 1 |
| Kimbi, HK | 1 |
| Nyabeyeu, HN | 1 |
| Bissemou, ZB | 1 |
| Lehman, LG | 3 |
| Mwandama, D | 3 |
| Wiegand, RE | 5 |
| Ali, D | 3 |
| Mathanga, DP | 3 |
| Skarbinski, J | 4 |
| Srivastava, P | 1 |
| Ratha, J | 1 |
| Sharma, SK | 3 |
| Das, MK | 4 |
| Gadalla, NB | 1 |
| Abdallah, TM | 1 |
| Atwal, S | 1 |
| Adam, I | 15 |
| Doumbo, S | 1 |
| Ongoiba, OA | 1 |
| Doumtabé, D | 1 |
| Ouologuem, TD | 1 |
| Traoré, B | 4 |
| Ohashi, J | 1 |
| Venkatesan, M | 3 |
| Marma, AS | 2 |
| Nakamura, M | 1 |
| Plowe, CV | 28 |
| Tanabe, K | 6 |
| Manirakiza, A | 2 |
| Sepou, A | 1 |
| Serdouma, E | 1 |
| Gondje, S | 1 |
| Bata, GG | 1 |
| Moussa, S | 1 |
| Boulay, A | 1 |
| Moyen, JM | 1 |
| Sakanga, O | 1 |
| Le-Fouler, L | 1 |
| Kazanji, M | 1 |
| Vray, M | 1 |
| Hien, TT | 3 |
| Faiz, MA | 2 |
| Mokuolu, OA | 1 |
| Metcalf, CJE | 1 |
| Gharbi, M | 1 |
| Shewchuk, T | 1 |
| Naidoo, I | 3 |
| Hailemeskel, E | 1 |
| Kassa, M | 3 |
| Taddesse, G | 1 |
| Mohammed, H | 3 |
| Woyessa, A | 2 |
| Tasew, G | 1 |
| Sleshi, M | 1 |
| Kebede, A | 3 |
| Petros, B | 2 |
| Hack, BB | 1 |
| Newport, MJ | 1 |
| Ngulube, E | 1 |
| Fadégnon, G | 1 |
| Klement, E | 1 |
| Pitché, P | 1 |
| Kendjo, E | 3 |
| Singo, A | 1 |
| Akouete, F | 1 |
| Akpaloo, Y | 1 |
| Tossa, K | 1 |
| Prince-Agbodjan, S | 1 |
| Patassi, A | 1 |
| Caumes, E | 1 |
| Abdul-Ghani, R | 3 |
| Farag, HF | 2 |
| Allam, AF | 2 |
| Shawky, SM | 1 |
| Marrocco, T | 1 |
| Skorokhod, OA | 1 |
| Nhabomba, A | 2 |
| Arese, P | 1 |
| Schwarzer, E | 1 |
| Mawili-Mboumba, DP | 4 |
| Bouyou-Akotet, MK | 5 |
| Kombila, M | 6 |
| Drabo, MK | 2 |
| Huybregts, L | 2 |
| Henry, MC | 2 |
| Roberfroid, D | 1 |
| Guiguemde, RT | 6 |
| Kolsteren, P | 2 |
| Sridaran, S | 1 |
| Rodriguez, B | 1 |
| Soto, AM | 1 |
| Matar, KM | 1 |
| Awad, AI | 1 |
| Elamin, SB | 4 |
| Chitnis, CE | 3 |
| Kümpornsin, K | 1 |
| Modchang, C | 1 |
| Heinberg, A | 1 |
| Ekland, EH | 1 |
| Jirawatcharadech, P | 1 |
| Chobson, P | 1 |
| Chaotheing, S | 1 |
| Wilairat, P | 3 |
| Deitsch, KW | 1 |
| Kirkman, LA | 1 |
| Chookajorn, T | 2 |
| Matondo, SI | 1 |
| Temba, GS | 1 |
| Kavishe, AA | 2 |
| Kauki, JS | 1 |
| Kalinga, A | 1 |
| van Zwetselaar, M | 1 |
| Reyburn, H | 2 |
| Kavishe, RA | 2 |
| McClure, EM | 1 |
| Lazebnik, N | 1 |
| Mungai, P | 1 |
| King, CL | 1 |
| Hudgens, M | 1 |
| Goldenberg, RL | 1 |
| Siega-Riz, AM | 1 |
| Dent, AE | 1 |
| Mbogo, GW | 1 |
| Nankoberanyi, S | 1 |
| Baliraine, FN | 3 |
| Kamya, M | 2 |
| Tappero, J | 1 |
| Plotkin, M | 1 |
| Said, K | 1 |
| Msellem, MI | 1 |
| Chase, RP | 1 |
| Hendler, N | 1 |
| Khamis, AR | 1 |
| Schwartz, AC | 1 |
| McElroy, PD | 2 |
| Tan, KR | 2 |
| Katalenich, BL | 2 |
| Chalwe, V | 5 |
| Filler, SJ | 3 |
| Kamuliwo, M | 2 |
| Craig, AS | 2 |
| Chilongola, J | 1 |
| Ndeserua, R | 1 |
| Mwingira, F | 1 |
| Kaitholia, K | 2 |
| Narayan, JP | 1 |
| Dev, V | 5 |
| Phookan, S | 2 |
| Bharti, RS | 1 |
| Sonal, GS | 2 |
| Sarma, DK | 1 |
| Prakash, A | 2 |
| Bora, K | 1 |
| Ahmed, MA | 1 |
| Sarma, B | 1 |
| Goswami, BK | 2 |
| Basuki, S | 1 |
| Riyanto, S | 1 |
| Dachlan, YP | 1 |
| Uemura, H | 2 |
| Ali, IM | 1 |
| Evehe, MS | 3 |
| Netongo, PM | 2 |
| Atogho-Tiedeu, B | 1 |
| Akindeh-Nji, M | 1 |
| Ngora, H | 1 |
| Domkam, IK | 1 |
| Diakite, M | 3 |
| Baldip, K | 1 |
| Ranford-Cartwright, L | 2 |
| Mimche, PN | 2 |
| Lamb, T | 1 |
| Mbacham, WF | 2 |
| Cisse, M | 3 |
| Sangare, I | 1 |
| Lougue, G | 1 |
| Bamba, S | 1 |
| Bayane, D | 1 |
| Toure, OA | 1 |
| Kone, PL | 1 |
| Coulibaly, MA | 1 |
| Ako, BA | 1 |
| Gbessi, EA | 1 |
| N' Guessan, LT | 1 |
| Koffi, D | 1 |
| Beourou, S | 1 |
| Soumahoro, A | 1 |
| Bassinka, I | 1 |
| Nogbou, M | 1 |
| Swa, T | 1 |
| Gba, B | 1 |
| Esmel, B | 1 |
| Bokossa, EM | 1 |
| Kalilani, L | 2 |
| Zhou, Z | 5 |
| Chaluluka, E | 3 |
| Dzinjalamala, F | 1 |
| Meshnick, S | 1 |
| Warsame, M | 8 |
| Hassan, AM | 3 |
| Barrette, A | 4 |
| Jibril, AM | 2 |
| Elmi, HH | 1 |
| Arale, AM | 2 |
| Mohammady, HE | 3 |
| Nada, RA | 4 |
| Amran, JG | 2 |
| Muse, A | 1 |
| Yusuf, FE | 2 |
| Omar, AS | 1 |
| Rouhani, M | 1 |
| Zakeri, S | 5 |
| Pirahmadi, S | 2 |
| Raeisi, A | 3 |
| Djadid, ND | 5 |
| Artimovich, E | 1 |
| Schneider, K | 1 |
| Taylor, TE | 9 |
| Kublin, JG | 12 |
| Dzinjalamala, FK | 6 |
| Escalante, AA | 6 |
| Takala-Harrison, S | 1 |
| von Seidlein, L | 6 |
| Dondorp, A | 2 |
| Beavogui, AH | 3 |
| Toure, O | 1 |
| Sangare, CP | 1 |
| Dama, S | 3 |
| N'Dong, C | 1 |
| Niangaly, H | 1 |
| Diallo, N | 1 |
| Dembele, D | 3 |
| Mubikayi, L | 2 |
| Mulele, CK | 2 |
| Okoth, SA | 2 |
| Komino, F | 1 |
| Onyona, P | 1 |
| Goldman, IF | 1 |
| Ljolje, D | 2 |
| Barnwell, JW | 4 |
| Koukouikila-Koussounda, F | 1 |
| Bakoua, D | 1 |
| Fesser, A | 1 |
| Nkombo, M | 1 |
| Vouvoungui, C | 1 |
| Ntoumi, F | 3 |
| Siame, MN | 1 |
| Thuma, P | 4 |
| Abdallah, J | 1 |
| Iriemenam, NC | 2 |
| Tawat, S | 1 |
| Lorry, L | 1 |
| Batty, KT | 2 |
| Davis, TM | 8 |
| Talawanich, Y | 1 |
| Hasang, W | 1 |
| Brown, GV | 1 |
| Chauvin, P | 1 |
| Nsango, SE | 1 |
| Tchioffo, MT | 1 |
| Abate, L | 1 |
| Awono-Ambéné, PH | 1 |
| Morlais, I | 1 |
| Ibitokou, SA | 1 |
| Denoeud-Ndam, L | 1 |
| Ezinmegnon, S | 1 |
| Ladékpo, R | 1 |
| Zannou, DM | 1 |
| Girard, PM | 1 |
| Kibuchi, E | 1 |
| Karuri, SW | 1 |
| Sang, G | 1 |
| Gitonga, CW | 2 |
| Noor, AM | 2 |
| Gupta, R | 2 |
| Tyagi, PK | 1 |
| Mbonye, AK | 2 |
| Birungi, J | 1 |
| Yanow, SK | 1 |
| Shokoples, S | 1 |
| Malamba, S | 1 |
| Ferenchick, E | 1 |
| Tshibola, ML | 1 |
| Nzong, J | 1 |
| Bahamontes-Rosa, N | 1 |
| Tsoumbou-Bakana, G | 2 |
| Harrington, WE | 2 |
| Moirangthem, R | 1 |
| Gahlawat, SK | 1 |
| Chandra, J | 1 |
| Gupta, P | 1 |
| Singh, V | 1 |
| Cano, J | 1 |
| Ariti, C | 1 |
| Collier, TJ | 1 |
| Erhart, A | 3 |
| Kazienga, A | 1 |
| Fitzhenry, R | 1 |
| VanOvermeir, C | 1 |
| Van Geertruyden, JP | 4 |
| Sharma, D | 1 |
| Lather, M | 1 |
| Dykes, CL | 1 |
| Dang, AS | 1 |
| Adak, T | 3 |
| Singh, OP | 1 |
| Tessema, SK | 1 |
| Leta, GT | 1 |
| Guma, GT | 1 |
| Adeel, AA | 3 |
| Saeed, NA | 1 |
| Aljasari, A | 1 |
| Almohager, AM | 1 |
| Galab, MH | 1 |
| AlMahdi, A | 1 |
| Mahammed, MH | 1 |
| AlDarsi, M | 1 |
| Salaeah, YA | 1 |
| Atta, H | 2 |
| Zamani, G | 2 |
| Basu, A | 1 |
| Saha, S | 1 |
| Farrington, LA | 1 |
| McIntyre, TI | 1 |
| Vance, HM | 1 |
| Bowen, K | 1 |
| Boyle, MJ | 1 |
| Wamala, S | 1 |
| Auma, A | 1 |
| Nalubega, M | 1 |
| Sikyomu, E | 1 |
| Naluwu, K | 1 |
| Bigira, V | 2 |
| Kapisi, J | 2 |
| Bamaga, OA | 1 |
| Mahdy, MA | 1 |
| Lim, YA | 1 |
| Babakhanyan, A | 1 |
| Tutterrow, YL | 1 |
| Bobbili, N | 1 |
| Wey, A | 1 |
| Fogako, J | 1 |
| Leke, RJ | 1 |
| Leke, RG | 1 |
| Ogbunugafor, CB | 1 |
| Wylie, CS | 1 |
| Diakite, I | 1 |
| Weinreich, DM | 2 |
| Hartl, DL | 3 |
| Sissoko, MS | 1 |
| Guindo, CO | 1 |
| Cissé, NH | 1 |
| Coulibaly, CO | 1 |
| Ringwald, P | 14 |
| Benoit-Vical, F | 1 |
| Alim, F | 1 |
| Hanpithakpong, W | 1 |
| Kar, NP | 1 |
| Chauhan, K | 1 |
| Nanda, N | 1 |
| Carlton, JM | 1 |
| Patel, JC | 1 |
| Boivin, MJ | 1 |
| Sikorskii, A | 1 |
| Familiar-Lopez, I | 1 |
| Ruiseñor-Escudero, H | 1 |
| Muhindo, M | 1 |
| Bass, JK | 1 |
| Opoka, RO | 1 |
| Nakasujja, N | 1 |
| Caillet, C | 1 |
| Elnour, FA | 1 |
| Elmardi, KA | 7 |
| Abd-Elmajid, MB | 1 |
| Elhelo, MM | 1 |
| Snounou, G | 3 |
| Al-Jasari, A | 1 |
| Sady, H | 1 |
| Nasr, NA | 1 |
| Lau, YL | 2 |
| Surin, J | 1 |
| Mwendera, C | 1 |
| de Jager, C | 2 |
| Longwe, H | 2 |
| Phiri, K | 3 |
| Hongoro, C | 2 |
| Mutero, CM | 2 |
| Kaingona-Daniel, EP | 1 |
| Gomes, LR | 1 |
| Gama, BE | 2 |
| Almeida-de-Oliveira, NK | 1 |
| Daniel-Ribeiro, CT | 2 |
| Ferreira-da-Cruz, Mde F | 2 |
| Moutandou Chiesa, S | 1 |
| Tshibola Mbuyi, ML | 1 |
| Zong, J | 1 |
| Ambounda, N | 1 |
| Kimani, J | 1 |
| Kamiza, S | 1 |
| Duparc, S | 1 |
| Ayoub, A | 1 |
| Rojo, R | 1 |
| Robbins, J | 1 |
| Orrico, R | 1 |
| Vandenbroucke, P | 1 |
| Protas, J | 1 |
| Tarimo, D | 2 |
| Moshiro, C | 1 |
| Kaaya, RD | 1 |
| Krogsgaard, C | 1 |
| Notland, JG | 1 |
| Ishengoma, D | 1 |
| Alareqi, LMQ | 1 |
| Mahdy, MAK | 1 |
| Fong, MY | 1 |
| Mahmud, R | 1 |
| Morton, LC | 1 |
| Huber, C | 2 |
| Griffing, S | 1 |
| Lucchi, N | 1 |
| Oscar, R | 2 |
| Townes, D | 1 |
| McMorrow, M | 1 |
| Kakar, Q | 1 |
| Sheikh, S | 1 |
| Ahmed, I | 1 |
| Khan, MA | 1 |
| Jamil, M | 1 |
| ElMohammady, H | 1 |
| Kateera, F | 1 |
| Hakizimana, E | 1 |
| Mutesa, L | 1 |
| Grobusch, MP | 9 |
| van Vugt, M | 1 |
| Kumar, N | 3 |
| Ouldabdallahi, MM | 1 |
| Sarr, O | 3 |
| Lebatt, SM | 1 |
| Lo, B | 1 |
| Norahmad, NA | 1 |
| Mohd Abd Razak, MR | 1 |
| Abdullah, NR | 1 |
| Sastu, UR | 1 |
| Muniandy, PK | 1 |
| Saat, MN | 1 |
| Muhammad, A | 1 |
| Jelip, J | 1 |
| Tikuson, M | 1 |
| Yusof, N | 1 |
| Rundi, C | 1 |
| Mudin, RN | 1 |
| Syed Mohamed, AF | 1 |
| Guerra, M | 1 |
| Neres, R | 1 |
| Salgueiro, P | 1 |
| Mendes, C | 1 |
| Ndong-Mabale, N | 1 |
| de Sousa, B | 1 |
| Arez, AP | 1 |
| Yongkiettrakul, S | 1 |
| Kampeera, J | 1 |
| Chareanchim, W | 1 |
| Rattanajak, R | 1 |
| Pornthanakasem, W | 1 |
| Kiatpathomchai, W | 1 |
| Oguike, MC | 1 |
| Shu, E | 2 |
| Watila, I | 1 |
| Baba, ES | 1 |
| Webster, J | 2 |
| Hamade, P | 1 |
| Meek, S | 1 |
| Warhurst, D | 2 |
| Mipando, M | 1 |
| Jensen, AT | 2 |
| Sepúlveda, N | 1 |
| Kwiatkowski, DP | 1 |
| Montgomery, J | 4 |
| Phiri, KS | 1 |
| Terlouw, A | 1 |
| Craig, A | 1 |
| Ocholla, H | 1 |
| Zhou, LJ | 1 |
| Xia, J | 1 |
| Wei, HX | 1 |
| Liu, XJ | 1 |
| Peng, HJ | 1 |
| Soulama, A | 1 |
| Hassan, AH | 1 |
| Mohamud, SA | 1 |
| Muse, AY | 1 |
| Mwendera, CA | 1 |
| Pholwat, S | 1 |
| Liu, J | 1 |
| Stroup, S | 1 |
| Jacob, ST | 1 |
| Banura, P | 1 |
| Moore, CC | 1 |
| Houpt, E | 1 |
| Guler, JL | 1 |
| Jovel, IT | 1 |
| Björkman, A | 11 |
| Certain, LK | 1 |
| Briceño, M | 1 |
| Nzila, AM | 5 |
| Watkins, WM | 17 |
| Ahouidi, AD | 1 |
| Ly, O | 1 |
| Daily, JP | 1 |
| Mboup, S | 1 |
| Ouédraogo, LT | 1 |
| Somé, IT | 1 |
| Guissou, IP | 1 |
| Maiteki-Sebuguzi, C | 2 |
| Yau, VM | 1 |
| Njama-Meya, D | 2 |
| Nzarubara, B | 3 |
| Talisuna, AO | 4 |
| Balogun, T | 1 |
| Adedeji, AA | 13 |
| Bolaji, OM | 2 |
| Fehintola, FA | 10 |
| Best Plummer, W | 1 |
| Pinto Pereira, L | 1 |
| Enosse, S | 4 |
| Abacassamo, F | 2 |
| Gómez-Olivé, X | 1 |
| Rønn, AM | 9 |
| Souares, A | 2 |
| Lalou, R | 2 |
| Sene, I | 2 |
| Sow, D | 3 |
| Le Hesran, JY | 3 |
| Cairo, J | 2 |
| Durand, S | 2 |
| Marquiño, W | 5 |
| Cabezas, C | 4 |
| Lachira, A | 1 |
| Quintana, F | 1 |
| Vegas, W | 1 |
| Ruebush, TK | 10 |
| Utz, G | 2 |
| Bacon, DJ | 2 |
| Clarke, SE | 1 |
| Jukes, MC | 1 |
| Njagi, JK | 1 |
| Khasakhala, L | 1 |
| Cundill, B | 1 |
| Otido, J | 1 |
| Crudder, C | 1 |
| Estambale, BB | 1 |
| Brooker, S | 1 |
| Naniche, D | 1 |
| Lahuerta, M | 1 |
| Sigauque, B | 7 |
| Romagosa, C | 1 |
| Berenguera, A | 1 |
| Mandomando, I | 9 |
| David, C | 1 |
| Aponte, J | 2 |
| Ordi, J | 3 |
| Alonso, P | 6 |
| Zhong, D | 1 |
| Githeko, A | 1 |
| Menge, DM | 1 |
| Yan, G | 2 |
| Pinoges, L | 2 |
| Turyakira, E | 1 |
| Checchi, F | 5 |
| Bukirwa, H | 2 |
| van den Broek, I | 2 |
| Urruta, PP | 1 |
| van Herp, M | 3 |
| Balkan, S | 5 |
| Taylor, WR | 2 |
| Olliaro, P | 6 |
| Guthmann, JP | 13 |
| Carmona-Fonseca, J | 2 |
| Arango, E | 2 |
| Blair, S | 4 |
| Ochong, E | 4 |
| Johnson, DJ | 1 |
| Muangnoicharoen, S | 1 |
| Winstanley, PA | 13 |
| Bray, PG | 1 |
| Owen, A | 1 |
| Clerk, CA | 1 |
| Affipunguh, PK | 1 |
| Mensah, N | 1 |
| Hodgson, A | 2 |
| McCollum, AM | 6 |
| Tahar, R | 10 |
| Lepère, JF | 1 |
| Zikusooka, CM | 1 |
| McIntyre, D | 1 |
| May, J | 10 |
| Adjei, S | 7 |
| Busch, W | 3 |
| Gabor, JJ | 2 |
| Issifou, S | 8 |
| Kobbe, R | 7 |
| Kreuels, B | 4 |
| Lell, B | 10 |
| Schwarz, NG | 2 |
| Adjei, O | 6 |
| Kremsner, PG | 15 |
| Bedu-Addo, G | 4 |
| Eggelte, TA | 11 |
| Hommerich, L | 3 |
| Holmberg, V | 2 |
| von Oertzen, C | 2 |
| Bienzle, U | 12 |
| Olliaro, PL | 2 |
| Delenne, H | 1 |
| Badiane, M | 1 |
| Olliaro, A | 1 |
| Vaillant, M | 1 |
| Brasseur, P | 1 |
| Figueiredo, P | 3 |
| Benchimol, C | 1 |
| Lopes, D | 2 |
| Bernardino, L | 1 |
| do Rosário, VE | 3 |
| Varandas, L | 2 |
| Nogueira, F | 1 |
| Takahashi, N | 4 |
| Ndounga, M | 6 |
| Dzodzomenyo, M | 1 |
| Akhwale, WS | 1 |
| Kobayakawa, T | 4 |
| Alker, AP | 3 |
| Kazadi, WM | 2 |
| Kutelemeni, AK | 1 |
| Bloland, PB | 8 |
| Drakeley, CJ | 3 |
| Al-Kabsi, AM | 1 |
| Al-Shamahy, HA | 1 |
| Al-Harazy, AH | 1 |
| Harmal, NS | 1 |
| Senn, M | 1 |
| Lin, E | 2 |
| Law, I | 2 |
| Gomorrai, PS | 1 |
| Oa, O | 3 |
| Griffin, S | 2 |
| Kotab, K | 1 |
| Suano, P | 1 |
| Tarongka, N | 1 |
| Ura, A | 1 |
| Lautu, D | 1 |
| Wong, R | 1 |
| Siba, P | 3 |
| Dietmann, A | 1 |
| Lackner, P | 1 |
| Helbok, R | 1 |
| Spora, K | 1 |
| Reindl, M | 1 |
| Schmutzhard, E | 1 |
| Fanello, CI | 5 |
| Karema, C | 6 |
| Avellino, P | 1 |
| Bancone, G | 1 |
| Lee, SJ | 1 |
| Modiano, D | 1 |
| Newman, RD | 7 |
| McMorrow, ML | 1 |
| Hoppe, A | 1 |
| Yattara, O | 2 |
| Traore, H | 1 |
| Kone, Y | 1 |
| Guirou, EA | 1 |
| Saye, R | 2 |
| Serra-Casas, E | 8 |
| Puyol, L | 5 |
| Gies, S | 1 |
| Ouattara, FT | 1 |
| Ogunfowokan, O | 1 |
| Dankyau, M | 1 |
| Madaki, AJ | 1 |
| Thacher, TD | 2 |
| Oesterholt, MJ | 1 |
| Omar, SA | 4 |
| Sawa, P | 3 |
| Howitt, C | 1 |
| Gouagna, LC | 3 |
| Sauerwein, RW | 6 |
| Sisowath, C | 1 |
| Petersen, I | 1 |
| Veiga, MI | 3 |
| Premji, Z | 10 |
| Gil, JP | 2 |
| Fofana, B | 3 |
| Ouologuem, D | 3 |
| Kone, A | 2 |
| Wele, M | 2 |
| Nahum, A | 2 |
| Ahounou, D | 1 |
| Bonou, D | 1 |
| Van Overmeir, C | 9 |
| Menten, J | 2 |
| Akogbeto, M | 2 |
| Coosemans, M | 2 |
| Abdelgadir, T | 2 |
| Ali, SH | 1 |
| Elsyed, AH | 1 |
| Mudather, MA | 1 |
| Elhassan, AH | 2 |
| Anderson, T | 2 |
| Pearce, RJ | 6 |
| Pota, H | 3 |
| Malisa, AL | 4 |
| Ord, R | 7 |
| Inojosa, W | 1 |
| Matondo, A | 2 |
| Diallo, DA | 5 |
| Mbacham, W | 2 |
| van den Broek, IV | 4 |
| Swarthout, TD | 2 |
| Getachew, A | 1 |
| Dejene, S | 1 |
| Njie, F | 1 |
| Dunyo, S | 4 |
| Kweku, M | 3 |
| Bonnet, M | 3 |
| Clarke, S | 3 |
| Katokele, ST | 1 |
| Uusiku, P | 1 |
| Agboghoroma, CO | 1 |
| Elegba, OY | 1 |
| A-Elbasit, IE | 4 |
| Giha, HA | 4 |
| Kachur, SP | 7 |
| Lynch, C | 1 |
| Rwakimari, JB | 1 |
| Chanda, P | 1 |
| Hawela, M | 1 |
| Sharp, B | 5 |
| Rulisa, S | 2 |
| Sissoko, K | 1 |
| Dara, N | 2 |
| Dicko, YT | 1 |
| Jansen, FH | 5 |
| Al-Saai, S | 1 |
| Abdel-Muhsin, AM | 3 |
| Al-Ghazali, A | 1 |
| Nwakanma, D | 2 |
| Swedberg, G | 7 |
| Bonizzoni, M | 1 |
| Amenya, DA | 1 |
| Githeko, AK | 1 |
| Fifer, H | 1 |
| bin Reza, F | 1 |
| Nicholas, M | 1 |
| Haustein, T | 1 |
| Njimgye-Tekumafor, NE | 1 |
| Doherty, JF | 1 |
| Gothard, P | 1 |
| Polley, SD | 1 |
| Chiodini, PL | 1 |
| Mwai, L | 1 |
| Abdirahman, A | 1 |
| Ward, S | 3 |
| Kokwaro, G | 4 |
| Sasi, P | 1 |
| Marsh, K | 11 |
| Borrmann, S | 1 |
| Mackinnon, M | 1 |
| Mutabingwa, TK | 5 |
| Muehlenbachs, A | 2 |
| Sorensen, B | 1 |
| Bolla, MC | 1 |
| Faucher, JF | 2 |
| Aubouy, A | 5 |
| Gourmel, B | 1 |
| Houzé, P | 1 |
| Kossou, H | 2 |
| Amedome, H | 1 |
| Abro, AH | 1 |
| Ustadi, AM | 1 |
| Abro, HA | 1 |
| Abdou, AS | 1 |
| Younis, NJ | 1 |
| Akaila, SI | 1 |
| Barger, B | 1 |
| Tembine, I | 2 |
| Gantt, S | 1 |
| Little, F | 7 |
| Camba, T | 1 |
| Cassam, Y | 3 |
| Boulle, A | 1 |
| Lozovsky, ER | 1 |
| Brown, KM | 2 |
| Neafsey, DE | 1 |
| Sinclair, D | 1 |
| Zani, B | 1 |
| Donegan, S | 1 |
| de Oliveira, NK | 1 |
| Zalis, MG | 1 |
| de Souza, JM | 1 |
| Santos, F | 1 |
| Broek, Iv | 1 |
| Urrutia, PP | 1 |
| Kyomuhendo, J | 1 |
| Ndosimao, CN | 1 |
| Ashley, E | 1 |
| Hombhanje, FW | 1 |
| Linge, D | 1 |
| Saweri, A | 1 |
| Kuanch, C | 1 |
| Jones, R | 1 |
| Toraso, S | 1 |
| Geita, J | 1 |
| Masta, A | 1 |
| Kevau, I | 1 |
| Hiawalyer, G | 1 |
| Sapuri, M | 1 |
| Menegon, M | 1 |
| Inojosa, WO | 1 |
| Pisani, V | 1 |
| Abel, PM | 1 |
| Bisoffi, Z | 2 |
| Majori, G | 1 |
| Warhurst, DC | 4 |
| Boly, MD | 1 |
| Le Bras, J | 10 |
| Gosling, RD | 3 |
| Gesase, S | 1 |
| Mosha, JF | 1 |
| Carneiro, I | 3 |
| Hashim, R | 1 |
| Lemnge, M | 2 |
| Mosha, FW | 1 |
| Schellenberg, D | 5 |
| Egan, A | 1 |
| Breckenridge, A | 1 |
| Critchley, J | 2 |
| Danquah, I | 1 |
| Dodoo, A | 1 |
| Sevene, E | 1 |
| Soulaymani-Becheikh, R | 1 |
| Winstanley, P | 3 |
| Anemana, S | 1 |
| Mockenhaupt, F | 1 |
| Tanner, M | 8 |
| Nyunt, MM | 1 |
| van Dijk, J | 1 |
| Mauff, K | 1 |
| Guirou, E | 1 |
| Doumbo, O | 7 |
| Sullivan, D | 2 |
| Smith, P | 1 |
| Lumb, V | 2 |
| Sharma, YD | 4 |
| Adjuik, M | 2 |
| Abudey, S | 1 |
| Bougouma, EC | 1 |
| Konaté, AT | 4 |
| Nakeesathit, S | 1 |
| Eastman, RT | 1 |
| Leslie, T | 3 |
| Kaur, H | 1 |
| Mohammed, N | 1 |
| Kolaczinski, K | 3 |
| Ord, RL | 1 |
| Rowland, M | 5 |
| Nawaz, F | 1 |
| Kiggundu, M | 2 |
| Joloba, M | 1 |
| Newman, PM | 1 |
| Wanzira, H | 1 |
| Tumwine, G | 1 |
| Waldman, S | 1 |
| Achan, J | 1 |
| Havlir, D | 1 |
| Cohan, D | 1 |
| Sijuade, A | 1 |
| Oduola, A | 1 |
| Chauhan, VS | 2 |
| Mixson-Hayden, T | 1 |
| Jain, V | 1 |
| Poe, A | 2 |
| Nagpal, AC | 2 |
| Dash, AP | 2 |
| Stiles, JK | 1 |
| Smith, TA | 4 |
| Hastings, IM | 3 |
| Müller, I | 2 |
| Sie, A | 3 |
| Baisor, M | 1 |
| Reeder, JC | 4 |
| Beck, HP | 7 |
| Tchantchou, Tde D | 1 |
| Eto, H | 2 |
| Tsukahara, T | 4 |
| Sarker, S | 1 |
| Endo, H | 1 |
| Ateh, IA | 1 |
| Ajua, A | 1 |
| Nji, AM | 1 |
| Irenee, D | 1 |
| Echouffo-Tcheugui, JB | 1 |
| Tawe, B | 1 |
| Targett, G | 5 |
| de Sousa, A | 2 |
| Salama, P | 1 |
| Chopra, M | 1 |
| Nzenze-Afene, S | 1 |
| Ngoungou, EB | 1 |
| Owono-Medang, M | 1 |
| Lekana-Douki, JB | 1 |
| Obono-Obiang, G | 1 |
| Mounanga, M | 1 |
| Okafor, HU | 2 |
| Shu, EN | 1 |
| Oguonu, T | 1 |
| Whegang, SY | 2 |
| Foumane, VN | 1 |
| Soula, G | 3 |
| Gwét, H | 2 |
| Thalabard, JC | 2 |
| Distiller, GB | 1 |
| Shekalaghe, SA | 1 |
| ter Braak, R | 1 |
| Daou, M | 1 |
| Kavishe, R | 1 |
| van den Bijllaardt, W | 1 |
| van den Bosch, S | 1 |
| Koenderink, JB | 1 |
| Whitty, CJ | 1 |
| Dlamini, SV | 1 |
| Beshir, K | 2 |
| Yusuf, RU | 1 |
| Ngure, RM | 1 |
| Somé, AF | 1 |
| Séré, YY | 1 |
| Dokomajilar, C | 8 |
| Rouamba, N | 4 |
| Aitken, EH | 1 |
| Mbewe, B | 2 |
| Friso, MJ | 1 |
| Fowkes, FJ | 1 |
| Beeson, JG | 2 |
| Kinzer, MH | 1 |
| Chand, K | 2 |
| Basri, H | 1 |
| Lederman, ER | 2 |
| Susanti, AI | 2 |
| Elyazar, I | 2 |
| Taleo, G | 1 |
| Rogers, WO | 1 |
| Bangs, MJ | 6 |
| Maguire, JD | 4 |
| Farahani, MS | 1 |
| Afsharpad, M | 3 |
| Salehi, M | 1 |
| Maharaj, R | 1 |
| Cairns, ME | 1 |
| Gregson, A | 1 |
| Toure, AM | 1 |
| Dao, A | 2 |
| Sacko, A | 1 |
| Niare, O | 1 |
| Picot, S | 2 |
| Okell, L | 1 |
| Shekalaghe, S | 2 |
| Omar, S | 2 |
| Sauerwein, R | 3 |
| Corredor, V | 1 |
| Murillo, C | 1 |
| Echeverry, DF | 1 |
| Benavides, J | 1 |
| Osorio, L | 3 |
| Abdulla, S | 5 |
| Kachur, PS | 2 |
| Bloland, P | 6 |
| Ballif, M | 1 |
| Hii, J | 1 |
| Crameri, A | 1 |
| Fafale, A | 1 |
| Felger, I | 2 |
| Nébié, IO | 1 |
| Liljander, A | 1 |
| Olsson, D | 1 |
| Montgomery, SM | 4 |
| Färnert, A | 2 |
| Scahill, MD | 1 |
| Dhillon, GP | 1 |
| Arora, U | 2 |
| Ayede, IA | 1 |
| Falade, AG | 4 |
| Maixenchs, M | 1 |
| Mabunda, S | 3 |
| Annie, A | 1 |
| Tine, RC | 3 |
| Hogan, B | 1 |
| Klein, P | 1 |
| Loag, W | 1 |
| Quelhas, D | 3 |
| Wilson, DW | 1 |
| Richards, JS | 1 |
| Nhampossa, T | 3 |
| Aide, P | 5 |
| Ghanchi, NK | 1 |
| Beg, MA | 1 |
| Jafri, S | 1 |
| Seboxa, T | 1 |
| Mao, P | 1 |
| Pinchouk, N | 1 |
| Anbessie, J | 1 |
| Alemu, H | 1 |
| Diro, E | 1 |
| Pitus, N | 1 |
| Winmai, J | 1 |
| Moore, B | 1 |
| Dimbu, R | 1 |
| Neto, Z | 1 |
| Alam, MT | 1 |
| de Souza, DK | 1 |
| Vinayak, S | 2 |
| Griffing, SM | 3 |
| Poe, AC | 2 |
| Duah, NO | 2 |
| Asamoa, K | 2 |
| Terlouw, DJ | 2 |
| Ranjitkar, S | 1 |
| Schousboe, ML | 1 |
| Thomsen, TT | 1 |
| Adhikari, M | 1 |
| Kapel, CM | 1 |
| Tipsuwan, W | 1 |
| Srichairatanakool, S | 1 |
| Mullick, S | 2 |
| Bera, DK | 2 |
| Sengupta, S | 1 |
| Roy, D | 1 |
| Das, M | 2 |
| Ray, K | 2 |
| Oyakhirome, S | 3 |
| Greutélaers, KC | 1 |
| Profanter, K | 1 |
| Greutélaers, B | 1 |
| Kurth, F | 1 |
| Kun, JF | 5 |
| Costanzo, MS | 1 |
| Menemedengue, V | 1 |
| Sahnouni, K | 1 |
| Basco, L | 2 |
| Bertin, G | 2 |
| Bonaventure, D | 1 |
| Carrieu, A | 1 |
| Diouf, I | 1 |
| Mengue, ML | 1 |
| Gaye, A | 1 |
| Mubjer, RA | 1 |
| Chance, ML | 1 |
| Hassan, AA | 1 |
| Malisa, A | 3 |
| Pearce, R | 5 |
| Abdullah, S | 2 |
| Mutayoba, B | 1 |
| Kachur, P | 1 |
| Ouédraogo, AZ | 1 |
| Kangoyé, DT | 1 |
| Kaboré, Y | 1 |
| Ouédraogo, E | 1 |
| Ouédraogo, IN | 1 |
| Cousens, S | 2 |
| Milligan, PJ | 2 |
| Greenwood, BM | 6 |
| Dicko, M | 1 |
| Diallo, AI | 1 |
| Dicko, Y | 1 |
| Santara, G | 1 |
| Conaré, T | 1 |
| Tsumori, Y | 1 |
| Sunahara, T | 1 |
| Hayashida, N | 1 |
| Inoue, M | 1 |
| Nakazawa, S | 1 |
| Casimiro, P | 1 |
| Isozumi, R | 1 |
| Kiyingi, HS | 1 |
| Egwang, TG | 4 |
| Nannyonga, M | 1 |
| Andriantsoanirina, V | 2 |
| Durand, R | 6 |
| Baret, E | 3 |
| Bouchier, C | 2 |
| Hand, CC | 1 |
| Mwandagalirwa, K | 1 |
| Messina, JP | 1 |
| Atua, B | 1 |
| Emch, M | 1 |
| Muwonga, J | 1 |
| Zeile, I | 1 |
| Gahutu, JB | 1 |
| Shyirambere, C | 1 |
| Steininger, C | 1 |
| Musemakweri, A | 1 |
| Sebahungu, F | 1 |
| Harms, G | 1 |
| Mutayoba, BM | 2 |
| Shah, M | 2 |
| Vanden Eng, J | 2 |
| Blackstock, AJ | 1 |
| Garner, K | 1 |
| Gatei, W | 2 |
| Gimnig, JE | 1 |
| Lindblade, K | 1 |
| Terlouw, D | 1 |
| ter Kuile, F | 2 |
| Hawley, WA | 1 |
| Phillips-Howard, P | 2 |
| Walker, E | 1 |
| Hamel, MJ | 5 |
| Bojang, KA | 1 |
| Conway, DJ | 1 |
| Koita, OA | 1 |
| Doumbia, SO | 1 |
| Coulibaly, TF | 1 |
| Coulibaly, M | 1 |
| Konaté, L | 1 |
| Sy, N | 1 |
| Sogoba, N | 1 |
| Jawara, M | 4 |
| Poudiougou, B | 1 |
| Diawara, S | 2 |
| Okebe, J | 1 |
| Sangaré, L | 1 |
| Abubakar, I | 1 |
| Sissako, A | 1 |
| Kéita, M | 1 |
| Kandeh, B | 1 |
| Long, CA | 1 |
| Fairhurst, RM | 1 |
| Duraisingh, M | 2 |
| Perry, R | 1 |
| Muskavitch, MA | 1 |
| Valim, C | 1 |
| Volkman, SK | 1 |
| Krogstad, DJ | 1 |
| Ndour, CT | 1 |
| Bassene, C | 1 |
| Ndour, JD | 1 |
| Tutu, EO | 1 |
| Lawson, B | 1 |
| Browne, E | 3 |
| Schellenberg, JR | 1 |
| Maokola, W | 1 |
| Shirima, K | 1 |
| Manzi, F | 1 |
| Mrisho, M | 1 |
| Mushi, A | 1 |
| Schellenberg, DM | 2 |
| Saito-Nakano, Y | 1 |
| Arango, EM | 1 |
| Upegui, YA | 1 |
| Ali, I | 2 |
| Durrani, N | 4 |
| Lee, S | 1 |
| Barends, M | 3 |
| Gil, M | 1 |
| Amalvict, R | 1 |
| Chattopadhyay, G | 1 |
| Mutabingwa, T | 2 |
| van Spronsen, JH | 1 |
| Schneider, TA | 1 |
| Atasige, S | 1 |
| Schneider, KA | 1 |
| Ter-Kuile, F | 1 |
| Lal, AA | 5 |
| Tiono, A | 1 |
| Konate, A | 1 |
| Theisen, M | 2 |
| Dodoo, D | 1 |
| Antonia, AL | 1 |
| Feng, G | 1 |
| Molyneux, ME | 9 |
| Amor, A | 1 |
| Toro, C | 1 |
| Fernández-Martínez, A | 1 |
| Baquero, M | 1 |
| Huho, BJ | 1 |
| Killeen, GF | 1 |
| Ferguson, HM | 1 |
| Tami, A | 1 |
| Lengeler, C | 2 |
| Charlwood, JD | 1 |
| Kihonda, A | 1 |
| Kihonda, J | 1 |
| Abdulla, SM | 4 |
| Ayisi, J | 2 |
| Owino, SO | 1 |
| Omosun, YO | 1 |
| Otieno, K | 2 |
| Moore, J | 1 |
| Ouma, P | 3 |
| Khatib, RA | 3 |
| Njau, JD | 1 |
| Goodman, CA | 2 |
| Elling, BF | 2 |
| Kahigwa, E | 5 |
| Roberts, JM | 1 |
| MacArthur, JR | 2 |
| Kabanywanyi, AM | 1 |
| Smith, EE | 2 |
| Somi, MF | 1 |
| Lyimo, T | 1 |
| Mwita, A | 2 |
| Mills, A | 2 |
| Manyando, C | 2 |
| Hamed, K | 1 |
| Wurtz, N | 1 |
| Fall, B | 1 |
| Sow, K | 1 |
| Diatta, B | 1 |
| Fall, KB | 1 |
| Mbaye, PS | 1 |
| Fall, F | 1 |
| Diémé, Y | 1 |
| Bercion, R | 1 |
| Wade, B | 1 |
| Al-Farsi, HM | 1 |
| Al-Hashami, ZS | 1 |
| Bin Dajem, SM | 1 |
| Al-Sheikh, AA | 1 |
| Al-Qahtani, A | 1 |
| Beja-Pereira, A | 1 |
| Idris, MA | 1 |
| Harrington, W | 1 |
| Duffy, P | 1 |
| Campos, PA | 1 |
| Valente, B | 1 |
| Campos, RB | 1 |
| Gonçalves, L | 1 |
| Rosário, VE | 1 |
| Silveira, H | 1 |
| Carter, TE | 1 |
| Warner, M | 1 |
| Mulligan, CJ | 1 |
| Victor, YS | 1 |
| Memnon, G | 1 |
| Fukuda, MM | 1 |
| Okech, BA | 2 |
| Sutanto, I | 2 |
| Suprianto, S | 2 |
| Widiaty, A | 1 |
| Ruckert, P | 2 |
| von Bethmann, A | 1 |
| de Monbrison, F | 1 |
| Laihad, F | 2 |
| Baird, JK | 4 |
| Hutchinson, P | 1 |
| Abuaku, BK | 1 |
| Sebeny, PJ | 1 |
| Kronmann, KC | 1 |
| Akbari, S | 1 |
| Vaidya, NK | 1 |
| Wahl, LM | 1 |
| Hecht, D | 1 |
| Fogel, GB | 1 |
| Lin, JT | 1 |
| Singh, JP | 1 |
| Ghosh, SK | 2 |
| Bhatt, RM | 1 |
| Pawluk, SA | 1 |
| Wilby, KJ | 1 |
| Ensom, MH | 1 |
| Das Sutar, SK | 1 |
| Dhangadamajhi, G | 1 |
| Kar, SK | 2 |
| Delfino, RT | 1 |
| Santos-Filho, OA | 1 |
| Figueroa-Villar, JD | 1 |
| Sangaré, D | 1 |
| Dolo, G | 1 |
| Guindo, A | 1 |
| Sissoko, M | 2 |
| Sogoba, M | 2 |
| Niambélé, MB | 1 |
| Yalcoué, D | 1 |
| Kaslow, DC | 1 |
| Klion, AD | 1 |
| Diallo, D | 1 |
| Miller, LH | 1 |
| Touré, Y | 1 |
| Méndez, F | 3 |
| Muñoz, A | 3 |
| Carrasquilla, G | 2 |
| Jurado, D | 1 |
| Arévalo-Herrera, M | 1 |
| Cortese, JF | 8 |
| Same-Ekobo, A | 2 |
| Ngane, VF | 2 |
| Metoh, T | 1 |
| Fryauff, DJ | 2 |
| Leksana, B | 1 |
| Masbar, S | 2 |
| Wiady, I | 2 |
| Sismadi, P | 3 |
| Nagesha, HS | 1 |
| Atmosoedjono, S | 1 |
| Ebrahim, GJ | 1 |
| Jerrard, DA | 1 |
| Broder, JS | 1 |
| Hanna, JR | 1 |
| Colletti, JE | 1 |
| Grundmann, KA | 1 |
| Geroff, AJ | 1 |
| Mattu, A | 1 |
| Aché, A | 1 |
| Escorihuela, M | 1 |
| Vivas, E | 1 |
| Páez, E | 1 |
| Miranda, L | 1 |
| Matos, A | 1 |
| Pérez, W | 1 |
| Díaz, O | 1 |
| Izarra, E | 1 |
| Caraballo, A | 2 |
| Contreras, CE | 1 |
| Malende, A | 1 |
| Wigayi, J | 1 |
| Msokame, C | 1 |
| Nirmalan, N | 1 |
| Wang, P | 5 |
| Sims, PF | 5 |
| Hyde, JE | 6 |
| Rason, MA | 2 |
| Rafidimanantsoa, L | 1 |
| Andrianantenaina, BH | 1 |
| Sahondra Harisoa, JL | 1 |
| Randrianarivelojosia, M | 8 |
| Abdillahi, A | 1 |
| Duale, ON | 1 |
| Ismail, AN | 1 |
| Mohamed, A | 1 |
| Warsame, A | 1 |
| Rieckmann, K | 1 |
| Cheng, Q | 3 |
| Sulo, J | 2 |
| Chimpeni, P | 4 |
| Hatcher, J | 2 |
| Zoungrana, EB | 1 |
| Guiguemde, TR | 4 |
| Van Marck, E | 5 |
| Khalil, I | 2 |
| Gabar, HA | 2 |
| Jelinek, T | 11 |
| Satti, GM | 2 |
| Aidoo, MA | 1 |
| Kolczak, MS | 3 |
| Oloo, AJ | 5 |
| Kager, PA | 5 |
| Nahlen, BL | 3 |
| Kuile, FO | 1 |
| Weerasinghe, KL | 1 |
| Galappaththy, G | 1 |
| Fernando, WP | 1 |
| Wickremasinghe, DR | 1 |
| Faizal, HM | 1 |
| Wickremasinghe, AR | 1 |
| Ladhani, S | 1 |
| Dosekun, E | 1 |
| Patel, V | 1 |
| Shingadia, D | 1 |
| Raharimalala, AL | 1 |
| Randriamanantena, A | 5 |
| Ranarivelo, LA | 1 |
| Jaureguiberry, S | 1 |
| Rakotomalala, E | 1 |
| Aida, AO | 2 |
| Peyerl-Hoffmann, G | 3 |
| Jordan, S | 3 |
| Heuschkel, C | 2 |
| el Valy, AO | 2 |
| von Sonnenburg, F | 4 |
| Christophel, EM | 4 |
| Bakary, M | 1 |
| Keundjian, A | 4 |
| Mbomat, B | 1 |
| Makita, JR | 1 |
| Migot-Nabias, F | 2 |
| Coulibaly, D | 1 |
| Thera, MA | 2 |
| Guindo, AB | 1 |
| Koné, AK | 1 |
| Cissoko, Y | 1 |
| Coulibaly, S | 1 |
| Lyke, K | 1 |
| Labbé, AC | 1 |
| Patel, S | 1 |
| Crandall, I | 1 |
| Kain, KC | 2 |
| Schwöbel, B | 1 |
| Vanisaveth, V | 3 |
| Phetsouvanh, R | 7 |
| Phompida, S | 8 |
| Lacy, MD | 1 |
| Laksana, B | 1 |
| Susanti, I | 1 |
| Basuki, W | 1 |
| Barcus, MJ | 1 |
| Marwoto, H | 1 |
| Edstein, MD | 4 |
| Tjokrosonto, S | 1 |
| Barat, LM | 5 |
| Oblitas, FE | 1 |
| Arrunátegui, M | 1 |
| Garavito, G | 1 |
| Chafloque, ML | 1 |
| Pardavé, B | 1 |
| Gutierrez, S | 3 |
| Arróspide, N | 4 |
| Carrillo, C | 1 |
| Ferro, BE | 1 |
| Castillo, CM | 1 |
| Huang, JR | 1 |
| Li, H | 1 |
| Chen, YZ | 1 |
| Jin, T | 1 |
| Schmider, N | 1 |
| Restrepo, M | 1 |
| Gasasira, AF | 1 |
| Nassali, A | 1 |
| Cattamanchi, A | 2 |
| Kyabayinze, D | 3 |
| Hubbard, A | 2 |
| Awad, MI | 1 |
| Alkadru, AM | 1 |
| Behrens, RH | 1 |
| Baraka, OZ | 1 |
| Eltayeb, IB | 2 |
| Bwijo, B | 1 |
| Takechi, M | 2 |
| Zungu, IL | 2 |
| Moriyama, Y | 1 |
| Lum, JK | 1 |
| Bergqvist, Y | 2 |
| Mishra, SS | 1 |
| Varma, HS | 1 |
| Subbarao, SK | 1 |
| Bredenkamp, B | 2 |
| Gumede, J | 1 |
| Mosha, F | 2 |
| Harisoa, JL | 1 |
| Rabarijaona, LP | 3 |
| Raharimalala, LA | 1 |
| Ranaivo, L | 1 |
| Pietra, V | 3 |
| Duchemin, JB | 1 |
| Rakotomanana, F | 1 |
| Robert, V | 5 |
| Mauclere, P | 1 |
| Bereckzy, S | 1 |
| Bousema, JT | 2 |
| Meutstege, AM | 2 |
| Okech, BE | 1 |
| Akim, NI | 1 |
| Githure, JI | 2 |
| Beier, JC | 3 |
| Strauss, R | 1 |
| Pfeifer, C | 1 |
| Tumwesigire, S | 1 |
| Watson, S | 1 |
| Parise, ME | 5 |
| Njunju, EM | 1 |
| Mukadam, RA | 3 |
| Wirima, JJ | 5 |
| Kazembe, PN | 5 |
| Kouriba, B | 2 |
| Mussano, P | 1 |
| Roche, J | 3 |
| Guerra-Neira, A | 1 |
| Nair, S | 4 |
| Williams, JT | 1 |
| Brockman, A | 5 |
| Paiphun, L | 1 |
| Smithuis, FM | 1 |
| Anderson, TJ | 2 |
| Rwagacondo, CE | 2 |
| Niyitegeka, F | 1 |
| Sarushi, J | 1 |
| Mugisha, V | 1 |
| Dujardin, JC | 4 |
| van den Ende, J | 2 |
| Fateye, BA | 13 |
| Berens, N | 1 |
| Schwoebel, B | 1 |
| JONES, SA | 2 |
| COVELL, G | 1 |
| SHUTE, PG | 1 |
| MARYON, M | 1 |
| JELLIFFE, DB | 1 |
| Langi, P | 3 |
| Watkins, WW | 3 |
| SINGH, J | 1 |
| RAY, AP | 1 |
| MISRA, BG | 1 |
| BASU, PC | 1 |
| JEFFERY, GM | 1 |
| YOUNG, MD | 2 |
| EYLES, DE | 1 |
| ARCHIBALD, HM | 2 |
| BRUCE-CHWATT, LJ | 1 |
| BURGESS, RW | 1 |
| CHARLES, LJ | 2 |
| VAN DER KAAY, HJ | 2 |
| VINCKE, IH | 1 |
| BRADY, J | 1 |
| CONTACOS, PG | 1 |
| LUNN, JS | 1 |
| COATNEY, GR | 1 |
| MCGREGOR, IA | 1 |
| POWELL, RD | 2 |
| BREWER, GJ | 2 |
| ALVING, AS | 2 |
| MILLAR, JW | 1 |
| LAING, AB | 1 |
| DEGOWIN, RL | 1 |
| Vong, S | 1 |
| Makina, BN | 1 |
| Mantshumba, JC | 1 |
| Kabuya, W | 1 |
| Kebela, BI | 1 |
| Ngimbi, NP | 1 |
| Levin, A | 1 |
| Gonzaga, V | 1 |
| Neyra, D | 1 |
| Khanthavong, M | 3 |
| Tiengkham, P | 1 |
| Vlahos, J | 1 |
| Cox-Singh, J | 3 |
| Lu, HY | 1 |
| Hackett, LP | 1 |
| Matusop, A | 1 |
| Singh, B | 1 |
| Stauffer, W | 1 |
| Fischer, PR | 1 |
| Nguyen, MH | 1 |
| Hewitt, S | 2 |
| Tran, QT | 1 |
| Tran, BK | 1 |
| Nguyen, TH | 1 |
| Vo, NP | 1 |
| Doan, HN | 1 |
| Le, DC | 1 |
| Zimmerman, PA | 2 |
| Lemnge, MM | 6 |
| Segeja, MD | 1 |
| Magesa, SM | 1 |
| Khalil, IF | 7 |
| Hugosson, E | 2 |
| Ndyomugyenyi, R | 4 |
| Depoortere, E | 2 |
| Sipilanyambe, N | 2 |
| Nkandu, E | 2 |
| Fermon, F | 1 |
| Legros, D | 3 |
| Kofoed, PE | 2 |
| Alfrangis, M | 1 |
| Poulsen, A | 1 |
| Gjedde, SB | 1 |
| Rønn, A | 1 |
| Rombo, L | 3 |
| Attaran, A | 1 |
| Curtis, C | 1 |
| Galinski, MR | 1 |
| Looareesuwan, S | 4 |
| Makanga, M | 1 |
| Talisuna, A | 3 |
| Trape, JF | 7 |
| Tarimo, DS | 2 |
| Marks, F | 4 |
| Sievertsen, J | 1 |
| Timmann, C | 1 |
| Evans, J | 1 |
| Horstmann, RD | 2 |
| Barman, K | 1 |
| Kamwendo, DS | 1 |
| Bararia, D | 1 |
| Yameen, M | 1 |
| Biswas, S | 2 |
| Ansari, MA | 3 |
| Nsimba, B | 4 |
| Malonga, DA | 4 |
| Mouata, AM | 2 |
| Louya, F | 2 |
| Kiori, J | 2 |
| Malanda, M | 2 |
| Yocka, D | 2 |
| Oko-Ossho, J | 1 |
| Ebata-Mongo, S | 1 |
| Muehlen, M | 1 |
| Schreiber, J | 3 |
| Ehrhardt, S | 3 |
| Otchwemah, R | 1 |
| Ezard, N | 1 |
| Nellepalli, P | 1 |
| Asha, AW | 1 |
| Mackinnon, MJ | 3 |
| Ali, E | 2 |
| Nassir, el-KA | 1 |
| Suleiman, S | 1 |
| Ahmed, S | 2 |
| Walliker, D | 4 |
| Hayton, K | 1 |
| Su, XZ | 1 |
| Gómez-Olivé, FX | 1 |
| Barreto, A | 1 |
| Nalunkuma-Kazibwe, A | 2 |
| Bakyaita, N | 3 |
| Kosack, C | 1 |
| Ardizzoni, E | 1 |
| Klarkowski, D | 1 |
| Kwezi, E | 1 |
| Priotto, G | 2 |
| Eriksen, J | 3 |
| Mwankusye, S | 2 |
| Mduma, S | 2 |
| Kitua, A | 3 |
| Tomson, G | 3 |
| Gustafsson, LL | 6 |
| Trotta, RF | 1 |
| Brown, ML | 1 |
| Terrell, JC | 1 |
| Geyer, JA | 1 |
| Tambo, E | 4 |
| Happi, TC | 7 |
| Oduola, AM | 12 |
| Sendagire, H | 3 |
| Lamola, S | 1 |
| Ayisi, JG | 3 |
| Otieno, JA | 2 |
| Misore, AO | 1 |
| Odondi, JO | 1 |
| Rosen, DH | 2 |
| Traore, C | 1 |
| Kouyate, B | 1 |
| Rahman, M | 2 |
| Rahman, R | 1 |
| Bangali, M | 1 |
| Talukder, MR | 1 |
| Mwenechanya, J | 1 |
| Tembo, M | 1 |
| McIlleron, H | 1 |
| Folb, PI | 1 |
| Ribeiro, I | 1 |
| Gomes, M | 1 |
| White, N | 1 |
| Supriyanto, S | 1 |
| Wilairatana, P | 1 |
| Alloueche, A | 4 |
| Bailey, W | 1 |
| Barton, S | 1 |
| Bwika, J | 2 |
| Horton, J | 1 |
| Jaffar, S | 4 |
| Kanyok, T | 1 |
| Lang, T | 1 |
| Missinou, MA | 4 |
| Mkandala, C | 1 |
| Robertson, L | 1 |
| van der Wardt, S | 1 |
| Talukder, L | 1 |
| Chakma, S | 1 |
| Anderson, TC | 1 |
| Akim, IN | 1 |
| Alvarez, T | 1 |
| Carmona, J | 1 |
| Kengne, P | 1 |
| Zampan, H | 1 |
| Veas, F | 1 |
| Dolo, A | 1 |
| Ouattara, A | 2 |
| Diakité, S | 1 |
| John, CC | 1 |
| Koech, DK | 1 |
| Sumba, PO | 1 |
| Ouma, JH | 1 |
| Staalsoe, T | 2 |
| Shulman, CE | 2 |
| Dorman, EK | 2 |
| Kawuondo, K | 2 |
| Randrianasolo, L | 2 |
| Ranarivelo, L | 1 |
| Domarle, O | 2 |
| Stivanello, E | 1 |
| Cavailler, P | 1 |
| Cassano, F | 1 |
| Kariuki, D | 2 |
| Mwangi, J | 2 |
| Omari, A | 1 |
| Elbashir, MI | 7 |
| Djaman, JA | 2 |
| Kauffy, PC | 1 |
| Yavo, W | 3 |
| Kone, M | 4 |
| Lindegårdh, N | 1 |
| Keola, S | 2 |
| Yapom, R | 1 |
| Annerberg, A | 1 |
| Babalola, CP | 2 |
| Bates, SJ | 1 |
| Ogwang, S | 1 |
| Engl, M | 1 |
| Vigl, M | 1 |
| Kollaritsch, H | 1 |
| Wiedermann, G | 1 |
| Wernsdorfer, WH | 1 |
| Osman, ME | 4 |
| Elghzali, G | 1 |
| Ahmed, GI | 1 |
| Gustafssons, LL | 1 |
| Nganda, RY | 1 |
| Marchant, T | 1 |
| Smithuis, F | 1 |
| Shahmanesh, M | 1 |
| Kyaw, MK | 1 |
| Savran, O | 1 |
| Lwin, S | 1 |
| Vreugdenhil, CJ | 1 |
| Scheper, FY | 1 |
| Hoogstraatte, SR | 1 |
| Smolders, M | 1 |
| Gikunda, S | 2 |
| Cobelens, FG | 1 |
| Okeke, IN | 1 |
| Raherinjafy, RH | 1 |
| Migliani, R | 1 |
| Mercereau-Puijalon, O | 2 |
| Bedja, SA | 2 |
| Mugittu, K | 3 |
| Ndejembi, M | 1 |
| Nkya, W | 1 |
| Kataraihya, J | 1 |
| Kaizer, E | 1 |
| Fox, SS | 1 |
| Talman, AM | 1 |
| Paul, RE | 1 |
| Sokhna, CS | 2 |
| Matteelli, A | 1 |
| Saleri, N | 1 |
| Gregis, G | 1 |
| Gaiera, G | 1 |
| Visonà, R | 1 |
| Tedoldi, S | 1 |
| Scolari, C | 1 |
| Marocco, S | 1 |
| Gulletta, M | 1 |
| Rakotoson, JD | 1 |
| Randriambelosoa, J | 1 |
| Raveloson, A | 2 |
| Rakotondrajaona, N | 1 |
| Tuseo, L | 2 |
| Pressé, J | 1 |
| de Pécoulas, PE | 2 |
| Roddy, P | 1 |
| Kamara, S | 1 |
| Williams, A | 1 |
| Morineau, G | 1 |
| Wurie, AR | 1 |
| Hora, B | 1 |
| Lamotte, Nd | 1 |
| Baerwaldt, T | 1 |
| Heinzelmann, A | 1 |
| Danks, A | 1 |
| Oloo, A | 1 |
| Smet, M | 1 |
| Wongsrichanalai, C | 1 |
| Prajakwong, S | 1 |
| Shanks, GD | 2 |
| Thimasarn, K | 3 |
| González, L | 1 |
| Ochoa, J | 1 |
| Franco, L | 1 |
| Arroyave, M | 1 |
| Restrepo, E | 1 |
| Maestre, A | 1 |
| Oduro, AR | 1 |
| Anyorigiya, T | 1 |
| Ansah, P | 1 |
| Ansah, NA | 1 |
| Atuguba, F | 1 |
| Mumuni, G | 1 |
| Amankwa, J | 1 |
| Amsalu, R | 1 |
| Balasegaram, M | 1 |
| Hepple, P | 1 |
| Alemu, E | 1 |
| Hussein, el B | 1 |
| Al-Faith, M | 1 |
| Nkya, WM | 2 |
| Salah, MT | 1 |
| Mohammed, MM | 2 |
| Himeidan, YE | 1 |
| Macheso, A | 8 |
| Nduati, E | 2 |
| Gilbert, K | 1 |
| Schoone, GJ | 1 |
| Yusuf, A | 1 |
| Kaniaru, S | 1 |
| Omer, GA | 1 |
| Schallig, HD | 1 |
| Nambei, WS | 1 |
| Gbagba, FE | 1 |
| Ndémanga, J | 1 |
| Doui-Doumgba, K | 1 |
| Diallo, TO | 1 |
| Ndadjimbaye, V | 1 |
| Flori, P | 1 |
| Perraut, R | 1 |
| Garraud, O | 1 |
| Zurovac, D | 2 |
| Ochola, SA | 2 |
| Midia, B | 2 |
| Wijeyaratne, PM | 1 |
| Chand, PB | 1 |
| Shahi, B | 1 |
| Jha, J | 1 |
| Pandey, S | 1 |
| Bannerjee, S | 1 |
| Bista, MB | 2 |
| Alexander, N | 2 |
| Coleman, R | 4 |
| Pinder, M | 5 |
| Walraven, G | 6 |
| Targett, GA | 1 |
| Taison, K | 1 |
| Negmu, K | 1 |
| Gohain, AC | 1 |
| Namchoom, NS | 1 |
| Wange, D | 1 |
| Borgohain, BK | 1 |
| Ogutu, BR | 2 |
| Mithwani, S | 1 |
| Wamola, B | 1 |
| Olola, CH | 1 |
| Lowe, B | 2 |
| Kokwaro, GO | 1 |
| Newton, CR | 2 |
| Graupner, J | 1 |
| Göbels, K | 1 |
| Lund, A | 1 |
| Richter, J | 1 |
| Häussinger, D | 1 |
| Hamour, S | 1 |
| Melaku, Y | 1 |
| Keus, K | 1 |
| Wambugu, J | 1 |
| Atkin, S | 1 |
| Ford, N | 1 |
| Hook, C | 1 |
| Ampuero, J | 1 |
| Gaboulaud, V | 1 |
| Tobback, S | 1 |
| Dunand, J | 1 |
| Saraiva, N | 1 |
| Gillet, P | 1 |
| Franco, J | 1 |
| Denoncin, A | 1 |
| Degefa, T | 1 |
| Ylquimiche, L | 1 |
| Hermenegildo, Y | 1 |
| Palacios, AM | 1 |
| Falconí, E | 1 |
| Yeka, A | 2 |
| Banek, K | 1 |
| Kironde, F | 4 |
| Nsobya, S | 1 |
| Kilian, A | 1 |
| Reingold, A | 3 |
| Wabwire-Mangen, F | 1 |
| Barnes, K | 4 |
| Mabuza, A | 4 |
| Govere, J | 4 |
| La Grange, K | 1 |
| Mngomezulu, N | 3 |
| Allen, E | 1 |
| Zitha, A | 1 |
| Mbokazi, F | 1 |
| Durrheim, D | 3 |
| Dzisi, SY | 1 |
| Teun Bousema, J | 2 |
| Wassilew, N | 2 |
| Anemana, SD | 1 |
| Cramer, JP | 1 |
| Otchwemah, RN | 2 |
| Rahim, S | 2 |
| Graham, K | 1 |
| Ahmad, F | 1 |
| Oduro-Boatey, C | 1 |
| Rodrigues, O | 1 |
| Idris, SM | 1 |
| Berzosa, PJ | 1 |
| Puente, S | 1 |
| Kaddumukasa, M | 1 |
| Ndagire, D | 1 |
| Aguttu, C | 2 |
| Nassejje, M | 1 |
| Pettersson, M | 1 |
| Akinboye, DO | 1 |
| Yusuf, BO | 1 |
| Ebong, OO | 1 |
| Kyle, DE | 2 |
| Milhous, W | 1 |
| Gerrish, SJ | 1 |
| De Koning, L | 1 |
| Duah, N | 1 |
| Quashie, N | 1 |
| Maung, UA | 1 |
| Peters, A | 1 |
| Liem, L | 1 |
| Kamal, M | 1 |
| Rahman, MR | 2 |
| Bangali, AM | 1 |
| Faiz, AM | 1 |
| Bamgboye, AE | 2 |
| Baruah, I | 1 |
| Talukdar, PK | 1 |
| Das, SC | 1 |
| Toma, H | 2 |
| Imada, Y | 1 |
| Vannachone, B | 1 |
| Miyagi, M | 1 |
| Kobayashi, J | 2 |
| Uechi, G | 1 |
| Pethuvang, R | 1 |
| Manivong, K | 1 |
| Sato, Y | 2 |
| Purfield, A | 1 |
| Kamwendo, DD | 2 |
| Tadesse, E | 1 |
| Taylor-Robinson, D | 1 |
| Jones, K | 1 |
| Khamiss, AH | 1 |
| Ahmed, ES | 2 |
| Pisciotta, J | 1 |
| Feldman, AB | 1 |
| Scholl, PF | 1 |
| Demirev, PA | 1 |
| Lin, JS | 1 |
| Shi, L | 1 |
| Wilson, PE | 1 |
| Kazadi, W | 1 |
| Nsimba, SE | 1 |
| Minzi, OM | 3 |
| Sanga, AJ | 1 |
| Petzold, M | 1 |
| Warsame, MY | 1 |
| Ibrahim, MH | 1 |
| A/elbasit, IA | 1 |
| Ali, AS | 1 |
| Malecela, EK | 1 |
| Sambu, E | 1 |
| Abdulla, R | 1 |
| Juma, MS | 1 |
| Fakih, K | 1 |
| Abdulla, KH | 1 |
| Njau, RJ | 1 |
| Uhlemann, AC | 1 |
| McIntosh, HM | 4 |
| Jones, KL | 1 |
| Mubyazi, GM | 1 |
| Gonzalez-Block, MA | 1 |
| Jima, D | 1 |
| Tesfaye, G | 1 |
| Medhin, A | 1 |
| Argaw, D | 1 |
| Babaniyi, O | 1 |
| Blokland, IE | 1 |
| Odhiambo, F | 2 |
| Bles, HM | 1 |
| Adazu, K | 1 |
| Lindblade, KA | 1 |
| Breman, JG | 2 |
| von Kalckreuth, V | 1 |
| Adjetey, TA | 2 |
| Affoumou, GB | 1 |
| Loukou, DD | 1 |
| Nebavi, NG | 2 |
| Barro-Kiki, P | 1 |
| Menan, EI | 2 |
| Lankoande, M | 1 |
| Campbell, P | 1 |
| Baruah, S | 1 |
| Narain, K | 1 |
| Rogers, CC | 1 |
| Falk, N | 1 |
| Masanja, H | 1 |
| Grandesso, F | 1 |
| Bachy, C | 1 |
| Donam, I | 1 |
| Ntambi, J | 1 |
| Habimana, J | 1 |
| Maikere, J | 1 |
| Vanlerberghe, V | 1 |
| Kerah, CH | 1 |
| Kadaru, AG | 1 |
| Gebru-Woldearegai, T | 1 |
| Hailu, A | 1 |
| Sileshi, M | 1 |
| Taye, G | 1 |
| Asfaw, M | 1 |
| Eggena, MP | 1 |
| Hopkins, H | 2 |
| Barugahare, B | 1 |
| Okello, M | 1 |
| Ssali, F | 1 |
| Mugyenyi, P | 1 |
| Cao, H | 1 |
| Eltaib, EH | 1 |
| Ahmed, OA | 1 |
| Ali, DM | 1 |
| Abdalla, MA | 1 |
| Mannoor, MK | 1 |
| Keokhamphavanh, B | 1 |
| Watanabe, H | 1 |
| Hatabu, T | 1 |
| Taguchi, N | 1 |
| Hongvangthong, B | 1 |
| Kano, S | 1 |
| Hapuarachchi, HC | 1 |
| Dayanath, MY | 1 |
| Bandara, KB | 1 |
| Abeysundara, S | 1 |
| Abeyewickreme, W | 1 |
| de Silva, NR | 1 |
| Hunt, SY | 1 |
| Djalle, D | 1 |
| Yapou, F | 1 |
| Talarmin, A | 1 |
| Schneider, P | 1 |
| Gouagna, L | 1 |
| Schallig, H | 1 |
| Boulanger, D | 1 |
| Milet, J | 1 |
| Bâ, el H | 1 |
| Richardson, K | 3 |
| Simondon, K | 1 |
| Simondon, F | 1 |
| Lines, J | 1 |
| Francis, D | 1 |
| Machekano, R | 1 |
| Burns, M | 1 |
| Baker, J | 1 |
| Auliff, AM | 1 |
| Gatton, ML | 3 |
| Kazembe, P | 9 |
| Patrick Kachur, S | 1 |
| Schulden, J | 1 |
| Kassala, H | 1 |
| Causer, LM | 1 |
| Mkikima, S | 1 |
| Mulligan, JA | 1 |
| Mandike, R | 1 |
| Palmer, N | 1 |
| Williams, H | 1 |
| English, M | 1 |
| Moran, AC | 1 |
| Benga-De, E | 1 |
| Yameogo, M | 1 |
| Lo, Y | 1 |
| Moreira, PM | 1 |
| Hwaihwanje, I | 1 |
| Osawa, H | 1 |
| Ayala, E | 1 |
| Lescano, AG | 2 |
| Gilman, RH | 2 |
| Calderón, M | 1 |
| Pinedo, VV | 1 |
| Terry, H | 1 |
| Cabrera, L | 1 |
| Vinetz, JM | 1 |
| Massele, A | 1 |
| Justin-Temu, M | 1 |
| Ericsson, O | 1 |
| Kalanda, GC | 1 |
| Verhoeff, FH | 4 |
| Brabin, BJ | 4 |
| van Doren, W | 2 |
| Myrick, A | 1 |
| Leemann, E | 1 |
| Mbaye, A | 2 |
| Balajo, B | 2 |
| Shulman, C | 4 |
| Malunga, P | 1 |
| Bennett, S | 3 |
| Fielding, K | 2 |
| de Radiguès, X | 1 |
| Diallo, KI | 1 |
| Diallo, M | 3 |
| Ngwakum, PA | 1 |
| Sacko, M | 1 |
| Bitarakwate, E | 1 |
| Pai, M | 1 |
| Nezien, D | 1 |
| Traoré, S | 1 |
| Koné, B | 1 |
| Hamel, M | 2 |
| Vulule, J | 2 |
| Schunk, M | 2 |
| Kumma, WP | 1 |
| Miranda, IB | 1 |
| Roewer, S | 1 |
| Alano, A | 1 |
| Löscher, T | 3 |
| Espasa, M | 1 |
| Thigpen, M | 1 |
| Shen, WJ | 1 |
| Thiero, M | 1 |
| Mohamed, TA | 1 |
| Mowien, RM | 1 |
| Mannan, AA | 1 |
| VangGeertruyden, JP | 1 |
| Mwananyanda, L | 3 |
| Moerman, F | 2 |
| Chilengi, R | 3 |
| Magzoub, M | 1 |
| Kasongo, W | 1 |
| Colebunders, R | 1 |
| Malamba, SS | 1 |
| Mermin, J | 1 |
| Lule, JR | 1 |
| Downing, R | 1 |
| Ransom, R | 1 |
| Kigozi, A | 1 |
| Hunt, BM | 1 |
| Youmba, JC | 1 |
| Abodo, RT | 1 |
| Obonyo, CO | 3 |
| Juma, EA | 1 |
| Vulule, JM | 1 |
| Lau, J | 1 |
| Touré, FS | 1 |
| Mezui-Me-Ndong, J | 1 |
| Ouwe-Missi-Oukem-Boyer, O | 1 |
| Ollomo, B | 1 |
| Mazier, D | 1 |
| Bisser, S | 1 |
| Kayembe, G | 1 |
| Ngamije, D | 1 |
| Amoo, AO | 1 |
| Ratcliff, A | 1 |
| Siswantoro, H | 1 |
| Kenangalem, E | 1 |
| Wuwung, M | 1 |
| Ebsworth, EP | 1 |
| Anstey, NM | 2 |
| Tjitra, E | 3 |
| Guindo, O | 1 |
| Tolo, Y | 1 |
| Fofana, M | 1 |
| Jansen, HF | 1 |
| Haque, R | 1 |
| Wagatsuma, Y | 1 |
| Salam, MA | 1 |
| Akther, S | 1 |
| Attlmayr, B | 1 |
| Fukuda, M | 1 |
| Schaecher, K | 1 |
| Miller, RS | 1 |
| Noedl, H | 1 |
| Randal, A | 1 |
| Malunga, F | 1 |
| Thuma, PE | 2 |
| Mbugi, EV | 1 |
| Balthazary, ST | 1 |
| Nyambo, TB | 1 |
| Shah, SN | 1 |
| Junge, C | 1 |
| Thesing, PC | 1 |
| Eddington, ND | 1 |
| Masonga, R | 1 |
| Takala, SL | 1 |
| Sumawinata, IW | 1 |
| Estiana, L | 1 |
| Hetzel, MW | 1 |
| Msechu, JJ | 1 |
| Goodman, C | 1 |
| Obrist, B | 1 |
| Makemba, A | 1 |
| Nathan, R | 1 |
| Schulze, A | 1 |
| Obua, C | 1 |
| Anokbonggo, WW | 1 |
| Ogwal-Okeng, JW | 1 |
| Chiria, J | 1 |
| Hellgren, U | 3 |
| Carnevale, EP | 1 |
| Kouri, D | 1 |
| DaRe, JT | 1 |
| McNamara, DT | 1 |
| Matsiegui, PB | 2 |
| Necek, M | 3 |
| Onwujekwe, O | 1 |
| Dike, N | 1 |
| Ojukwu, J | 1 |
| Uzochukwu, B | 1 |
| Ezumah, N | 1 |
| Okonkwo, P | 1 |
| von Gaertner, C | 1 |
| Boyé, R | 1 |
| Fricke, K | 1 |
| Hannibal, I | 1 |
| Karakaya, F | 1 |
| Schaller, M | 1 |
| Ulmen, U | 1 |
| Acquah, PA | 2 |
| Dietz, E | 1 |
| Aaby, P | 1 |
| Evans, A | 1 |
| Noranate, N | 1 |
| Tall, A | 3 |
| Marrama, L | 1 |
| Spiegel, A | 2 |
| Cojean, S | 1 |
| Guillotte, M | 1 |
| Bischoff, E | 1 |
| Ekala, MT | 1 |
| Patarapotikul, J | 1 |
| Ohmae, H | 1 |
| Krudsood, S | 1 |
| Schönfeld, M | 1 |
| Barreto Miranda, I | 1 |
| Maduhu, I | 1 |
| Maboko, L | 1 |
| Hoelscher, M | 1 |
| Ngasala, B | 1 |
| Isabel Veiga, M | 1 |
| Wiklund, L | 1 |
| Membi, C | 1 |
| Ibrahium, AM | 1 |
| Kheir, MM | 1 |
| Crawley, J | 1 |
| Yartey, J | 1 |
| Robalo, M | 1 |
| Serufilira, A | 1 |
| Ba-Nguz, A | 1 |
| Palmer, A | 1 |
| Steketee, R | 3 |
| Fadero, FF | 1 |
| Dada-Adegbola, HO | 1 |
| Ayede, I | 1 |
| Salako, LA | 4 |
| Mueller, K | 1 |
| Villegas, L | 1 |
| Morrow, RH | 1 |
| Ilboudo-Sanogo, E | 1 |
| Cousens, SN | 1 |
| Kiguli, J | 1 |
| Taylor, AM | 1 |
| Mazabraud, A | 2 |
| Pongratz, P | 2 |
| Barondi, F | 1 |
| Gupta, A | 1 |
| Haule, AF | 1 |
| Kagashe, GA | 1 |
| Massele, AY | 1 |
| Fernandes, N | 1 |
| Cravo, P | 1 |
| Fiestas, V | 1 |
| Puray, M | 1 |
| Lucas, C | 1 |
| Salas, C | 1 |
| Abebe, W | 1 |
| Félix, M | 1 |
| Coulibaly, L | 1 |
| Kankolongo, GM | 1 |
| Brouwer, KC | 1 |
| Mirel, LB | 1 |
| Yang, C | 1 |
| Lal, RB | 1 |
| Andrianina, NN | 1 |
| Ramiandrasoa, Z | 1 |
| Rasoarilalao, N | 1 |
| Jahevitra, M | 2 |
| Staedke, S | 1 |
| Taylor, W | 1 |
| Ekvall, H | 2 |
| Bygbjerg, I | 1 |
| Peters, PJ | 1 |
| Thigpen, MC | 1 |
| Maïga, O | 1 |
| Hubert, V | 1 |
| Renard, E | 1 |
| Koram, K | 1 |
| Le Bras, J | 1 |
| Clain, J | 1 |
| Nkhoma, S | 1 |
| Molyneux, M | 1 |
| Pérez, Ldel P | 1 |
| González, IJ | 1 |
| Mlambo, G | 1 |
| Mutambu, SL | 1 |
| Soko, W | 1 |
| Mbedzi, J | 1 |
| Chivenga, J | 1 |
| Gemperli, A | 1 |
| Kreuzberg, C | 2 |
| Thompson, B | 2 |
| Langefeld, I | 1 |
| Thompson, PA | 2 |
| Abruquah, HH | 1 |
| Ayim, M | 1 |
| Amoah, K | 1 |
| Opoku, E | 2 |
| Tukur, IU | 1 |
| Sagay, AS | 1 |
| Madaki, JK | 1 |
| Al Harthi, SA | 1 |
| Sagbo, JC | 1 |
| Kinde-Gazard, D | 1 |
| Kiniffo, R | 1 |
| Sudimack, D | 1 |
| Tanomsing, N | 1 |
| Mayengue, PI | 1 |
| Casimiro, PN | 2 |
| Matondo Maya, DW | 1 |
| Miakassissa-Mpassi, V | 1 |
| Nsonde-Ntandou, F | 1 |
| Mallanda, G | 1 |
| Vountasou, P | 1 |
| Masuadi, EM | 1 |
| Enevold, A | 3 |
| Ouma, PO | 1 |
| Sikuku, E | 1 |
| Thapa, S | 1 |
| Hollander, J | 1 |
| Linehan, M | 1 |
| Thakur, GD | 1 |
| Davis, WA | 1 |
| Herrera, S | 1 |
| Murrain, B | 1 |
| Gutiérrez, A | 1 |
| Moreno, LA | 1 |
| Manzano, M | 1 |
| Ndaro, A | 1 |
| van Meegeren, M | 1 |
| Randall, A | 1 |
| Schreiber, N | 2 |
| Klinkert, MQ | 1 |
| Mavoungou, E | 1 |
| Lammey, J | 1 |
| Gatarayiha, JP | 1 |
| Kabarisa, T | 1 |
| Ndayisaba, G | 1 |
| Maku, P | 1 |
| Goroti, M | 1 |
| Séré, Y | 1 |
| Hamer, DH | 1 |
| Mwanakasale, V | 1 |
| Macleod, WB | 1 |
| Mukwamataba, D | 1 |
| Champo, D | 1 |
| Thea, DM | 1 |
| Gill, CJ | 1 |
| Gabor, J | 1 |
| Dornemann, J | 1 |
| Potschke, M | 1 |
| Kiessling, GC | 1 |
| Langin, MU | 1 |
| Klein Klouwenberg, P | 1 |
| Klopfer, A | 1 |
| Naumann, B | 1 |
| Altun, H | 1 |
| Agnandji, ST | 1 |
| Goesch, J | 1 |
| Decker, M | 1 |
| Salazar, CL | 1 |
| Supan, C | 1 |
| Kombila, DU | 1 |
| Borchert, L | 1 |
| Koster, KB | 1 |
| Adegnika, AA | 1 |
| Glasenapp, Iv | 1 |
| Vestergaard, LS | 1 |
| de Oliveira, AM | 1 |
| Quezada, WM | 1 |
| Tosun, M | 1 |
| El-Sayed, B | 1 |
| El-Zaki, SE | 1 |
| Babiker, H | 1 |
| Gadalla, N | 1 |
| Ageep, T | 1 |
| Mansour, F | 1 |
| Baraka, O | 1 |
| Babiker, A | 1 |
| Petzold, MG | 1 |
| Gazard, D | 1 |
| Agbowai, C | 1 |
| van Loen, H | 1 |
| Elhardello, OA | 1 |
| Elhadi, MO | 1 |
| Abdalla, E | 1 |
| Randrianarivo-Solofoniaina, AE | 1 |
| Ahmed, BS | 1 |
| Rasolofomanana, JR | 1 |
| Dabo, CA | 1 |
| Diarra, MA | 1 |
| Ongoiba, A | 1 |
| Sangho, H | 1 |
| Guiyedi, V | 1 |
| Mabika-Mamfoumbi, M | 1 |
| Mourou-Mbina, JR | 1 |
| Ngoungou, E | 1 |
| Bouyou-Akotet, M | 1 |
| Loembet, R | 1 |
| Gikandi, PW | 1 |
| Ajanga, AA | 1 |
| McCollum, A | 1 |
| Escalante, A | 1 |
| Toure, S | 1 |
| Penali, LK | 1 |
| Ogungbamigbe, TO | 1 |
| Ogunro, PS | 1 |
| Okanlawon, BM | 1 |
| Kolawole, SO | 1 |
| Kerketta, AS | 1 |
| Mohapatra, SS | 1 |
| Blanke, CH | 1 |
| Naisabha, GB | 1 |
| Balema, MB | 1 |
| Mbaruku, GM | 1 |
| Heide, L | 1 |
| Müller, MS | 1 |
| Watkins, B | 1 |
| Mkulama, MA | 1 |
| Chishimba, S | 1 |
| Sikalima, J | 1 |
| Rouse, P | 1 |
| Brown, N | 1 |
| Puta, C | 3 |
| Hansen, MB | 1 |
| Molina, R | 2 |
| Amela, C | 2 |
| Alvar, J | 2 |
| Nevill, CG | 1 |
| Ochen, K | 1 |
| Munafu, CG | 1 |
| Bekobita, D | 1 |
| Sezi, CL | 1 |
| Akindele, JA | 1 |
| Abohweyere, AE | 1 |
| Beadle, C | 1 |
| Oster, CN | 1 |
| Onyango, FK | 1 |
| Chumo, DK | 1 |
| Bales, JD | 1 |
| Sherwood, JA | 1 |
| Hoffman, SL | 1 |
| Adagu, SI | 1 |
| Okoyeh, JN | 3 |
| Lege-Oguntoye, L | 3 |
| Ogala, WN | 1 |
| Ogunrinde, GO | 2 |
| Faji, JT | 1 |
| Sani, AH | 1 |
| Bouare, M | 1 |
| Wellems, TE | 2 |
| Satti, G | 1 |
| Del Nero, L | 2 |
| Lamizana, L | 2 |
| Deacon, HE | 1 |
| Freese, JA | 1 |
| Sharp, BL | 3 |
| Eldin de Pécoulas, P | 1 |
| Wilson, CM | 1 |
| Schultz, LJ | 3 |
| Chitsulo, L | 4 |
| Gereige, RS | 1 |
| Cimino, D | 1 |
| Dua, VK | 3 |
| Sarin, R | 2 |
| Sharma, VP | 4 |
| Hetzel, C | 1 |
| Fleck, SL | 1 |
| Kruse, NA | 1 |
| Jones, I | 1 |
| Sinden, RE | 2 |
| Al-Yaman, F | 1 |
| Mokela, D | 1 |
| Kamugisha, J | 1 |
| Kipp, W | 1 |
| Burnham, G | 1 |
| Manenti, F | 1 |
| Porta, E | 1 |
| Esposito, R | 1 |
| Antinori, S | 1 |
| Mugochi, T | 2 |
| Eamsila, C | 1 |
| Singharaj, P | 1 |
| Yooyen, P | 1 |
| Chatnugrob, P | 1 |
| Nopavong Na Ayuthya, A | 1 |
| Webster, HK | 2 |
| Lasserre, R | 1 |
| Mittelholzer, ML | 4 |
| Stürchler, D | 7 |
| Aouba, A | 1 |
| Walker, O | 2 |
| Omokhodion, SJ | 1 |
| Adio, R | 1 |
| Steffen, R | 1 |
| Fuchs, E | 1 |
| Schildknecht, J | 1 |
| Naef, U | 1 |
| Funk, M | 1 |
| Schlagenhauf, P | 1 |
| Nevill, C | 2 |
| Karbwang, J | 5 |
| Bangchang, KN | 1 |
| Rooney, W | 2 |
| Bunnag, D | 4 |
| Harinasuta, T | 4 |
| Soudouem, G | 1 |
| Hagos, B | 1 |
| Khan, B | 1 |
| Ofulla, AV | 1 |
| Martin, SK | 1 |
| Handunnetti, SM | 1 |
| Jayasinghe, S | 1 |
| Pathirana, PP | 1 |
| Fernando, R | 1 |
| Sheriff, MH | 1 |
| Mendis, KN | 1 |
| Angel, VH | 1 |
| Friman, G | 1 |
| Donald, RG | 1 |
| Roos, DS | 1 |
| Na Bangchang, K | 1 |
| Banmairuroi, V | 1 |
| Wezam, A | 1 |
| Ayecaba, S | 1 |
| Neurath, M | 1 |
| Benzing, A | 1 |
| Knolle, P | 1 |
| Grundmann, H | 1 |
| Dippold, W | 1 |
| Meyer zum Büschenfelde, KH | 1 |
| Edrissian, GH | 1 |
| Afshar, A | 1 |
| Sayedzadeh, A | 1 |
| Mohsseni, G | 1 |
| Satvat, MT | 1 |
| Woodrow, C | 1 |
| Emembolu, JO | 1 |
| Sarki, U | 1 |
| Slotboom, AB | 1 |
| Burgmann, H | 1 |
| Winkler, S | 1 |
| Uhl, F | 1 |
| Feucht, M | 1 |
| Feistauer, S | 1 |
| Breyer, S | 1 |
| Graninger, W | 2 |
| Lackritz, EM | 1 |
| Were, JB | 1 |
| Campbell, CC | 1 |
| Schubarth, P | 1 |
| Wallace, MR | 1 |
| Sharp, TW | 1 |
| Smoak, B | 1 |
| Iriye, C | 1 |
| Rozmajzl, P | 1 |
| Thornton, SA | 1 |
| Batchelor, R | 1 |
| Magill, AJ | 1 |
| Lobel, HO | 1 |
| Longer, CF | 1 |
| Burans, JP | 1 |
| Metzger, W | 1 |
| Mordmüller, B | 1 |
| Van Gompel, A | 1 |
| Lynen, L | 1 |
| Van Damme, W | 1 |
| Sirichaisinthop, J | 2 |
| Vijaykadga, S | 1 |
| Tansophalaks, S | 1 |
| Yamokgul, P | 1 |
| Laomiphol, A | 1 |
| Palananth, C | 1 |
| Thamewat, U | 1 |
| Tháithong, S | 3 |
| Nwanyanwu, OC | 4 |
| Ziba, C | 4 |
| Kumwenda, N | 1 |
| Redd, SC | 2 |
| van Hensbroek, MB | 2 |
| Okorie, C | 1 |
| Joof, D | 1 |
| Mbori-Ngacha, DA | 1 |
| Onyango, FE | 1 |
| Chunge, C | 1 |
| Luta, M | 1 |
| Muga, RO | 1 |
| Anabwani, GM | 1 |
| Esamai, FO | 1 |
| Menya, DA | 1 |
| Lorry, K | 1 |
| Wines, B | 1 |
| Cowman, AF | 2 |
| Giadom, B | 1 |
| de Veer, GE | 1 |
| Corrah, PT | 1 |
| Ezedinachi, E | 1 |
| Radloff, PD | 1 |
| Philipps, J | 1 |
| Nkeyi, M | 1 |
| Handschin, J | 2 |
| Zindrou, S | 1 |
| Nguyen, PD | 1 |
| Nguyen, DS | 1 |
| Sköld, O | 1 |
| Watson, P | 1 |
| Docters van Leeuwen, B | 1 |
| Bakker, DA | 1 |
| Kluin, J | 1 |
| Diop, S | 1 |
| Alene, GD | 1 |
| Pillai, CR | 1 |
| Devi, CU | 1 |
| Na-Bangchang, K | 2 |
| Tipwangso, P | 1 |
| Thanavibul, A | 1 |
| Tan-ariya, P | 1 |
| Suprakob, K | 1 |
| Kanda, T | 1 |
| Gamadzi, G | 1 |
| Gandwe, J | 1 |
| Read, M | 1 |
| Potkar, CN | 1 |
| Kshirsagar, NA | 3 |
| Kathuria, R | 1 |
| Trigg, JK | 1 |
| Mbwana, H | 1 |
| Chambo, O | 1 |
| Hills, E | 2 |
| Watkins, W | 3 |
| Curtis, CF | 1 |
| Ugbode, RO | 1 |
| Wakibara, JV | 1 |
| Mboera, LE | 1 |
| Ndawi, BT | 1 |
| Garg, MR | 1 |
| Gogtay, NJ | 2 |
| Singh, PS | 1 |
| Martin, RB | 1 |
| Masache, P | 1 |
| Kachale, B | 1 |
| Vounatsou, P | 1 |
| Acosta, CJ | 1 |
| Galindo, CM | 1 |
| Kimario, J | 1 |
| Urassa, H | 1 |
| Brabin, B | 1 |
| Kitua, AY | 1 |
| Amukoye, E | 1 |
| Mosobo, M | 1 |
| Ngumbao, E | 1 |
| Ton, M | 1 |
| Minyiri, G | 1 |
| Falaschi, F | 1 |
| Ansaloni, L | 1 |
| Sheng, WD | 1 |
| Jiddawi, MS | 1 |
| Hong, XQ | 1 |
| Lee, CS | 1 |
| Bayoumi, R | 1 |
| Dao, LD | 1 |
| Omitowoju, GO | 1 |
| Makler, MT | 1 |
| Ogundahunsi, OA | 1 |
| Piper, RC | 1 |
| Schuster, BG | 1 |
| Sondorp, E | 1 |
| Curtis, J | 4 |
| Duraisingh, MT | 3 |
| Mhina, J | 2 |
| Estrada-Franco, JG | 1 |
| Mollinedo, RE | 1 |
| Avila, JC | 1 |
| Cespedes, JL | 1 |
| Carter, D | 1 |
| Lwin, M | 2 |
| Aung, S | 2 |
| Kyaw, MP | 2 |
| Aung, H | 1 |
| Sint, N | 1 |
| Win, Y | 1 |
| Oo, H | 1 |
| Thein, H | 1 |
| Tun, SM | 1 |
| Lin, H | 1 |
| Linn, N | 1 |
| Ohn, M | 1 |
| Maung, NS | 1 |
| Soe, K | 1 |
| Oo, T | 1 |
| Nzila-Mounda, A | 1 |
| Mberu, EK | 4 |
| Gamage-Mendis, A | 1 |
| Butcher, GA | 1 |
| Begtrup, K | 1 |
| Mendis, C | 1 |
| Enosse, SM | 1 |
| Eling, W | 1 |
| Durrheim, DN | 3 |
| Schmidt-Ott, JR | 1 |
| Jones, P | 1 |
| Obaro, S | 1 |
| Doherty, T | 4 |
| Haywood, M | 1 |
| Gemperli, B | 1 |
| Gathmann, I | 1 |
| Royce, C | 1 |
| McAdam, K | 2 |
| Nwagwu, M | 1 |
| Anumudu, CA | 1 |
| Sodeinde, O | 1 |
| Ologunde, CA | 1 |
| Obi, TU | 1 |
| Wirtz, RA | 1 |
| Gordon, DM | 1 |
| Lyon, JA | 1 |
| Witzig, RS | 1 |
| Shankar, AH | 1 |
| Zurita, JQ | 1 |
| Guarda, JA | 1 |
| Chimsuku, L | 2 |
| Russell, WB | 1 |
| Broadhead, RL | 2 |
| Himonga, B | 2 |
| Nkunika, S | 1 |
| Ettling, M | 1 |
| Kapelwa, W | 1 |
| Gupta, NC | 1 |
| Cutts, F | 1 |
| Bulmer, JN | 1 |
| Peshu, N | 1 |
| Bourgeade, A | 1 |
| Delmont, J | 1 |
| Hart, CA | 1 |
| Ejov, MN | 1 |
| Tun, T | 1 |
| Sein, K | 1 |
| Bustos, DG | 2 |
| Canfield, CJ | 3 |
| Canete-Miguel, E | 1 |
| Hutchinson, DB | 3 |
| Sims, P | 1 |
| Sumawinata, I | 1 |
| Richie, TL | 1 |
| Kadir, A | 1 |
| Ingkokusumo, G | 1 |
| Ouma, J | 1 |
| Newbold, CI | 1 |
| Danis, M | 1 |
| Anderson, RM | 1 |
| Brobey, RK | 1 |
| Horii, T | 1 |
| Sukwa, TY | 1 |
| Barat, L | 1 |
| Chipipa, J | 1 |
| Kolczak, M | 1 |
| Sukwa, T | 1 |
| Ezedinachi, EN | 1 |
| Ekanem, OJ | 1 |
| Chukwuani, CM | 1 |
| Meremikwu, MM | 1 |
| Ojar, EA | 1 |
| Alaribe, AA | 1 |
| Umotong, AB | 1 |
| Haller, L | 1 |
| Rodriguez-Acosta, A | 1 |
| Mookherjee, S | 1 |
| Howard, V | 1 |
| Nzila-Mouanda, A | 1 |
| Rallón, NI | 1 |
| Osorio, LE | 2 |
| Giraldo, LE | 2 |
| Kapoor, AK | 1 |
| Lal, B | 1 |
| Dutta, GP | 1 |
| Swaroop, A | 1 |
| Diourté, Y | 1 |
| Coulibaly, Y | 1 |
| Kilian, AH | 2 |
| Westermeier, A | 1 |
| Pröll, S | 1 |
| Kabagambe, G | 2 |
| Nothdurft, HD | 1 |
| Schmidt-Ott, R | 1 |
| Thies, FL | 1 |
| Ademowo, OG | 1 |
| Urdaneta, L | 1 |
| Plowe, C | 1 |
| Goldman, I | 1 |
| Makwaya, C | 1 |
| Minjas, JN | 2 |
| Klabunde, J | 1 |
| Luckner, D | 1 |
| Alpers, M | 1 |
| Meyer, C | 1 |
| Watt, G | 1 |
| Anyalebechi, C | 1 |
| Ude, JI | 1 |
| Sadiq, A | 1 |
| Grajales, LF | 1 |
| Arriaga, AL | 1 |
| Andrade, AL | 1 |
| Parola, P | 1 |
| Djermakoye, F | 1 |
| Crassard, N | 1 |
| Bendavid, C | 1 |
| Faugère, B | 1 |
| Condomines, P | 1 |
| Ortelli, F | 1 |
| Maxwell, CA | 1 |
| Dayo, H | 1 |
| Chavalitshewinkoon-Petmitr, P | 1 |
| Pongvilairat, G | 1 |
| Auparakkitanon, S | 1 |
| Hamad, A | 1 |
| Hill, WG | 1 |
| Mosnier, J | 1 |
| Fusai, T | 1 |
| Boyd, HA | 1 |
| Ostrowski, SR | 1 |
| Cookson, ST | 1 |
| Gonzaga, PS | 1 |
| Addiss, DG | 1 |
| Wilson, M | 1 |
| Nguyen-Dinh, P | 1 |
| Wahlquist, SP | 1 |
| Weld, LH | 1 |
| Wainwright, RB | 1 |
| Gushulak, BD | 1 |
| Cetron, MS | 1 |
| Banguero, M | 1 |
| Sanchez, P | 1 |
| Carvajal, F | 1 |
| Barker, RH | 1 |
| Gervais, GW | 1 |
| Algarin, E | 1 |
| Serrano, AE | 1 |
| Cultrera, R | 1 |
| Contini, C | 1 |
| Tippawangkosol, P | 1 |
| Ubalee, R | 1 |
| Congpuong, K | 1 |
| Awono-Ambene, HP | 1 |
| Challand, S | 1 |
| Hassan, MR | 1 |
| Samad, R | 1 |
| Paul, B | 1 |
| Jalil, MA | 1 |
| Akinyinka, OO | 1 |
| Gorissen, E | 1 |
| Ashruf, G | 1 |
| Lamboo, M | 1 |
| Bennebroek, J | 1 |
| Mbaruku, G | 1 |
| Desai, S | 1 |
| Kadam, VS | 1 |
| Kamtekar, KD | 1 |
| Dalvi, SS | 1 |
| Bijl, HM | 1 |
| Kager, J | 1 |
| Koetsier, DW | 1 |
| van der Werf, TS | 1 |
| Same Ekobo, A | 1 |
| Sowunmi, CO | 1 |
| Sijuade, AO | 1 |
| Saul, A | 2 |
| Lacharme, LL | 1 |
| Fonseca, JC | 1 |
| Tobón, A | 1 |
| Raharimalala, L | 1 |
| Jambou, R | 1 |
| Deen, J | 1 |
| Vidal, J | 1 |
| Kigonya, CN | 1 |
| McFarland, W | 1 |
| Oga, A | 1 |
| Sadamitu, D | 1 |
| Hattori, Y | 1 |
| Nakamura, Y | 1 |
| Kohno, M | 1 |
| Kawauchi, S | 1 |
| Sasaki, K | 1 |
| Matsuo, M | 1 |
| Butao, D | 1 |
| Chakanika, I | 1 |
| Bustos, MD | 1 |
| Ranford-Cartwright, LC | 1 |
| Siripoon, N | 1 |
| Harnyuttanakorn, P | 1 |
| Kanchanakhan, NS | 1 |
| Seugorn, A | 1 |
| Rungsihirunrat, K | 1 |
| Cravo, PV | 1 |
| Beale, GH | 1 |
| Llanos-Cuentas, A | 1 |
| Campos, P | 1 |
| Clendenes, M | 1 |
| Gasasira, A | 1 |
| Ndeezi, G | 1 |
| Böhme, T | 1 |
| Thompson, WN | 1 |
| Athan, E | 1 |
| Mngomezulu, NM | 1 |
| Elkheir, HK | 1 |
| Elkarim, EF | 1 |
| Elkadaru, AE | 1 |
| Ibrahim, AM | 1 |
| Iyer, JK | 1 |
| Mberu, E | 2 |
| Till, H | 1 |
| Eberl, KJ | 1 |
| Currie, BJ | 1 |
| Morris, PS | 1 |
| Saunders, JR | 1 |
| Buttiëns, H | 1 |
| MacArthur, J | 1 |
| Stennies, GM | 1 |
| Green, MD | 1 |
| Ngouesse, B | 1 |
| Blackett, KN | 1 |
| Malkin, EM | 1 |
| Martino, LM | 1 |
| Hogarth, W | 1 |
| Bredenkamp, BL | 1 |
| Mthembu, SD | 1 |
| D'Acremont, V | 1 |
| Landry, P | 1 |
| Darioli, R | 1 |
| Stuerchler, D | 1 |
| Pécoud, A | 1 |
| Barro-Kiki, PC | 1 |
| Nigué, L | 1 |
| Konan, YJ | 1 |
| Driessen, GJ | 1 |
| van Kerkhoven, S | 1 |
| Schouwenberg, BJ | 1 |
| Bonsu, G | 1 |
| Verhave, JP | 1 |
| Lazaro, JE | 1 |
| Gay, F | 1 |
| Pottier, A | 1 |
| Laracas, CJ | 1 |
| Diquet, B | 1 |
| Thind, J | 1 |
| Garber, G | 1 |
| Yadav, RS | 1 |
| Malikul, S | 1 |
| Chittamas, S | 1 |
| Chindanond, D | 1 |
| Fernex, M | 1 |
| Kristiansen, S | 1 |
| Adio, RA | 1 |
| Reber-Liske, R | 1 |
| Dickschat, U | 1 |
| Weinke, T | 1 |
| Held, T | 1 |
| Trautmann, M | 1 |
| Rögler, G | 1 |
| Mravak, S | 1 |
| Alexander, M | 1 |
| Pohle, HD | 1 |
| Sijumbila, G | 1 |
| Nzala, S | 1 |
| Viravan, C | 1 |
| Chitamas, S | 1 |
| Molta, NB | 1 |
| Daniel, HI | 1 |
| Watila, IM | 1 |
| Oguche, SO | 1 |
| Otu, TI | 1 |
| Ameh, JO | 1 |
| Gadzama, NM | 1 |
| Keuter, M | 1 |
| Sanders, J | 1 |
| Ronday, M | 1 |
| Veltkamp, S | 1 |
| Kamsteeg, H | 1 |
| Schouten, E | 1 |
| Khalumi, G | 1 |
| Ngwawe, W | 1 |
| Wetsteyn, JC | 1 |
| Brandling-Bennett, AD | 1 |
| Pividal, J | 1 |
| Viktinski, V | 1 |
| Sudre, P | 1 |
| McFarland, D | 1 |
| Koplan, JP | 1 |
| Warn, PA | 1 |
| Waruiru, CM | 1 |
| Mwangi, IN | 1 |
| Warrell, DA | 1 |
| Reisinger, EC | 1 |
| Chan, SW | 1 |
| Songsomboon, S | 1 |
| Seesod, N | 1 |
| Sueblinwong, T | 1 |
| Goman, M | 1 |
| Ridley, R | 1 |
| Beale, G | 1 |
| Suriyamongkol, V | 1 |
| Timsaad, S | 1 |
| Chen, C | 1 |
| Zheng, X | 1 |
| Luxemburger, C | 1 |
| ter Kuiile, F | 1 |
| Frejacques, L | 1 |
| Chongsuphajaisiddhi, T | 1 |
| Irare, SG | 1 |
| Mhina, JI | 1 |
| Denis, MB | 1 |
| Kouznetsov, RL | 1 |
| Giboda, M | 1 |
| Boudreau, EF | 1 |
| Pang, LW | 1 |
| Chaikummao, S | 1 |
| Witayarut, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| ERASE - Rise Against Malaria Project - Support for Malaria Prevention, Diagnosis and Treatment in the Context of the Covid-19 Pandemic Among Pregnant Women in Northern Uganda: a Prospective Observational Study[NCT05348746] | 300 participants (Anticipated) | Observational | 2022-05-01 | Not yet recruiting | |||
| Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE)[NCT03178643] | Phase 4 | 246 participants (Actual) | Interventional | 2018-01-23 | Completed | ||
| Effect of Single-course Malaria Chemoprevention on Clearance of and Protection From Plasmodium Falciparum Infection in the Presence of Resistance-associated Genotypes in Cameroon[NCT06173206] | Phase 3 | 900 participants (Anticipated) | Interventional | 2024-03-15 | Not yet recruiting | ||
| Markers of T Cell Suppression: Associations With Malaria Infection and Antimalarial Treatment[NCT02504918] | 200 participants (Actual) | Observational | 2015-07-21 | Completed | |||
| Prevention of Malaria in HIV-uninfected Pregnant Women and Infants[NCT02793622] | Phase 3 | 782 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali[NCT01168271] | 15,000 participants (Anticipated) | Observational | 2010-08-30 | Recruiting | |||
| Operational Feasibility, Impact of Additional Screening Using Highly-sensitives RDTs Combined With High Coverage of IPTp on Placental Malaria and Low Birth Weight[NCT04147546] | Phase 3 | 340 participants (Actual) | Interventional | 2020-08-31 | Completed | ||
| Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity[NCT05757167] | Phase 4 | 2,500 participants (Anticipated) | Interventional | 2023-11-06 | Recruiting | ||
| Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants (PROMOTE Birth Cohort 1)[NCT02163447] | Phase 3 | 300 participants (Actual) | Interventional | 2014-06-23 | Completed | ||
| Efficacy, Safety, and Pharmacokinetics of Sulphadoxine-pyrimethamine-amodiaquine (SP-AQ), SP-AQ Plus Primaquine, Dihydroartemisinin-piperaquine (DP), DP Plus Methylene Blue for Preventing Transmission of P. Falciparum Gametocytes in Mali[NCT02831023] | Phase 2 | 80 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| A Study to Assess Current Standard Malaria Treatment Guidelines and Evaluate Recently Developed G6PD Diagnostic Tools in the Republic of the Sudan[NCT02592408] | Phase 4 | 320 participants (Actual) | Interventional | 2015-11-30 | Completed | ||
| Comparison of IST Using Ultra-sensitive Malaria Rapid Diagnostic Test and Pyronaridine - Artesunate - PYRAMAX®) to Standard IPT Sulfadoxine-pyrimethamine to Prevent Malaria in Pregnant Women Living in Endemic Areas[NCT04783051] | Phase 3 | 250 participants (Actual) | Interventional | 2021-05-06 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise[NCT00121641] | Phase 3 | 1,035 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| Age of Exposure and Immunity to Malaria in Infants[NCT00231452] | 349 participants (Actual) | Interventional | 2005-09-30 | Completed | |||
| Discontinuation of Trimethoprim-sulfamethoxazole Prophylaxis in Adults on Antiretroviral Therapy in Kenya: a Randomized Trial[NCT01425073] | 500 participants (Actual) | Interventional | 2012-02-29 | Completed | |||
| Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Children With Sickle Cell Anaemia in Eastern and Southern Africa: a Double Blind Randomised Trial (CHEMCHA)[NCT04844099] | Phase 3 | 723 participants (Actual) | Interventional | 2021-04-09 | Completed | ||
| Assessing the Prevalence and Impact of Dihydropteroate Synthase-431V Mutation on the Protective Efficacy of Intermittent Preventive Treatment During Pregnancy Using Sulphadoxine-pyrimethamine[NCT04634695] | 288 participants (Anticipated) | Observational [Patient Registry] | 2020-08-10 | Recruiting | |||
| Lungwena Antenatal Intervention Study. A Single-centre Intervention Trial in Rural Malawi, Testing Maternal and Infant Health Effects of Presumptive Intermittent Treatment of Pregnant Women With Sulfadoxine-pyrimethamine and Azithromycin[NCT00131235] | Phase 3 | 1,320 participants (Actual) | Interventional | 2003-12-31 | Active, not recruiting | ||
| Comparative Study of Efficacy of Two Antifolates Prophylactic Strategies Against Malaria in HIV Positive Pregnant Women (MACOMBA Study)[NCT01746199] | Phase 3 | 193 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| Incorporation of the 'Ottawa Malaria Decision Aid' Into the Pre-travel Consultation Process: Assessment of Travelers' Knowledge, Decisional Conflict, Preparation for Decision-making and Medication Adherence Compared to Standard Care[NCT01976325] | 100 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | |||
| Infections in Migrants in Sweden - the Importance of Malaria and Other Parasitic Infections[NCT05086887] | 715 participants (Anticipated) | Observational [Patient Registry] | 2019-04-15 | Recruiting | |||
| Clinical Efficacy of Artemisinin-based Combination Therapy for Treatment of Uncomplicated Plasmodium Falciparum Malaria in North Sumatera, Indonesia and the Association of Molecular Markers With Treatment Outcomes[NCT02325180] | Phase 4 | 338 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Effect of Single-course Malaria Chemoprevention on Clearance of and Protection From Plasmodium Falciparum Infection in the Presence of Resistance-associated Genotypes in Zambia[NCT06166498] | Phase 3 | 600 participants (Anticipated) | Interventional | 2024-02-15 | Not yet recruiting | ||
| Development of Safer Drugs for Malaria in U.S. Troops, Civilian Personnel, and Travelers: Clinical Evaluation of Primaquine Enantiomer[NCT02898779] | Phase 1 | 36 participants (Actual) | Interventional | 2017-05-01 | Completed | ||
| Assessment of the Efficacy and Effectiveness of Sulphadoxine-pyrimethamine for Intermittent Preventive Treatment of Malaria in Pregnancy in Malawi[NCT01120145] | 1,410 participants (Actual) | Observational | 2010-03-31 | Completed | |||
| Intermittent Preventive Treatment With Azithromycin-containing Regimens for the Prevention of Malarial Infections and Anaemia and the Control of Sexually Transmitted Infections in Pregnant Women in Papua New Guinea[NCT01136850] | Phase 3 | 2,793 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Efficacy and Safety of Artesunate+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Malaria Control Centers in Nangarhar, Kunar, Thakhar and Faryab Provinces of Afghanistan[NCT01115439] | 100 participants (Actual) | Observational | 2010-03-31 | Completed | |||
| Randomized Clinical Trial of the Efficacy and Safety of Dihydroartimisinine+Papiraquine (Artekin) Compared With First Line Drugs for Treatment of Vivax and Uncomplicated Falciparum Malaria in Afghanistan[NCT00682578] | Phase 3 | 1,086 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Efficacy and Safety of Artesunate+Sulphadoxine-Pyrimethamine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Malaria Control Center Asadabad in Kunar Province of Afghanistan[NCT01707199] | 83 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| A Phase 3, Open Label, Randomized, Comparative Study To Evaluate Azithromycin Plus Chloroquine And Sulfadoxine Plus Pyrimethamine Combinations For Intermittent Preventive Treatment Of Falciparum Malaria Infection In Pregnant Women In Africa[NCT01103063] | Phase 3 | 2,891 participants (Actual) | Interventional | 2010-10-31 | Terminated (stopped due to See termination reason in detailed description.) | ||
| Longitudinal Comparison of Combination Antimalarial Therapies in Ugandan Children: Evaluation of Safety, Tolerability, and Efficacy[NCT00123552] | Phase 3 | 601 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Intermittent Preventive Treatment in Schools: a Randomised Controlled Trial of the Impact of IPT on Malaria, Anaemia and Education Amongst Schoolchildren in Western Kenya[NCT00142246] | Phase 3 | 6,758 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Effect of Intermittent Preventive Treatment (IPTp) With Sulfadoxine-Pyrimethamine Plus Insecticide Treated Nets, Delivered Through Antenatal Clinics for the Prevention of Malaria in Mozambican Pregnant Women[NCT00209781] | 1,028 participants | Interventional | 2003-08-31 | Active, not recruiting | |||
| [NCT01075945] | Phase 4 | 140 participants (Anticipated) | Interventional | 2010-02-28 | Recruiting | ||
| Efficacy of Sulphadoxine-pyrimethamine and Amodiaquine Alone or in Combination as Intermittent Preventive Treatment in Pregnancy in the Kassena-Nankana District of Ghana: a Randomized Controlled Trial[NCT00146783] | Phase 2/Phase 3 | 3,642 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| Assessment of Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa[NCT02974348] | Phase 3 | 300 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| A Longitudinal Study Assessing the Infectious Status and Immunity of Mothers and Their Children in Lambaréné, Including Intermittent Treatment of Children With Sulfadoxine-pyrimethamine for Malaria Control and Its Impact on Long-term Health[NCT00167843] | Phase 4 | 1,189 participants | Interventional | 2002-12-31 | Completed | ||
| Intermittent Treatment With Sulfadoxine-pyrimethamine for Malaria Control in Infant: a Randomized, Double-blind, and Placebo-controlled Clinical Trial[NCT00206739] | Phase 4 | 1,070 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| Open Study on the Tolerability and Efficacy of the Combination Chlorproguanil-Dapsone+Artesunate Compared to Amodiaquine+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Falciparum Malaria in Rwandan Children[NCT00461578] | 800 participants | Interventional | 2005-04-30 | Completed | |||
| Open Randomized Multi-Centre Trial, Comparing Artesunate-Sulfamethoxypyrazine-Pyrimethamine FDC Over 3 Days, Artesunate-Sulfamethoxypyrazine-Pyrimethamine FDC Over 48 Hours and Artemether-Lumefantrine FDC Over 3 Days on P. Falciparum Malaria[NCT00484900] | Phase 3 | 1,390 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Sulfadoxine-Pyrimethamine Versus Artemether-Lumefantrine Versus Amodiaquine-Artesunate Coformulation in Uncomplicated Plasmodium Falciparum Malaria : an Open Randomized Study[NCT00460369] | 240 participants (Actual) | Interventional | 2007-04-30 | Completed | |||
| Open Label Drug Study (With Single and Parallel Group Components) to Evaluate Combination Antimalarial Therapy for Efficacy, Gametocyte Carriage and Molecular Markers Associated With SP Resistance in Uncomplicated Plasmodium Falciparum Infections[NCT00203736] | 240 participants | Interventional | 2003-01-31 | Completed | |||
| Open-Label, Randomised, Parallel Group in Vivo Drug Study to Evaluate Combination Anti-Malarial Therapy (CAT), Artesunate and Sulfadoxine-Pyrimethamine Versus Sulfadoxine-Pyrimethamine Alone, in Terms of Therapeutic Efficacy, Prevalence of Gametocyte Carr[NCT00203814] | 280 participants | Interventional | 2004-01-31 | Completed | |||
| Determining the Impact of Scaling up Mass Testing, Treatment and Tracking on Malaria Prevalence Among Children in the Pakro Sub District of Ghana[NCT04301531] | 5,861 participants (Actual) | Interventional | 2020-03-01 | Completed | |||
| Exploring the Impact of Scaling up Mass Testing, Treatment and Tracking on Malaria Prevalence Among Children in the Pakro Sub District of Ghana[NCT04167566] | 5,000 participants (Actual) | Interventional | 2017-07-01 | Completed | |||
| Drug Options for Intermittent Preventive Treatment for Malaria in Infants in an Area With High Resistance to Sulfadoxine/Pyrimethamine: an Evaluation of Short and Long-acting Antimalarial Drugs[NCT00158574] | Phase 2/Phase 3 | 2,419 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| A Study Of Impact Of Intermittent Preventive Treatment In Children With Amodiaquine Plus Artesunate Versus Sulphadoxine-Pyrimethamine On Hemoglobin Levels And Malaria Morbidity In Hohoe District Of Ghana[NCT00119132] | Phase 2/Phase 3 | 2,602 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Safety, Tolerability and Pharmacokinetics of Tafenoquine After Weekly and Escalating Monthly Doses of Tafenoquine in Healthy Vietnamese Volunteers[NCT05203744] | Phase 4 | 200 participants (Anticipated) | Interventional | 2022-05-10 | Not yet recruiting | ||
| Mass-Drug Administration With a Gametocytocidal Drug Combination, a Model for a Transmission Blocking Vaccine[NCT00509015] | 6,000 participants (Anticipated) | Interventional | 2008-02-29 | Completed | |||
| Evaluation of the Efficacy and Safety of Primaquine for Clearance of Gametocytes in Uncomplicated Falciparum Malaria in Uganda[NCT01365598] | Phase 3 | 468 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| Phase 2a Dose Escalation Study of the Efficacy, Safety, and Pharmacokinetics of Low Dose Primaquine for Gametocytocidal Activity Against P. Falciparum in Sub-Saharan Africa and South East Asia[NCT01743820] | Phase 2 | 81 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Efficacy of Sulfadoxine-Pyrimethamine in the Treatment of Symptomatic, Uncomplicated Plasmodium Falciparum Malaria Among 6-59 Month Old Children in Lambaréné[NCT00453856] | Phase 4 | 139 participants (Anticipated) | Interventional | 2007-03-31 | Terminated (stopped due to The study was terminated because of Early Treatment Failure in child.The justification for this decision are concerns about safety of children.) | ||
| A Trial of the Combined Impact of Intermittent Preventive Treatment and Insecticide Treated Bednets in Reducing Morbidity From Malaria in African Children[NCT00738946] | 6,000 participants (Anticipated) | Interventional | 2008-08-31 | Completed | |||
| Community Effectiveness of Intermittent Preventive Treatment Delivered Through the Expanded Programme of Immunisation for Malaria and Anaemia Control in Tanzanian Infants[NCT00152204] | Phase 3 | 13,000 participants (Anticipated) | Interventional | 2005-03-31 | Active, not recruiting | ||
| Pseudo-randomised, Double-blinded Placebo-controlled Trial of Chloroquine or Sulphadoxine-pyrimethamine Alone or in Combination With Primaquine or Artesunate for the Treatment of Uncomplicated Falciparum Malaria in Pakistan[NCT00959517] | Phase 2 | 588 participants (Actual) | Interventional | 2001-07-31 | Completed | ||
| Effect of Prenatal Nutritional Supplementation on Birth Outcome in Hounde District, Burkina Faso[NCT00909974] | Phase 4 | 1,302 participants (Anticipated) | Interventional | 2006-02-28 | Completed | ||
| Short Course of Quinine Plus a Single Dose of Sulphadoxine-Pyrimethamine for Plasmodium Falciparum Malaria[NCT00167739] | Phase 4 | 50 participants | Interventional | 2003-04-30 | Completed | ||
| Presumptive Treatment With Sulfadoxine- Pyrimethamine Versus Weekly Chloroquine for Malaria Prophylaxis in Children With Sickle Cell Anemia[NCT00399074] | Phase 3 | 220 participants (Anticipated) | Interventional | 2006-10-31 | Completed | ||
| A Double-blind, Randomised, Placebo-controlled Trial to Measure the Potential of Intermittent Treatment With Artesunate Plus Sulphadoxine/Pyrimethamine (SP) to Reduce the Malaria Burden in Sub-Saharan Africa[NCT00132561] | Phase 2/Phase 3 | 1,200 participants | Interventional | 2002-06-30 | Completed | ||
| Intermittent Preventive Treatment With Sulfadoxine/Pyrimethamine During Pregnancy Among HIV-Positive and HIV-Negative Women: 2-Dose Versus Monthly - Malawi[NCT00126906] | 700 participants | Interventional | 2002-10-31 | Completed | |||
| Comparative Evaluation of the Safety and the Efficacy of Artemether + Lumefantrine (Coartem™) vs. Sulfadoxine + Pyrimethamine (SP) in Both HIV+ and HIV- Adults With Uncomplicated P. Falciparum Malaria in Zambia[NCT00304980] | 3,000 participants | Interventional | 2003-03-31 | Terminated | |||
| A Randomised Double Blind Clinical Trial of Amodiaquine (AQ) and Sulphadoxine-pyrimethamine (SP) Used Singly and in Combination (AQ+SP) Compared With Chloroquine (CQ) in the Treatment of Falciparum Malaria Infection in Pregnancy[NCT00131703] | Phase 3 | 900 participants | Interventional | 2003-03-31 | Completed | ||
| Chloroquine and Sulfadoxine-Pyrimethamine Efficacy for the Treatment of Uncomplicated Falciparum Malaria in Blantyre, Malawi[NCT00125489] | Phase 4 | 210 participants | Interventional | 2005-05-31 | Completed | ||
| Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine (PQ) for the Treatment of Uncomplicated Plasmodium Vivax Infection[NCT02691910] | Phase 2/Phase 3 | 204 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| A Randomised Non-Inferiority Trial of Sulfadoxine-Pyrimethamine Plus Artesunate Compared to Chloroquine for the Treatment of Vivax Malaria in Eastern Afghanistan.[NCT00486694] | Phase 2 | 190 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| Intermittent Preventive Treatment of Malaria With Sulfadoxine-Pyrimethamine in HIV-Seropositive and HIV-Seronegative Pregnant Women in Zambia[NCT00270530] | Phase 4 | 454 participants | Interventional | 2002-11-30 | Completed | ||
| Randomized Trial of Sulfadoxine-Pyrimethamine Plus Artesunate (SP+AS) Versus SP+AS Plus Primaquine for Clearance of Low Density P. Falciparum Infection in Eastern Sudan[NCT00330902] | Phase 3 | 104 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| A Phase IIIB Comparative Trial of Seasonal Vaccination With the Malaria Vaccine RTS,S/AS01, Seasonal Malaria Chemoprevention and of the Two Interventions Combined[NCT03143218] | Phase 3 | 5,920 participants (Actual) | Interventional | 2017-04-17 | Completed | ||
| The Impact of Intermittent Malaria Treatment Administered Through the EPI Scheme on Malaria Morbidity in Mozambican Children[NCT00209794] | Phase 1/Phase 2 | 1,498 participants | Interventional | 2002-09-30 | Active, not recruiting | ||
| Intermittent Treatment With Sulfadoxine-Pyrimethamine for Malaria Control in Children: A Randomised, Double Blind, and Placebo-Controlled Clinical Trial[NCT00168948] | Phase 4 | 1,200 participants | Interventional | 2003-03-31 | Active, not recruiting | ||
| The Prevention of Anaemia and Malaria in Infants in an Area of Intense and Perennial Malaria Transmission[NCT00497471] | 832 participants (Actual) | Interventional | 1995-02-28 | Terminated (stopped due to Follow-up end in 1999) | |||
| A Comparative Assessment of the Efficacy of Fosmidomycin-Clindamycin Versus Sulfadoxine-Pyrimethamine for the Treatment of Children With Uncomplicated Plasmodium Falciparum Malaria[NCT00214643] | Phase 3 | 160 participants | Interventional | 2005-06-30 | Completed | ||
| Efficacy and Safety of Pediatric Immunization-linked Preventive Intermittent Treatment With Antimalarials in Decreasing Anemia and Malaria Morbidity in Rural Western Kenya[NCT00111163] | 1,516 participants | Interventional | 2004-03-31 | Completed | |||
| Preventing Anemia in Children (6months-30months) in a Malaria Endemic Rural Area in Ghana - A Randomized Double Blind Study[NCT00301054] | 872 participants | Interventional | 2005-06-30 | Completed | |||
| Pharmacokinetics of Chlorproguanil-Dapsone in Pregnant Women With Plasmodium Falciparum Infection, and Reinfection With P. Falciparum During Pregnancy Following Treatment[NCT00126971] | Phase 1 | 132 participants | Interventional | 2005-07-31 | Suspended | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Complicated malaria defined as an episode of malaria with danger signs (any of the following: less than 3 convulsions over 24 h, inability to sit or stand, vomiting everything, unable to breastfeed or drink) or the meeting standardized criteria for severe malaria. (NCT02793622)
Timeframe: Birth up to 12 months of age or early termination
| Intervention | Participants (Count of Participants) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 44 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 24 |
Admission to the pediatric ward for any cause (NCT02793622)
Timeframe: Birth up to 12 months of age or early termination
| Intervention | Participants (Count of Participants) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 19 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 8 |
episodes per person year (NCT02793622)
Timeframe: Time at risk will begin at birth and end when study participants reaches 12 months of age or early study termination
| Intervention | episodes per person year (Number) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 1.98 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 1.71 |
Any deaths occurring after birth (NCT02793622)
Timeframe: Birth up to 12 months of age
| Intervention | Participants (Count of Participants) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 9 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 7 |
Gestational age in weeks determined by ultrasound dating (gold standard) and by the metabolic profiling outcome from biological specimens including placental tissue and placental blood. (NCT02793622)
Timeframe: At the time of delivery
| Intervention | weeks (Mean) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 39.4 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 39.6 |
Composite adverse birth outcome defined as any one of the following: 1) Low birth weight (< 2500 gm); 2) Preterm delivery (< 37 weeks gestational age); 3) Small for gestational age (< 10th percentile relative to an external growth reference) (NCT02793622)
Timeframe: Delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 60 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 54 |
All grade 3 and 4 adverse events (NCT02793622)
Timeframe: Starting at the time of their first study drug administration, approximately gestational age between 12-20 weeks, up to one month post-delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 54 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 43 |
"Defined as the proportion with hemoglobin < 10 g/dL measure routinely at 12, 28, and 52 weeks of age. Number of cases per person year (PPY).~This is a prevalence measure but are repeated measures during infancy. In other words we measured this outcome up to 3 times for each participant during infancy (at 12, 28 and 52 weeks of age)." (NCT02793622)
Timeframe: Birth up to 12 months of age or early termination
| Intervention | routine hemoglobin measurement (Count of Units) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 222 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 216 |
hemoglobin < 11 g/dL (NCT02793622)
Timeframe: Starting at the time of their first study drug administration, approximately gestational age between 12-20 weeks, up to one month post-delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 28 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 8 |
Proportion of routine monthly samples positive for parasites by microscopy and LAMP (NCT02793622)
Timeframe: Birth up to 12 months of age or early termination
| Intervention | blood smears (Count of Units) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 344 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 357 |
Proportion of routine monthly samples positive for parasites by microscopy and LAMP (NCT02793622)
Timeframe: Starting at the time of their first study drug administration, approximately gestational age between 12-20 weeks, up to one month post-delivery
| Intervention | blood smears (Count of Units) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 519 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 9 |
Maternal blood positive for malaria parasites by microscopy. (NCT02793622)
Timeframe: Gestational age between 12-20 weeks (at study entry) up to delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 28 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 1 |
Any evidence of placental infection (parasites or pigment). Number of participants with placental tissue positive for malaria parasites or pigment. (NCT02793622)
Timeframe: Delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 197 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 94 |
Proportion of placental blood samples positive for parasites by Loop-mediated isothermal amplification (LAMP) or microscopy (NCT02793622)
Timeframe: Delivery
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| LAMP | Microscopy | |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 7 | 1 |
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 71 | 29 |
Any treatment for malaria meeting criteria for severe malaria or danger signs (NCT02163447)
Timeframe: Birth up to 24 months of age or early study termination
| Intervention | Events per person years (Number) |
|---|---|
| 3 Dose SP Pregnancy / 3 Monthly DP Infancy | 0.022 |
| 3 Dose DP Pregnancy / 3 Monthly DP Infancy | 0.024 |
| 3 Dose DP Pregnancy / Monthly DP Infancy | 0.000 |
| Monthly DP Pregnancy / 3 Monthly DP Infancy | 0.035 |
| Monthly DP Pregnancy / Monthly DP Infancy | 0.000 |
Admission to a hospital for pediatric inpatient care for any reason (NCT02163447)
Timeframe: Birth up to 24 months of age or early study termination
| Intervention | Events per person years (Number) |
|---|---|
| 3 Dose SP Pregnancy / 3 Monthly DP Infancy | 0.043 |
| 3 Dose DP Pregnancy / 3 Monthly DP Infancy | 0.036 |
| 3 Dose DP Pregnancy / Monthly DP Infancy | 0.089 |
| Monthly DP Pregnancy / 3 Monthly DP Infancy | 0.082 |
| Monthly DP Pregnancy / Monthly DP Infancy | 0.043 |
Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days. The study investigators will test the hypotheses that A) infants born to mothers randomized to receive IPTp with 3 dose DP or monthly DP will have a lower incidence of malaria during the first 24 months of life compared to infants born to mothers who were randomized to receive IPTp with 3 doses of SP, and, B) infants randomized to receive monthly DP between 2-24 months of age will have a lower incidence of malaria between 24-36 months of age after the intervention is stopped compared to infants randomized q 3 monthly DP between 2-24 months of age. (NCT02163447)
Timeframe: Time at risk will begin at 24 months of age and will end when study participants reaches 36 months of age or termination
| Intervention | Events per person years (Number) |
|---|---|
| 3 Dose SP Pregnancy / 3 Monthly DP Infancy | 0.87 |
| 3 Dose DP Pregnancy / 3 Monthly DP Infancy | 0.88 |
| 3 Dose DP Pregnancy / Monthly DP Infancy | 0.83 |
| Monthly DP Pregnancy / 3 Monthly DP Infancy | 1.24 |
| Monthly DP Pregnancy / Monthly DP Infancy | 0.64 |
Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days. The study investigators will test the hypotheses that A) infants born to mothers randomized to receive IPTp with 3 dose DP or monthly DP will have a lower incidence of malaria during the first 24 months of life compared to infants born to mothers who were randomized to receive IPTp with 3 doses of SP, and, B) infants randomized to receive monthly DP between 2-24 months of age will have a lower incidence of malaria between 24-36 months of age after the intervention is stopped compared to infants randomized q 3 monthly DP between 2-24 months of age. (NCT02163447)
Timeframe: Time at risk will begin at birth and will end when study participants reaches 24 months of age or early study termination (if prior to 24 months of age)
| Intervention | Events per person years (Number) |
|---|---|
| 3 Dose SP Pregnancy / 3 Monthly DP Infancy | 0.26 |
| 3 Dose DP Pregnancy / 3 Monthly DP Infancy | 0.30 |
| 3 Dose DP Pregnancy / Monthly DP Infancy | 0.00 |
| Monthly DP Pregnancy / 3 Monthly DP Infancy | 0.43 |
| Monthly DP Pregnancy / Monthly DP Infancy | 0.03 |
Incidence of malaria, defined as the number of incident episodes per time at risk. Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days. (NCT02163447)
Timeframe: Time at risk will begin after first dose of study drug and will end when study participants deliver or early study termination
| Intervention | events per person years (Number) |
|---|---|
| Mothers - 3 Dose SP | 0.95 |
| Mothers - 3 Dose DP | 0.31 |
| Mothers - Monthly DP | 0 |
Congenital malformations, spontaneous abortion, LBW (<2500g), still birth, pre-term delivery (NCT02163447)
Timeframe: Delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Mothers - 3 Dose SP | 19 |
| Mothers - 3 Dose DP | 19 |
| Mothers - Monthly DP | 9 |
Prevalence of routine hemoglobin measurements < 11 g/dL (NCT02163447)
Timeframe: After first dose of study drugs up to delivery or early termination
| Intervention | hemoglobin measurements taken every 12wk (Number) |
|---|---|
| Mothers - 3 Dose SP | 94 |
| Mothers - 3 Dose DP | 72 |
| Mothers - Monthly DP | 61 |
Proportion of routine blood smears positive for gametocytes (NCT02163447)
Timeframe: Birth up to 24 months of age or early study termination
| Intervention | Positive blood smears (Number) |
|---|---|
| 3 Dose SP Pregnancy / 3 Monthly DP Infancy | 7 |
| 3 Dose DP Pregnancy / 3 Monthly DP Infancy | 1 |
| 3 Dose DP Pregnancy / Monthly DP Infancy | 0 |
| Monthly DP Pregnancy / 3 Monthly DP Infancy | 4 |
| Monthly DP Pregnancy / Monthly DP Infancy | 0 |
Proportion of urgent blood smears positive for gametocytes (NCT02163447)
Timeframe: Gestational age between 12-20 weeks (at study entry) up to delivery
| Intervention | Positive blood smears (Number) |
|---|---|
| Mothers - 3 Dose SP | 4 |
| Mothers - 3 Dose DP | 1 |
| Mothers - Monthly DP | 3 |
Detection of malaria parasites by LAMP during pregnancy (NCT02163447)
Timeframe: After first dose of study drug through delivery or early termination
| Intervention | Positive specimens (Number) |
|---|---|
| Mothers - 3 Dose SP | 206 |
| Mothers - 3 Dose DP | 74 |
| Mothers - Monthly DP | 26 |
Proportion of routine monthly samples positive for parasites by LAMP. Proportion of routine samples (LAMP or blood smears) positive for asexual parasites. (NCT02163447)
Timeframe: Birth up to 24 months of age or early study termination
| Intervention | Positive blood smears (Number) |
|---|---|
| 3 Dose SP Pregnancy / 3 Monthly DP Infancy | 59 |
| 3 Dose DP Pregnancy / 3 Monthly DP Infancy | 25 |
| 3 Dose DP Pregnancy / Monthly DP Infancy | 7 |
| Monthly DP Pregnancy / 3 Monthly DP Infancy | 52 |
| Monthly DP Pregnancy / Monthly DP Infancy | 4 |
Prevalence of placental malaria based on placental histopathology dichotomized into any evidence of placental infection (parasites or pigment) vs. no evidence and by histopathology as a categorical variable based on Rogerson et al criteria. (NCT02163447)
Timeframe: Delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Mothers - 3 Dose SP | 49 |
| Mothers - 3 Dose DP | 30 |
| Mothers - Monthly DP | 26 |
Prevalence of placental blood samples positive for parasites by microscopy or LAMP (NCT02163447)
Timeframe: Delivery
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Micropscopic assessment of placental blood | LAMP assessment of placental blood | |
| Mothers - 3 Dose DP | 3 | 3 |
| Mothers - 3 Dose SP | 5 | 19 |
| Mothers - Monthly DP | 0 | 2 |
Prevalence of maternal parasitemia at delivery by microscopy and LAMP (NCT02163447)
Timeframe: At delivery
| Intervention | participants (Number) | |
|---|---|---|
| Microscopy | LAMP | |
| Mothers - 3 Dose DP | 1 | 3 |
| Mothers - 3 Dose SP | 5 | 25 |
| Mothers - Monthly DP | 0 | 1 |
Hypoglycemic Events are based upon the Saxagliptin Predefined List of Events, which included hypoglycemia, blood glucose decreased, and hypoglycemic unconsciousness. (NCT00121641)
Timeframe: AEs: up to last treatment day + 1 day or last visit; SAEs: up to last treatment day + 30 days or last visit + 30 days. Mean duration of exposure was 109 weeks in 10 mg arm, 94.7 weeks in 2.5 mg arm, 103 weeks in 5 mg arm, and 98.4 weeks in placebo arm.
| Intervention | participants (Number) |
|---|---|
| Saxagliptin 2.5 mg | 9 |
| Saxagliptin 5 mg | 11 |
| Saxagliptin 10 mg | 10 |
| Placebo | 9 |
Hypoglycemic Events are based upon the Saxagliptin Predefined List of Events, which included hypoglycemia, blood glucose decreased, and hypoglycemic unconsciousness. (NCT00121641)
Timeframe: AEs: up to last treatment day + 1 day or last visit; SAEs: up to last treatment day + 30 days or last visit + 30 days. Mean duration of exposure was 34 weeks.
| Intervention | participants (Number) |
|---|---|
| Open-Label Treatment Cohort (Direct Enrollees) | 2 |
This cohort represents a different population (screening A1C > 10.0% and ≤ 12.0%) than the double-blind cohort, and was presented separately in the study report. (NCT00121641)
Timeframe: Baseline
| Intervention | years (Mean) |
|---|---|
| Open-Label Treatment Cohort (Direct Enrollees) | 49.09 |
This cohort represents a different population (screening A1C > 10.0% and ≤ 12.0%) than the double-blind cohort, and was presented separately in the study report. (NCT00121641)
Timeframe: Baseline
| Intervention | kg/m^2 (Mean) |
|---|---|
| Open-Label Treatment Cohort (Direct Enrollees) | 31.73 |
This cohort represents a different population (screening A1C > 10.0% and ≤ 12.0%) than the double-blind cohort, and was presented separately in the study report. (NCT00121641)
Timeframe: Baseline
| Intervention | kg (Mean) |
|---|---|
| Open-Label Treatment Cohort (Direct Enrollees) | 91.41 |
'Confirmed' = recorded on the hypoglycemia AE case report form page with a fingerstick glucose <= 50 mg/dL and associated symptoms (NCT00121641)
Timeframe: AEs: up to last treatment day + 1 day or last visit; SAEs: up to last treatment day + 30 days or last visit + 30 days. Mean duration of exposure was 109 weeks in 10 mg arm, 94.7 weeks in 2.5 mg arm, 103 weeks in 5 mg arm, and 98.4 weeks in placebo arm.
| Intervention | participants (Number) |
|---|---|
| Saxagliptin 2.5 mg | 1 |
| Saxagliptin 5 mg | 1 |
| Saxagliptin 10 mg | 0 |
| Placebo | 0 |
'Confirmed' = recorded on the hypoglycemia AE case report form page with a fingerstick glucose <= 50 mg/dL and associated symptoms (NCT00121641)
Timeframe: AEs: up to last treatment day + 1 day or last visit; SAEs: up to last treatment day + 30 days or last visit + 30 days. Mean duration of exposure was 34 weeks.
| Intervention | participants (Number) |
|---|---|
| Open-Label Treatment Cohort (Direct Enrollees) | 0 |
(NCT00121641)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Saxagliptin 2.5 mg | 35.0 |
| Saxagliptin 5 mg | 37.9 |
| Saxagliptin 10 mg | 41.1 |
| Placebo | 23.9 |
(NCT00121641)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Open Label Cohort (Direct Enrollees) | 14.1 |
To compare the change from baseline in HbA1c achieved with each dose of saxagliptin versus placebo in treatment naive subjects with type 2 diabetes who have inadequate glycemic control defined as A1C ≥7.0% and ≤10.0%. (NCT00121641)
Timeframe: Baseline, Week 24
| Intervention | Percentage of glycosylated hemoglobins (Mean) | |
|---|---|---|
| Baseline Mean | Mean Change from Baseline | |
| Open Label Cohort (Direct Enrollees) | 10.70 | -1.87 |
(NCT00121641)
Timeframe: Baseline, Week 24
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Baseline | Adjusted Change from Baseline | |
| Placebo | 171.85 | 6.06 |
| Saxagliptin 10 mg | 176.51 | -16.75 |
| Saxagliptin 2.5 mg | 177.72 | -14.53 |
| Saxagliptin 5 mg | 171.31 | -8.67 |
(NCT00121641)
Timeframe: Baseline, Week 24
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Open-Label Cohort (Direct Enrollees) | 241.08 | -33.42 |
(NCT00121641)
Timeframe: Baseline, Week 24
| Intervention | mg*min/dL (Mean) | |
|---|---|---|
| Baseline | Adjusted Change from Baseline | |
| Placebo | 46030 | -646.6 |
| Saxagliptin 10 mg | 44614 | -8084 |
| Saxagliptin 2.5 mg | 45030 | -6868 |
| Saxagliptin 5 mg | 45691 | -6896 |
(NCT00121641)
Timeframe: Baseline, Week 24
| Intervention | mg*min/dL (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Open Label Cohort (Direct Enrollees) | 60687 | -11078 |
(NCT00121641)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206
| Intervention | x 10^3 c/µL (Mean) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (BL) (Week 0) (n=102, 106, 98, 94) | Change from BL at Week 2 (n=95, 99, 92, 86) | Change from BL at Week 4 (n=91, 99, 90, 90) | Change from BL at Week 6 (n=89, 95, 87, 82) | Change from BL at Week 8 (n=91, 88, 90, 79) | Change from BL at Week 10 (n=68, 76, 69, 63) | Change from BL at Week 12 (n=83, 88, 87, 82) | Change from BL at Week 14 (n=76, 77, 80, 75) | Change from BL at Week 16 (n=90, 91, 83, 71) | Change from BL at Week 18 (n=78, 75, 82, 71) | Change from BL at Week 20 (n=83, 79, 78, 72) | Change from BL at Week 22 (n=77, 74, 75, 65) | Change from BL at Week 24 (n=83, 81, 78, 74) | Change from BL at Week 30 (n=76, 78, 79, 67) | Change from BL at Week 37 (n=74, 72, 70, 60) | Change from BL at Week 50 (n=67, 69, 71, 61) | Change from BL at Week 63 (n=60, 66, 67, 55) | Change from BL at Week 76 (n=51, 58, 63, 49) | Change from BL at Week 89 (n=48, 58, 56, 42) | Change from BL at Week 102 (n=39, 47, 50, 40) | Change from BL at Week 115 (n=34, 43, 42, 34) | Change from BL at Week 128 (n=30, 40, 40, 29) | Change from BL at Week 141 (n=28, 38, 34, 28) | Change from BL at Week 154 (n=26, 33, 31, 24) | Change from BL at Week 167 (n=24, 33, 30, 25) | Change from BL at Week 180 (n=21, 28, 28, 26) | Change from BL at Week 193 (n=19, 25, 26, 23) | Change from BL at Week 206 (n=17, 22, 23, 21) | |
| Placebo | 0.02 | 0.00 | -0.00 | -0.01 | -0.01 | -0.01 | -0.00 | -0.00 | -0.01 | -0.01 | -0.00 | -0.00 | -0.01 | 0.01 | 0.00 | 0.02 | 0.02 | 0.01 | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 | 0.01 | 0.02 | 0.02 | 0.02 | 0.01 |
| Saxagliptin 10 mg | 0.02 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.00 | -0.01 | -0.01 | -0.00 | -0.01 | 0.00 | -0.01 | -0.01 | 0.00 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | 0.00 | 0.01 | 0.01 |
| Saxagliptin 2.5 mg | 0.01 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.02 | 0.03 | 0.02 | 0.01 | 0.01 | 0.00 |
| Saxagliptin 5 mg | 0.02 | -0.01 | -0.01 | -0.01 | -0.00 | -0.01 | -0.01 | 0.00 | -0.00 | 0.00 | -0.01 | -0.00 | -0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 |
(NCT00121641)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206
| Intervention | x 10^3 c/µL (Mean) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (BL) (Week 0) (n=102, 106, 98, 94) | Change from BL at Week 2 (n=95, 99, 92, 86) | Change from BL at Week 4 (n=91, 99, 90, 90) | Change from BL at Week 6 (n=89, 95, 87, 82) | Change from BL at Week 8 (n=91, 88, 90, 79) | Change from BL at Week 10 (n=68, 76, 69, 63) | Change from BL at Week 12 (n=83, 88, 87, 82) | Change from BL at Week 14 (n=76, 77, 80, 75) | Change from BL at Week 16 (n=90, 91, 83, 71) | Change from BL at Week 18 (n=78, 75, 82, 71) | Change from BL at Week 20 (n=83, 79, 78, 72) | Change from BL at Week 22 (n=77, 74, 75, 65) | Change from BL at Week 24 (n=83, 81, 78, 74) | Change from BL at Week 30 (n=76, 78, 79, 67) | Change from BL at Week 37 (n=74, 72, 70, 60) | Change from BL at Week 50 (n=67, 69, 71, 61) | Change from BL at Week 63 (n=60, 66, 67, 55) | Change from BL at Week 76 (n=51, 58, 63, 49) | Change from BL at Week 89 (n=48, 58, 56, 42) | Change from BL at Week 102 (n=39, 47, 50, 40) | Change from BL at Week 115 (n=34, 43, 42, 34) | Change from BL at Week 128 (n=30, 40, 40, 29) | Change from BL at Week 141 (n=28, 38, 34, 28) | Change from BL at Week 154 (n=26, 33, 31, 24) | Change from BL at Week 167 (n=24, 33, 30, 25) | Change from BL at Week 180 (n=21, 28, 28, 26) | Change from BL at Week 193 (n=19, 25, 26, 23) | Change from BL at Week 206 (n=17, 22, 23, 21) | |
| Placebo | 0.20 | -0.02 | -0.02 | -0.02 | -0.01 | 0.01 | -0.02 | -0.01 | -0.00 | 0.00 | -0.03 | -0.02 | -0.04 | -0.03 | -0.02 | -0.01 | -0.02 | -0.03 | -0.02 | -0.01 | -0.00 | -0.01 | 0.01 | 0.03 | 0.06 | 0.07 | 0.05 | 0.06 |
| Saxagliptin 10 mg | 0.20 | -0.02 | -0.01 | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 | -0.03 | -0.03 | -0.04 | -0.04 | -0.03 | -0.02 | -0.04 | -0.02 | -0.00 | -0.02 | -0.02 | 0.02 | -0.01 | -0.03 | -0.00 | -0.01 | 0.01 | -0.00 | 0.00 | 0.03 |
| Saxagliptin 2.5 mg | 0.18 | -0.01 | -0.02 | 0.01 | 0.00 | -0.01 | 0.00 | -0.01 | -0.02 | -0.02 | -0.02 | -0.00 | -0.02 | -0.03 | -0.03 | -0.03 | -0.00 | -0.03 | -0.03 | 0.02 | -0.00 | -0.02 | -0.01 | 0.00 | -0.02 | -0.02 | -0.01 | 0.00 |
| Saxagliptin 5 mg | 0.20 | 0.01 | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 | -0.01 | -0.02 | -0.02 | -0.03 | -0.03 | -0.03 | -0.03 | -0.01 | -0.01 | 0.00 | -0.04 | -0.02 | 0.01 | 0.07 | 0.02 | -0.00 | -0.00 | -0.02 | -0.01 | -0.01 | -0.00 |
(NCT00121641)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206
| Intervention | x 10^3 c/µL (Mean) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (BL) (Week 0) (n=102, 106, 98, 94) | Change from BL at Week 2 (n=95, 99, 92, 86) | Change from BL at Week 4 (n=91, 99, 90, 90) | Change from BL at Week 6 (n=89, 95, 87, 82) | Change from BL at Week 8 (n=91, 88, 90, 79) | Change from BL at Week 10 (n=68, 76, 69, 63) | Change from BL at Week 12 (n=83, 88, 87, 82) | Change from BL at Week 14 (n=76, 77, 80, 75) | Change from BL at Week 16 (n=90, 91, 83, 71) | Change from BL at Week 18 (n=78, 75, 82, 71) | Change from BL at Week 20 (n=83, 79, 78, 72) | Change from BL at Week 22 (n=77, 74, 75, 65) | Change from BL at Week 24 (n=83, 81, 78, 74) | Change from BL at Week 30 (n=76, 78, 79, 67) | Change from BL at Week 37 (n=74, 72, 70, 60) | Change from BL at Week 50 (n=67, 69, 71, 61) | Change from BL at Week 63 (n=60, 66, 67, 55) | Change from BL at Week 76 (n=51, 58, 63, 49) | Change from BL at Week 89 (n=49, 58, 56, 42) | Change from BL at Week 102 (n=39, 48, 51, 40) | Change from BL at Week 115 (n=34, 43, 43, 35) | Change from BL at Week 128 (n=30, 40, 40, 30) | Change from BL at Week 141 (n=28, 38, 34, 28) | Change from BL at Week 154 (n=26, 33, 31, 24) | Change from BL at Week 167 (n=24, 33, 30, 25) | Change from BL at Week 180 (n=21, 28, 28, 26) | Change from BL at Week 193 (n=19, 25, 26, 23) | Change from BL at Week 206 (n=17, 22, 23, 21) | |
| Placebo | 2.22 | -0.13 | -0.04 | -0.09 | -0.00 | 0.05 | -0.02 | 0.06 | 0.01 | 0.08 | -0.11 | 0.09 | -0.01 | -0.03 | -0.08 | -0.03 | -0.16 | -0.20 | -0.23 | -0.16 | -0.10 | -0.06 | 0.00 | -0.14 | -0.16 | -0.05 | 0.01 | -0.08 |
| Saxagliptin 10 mg | 2.14 | -0.11 | -0.18 | -0.23 | -0.20 | -0.10 | -0.16 | -0.01 | -0.11 | 0.01 | -0.10 | -0.07 | -0.13 | -0.09 | -0.17 | -0.25 | -0.19 | -0.18 | -0.19 | -0.23 | -0.21 | -0.16 | -0.10 | -0.23 | -0.11 | -0.06 | -0.04 | -0.05 |
| Saxagliptin 2.5 mg | 2.16 | -0.04 | -0.03 | -0.04 | -0.07 | 0.07 | -0.06 | 0.20 | 0.03 | 0.11 | 0.08 | 0.16 | -0.00 | 0.08 | 0.05 | -0.06 | -0.06 | -0.10 | -0.12 | -0.17 | -0.15 | -0.12 | -0.13 | -0.23 | -0.23 | -0.15 | -0.06 | -0.17 |
| Saxagliptin 5 mg | 2.21 | -0.10 | -0.12 | -0.09 | -0.11 | 0.02 | -0.12 | 0.08 | 0.01 | 0.13 | -0.02 | 0.13 | -0.07 | -0.00 | 0.02 | -0.09 | -0.10 | -0.09 | -0.02 | -0.07 | -0.00 | -0.00 | -0.03 | 0.04 | -0.13 | -0.22 | -0.09 | -0.14 |
(NCT00121641)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206
| Intervention | x 10^3 c/µL (Mean) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (BL) (Week 0) (n=102, 106, 98, 94) | Change from BL at Week 2 (n=95, 99, 92, 86) | Change from BL at Week 4 (n=91, 99, 90, 90) | Change from BL at Week 6 (n=89, 95, 87, 82) | Change from BL at Week 8 (n=91, 88, 90, 79) | Change from BL at Week 10 (n=68, 76, 69, 63) | Change from BL at Week 12 (n=83, 88, 87, 82) | Change from BL at Week 14 (n=76, 77, 80, 75) | Change from BL at Week 16 (n=90, 91, 83, 71) | Change from BL at Week 18 (n=78, 75, 82, 71) | Change from BL at Week 20 (n=83, 79, 78, 72) | Change from BL at Week 22 (n=77, 74, 75, 65) | Change from BL at Week 24 (n=83, 81, 78, 74) | Change from BL at Week 30 (n=76, 78, 79, 67) | Change from BL at Week 37 (n=74, 72, 70, 60) | Change from BL at Week 50 (n=67, 69, 71, 61) | Change from BL at Week 63 (n=60, 66, 67, 55) | Change from BL at Week 76 (n=51, 58, 63, 49) | Change from BL at Week 89 (n=48, 58, 56, 42) | Change from BL at Week 102 (n=39, 47, 50, 40) | Change from BL at Week 115 (n=34, 43, 42, 34) | Change from BL at Week 128 (n=30, 40, 40, 29) | Change from BL at Week 141 (n=28, 38, 34, 28) | Change from BL at Week 154 (n=26, 33, 31, 24) | Change from BL at Week 167 (n=24, 33, 30, 25) | Change from BL at Week 180 (n=21, 28, 28, 26) | Change from BL at Week 193 (n=19, 25, 26, 23) | Change from BL at Week 206 (n=17, 22, 23, 21) | |
| Placebo | 0.32 | -0.01 | 0.01 | 0.02 | -0.02 | 0.03 | 0.01 | 0.04 | 0.01 | 0.04 | 0.01 | 0.05 | 0.03 | 0.03 | 0.00 | 0.06 | 0.07 | 0.05 | 0.05 | 0.07 | 0.13 | 0.07 | 0.10 | 0.08 | 0.11 | 0.11 | 0.13 | 0.09 |
| Saxagliptin 10 mg | 0.32 | -0.05 | -0.01 | -0.01 | -0.01 | 0.04 | 0.00 | 0.03 | 0.04 | 0.06 | 0.04 | 0.06 | 0.03 | 0.04 | 0.04 | 0.05 | 0.07 | 0.06 | 0.08 | 0.09 | 0.06 | 0.07 | 0.10 | 0.06 | 0.10 | 0.11 | 0.11 | 0.13 |
| Saxagliptin 2.5 mg | 0.31 | 0.01 | 0.05 | 0.05 | 0.03 | 0.08 | 0.05 | 0.09 | 0.06 | 0.06 | 0.04 | 0.08 | 0.04 | 0.05 | 0.06 | 0.07 | 0.08 | 0.12 | 0.11 | 0.14 | 0.12 | 0.12 | 0.08 | 0.10 | 0.07 | 0.08 | 0.09 | 0.05 |
| Saxagliptin 5 mg | 0.34 | 0.01 | 0.00 | -0.01 | 0.03 | 0.04 | 0.00 | 0.06 | 0.04 | 0.05 | 0.02 | 0.05 | 0.01 | 0.03 | 0.02 | 0.03 | 0.05 | 0.04 | 0.03 | 0.04 | 0.05 | 0.04 | 0.02 | 0.05 | 0.04 | 0.04 | 0.04 | 0.05 |
(NCT00121641)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206
| Intervention | x 10^3 c/µL (Mean) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (BL) (Week 0) (n=102, 106, 98, 94) | Change from BL at Week 2 (n=95, 99, 92, 86) | Change from BL at Week 4 (n=91, 99, 90, 90) | Change from BL at Week 6 (n=89, 95, 87, 82) | Change from BL at Week 8 (n=91, 88, 90, 79) | Change from BL at Week 10 (n=68, 76, 69, 63) | Change from BL at Week 12 (n=83, 88, 87, 82) | Change from BL at Week 14 (n=76, 77, 80, 75) | Change from BL at Week 16 (n=90, 91, 83, 71) | Change from BL at Week 18 (n=78, 75, 82, 71) | Change from BL at Week 20 (n=83, 79, 78, 72) | Change from BL at Week 22 (n=77, 74, 75, 65) | Change from BL at Week 24 (n=83, 81, 78, 74) | Change from BL at Week 30 (n=76, 78, 79, 67) | Change from BL at Week 37 (n=74, 72, 70, 60) | Change from BL at Week 50 (n=67, 69, 71, 61) | Change from BL at Week 63 (n=60, 66, 67, 55) | Change from BL at Week 76 (n=51, 58, 63, 49) | Change from BL at Week 89 (n=48, 58, 56, 42) | Change from BL at Week 102 (n=39, 47, 50, 40) | Change from BL at Week 115 (n=34, 43, 42, 34) | Change from BL at Week 128 (n=30, 40, 40, 29) | Change from BL at Week 141 (n=28, 38, 34, 28) | Change from BL at Week 154 (n=26, 33, 31, 24) | Change from BL at Week 167 (n=24, 33, 30, 25) | Change from BL at Week 180 (n=21, 28, 28, 26) | Change from BL at Week 193 (n=19, 25, 26, 23) | Change from BL at Week 206 (n=17, 22, 23, 21) | |
| Placebo | 4.01 | -0.07 | 0.23 | 0.17 | 0.19 | 0.45 | 0.30 | 0.46 | 0.18 | 0.21 | 0.15 | 0.32 | -0.03 | 0.00 | 0.20 | 0.27 | 0.16 | -0.01 | 0.01 | 0.01 | 0.42 | 0.22 | 0.40 | 0.41 | 0.33 | 0.51 | -0.01 | 0.31 |
| Saxagliptin 10 mg | 4.16 | 0.00 | 0.05 | 0.04 | 0.03 | 0.17 | 0.18 | 0.17 | 0.16 | 0.32 | 0.07 | 0.44 | 0.16 | 0.32 | 0.24 | 0.19 | 0.08 | 0.08 | 0.05 | 0.24 | 0.29 | 0.56 | 0.45 | 0.47 | 0.27 | 0.55 | 0.51 | 0.90 |
| Saxagliptin 2.5 mg | 4.00 | -0.06 | 0.09 | 0.01 | 0.02 | 0.18 | 0.01 | 0.07 | 0.17 | 0.23 | 0.19 | 0.44 | 0.09 | 0.04 | 0.13 | 0.03 | 0.11 | 0.05 | 0.58 | 0.19 | 0.28 | 0.61 | 0.41 | 0.25 | -0.04 | 0.23 | 0.34 | 0.15 |
| Saxagliptin 5 mg | 3.98 | 0.11 | 0.16 | 0.19 | 0.27 | 0.48 | 0.21 | 0.64 | 0.49 | 0.67 | 0.32 | 0.58 | 0.57 | 0.29 | 0.42 | 0.40 | 0.25 | 0.33 | 0.18 | 0.43 | 0.81 | 0.59 | 0.80 | 0.39 | 0.56 | 0.50 | 0.08 | 0.63 |
(NCT00121641)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206
| Intervention | percentage red blood cells (Mean) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (BL) (Week 0) (n=102, 106, 98, 94) | Change from BL at Week 2 (n=95,100, 93, 87) | Change from BL at Week 4 (n=92, 99, 91, 91) | Change from BL at Week 6 (n=91, 96, 87, 82) | Change from BL at Week 8 (n=92, 90, 91, 79) | Change from BL at Week 10 (n=70, 76, 69, 63) | Change from BL at Week 12 (n=85, 88, 87, 82) | Change from BL at Week 14 (n=76, 80, 81, 75) | Change from BL at Week 16 (n=90. 91, 83, 71) | Change from BL at Week 18 (n=78, 75, 82, 71) | Change from BL at Week 20 (n=83, 80, 78, 72) | Change from BL at Week 22 (n=78, 74, 76, 65) | Change from BL at Week 24 (n=83, 82, 78, 74) | Change from BL at Week 30 (n=77, 78, 79, 67) | Change from BL at Week 37 (n=75, 73, 70, 62) | Change from BL at Week 50 (n=67, 71, 71, 61) | Change from BL at Week 63 (n=61, 66, 67, 55) | Change from BL at Week 76 (n=51, 59, 63, 49) | Change from BL at Week 89 (n=49, 58, 56, 42) | Change from BL at Week 102 (n=40, 49, 51, 40) | Change from BL at Week 115 (n=34, 43, 43, 35) | Change from BL at Week 128 (n=30, 40, 40, 30) | Change from BL at Week 141 (n=28, 39, 34, 28) | Change from BL at Week 154 (n=26, 34, 31, 24) | Change from BL at Week 167 (n=24, 33, 30, 26) | Change from BL at Week 180 (n=21, 28, 28, 26) | Change from BL at Week 193 (n=19, 26, 26, 23) | Change from BL at Week 206 (n=17, 22, 24, 21) | |
| Placebo | 42.8 | -0.4 | 0.3 | 0.3 | 0.5 | 0.5 | 0.7 | 0.2 | 0.3 | 0.4 | 0.2 | 0.5 | 0.5 | 0.4 | -0.4 | 0.2 | 0.7 | 0.8 | 0.4 | -0.7 | 0.2 | -0.1 | -0.2 | -0.3 | -0.4 | -0.5 | -0.0 | -0.5 |
| Saxagliptin 10 mg | 42.7 | -0.7 | -0.1 | 0.0 | 0.2 | -0.2 | 0.6 | 0.2 | 0.6 | 0.3 | 0.1 | -0.3 | -0.1 | 0.2 | 0.4 | 0.1 | 0.6 | 0.7 | 1.2 | -0.0 | 0.2 | 0.0 | 0.2 | -1.0 | 0.2 | 1.0 | 0.5 | 0.2 |
| Saxagliptin 2.5 mg | 42.5 | -0.4 | -0.2 | 0.1 | 0.5 | 0.6 | 0.6 | 0.6 | 0.5 | 0.2 | 0.7 | 0.3 | 0.0 | 0.5 | 0.0 | 0.1 | 0.3 | 0.7 | 0.9 | -0.2 | -0.0 | 0.2 | -0.1 | -0.8 | -0.1 | 1.1 | 0.6 | -0.4 |
| Saxagliptin 5 mg | 42.8 | -0.2 | -0.2 | 0.3 | 0.4 | -0.0 | 0.4 | 0.6 | 0.7 | 0.4 | 0.4 | 0.2 | 0.2 | -0.1 | -0.1 | 0.3 | 0.1 | 0.5 | 0.9 | 0.5 | 0.6 | 0.3 | -0.1 | -0.8 | 0.2 | 0.6 | 1.1 | 0.2 |
(NCT00121641)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206
| Intervention | g/dL (Mean) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (BL) (Week 0) (n=102, 106, 98, 94) | Change from BL at Week 2 (n=95,100, 93, 87) | Change from BL at Week 4 (n=92, 99, 91, 91) | Change from BL at Week 6 (n=91, 96, 87, 82) | Change from BL at Week 8 (n=92, 90, 91, 79) | Change from BL at Week 10 (n=70, 76, 69, 63) | Change from BL at Week 12 (n=85, 88, 87, 82) | Change from BL at Week 14 (n=76, 80, 81, 75) | Change from BL at Week 16 (n=90, 91, 83, 71) | Change from BL at Week 18 (n=78, 75, 82, 71) | Change from BL at Week 20 (n=83, 80, 78, 72) | Change from BL at Week 22 (n=78, 74, 76, 65) | Change from BL at Week 24 (n=83, 82, 78, 74) | Change from BL at Week 30 (n=77, 78, 79, 67) | Change from BL at Week 37 (n=75, 73, 70, 62) | Change from BL at Week 50 (n=67, 71, 71, 61) | Change from BL at Week 63 (n=61, 66, 67, 55) | Change from BL at Week 76 (n=51, 59, 63, 49) | Change from BL at Week 89 (n=49, 58, 56, 42) | Change from BL at Week 102 (n=40, 49, 51, 40) | Change from BL at Week 115 (n=34, 43, 43, 35) | Change from BL at Week 128 (n=30, 40, 40, 30) | Change from BL at Week 141 (n=28, 39, 34, 28) | Change from BL at Week 154 (n=26, 34, 31, 24) | Change from BL at Week 167 (n=24, 33, 30, 26) | Change from BL at Week 180 (n=21, 28, 28, 26) | Change from BL at Week 193 (n=19, 26, 26, 23) | Change from BL at Week 206 (n=17, 22, 24, 21) | |
| Placebo | 14.50 | -0.09 | 0.10 | 0.04 | 0.09 | 0.04 | 0.16 | -0.03 | 0.04 | -0.03 | -0.19 | -0.18 | -0.14 | -0.18 | -0.33 | -0.01 | 0.08 | -0.10 | -0.10 | -0.29 | -0.19 | -0.33 | -0.36 | -0.25 | -0.24 | -0.61 | -0.39 | -0.32 |
| Saxagliptin 10 mg | 14.47 | -0.22 | -0.09 | -0.07 | -0.02 | -0.13 | -0.07 | -0.12 | 0.00 | -0.07 | -0.25 | -0.36 | -0.32 | -0.19 | -0.06 | -0.02 | 0.07 | -0.07 | -0.04 | -0.07 | -0.18 | -0.25 | -0.15 | -0.24 | -0.03 | -0.08 | -0.16 | 0.10 |
| Saxagliptin 2.5 mg | 14.49 | -0.21 | -0.16 | -0.12 | -0.00 | 0.01 | -0.04 | -0.09 | -0.10 | -0.26 | -0.16 | -0.35 | -0.37 | -0.25 | -0.31 | -0.17 | -0.18 | -0.27 | -0.18 | -0.32 | -0.41 | -0.38 | -0.40 | -0.45 | -0.51 | -0.38 | -0.45 | -0.51 |
| Saxagliptin 5 mg | 14.45 | -0.13 | -0.15 | -0.00 | 0.04 | -0.20 | -0.07 | -0.05 | 0.01 | -0.10 | -0.14 | -0.23 | -0.25 | -0.29 | -0.22 | 0.06 | -0.11 | -0.19 | -0.09 | -0.00 | -0.07 | -0.17 | -0.35 | -0.37 | -0.05 | -0.08 | -0.03 | -0.07 |
(NCT00121641)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206
| Intervention | x 10^9 c/L (Mean) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (BL) (Week 0) (n=101, 106, 96, 94) | Change from BL at Week 2 (n=92, 96, 85, 82) | Change from BL at Week 4 (n=88, 97, 90, 90) | Change from BL at Week 6 (n=88, 93, 84, 81) | Change from BL at Week 8 (n=86, 85, 86, 77) | Change from BL at Week 10 (n=68, 75, 67, 62) | Change from BL at Week 12 (n=83, 84, 85, 82) | Change from BL at Week 14 (n=72, 79, 77, 74) | Change from BL at Week 16 (n=86, 88, 81, 69) | Change from BL at Week 18 (n=77, 71, 79, 70) | Change from BL at Week 20 (n=78, 78, 72, 70) | Change from BL at Week 22 (n=74, 72, 73, 62) | Change from BL at Week 24 (n=80, 76, 73, 72) | Change from BL at Week 30 (n=73, 74, 74, 67) | Change from BL at Week 37 (n=70, 68, 66, 59) | Change from BL at Week 50 (n=66, 67, 66, 59) | Change from BL at Week 63 (n=59, 64, 65, 54) | Change from BL at Week 76 (n=50, 58, 61, 49) | Change from BL at Week 89 (n=47, 56, 54, 42) | Change from BL at Week 102 (n=39, 47, 49, 39) | Change from BL at Week 115 (n=33, 41, 41, 34) | Change from BL at Week 128 (n=30, 38, 39, 30) | Change from BL at Week 141 (n=27, 39, 33, 27) | Change from BL at Week 154 (n=25, 35, 31, 23) | Change from BL at Week 167 (n=22, 32, 28, 26) | Change from BL at Week 180 (n=20, 27, 27, 25) | Change from BL at Week 193 (n=17, 25, 25, 22) | Change from BL at Week 206 (n=15, 21, 23, 21) | |
| Placebo | 259.8 | 9.5 | 11.3 | 9.5 | 4.0 | 7.1 | 4.0 | 5.2 | 3.2 | 5.8 | -1.3 | 5.0 | -3.0 | 4.5 | 0.1 | 6.6 | 10.2 | 1.2 | 2.7 | 9.7 | 9.2 | 2.6 | -1.3 | 8.8 | 4.3 | 4.0 | -12.0 | -6.1 |
| Saxagliptin 10 mg | 261.6 | 2.2 | 5.6 | -0.2 | -4.3 | -4.4 | -4.8 | -3.7 | -6.0 | -2.7 | -8.3 | -5.4 | -15.5 | -9.9 | -15.6 | -11.5 | -6.3 | -6.0 | -6.7 | -4.8 | -12.0 | -2.6 | -0.3 | -2.9 | -14.6 | -17.3 | -13.4 | 6.2 |
| Saxagliptin 2.5 mg | 251.1 | 1.8 | 11.2 | 4.3 | 0.4 | -0.8 | -6.3 | 1.2 | -2.3 | -1.1 | -1.9 | 0.3 | -7.1 | -2.0 | -14.3 | -2.5 | -3.1 | -2.0 | 3.5 | 3.2 | 5.0 | 3.8 | -1.1 | 5.0 | -18.0 | -11.1 | -13.6 | -2.6 |
| Saxagliptin 5 mg | 253.1 | 4.4 | 8.6 | 4.3 | 1.0 | 3.0 | -1.3 | 3.2 | 1.1 | 2.0 | -4.8 | -2.5 | -6.0 | -3.3 | -8.1 | -5.6 | -3.4 | -1.5 | 1.9 | -2.3 | -8.8 | -2.1 | -4.6 | 5.8 | -0.1 | -24.0 | -13.4 | -18.7 |
(NCT00121641)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206
| Intervention | x 10^6 c/µL (Mean) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (BL) (Week 0) (n=102, 106, 98, 94) | Change from BL at Week 2 (n=95,100, 93, 87 | Change from BL at Week 4 (n=92, 99, 91, 91) | Change from BL at Week 6 (n=91, 96, 87, 82) | Change from BL at Week 8 (n=92, 90, 91, 79) | Change from BL at Week 10 (n=70, 76, 69, 63) | Change from BL at Week 12 (n=85, 88, 87, 82) | Change from BL at Week 14 (n=76, 80, 81, 75) | Change from BL at Week 16 (n=90, 91, 83, 71) | Change from BL at Week 18 (n=78, 75, 82, 71) | Change from BL at Week 20 (n=83, 80, 78, 72) | Change from BL at Week 22 (n=78, 74, 76, 65) | Change from BL at Week 24 (n=83, 82, 78, 74) | Change from BL at Week 30 (n=77, 78, 79, 67) | Change from BL at Week 37 (n=75, 73, 70, 62) | Change from BL at Week 50 (n=67, 71, 71, 61) | Change from BL at Week 63 (n=61, 66, 67, 55) | Change from BL at Week 76 (n=51, 59, 63, 49) | Change from BL at Week 89 (n=49, 58, 56, 42) | Change from BL at Week 102 (n=40, 49, 51, 40) | Change from BL at Week 115 (n=34, 43, 43, 35) | Change from BL at Week 128 (n=30, 40, 40, 30) | Change from BL at Week 141 (n=28, 39, 34, 28) | Change from BL at Week 154 (n=26, 35, 31, 24) | Change from BL at Week 167 (n=24, 33, 30, 26) | Change from BL at Week 180 (n=21, 28, 28, 26) | Change from BL at Week 193 (n=19, 26, 26, 23) | Change from BL at Week 206 (n=17, 22, 24, 21) | |
| Placebo | 4.82 | -0.05 | 0.04 | 0.02 | 0.05 | 0.07 | 0.08 | 0.04 | 0.06 | 0.04 | -0.01 | -0.01 | -0.01 | -0.03 | -0.09 | 0.01 | 0.05 | -0.03 | -0.07 | -0.13 | -0.06 | -0.10 | -0.11 | -0.09 | -0.10 | -0.17 | -0.10 | -0.08 |
| Saxagliptin 10 mg | 4.82 | -0.08 | -0.02 | 0.00 | 0.03 | -0.02 | 0.07 | 0.04 | 0.08 | 0.05 | 0.01 | -0.05 | -0.03 | -0.01 | 0.04 | 0.02 | 0.08 | 0.00 | -0.01 | -0.03 | -0.02 | -0.04 | -0.02 | -0.08 | -0.01 | -0.01 | -0.02 | 0.06 |
| Saxagliptin 2.5 mg | 4.80 | -0.06 | -0.01 | 0.00 | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 | 0.01 | 0.03 | -0.01 | -0.04 | 0.00 | -0.04 | -0.02 | 0.00 | -0.07 | -0.04 | -0.10 | -0.04 | -0.05 | -0.10 | -0.13 | -0.11 | -0.05 | -0.05 | -0.03 |
| Saxagliptin 5 mg | 4.80 | -0.04 | -0.04 | 0.02 | 0.03 | -0.03 | 0.03 | 0.03 | 0.08 | 0.04 | 0.02 | -0.01 | -0.04 | -0.07 | -0.04 | 0.04 | -0.01 | -0.07 | -0.06 | -0.03 | -0.01 | -0.07 | -0.13 | -0.13 | -0.04 | -0.08 | -0.06 | -0.06 |
(NCT00121641)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206
| Intervention | x 10^3 c/µL (Mean) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (BL) (Week 0) (n=102, 106, 98, 94) | Change from BL at Week 2 (n=95, 99, 92, 86) | Change from BL at Week 4 (n=92, 99, 90, 90) | Change from BL at Week 6 (n=89, 95, 87, 82) | Change from BL at Week 8 (n=91, 89, 90, 79) | Change from BL at Week 10 (n=68, 76, 69, 63) | Change from BL at Week 12 (n=83, 88, 87, 82) | Change from BL at Week 14 (n=76, 78, 80, 75) | Change from BL at Week 16 (n=90, 91, 83, 71) | Change from BL at Week 18 (n=78, 75, 82, 71) | Change from BL at Week 20 (n=83, 79, 78, 72) | Change from BL at Week 22 (n=77, 74, 76, 65) | Change from BL at Week 24 (n=83, 82, 78, 74) | Change from BL at Week 30 (n=77, 78, 79, 67) | Change from BL at Week 37 (n=74, 73, 70, 62) | Change from BL at Week 50 (n=67, 69, 71, 61) | Change from BL at Week 63 (n=60, 66, 67, 55) | Change from BL at Week 76 (n=51, 58, 63, 49) | Change from BL at Week 89 (n=48, 58, 56, 42) | Change from BL at Week 102 (n=39, 47, 51, 40) | Change from BL at Week 115 (n=34, 43, 42, 34) | Change from BL at Week 128 (n=30, 40, 40, 29) | Change from BL at Week 141 (n=28, 39, 34, 28) | Change from BL at Week 154 (n=26, 34, 31, 24) | Change from BL at Week 167 (n=24, 33, 30, 25) | Change from BL at Week 180 (n=21, 28, 28, 26) | Change from BL at Week 193 (n=19, 26, 26, 23) | Change from BL at Week 206 (n=17, 22, 23, 21) | |
| Placebo | 6.79 | -0.23 | 0.17 | 0.09 | 0.16 | 0.53 | 0.26 | 0.56 | 0.19 | 0.32 | 0.02 | 0.45 | -0.06 | -0.03 | 0.14 | 0.29 | 0.06 | -0.20 | -0.18 | -0.09 | 0.44 | 0.22 | 0.51 | 0.38 | 0.35 | 0.65 | 0.19 | 0.38 |
| Saxagliptin 10 mg | 6.82 | -0.14 | -0.16 | -0.18 | -0.17 | 0.12 | 0.05 | 0.22 | 0.04 | 0.42 | 0.01 | 0.44 | 0.08 | 0.28 | 0.12 | -0.03 | -0.04 | -0.07 | -0.10 | 0.10 | 0.11 | 0.44 | 0.44 | 0.30 | 0.27 | 0.59 | 0.60 | 1.01 |
| Saxagliptin 2.5 mg | 6.71 | -0.11 | 0.06 | 0.01 | -0.02 | 0.32 | -0.00 | 0.33 | 0.24 | 0.37 | 0.29 | 0.66 | 0.10 | 0.15 | 0.21 | 0.01 | 0.12 | 0.03 | 0.51 | 0.16 | 0.24 | 0.58 | 0.35 | 0.12 | -0.22 | 0.13 | 0.34 | 0.01 |
| Saxagliptin 5 mg | 6.75 | 0.05 | 0.05 | 0.10 | 0.18 | 0.55 | 0.09 | 0.71 | 0.54 | 0.82 | 0.29 | 0.72 | 0.47 | 0.33 | 0.42 | 0.33 | 0.20 | 0.23 | 0.17 | 0.44 | 0.93 | 0.66 | 0.78 | 0.44 | 0.44 | 0.30 | 0.02 | 0.55 |
This cohort represents a different population (screening A1C > 10.0% and ≤ 12.0%) than the double-blind cohort, and was presented separately in the study report. (NCT00121641)
Timeframe: Baseline
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age <65 years | Age >=65 years | Age >=75 years | Gender, Male | Gender, Female | Age =<50 years, females only | Age >50 years, females only | Race, White | Race, Black/African American | Race, Asian | Race, Other | Ethnicity, Hispanic/Latino | Ethnicity, Not Hispanic/Latino | Ethnicity, Not Reported | Body Mass Index <30% | Body Mass Index >=30% | |
| Open-Label Treatment Cohort (Direct Enrollees) | 64 | 2 | 0 | 32 | 34 | 19 | 15 | 61 | 3 | 1 | 1 | 13 | 37 | 16 | 22 | 44 |
(NCT00121641)
Timeframe: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206
| Intervention | mmHg (Mean) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change from BL at Week 2 (n=96, 100, 94, 89) | Change from BL at Week 4 (n=96, 100, 92, 91) | Change from BL at Week 6 (n=91, 98, 88, 84) | Change from BL at Week 8 (n=94, 91, 91, 80) | Change from BL at Week 10 (n=51, 66, 51, 50) | Change from BL at Week 12 (n=82, 83, 87, 79) | Change from BL at Week 14 (n=65, 72, 66, 62) | Change from BL at Week 16 (n=87, 87, 81, 72) | Change from BL at Week 18 (n=73, 69, 76, 66) | Change from BL at Week 20 (n=84, 80, 76, 73) | Change from BL at Week 22 (n=78, 73, 76, 64) | Change from BL at Week 24 (n=84, 83, 77, 75) | Change from BL at Week 30 (n=79, 78, 79, 66) | Change from BL at Week 37 (n=77, 74, 71, 66) | Change from BL at Week 50 (n=70, 73, 73, 62) | Change from BL at Week 63 (n=61, 66, 69, 56) | Change from BL at Week 76 (n=53, 59, 64, 50) | Change from BL at Week 89 (n=49, 58, 56, 44) | Change from BL at Week 102 (n=42, 51, 51, 42) | Change from BL at Week 115 (n=34, 43, 43, 37) | Change from BL at Week 128 (n=31, 40, 41, 31) | Change from BL at Week 141 (n=29, 40, 35, 29) | Change from BL at Week 154 (n=27, 36, 33, 27) | Change from BL at Week 167 (n=24, 33, 30, 27) | Change from BL at Week 180 (n=21, 28, 28, 27) | Change from BL at Week 193 (n=19, 26, 27, 24) | Change from BL at Week 206 (n=17, 24, 24, 23) | |
| Placebo | -1.5 | -1.8 | -1.9 | -2.4 | -3.4 | -1.8 | -2.7 | -2.1 | -2.1 | -2.2 | -1.7 | -3.4 | -2.8 | -2.0 | -0.6 | -0.5 | -0.3 | -0.1 | -1.2 | -1.0 | 1.0 | 1.3 | 1.3 | -1.1 | -0.8 | -0.2 | -0.2 |
| Saxagliptin 10 mg | -0.5 | 0.3 | -0.8 | -0.7 | -1.3 | -0.7 | -2.4 | -0.1 | -1.9 | -1.9 | -2.5 | -2.3 | -0.3 | -0.6 | -0.3 | -0.0 | 0.1 | -1.6 | -0.4 | -1.1 | 1.1 | 1.1 | 2.5 | 2.4 | 0.5 | 0.5 | 1.9 |
| Saxagliptin 2.5 mg | -0.0 | -1.4 | -1.5 | -1.4 | -0.8 | -1.3 | -2.5 | -1.5 | -2.3 | -2.2 | -3.0 | -1.5 | -1.4 | -0.4 | -1.7 | -0.1 | -1.6 | 0.4 | -1.1 | -0.9 | -1.8 | 0.9 | 1.2 | 0.8 | 1.4 | 0.8 | 0.3 |
| Saxagliptin 5 mg | -1.2 | -1.1 | -0.9 | -0.9 | -1.1 | -2.0 | -2.4 | -0.5 | -1.6 | -1.8 | -2.0 | -1.7 | -2.2 | -1.7 | 0.3 | -0.4 | -2.0 | -2.1 | -2.0 | -2.7 | -3.7 | -2.0 | -0.8 | 0.3 | -2.0 | -1.6 | -0.6 |
(NCT00121641)
Timeframe: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167
| Intervention | mmHg (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change from BL at Week 2 (n=62) | Change from BL at Week 4 (n=59) | Change from BL at Week 6 (n=60) | Change from BL at Week 8 (n=49) | Change from BL at Week 10 (n=24) | Change from BL at Week 12 (n=47) | Change from BL at Week 14 (n=35) | Change from BL at Week 16 (n=46) | Change from BL at Week 18 (n=42) | Change from BL at Week 20 (n=45) | Change from BL at Week 22 (n=44) | Change from BL at Week 24 (n=44) | Change from BL at Week 30 (n=40) | Change from BL at Week 37 (n=35) | Change from BL at Week 50 (n=36) | Change from BL at Week 63 (n=26) | Change from BL at Week 76 (n=24) | Change from BL at Week 89 (n=23) | Change from BL at Week 102 (n=15) | Change from BL at Week 115 (n=13) | Change from BL at Week 128 (n=11) | Change from BL at Week 141 (n=10) | Change from BL at Week 154 (n=10) | Change from BL at Week 167 (n=10) | |
| Open-Label Treatment Cohort (Direct Enrollees) | -3.7 | -1.7 | -2.8 | -2.0 | -1.0 | -3.7 | -4.5 | -2.8 | -3.3 | -2.1 | -2.8 | -3.4 | -3.8 | -2.0 | -1.3 | -0.9 | -1.0 | -2.6 | 1.0 | -4.1 | -3.7 | -6.0 | -0.5 | -2.5 |
(NCT00121641)
Timeframe: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206
| Intervention | beats per minute (Mean) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change from BL at Week 2 (n=96, 100, 94, 89) | Change from BL at Week 4 (n=96, 100, 92, 91) | Change from BL at Week 6 (n=91, 98, 88, 84) | Change from BL at Week 8 (n=94, 91, 91, 80) | Change from BL at Week 10 (n=51, 66, 51, 49) | Change from BL at Week 12 (n=82, 83, 87, 79) | Change from BL at Week 14 (n=65, 72, 65, 62) | Change from BL at Week 16 (n=87, 87, 81, 72) | Change from BL at Week 18 (n=73, 69, 76, 66) | Change from BL at Week 20 (n=84, 80, 76, 73) | Change from BL at Week 22 (n=78, 73, 76, 64) | Change from BL at Week 24 (n=84, 83, 77, 75) | Change from BL at Week 30 (n=79, 78, 79, 66) | Change from BL at Week 37 (n=77, 74, 71, 66) | Change from BL at Week 50 (n=70, 73, 73, 62) | Change from BL at Week 63 (n=62, 66, 69, 56) | Change from BL at Week 76 (n=53, 59, 64, 50) | Change from BL at Week 89 (n=49, 58, 56, 44) | Change from BL at Week 102 (n=42, 51, 51, 42) | Change from BL at Week 115 (n=34, 43, 43, 37) | Change from BL at Week 128 (n=31, 40, 41, 31) | Change from BL at Week 141 (n=29, 40, 35, 29) | Change from BL at Week 154 (n=27, 36, 33, 27) | Change from BL at Week 167 (n=24, 33, 30, 27) | Change from BL at Week 180 (n=21, 28, 28, 27) | Change from BL at Week 193 (n=19, 26, 27, 24) | Change from BL at Week 206 (n=17, 24, 24, 23) | |
| Placebo | 0.3 | -0.1 | 1.4 | -0.2 | 0.1 | 0.8 | 1.9 | -0.1 | 2.6 | 0.8 | 1.5 | -0.4 | -1.2 | -0.9 | -0.2 | 0.6 | 0.2 | -0.3 | -0.0 | 0.8 | 1.7 | 0.9 | -0.6 | 0.5 | -1.2 | 1.1 | -0.8 |
| Saxagliptin 10 mg | 0.2 | 0.7 | -0.6 | 0.2 | -1.0 | 0.5 | 0.6 | -0.1 | 1.5 | 1.3 | 0.9 | -0.7 | -0.7 | 0.5 | -0.2 | 0.9 | 0.4 | -0.9 | -0.1 | 1.0 | -0.7 | -0.6 | -1.3 | -2.1 | -2.0 | -2.4 | 0.0 |
| Saxagliptin 2.5 mg | -0.1 | 0.2 | -1.5 | -0.5 | -0.2 | 0.3 | 0.1 | -0.8 | -0.0 | 1.3 | 0.1 | -0.3 | -0.1 | -0.4 | -0.1 | -0.4 | -0.3 | -0.5 | -2.8 | -3.2 | -2.1 | -2.8 | -2.0 | -5.1 | -3.1 | -4.6 | -5.3 |
| Saxagliptin 5 mg | -0.5 | -1.1 | -0.6 | -0.9 | -1.5 | -1.2 | -0.5 | -1.5 | -0.8 | -1.5 | -0.3 | 0.1 | -1.2 | -1.4 | -0.7 | -2.5 | -3.3 | -1.5 | -1.5 | -2.3 | -4.5 | -3.5 | -2.6 | -0.8 | -5.3 | -4.2 | -2.6 |
(NCT00121641)
Timeframe: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167
| Intervention | beats per minute (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change from BL at Week 2 (n=62) | Change from BL at Week 4 (n=59) | Change from BL at Week 6 (n=60) | Change from BL at Week 8 (n=49) | Change from BL at Week 10 (n=23) | Change from BL at Week 12 (n=47) | Change from BL at Week 14 (n=34) | Change from BL at Week 16 (n=46) | Change from BL at Week 18 (n=42) | Change from BL at Week 20 (n=45) | Change from BL at Week 22 (n=43) | Change from BL at Week 24 (n=44) | Change from BL at Week 30 (n=40) | Change from BL at Week 37 (n=35) | Change from BL at Week 50 (n=36) | Change from BL at Week 63 (n=26) | Change from BL at Week 76 (n=24) | Change from BL at Week 89 (n=23) | Change from BL at Week 102 (n=15) | Change from BL at Week 115 (n=13) | Change from BL at Week 128 (n=11) | Change from BL at Week 141 (n=10) | Change from BL at Week 154 (n=10) | Change from BL at Week 167 (n=10) | |
| Open-Label Treatment Cohort (Direct Enrollees) | -0.8 | -0.4 | -0.3 | -0.7 | -1.8 | -3.0 | -2.0 | -0.7 | -2.0 | 1.6 | -0.4 | -0.4 | 0.6 | -1.6 | -2.9 | -3.0 | -0.4 | -1.3 | -0.3 | 1.7 | -1.6 | -3.4 | -1.5 | -1.9 |
(NCT00121641)
Timeframe: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206
| Intervention | mmHg (Mean) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change from BL at Week 2 (n=96, 100, 94, 89) | Change from BL at Week 4 (n=96, 100, 92, 91) | Change from BL at Week 6 (n=91, 98, 88, 84) | Change from BL at Week 8 (n=94, 91, 91, 80) | Change from BL at Week 10 (n=51, 66, 51, 50) | Change from BL at Week 12 (n=82, 83, 87, 79) | Change from BL at Week 14 (n=65, 72, 66, 62) | Change from BL at Week 16 (n=87, 87, 81, 72) | Change from BL at Week 18 (n=73, 69, 76, 66) | Change from BL at Week 20 (n=84, 80, 76, 73) | Change from BL at Week 22 (n=78, 73, 76, 64) | Change from BL at Week 24 (n=84, 83, 77, 75) | Change from BL at Week 30 (n=79, 78, 79, 66) | Change from BL at Week 37 (n=77, 74, 71, 66) | Change from BL at Week 50 (n=70, 73, 73, 62) | Change from BL at Week 63 (n=62, 66, 69, 56) | Change from BL at Week 76 (n=53, 59, 64, 50) | Change from BL at Week 89 (n=49, 58, 56, 44) | Change from BL at Week 102 (n=42, 47, 50, 40) | Change from BL at Week 115 (n=34, 43, 43, 37) | Change from BL at Week 128 (n=31, 40, 41, 31) | Change from BL at Week 141 (n=29, 40, 35, 29) | Change from BL at Week 154 (n=27, 36, 33, 27) | Change from BL at Week 167 (n=24, 33, 30, 27) | Change from BL at Week 180 (n=21, 28, 28, 27) | Change from BL at Week 193 (n=19, 26, 27, 24) | Change from BL at Week 206 (n=17, 24, 24, 23) | |
| Placebo | -3.1 | -4.3 | -4.5 | -5.5 | -6.1 | -3.2 | -1.9 | -2.1 | -4.7 | -4.9 | -3.9 | -6.3 | -5.4 | -3.6 | -0.4 | -2.4 | -0.9 | -2.2 | -1.0 | 0.9 | 1.1 | -1.4 | 2.3 | -0.6 | -0.8 | -2.6 | 0.7 |
| Saxagliptin 10 mg | -2.3 | -2.3 | -3.5 | -4.0 | -5.0 | -2.8 | -6.0 | -3.8 | -4.3 | -3.3 | -5.9 | -6.2 | -3.9 | -5.2 | -3.3 | -1.1 | -3.1 | -5.4 | -2.9 | -1.6 | 0.0 | 0.3 | 3.5 | 4.0 | 0.9 | 0.0 | 2.3 |
| Saxagliptin 2.5 mg | -1.0 | -1.9 | -1.5 | -3.0 | -3.6 | -3.3 | -4.9 | -3.2 | -5.1 | -5.0 | -6.1 | -2.8 | -3.6 | -3.0 | -2.5 | -1.2 | -2.9 | -2.8 | -0.6 | -2.6 | -5.1 | -1.8 | -0.8 | 0.7 | 0.9 | 3.4 | 4.8 |
| Saxagliptin 5 mg | -2.0 | -1.2 | -2.1 | -1.8 | -2.9 | -2.9 | -2.0 | -2.1 | -0.9 | -3.2 | -4.5 | -4.1 | -3.8 | -3.5 | 0.1 | -0.3 | -2.6 | -3.4 | -1.1 | -2.6 | -5.5 | -5.2 | -0.5 | -1.8 | -5.4 | -7.5 | -2.8 |
(NCT00121641)
Timeframe: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167
| Intervention | mmHg (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change from BL at Week 2 (n=62) | Change from BL at Week 4 (n=59) | Change from BL at Week 6 (n=60) | Change from BL at Week 8 (n=49) | Change from BL at Week 10 (n=24) | Change from BL at Week 12 (n=47) | Change from BL at Week 14 (n=35) | Change from BL at Week 16 (n=46) | Change from BL at Week 18 (n=42) | Change from BL at Week 20 (n=45) | Change from BL at Week 22 (n=44) | Change from BL at Week 24 (n=44) | Change from BL at Week 30 (n=40) | Change from BL at Week 37 (n=35) | Change from BL at Week 50 (n=36) | Change from BL at Week 63 (n=26) | Change from BL at Week 76 (n=24) | Change from BL at Week 89 (n=23) | Change from BL at Week 102 (n=15) | Change from BL at Week 115 (n=13) | Change from BL at Week 128 (n=11) | Change from BL at Week 141 (n=10) | Change from BL at Week 154 (n=10) | Change from BL at Week 167 (n=10) | |
| Open-Label Treatment Cohort (Direct Enrollees) | -4.4 | -3.8 | -2.7 | -5.1 | -4.2 | -4.9 | -5.1 | -1.9 | -5.8 | -3.6 | -4.0 | -4.3 | -4.8 | -4.7 | -1.6 | -0.7 | -1.9 | -4.0 | 0.9 | -6.6 | -5.6 | -7.2 | 5.7 | -2.2 |
The normality/abnormality of the ECG tracing was determined by the investigator. (NCT00121641)
Timeframe: Baseline, Weeks 12, 24, 76, 102, 154, 206
| Intervention | participants (Number) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Normal BL, Normal Week 12 (BL n=65, 66, 67, 47) | Normal BL, Abnormal Week 12 (BL n=65, 66, 67, 47) | Abnormal BL, Normal Week 12 (BL n=27, 32, 26, 43) | Abnormal BL, Abnormal Week 12(BL n=27, 32, 26, 43) | Normal BL, Normal Week 24 (BL n=53, 52, 47, 33) | Normal BL, Abnormal Week 24 (BL n=53, 52, 47, 33) | Abnormal BL, Normal Week 24 (BL n=19, 24, 21, 25) | Abnormal BL, Abnormal Week 24(BL n=19, 24, 21, 25) | Normal BL, Normal Week 76 (BL n=48, 49, 48, 36) | Normal BL, Abnormal Week 76 (BL n=48, 49, 48, 36) | Abnormal BL, Normal Week 76 (BL n=19, 23, 21, 27) | Abnormal BL, Abnormal Week 76(BL n=19, 23, 21, 27) | Normal BL, Normal Week 102 (BL n=32, 32, 36, 22) | Normal BL, Abnormal Week 102 (BL n=32, 32, 36, 22) | Abnormal BL, Normal Week 102 (BL n=12, 18, 17, 20) | Abnormal BL,Abnormal Week 102(BL n=12, 18, 17, 20) | Normal BL, Normal Week 154 (BL n=20, 21, 26, 15) | Normal BL, Abnormal Week 154 (BL n=20, 21, 26, 15) | Abnormal BL, Normal Week 154 (BL n=7, 16, 11, 13) | Abnormal BL, Abnormal Week 154(BL n=7, 16, 11, 13) | Normal BL, Normal Week 206 (BL n=15, 13, 20, 14) | Normal BL, Abnormal Week 206 (BL n=15, 13, 20, 14) | Abnormal BL, Normal Week 206 (BL n=4, 13, 8, 11) | Abnormal BL, Abnormal Week 206 (BL n=4, 13, 8, 11) | |
| Placebo | 43 | 4 | 15 | 28 | 31 | 2 | 8 | 17 | 30 | 6 | 13 | 14 | 18 | 4 | 11 | 9 | 14 | 1 | 7 | 6 | 11 | 3 | 4 | 7 |
| Saxagliptin 10 mg | 59 | 8 | 9 | 17 | 43 | 4 | 9 | 12 | 40 | 8 | 6 | 15 | 31 | 5 | 12 | 5 | 23 | 3 | 5 | 6 | 18 | 2 | 4 | 4 |
| Saxagliptin 2.5 mg | 57 | 8 | 6 | 21 | 43 | 10 | 5 | 14 | 37 | 11 | 8 | 11 | 25 | 7 | 4 | 8 | 16 | 4 | 4 | 3 | 15 | 0 | 2 | 2 |
| Saxagliptin 5 mg | 56 | 10 | 6 | 26 | 44 | 8 | 8 | 16 | 44 | 5 | 8 | 15 | 26 | 6 | 5 | 13 | 17 | 4 | 4 | 12 | 12 | 1 | 3 | 10 |
The normality/abnormality of the ECG tracing was determined by the investigator. (NCT00121641)
Timeframe: Baseline, Weeks 12, 24, 76, 102, 154, 206
| Intervention | participants (Number) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Normal BL, Normal Week 12 (BL n=23) | Normal BL, Abnormal Week 12 (BL n=23) | Abnormal BL, Normal Week 12 (BL n=18) | Abnormal BL, Abnormal Week 12 (BL n=18) | Normal BL, Normal Week 24 (BL n=10) | Normal BL, Abnormal Week 24 (BL n=10) | Abnormal BL, Normal Week 24 (BL n=6) | Abnormal BL, Abnormal Week 24(BL n=6) | Normal BL, Normal Week 76 (BL n=17) | Normal BL, Abnormal Week 76 (BL n=17) | Abnormal BL, Normal Week 76 (BL n=13) | Abnormal BL, Abnormal Week 76 (BL n=13) | Normal BL, Normal Week 102 (BL n=8) | Normal BL, Abnormal Week 102 (BL n=8) | Abnormal BL, Normal Week 102 (BL n=4) | Abnormal BL, Abnormal Week 102 (BL n=4) | Normal BL, Normal Week 154 (BL n=4) | Normal BL, Abnormal Week 154 (BL n=4) | Abnormal BL, Normal Week 154 (BL n=2) | Abnormal BL, Abnormal Week 154 (BL n=2) | Normal BL, Normal Week 206 (BL n=3) | Normal BL, Abnormal Week 206 (BL n=3) | Abnormal BL, Normal Week 206 (BL n=1) | Abnormal BL, Abnormal Week 206 (BL n=1) | |
| Open-Label Treatment Cohort (Direct Enrollees) | 19 | 4 | 5 | 13 | 8 | 2 | 2 | 4 | 13 | 4 | 4 | 9 | 6 | 2 | 1 | 3 | 3 | 1 | 0 | 2 | 2 | 1 | 0 | 1 |
To compare the change from baseline in HbA1c achieved with each dose of saxagliptin versus placebo in treatment naive subjects with type 2 diabetes who have inadequate glycemic control defined as A1C ≥7.0% and ≤10.0%. (NCT00121641)
Timeframe: Baseline, Week 24
| Intervention | Percentage of glycosylated hemoglobins (Mean) | |
|---|---|---|
| Baseline Mean | Adjusted Mean Change from Baseline | |
| Placebo | 7.88 | 0.19 |
| Saxagliptin 10 mg | 7.85 | -0.54 |
| Saxagliptin 2.5 mg | 7.91 | -0.43 |
| Saxagliptin 5 mg | 7.98 | -0.46 |
A laboratory value was considered a marked abnormality if it is outside the pre-defined criteria for marked abnormality and the on-treatment value was more extreme (farther from the limit) than the baseline value. Pre-Rx=pretreatment; ULN=upper limit of normal; ALP=alkaline phosphatase; AST=aspartate aminotransferase; ALT=alanine aminotransferase; unspec=unspecified; sodium serum low: <0.9 x Pre-Rx & <=130mEq/L / high: >1.1 x Pre-Rx & >=150mEq/L; potassium, serum low: <=0.8 x Pre-Rx & >=6.0mEq/L / high: 1.2 x Pre-Rx & >=6.0mEq/L; LLN=lower limit of normal. (NCT00121641)
Timeframe: Lab assessments taken during and up to 14 days after the last dose of study drug during the ST + LT Treatment Period. Mean duration of exposure was 109 weeks in 10 mg arm, 94.7 weeks in 2.5 mg arm, 103 weeks in 5 mg arm, and 98.4 weeks in placebo arm.
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin < 8 g/dL (n=101, 105, 97, 93) | Hematocrit < 0.75 x pre-Rx (n=101, 105, 97, 93) | Platelets < 50 x 10^9 c/L (n=100, 104, 94, 93) | Platelets > 1.5 x ULN (n=100,104, 94, 93) | Leukocytes < 2 x 1000 c/µL (n=101, 105, 97, 93) | Neutrophils+Bands <1x1000 c/µL(n=101, 105, 97, 93) | Eosinophils >0.9x1000 c/µL (n=101, 105, 97, 93) | Lymphocytes <=0.75x1000 c/µL (n=101, 105, 97, 93) | ALP >3 x pre-Rx and >ULN (n=101,105, 97, 94) | ALP >1.5 x ULN (n=101, 105, 97, 94) | AST >3 x ULN (n=101, 105, 97, 94) | AST >5 x ULN (n=101, 105, 97, 94) | AST >10 x ULN (n=101, 105, 97, 94) | AST >20 x ULN (n=101, 105, 97, 94) | ALT >3 x ULN (n=101, 105, 97, 94) | ALT >5 x ULN (n=101, 105, 97, 94) | ALT >10 x ULN (n=101, 105, 97, 94) | ALT >20 x ULN (n=101, 105, 97, 94) | Bilirubin Total >2mg/dL (n=101, 105, 97, 94) | Bilirubin Total >1.5xULN (n=101, 105, 97, 94) | Bilirubin Total >2xULN (n=101, 105, 97, 94) | BUN >2 x pre-Rx and >ULN (n=101, 105, 97, 94) | Creatinine >2.5 mg/dL (n=101, 105, 97, 94) | Glucose, Serum Fasting < 50 mg/dL (n=0, 0, 0, 0) | Glucose, Serum Fasting > 500 mg/dL (n=0, 0, 0, 0) | Glucose, Serum Unspec. < 50 mg/dL (n=0,0,0,0) | Glucose, Serum Unspec. > 500 mg/dL (n=0,0,0,0) | Glucose, Plasma Fasting<50mg/dL(n=101, 104, 96,94) | Glucose,Plasma Fasting>500mg/dL(n=101, 104, 96,94) | Glucose, Plasma Unspec.<50mg/dL(n=102, 105, 98,95) | Glucose,Plasma Unspec.>500mg/dL(n=102, 105, 98,95) | Sodium,Serum Low (see above) (n=101, 105, 97, 94) | Sodium,Serum High(see above) (n=101, 105, 97, 94) | Potassium,Serum Low(see above)(n=101, 105, 97, 94) | Potassium, Serum High(see above)(n=101,105,97,94) | Chloride < 90 mEq/L (n=101, 105, 97, 94) | Chloride > 120 mEq/L (n=101, 105, 97, 94) | Albumin < 0.9 LLN (n=101, 105, 97, 94) | Creatine Kinase > 5 x ULN (n=101, 105, 97, 94) | Uric Acid > 1.5 x ULN (n=0, 0, 0, 0) | Protein Urine, >=2-4 (n=99, 103, 94, 92) | Blood Urine, >=2-4 (n=99, 103, 94, 92) | Red Blood Cells Urine >=2-4 (n=95, 97, 89, 88) | White Blood Cells Urine >=2-4 (n=95, 97, 89, 88) | |
| Placebo | 0 | 0 | 0 | 1 | 0 | 0 | 4 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 3 | 2 | 1 | 0 | 0 | 3 | 1 | 0 | 0 | 4 | 0 | 3 | 16 | 14 | 12 |
| Saxagliptin 10 mg | 0 | 1 | 0 | 0 | 0 | 1 | 3 | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 4 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 4 | 8 | 8 | 15 |
| Saxagliptin 2.5 mg | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 4 | 0 | 2 | 3 | 2 | 1 | 0 | 3 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 7 | 0 | 0 | 1 | 0 | 3 | 0 | 0 | 0 | 2 | 0 | 8 | 5 | 6 | 13 |
| Saxagliptin 5 mg | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 2 | 0 | 1 | 2 | 1 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 4 | 0 | 9 | 11 | 8 | 19 |
A laboratory value was considered a marked abnormality if it is outside the pre-defined criteria for marked abnormality and the on-treatment value was more extreme (farther from the limit) than the baseline value. Pre-Rx=pretreatment; ULN=upper limit of normal; ALP=alkaline phosphatase; AST=aspartate aminotransferase; ALT=alanine aminotransferase; unspec=unspecified; sodium serum low: <0.9 x Pre-Rx & <=130mEq/L / high: >1.1 x Pre-Rx & >=150mEq/L; potassium, serum low: <=0.8 x Pre-Rx & >=6.0mEq/L / high: 1.2 x Pre-Rx & >=6.0mEq/L; LLN=lower limit of normal. (NCT00121641)
Timeframe: Lab assessments taken during and up to 14 days after the last dose of study drug during the ST + LT Treatment Period. Mean duration of exposure was 34 weeks.
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin < 8 g/dL (n=64) | Hematocrit < 0.75 x pre-Rx (n=64) | Platelets < 50 x 10^9 c/L (n=64) | Platelets > 1.5 x ULN (n=64) | Leukocytes < 2 x 1000 c/µL (n=64) | Neutrophils+Bands <1x1000 c/uL (n=64) | Eosinophils >0.9x1000 c/µL (n=64) | Lymphocytes <=0.75x1000 c/uL (n=64) | ALP >3 x pre-Rx and >ULN (n=64) | ALP >1.5 x ULN (n=64) | AST >3 x ULN (n=64) | AST >5 x ULN (n=64) | AST >10 x ULN (n=64) | AST >20 x ULN (n=64) | ALT >3 x ULN (n=64) | ALT >5 x ULN (n=64) | ALT >10 x ULN (n=64) | ALT >20 x ULN (n=64) | Bilirubin Total >2mg/dL (n=64) | Bilirubin Total >1.5xULN (n=64) | Bilirubin Total >2xULN (n=64) | BUN >2 x pre-Rx and >ULN (n=64) | Creatinine >2.5 mg/dL (n=64) | Glucose, Serum Fasting < 50 mg/dL (n=1) | Glucose, Serum Fasting > 500 mg/dL (n=1) | Glucose, Serum Unspec. < 50 mg/dL (n=1) | Glucose, Serum Unspec. > 500 mg/dL (n=1) | Glucose, Plasma Fasting <50 mg/dL (n=64) | Glucose,Plasma Fasting >500 mg/dL (n=64) | Glucose, Plasma Unspec. <50 mg/dL (n=65) | Glucose,Plasma Unspec. >500 mg/dL (n=65) | Sodium,Serum Low (see above) (n=65) | Sodium,Serum High (see above) (n=65) | Potassium,Serum Low (see above) (n=65) | Potassium, Serum High (see above) (n=65) | Chloride < 90 mEq/L (n=65) | Chloride > 120 mEq/L (n=65) | Albumin < 0.9 LLN (n=64) | Creatine Kinase > 5 x ULN (n=64) | Uric Acid > 1.5 x ULN (n=0) | Protein Urine, >=2-4 (n=64) | Blood Urine, >=2-4 (n=64) | Red Blood Cells Urine >=2-4 (n=58) | White Blood Cells Urine >=2-4 (n=58) | |
| Open-Label Treatment Cohort (Direct Enrollees) | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 2 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 2 | 4 | 7 | 6 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Related events=relationship of certain, probable, possible, or missing. (NCT00121641)
Timeframe: AEs: up to last treatment day + 1 day or last visit; SAEs: up to last treatment day + 30 days or last visit + 30 days. Mean duration of exposure was 109 weeks in 10 mg arm, 94.7 weeks in 2.5 mg arm, 103 weeks in 5 mg arm, and 98.4 weeks in placebo arm.
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| At Least 1 AE | At Least 1 Related AE | Deaths | At Least 1 SAE | At Least 1 Related SAE | Discontinuations Due to SAEs | Discontinuations Due to AEs | |
| Placebo | 77 | 25 | 1 | 11 | 0 | 1 | 5 |
| Saxagliptin 10 mg | 87 | 25 | 0 | 9 | 0 | 3 | 10 |
| Saxagliptin 2.5 mg | 89 | 25 | 0 | 11 | 0 | 6 | 9 |
| Saxagliptin 5 mg | 94 | 23 | 0 | 18 | 1 | 2 | 10 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Related events=relationship of certain, probable, possible, or missing. (NCT00121641)
Timeframe: AEs: up to last treatment day + 1 day or last visit; SAEs: up to last treatment day + 30 days or last visit + 30 days. Mean duration of exposure was 34 weeks.
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| At Least 1 AE | At Least 1 Related AE | Deaths | At Least 1 SAE | At Least 1 Related SAE | Discontinuations Due to SAEs | Discontinuations Due to AEs | |
| Open-Label Treatment Cohort (Direct Enrollees) | 49 | 9 | 0 | 6 | 0 | 2 | 5 |
Birth weight of live borne neonates were calculated in grams. (NCT01103063)
Timeframe: Approximately 40 weeks of gestational age.
| Intervention | grams (Least Squares Mean) |
|---|---|
| Azithromycin + Chloroquine | 3148.3 |
| Sulfadoxine + Pyrimethamine | 3146.2 |
Change from Baseline to 36-38 weeks of gestation in Hb concentration was noted. (NCT01103063)
Timeframe: Baseline, at 36-38 weeks of gestation.
| Intervention | g/dL (Least Squares Mean) |
|---|---|
| Azithromycin + Chloroquine | 0.13 |
| Sulfadoxine + Pyrimethamine | 0.27 |
This outcome measure determined if an episode of malaria started within the time period of first dose to delivery. Clinical episode of malaria was determined if the participant presented with clinical symptoms of malaria (fever >37.5°C, oral) and diagnosed (either by rapid diagnostic tests or microscopy) with malaria. (NCT01103063)
Timeframe: Approximately 40 weeks of gestational age
| Intervention | Number of episodes (Least Squares Mean) |
|---|---|
| Azithromycin + Chloroquine | 0.06 |
| Sulfadoxine + Pyrimethamine | 0.13 |
Neonates with congenital abnormalities at birth were noted. (NCT01103063)
Timeframe: Approximately 40 weeks of gestational age.
| Intervention | Percentage of neonates (Number) |
|---|---|
| Azithromycin + Chloroquine | 2.19 |
| Sulfadoxine + Pyrimethamine | 2.44 |
LBW was defined as live birth weight <2500 g (up to and including 2499 g). (NCT01103063)
Timeframe: Approximately 40 weeks of gestational age
| Intervention | Percentage of neonates (Number) |
|---|---|
| Azithromycin + Chloroquine | 4.72 |
| Sulfadoxine + Pyrimethamine | 5.21 |
LBW was defined as live birth weight <2500 g (up to and including 2499 g). (NCT01103063)
Timeframe: Approximately 40 weeks of gestational age
| Intervention | Percentage of neonates (Number) |
|---|---|
| Azithromycin + Chloroquine | 5.01 |
| Sulfadoxine + Pyrimethamine | 5.72 |
Ophthalmia neonatorum was diagnosed at birth. The laboratory diagnosis was performed among neonates with purulent discharge. (NCT01103063)
Timeframe: Approximately 40 weeks of gestational age
| Intervention | Percentage of neonates (Number) |
|---|---|
| Azithromycin + Chloroquine | 0.35 |
| Sulfadoxine + Pyrimethamine | 0.17 |
This outcome measure evaluated the participants requiring additional treatments for malaria during the study period following the first dose (diagnosed based on clinical presentation and/or lab test results). (NCT01103063)
Timeframe: Approximately 40 weeks of gestational age
| Intervention | Percentage of participants (Number) |
|---|---|
| Azithromycin + Chloroquine | 5.74 |
| Sulfadoxine + Pyrimethamine | 10.52 |
Participants positive for bacterial infections including other lower respiratory tract infections were measured anytime from first dose administration to delivery. (NCT01103063)
Timeframe: Up to approximately 40 weeks of gestational age
| Intervention | Percentage of participants (Number) |
|---|---|
| Azithromycin + Chloroquine | 0.48 |
| Sulfadoxine + Pyrimethamine | 1.25 |
Bacterial vaginosis was diagnosed based on laboratory result at 36-38 weeks of gestation. A vaginal swab was collected for the Gram staining. (NCT01103063)
Timeframe: At 36-38 weeks of gestation
| Intervention | Percentage of participants (Number) |
|---|---|
| Azithromycin + Chloroquine | 8.58 |
| Sulfadoxine + Pyrimethamine | 11.84 |
Participants positive for Chlamydia trachomatis infection was diagnosed based on laboratory result at 36-38 weeks of gestation. A vaginal swab was collected and PCR assay was used for analysis. (NCT01103063)
Timeframe: At 36-38 weeks of gestation
| Intervention | Percentage of participants (Number) |
|---|---|
| Azithromycin + Chloroquine | 1.47 |
| Sulfadoxine + Pyrimethamine | 0.63 |
This outcome measure evaluated the percentage of participants positive for cord blood parasitemia at delivery. A participant was positive for parasitemia if the number of asexual parasites per μL was >0. (NCT01103063)
Timeframe: Approximately 40 weeks of gestational age
| Intervention | Percentage of participants (Number) |
|---|---|
| Azithromycin + Chloroquine | 0.49 |
| Sulfadoxine + Pyrimethamine | 0.75 |
Anemia was defined as Hb <11 g/dL. (NCT01103063)
Timeframe: At 36-38 weeks of gestation.
| Intervention | Percentage of Participants (Number) |
|---|---|
| Azithromycin + Chloroquine | 50.57 |
| Sulfadoxine + Pyrimethamine | 49.11 |
Participants positive for Neisseria gonorrhoeae infection was diagnosed based on laboratory result at 36-38 weeks of gestation. A vaginal swab was collected and PCR assay was used for analysis. (NCT01103063)
Timeframe: At 36-38 weeks of gestation
| Intervention | Percentage of participants (Number) |
|---|---|
| Azithromycin + Chloroquine | 0.40 |
| Sulfadoxine + Pyrimethamine | 1.64 |
This outcome measure evaluated the percentage of participants positive for peripheral parasitemia at 36-38 weeks of gestation. A participant was positive for parasitemia if the number of asexual parasites per μL was >0. (NCT01103063)
Timeframe: At 36-38 weeks of gestation
| Intervention | Percentage of participants (Number) |
|---|---|
| Azithromycin + Chloroquine | 2.71 |
| Sulfadoxine + Pyrimethamine | 4.38 |
This outcome measure evaluated the percentage of participants positive for peripheral parasitemia at delivery. A participant was positive for parasitemia if the number of asexual parasites per μL was >0. (NCT01103063)
Timeframe: Approximately 40 weeks of gestational age
| Intervention | Percentage of participants (Number) |
|---|---|
| Azithromycin + Chloroquine | 6.05 |
| Sulfadoxine + Pyrimethamine | 7.46 |
Participants positive for placental malaria at delivery were evaluated based on placental histology. (NCT01103063)
Timeframe: Approximately 40 weeks of gestational age
| Intervention | Percentage of participants (Number) |
|---|---|
| Azithromycin + Chloroquine | 4.81 |
| Sulfadoxine + Pyrimethamine | 5.73 |
Participants with placental parasitemia at delivery were diagnosed using Placental blood smear at birth from participants who deliver at hospital. (NCT01103063)
Timeframe: Approximately 40 weeks of gestational age
| Intervention | Percentage of participants (Number) |
|---|---|
| Azithromycin + Chloroquine | 5.30 |
| Sulfadoxine + Pyrimethamine | 5.67 |
Pre-eclampsia was diagnosed as systolic blood pressure of at least 140 mmHg and/or diastolic blood pressure of at least 90 mmHg on two separate readings taken at least 4 hours apart and proteinuria at least 300 mg protein in a 24 hour urine collection. (NCT01103063)
Timeframe: From Week 20 to approximately 40 weeks of gestational age
| Intervention | Percentage of participants (Number) |
|---|---|
| Azithromycin + Chloroquine | 0.63 |
| Sulfadoxine + Pyrimethamine | 1.04 |
Severe maternal anemia was defined as Hb <8 g/dL. (NCT01103063)
Timeframe: At 36-38 weeks of gestation.
| Intervention | Percentage of participants (Number) |
|---|---|
| Azithromycin + Chloroquine | 1.80 |
| Sulfadoxine + Pyrimethamine | 2.00 |
Sexual transmitted disease included Treponema pallidum, Neisseria gonorrhoeae, and Chlamydia trachomatis infections. This was diagnosed based on clinical presentation prior to Week 36-38 and/or lab test results between Week 36-38. (NCT01103063)
Timeframe: Upto 36-38 weeks of gestation
| Intervention | Percentage of participants (Number) |
|---|---|
| Azithromycin + Chloroquine | 12.32 |
| Sulfadoxine + Pyrimethamine | 16.47 |
Adverse pregnancy outcomes were defined as live-borne neonate (singleton) with LBW (<2,500g), premature births (<37 weeks as confirmed by the Ballard score), abortion (≤28 weeks), still birth (>28 weeks), lost to follow-up prior to termination of pregnancy or delivery, or missing birth weight of the neonates. (NCT01103063)
Timeframe: Approximately 40 weeks of gestational age
| Intervention | Percentage of Participants (Number) |
|---|---|
| Azithromycin + Chloroquine | 10.38 |
| Sulfadoxine + Pyrimethamine | 10.12 |
Sub-optimal pregnancy outcome including neonatal deaths and congenital malformations, defined as any of the following: live-borne neonate (singleton) with low birth-weight (or LBW for short, defined as live birth weight <2,500g), premature birth (<37 weeks), abortion (≤28 weeks), still birth (>28 weeks), neonatal death, congenital malformation, lost to follow-up prior to termination of pregnancy or delivery, or missing birth weight of the neonates. (NCT01103063)
Timeframe: Approximately 40 weeks of gestational age.
| Intervention | Percentage of participants (Number) |
|---|---|
| Azithromycin + Chloroquine | 28.51 |
| Sulfadoxine + Pyrimethamine | 26.51 |
Participants positive for Treponema pallidum infection was diagnosed based on laboratory result at 36-38 weeks of gestation. Treponema Pallidum particle Agglutination Assay was used. (NCT01103063)
Timeframe: At 36-38 weeks of gestation
| Intervention | Percentage of participants (Number) |
|---|---|
| Azithromycin + Chloroquine | 0.93 |
| Sulfadoxine + Pyrimethamine | 2.01 |
Participants positive for Trichomonas vaginalis infection was diagnosed based on laboratory result at 36-38 weeks of gestation. A vaginal swab was collected for the laboratory test. (NCT01103063)
Timeframe: At 36-38 weeks of gestation
| Intervention | Percentage of participants (Number) |
|---|---|
| Azithromycin + Chloroquine | 8.24 |
| Sulfadoxine + Pyrimethamine | 10.67 |
Percentage of perinatal or neonatal deaths were noted. (NCT01103063)
Timeframe: Day 28 after delivery.
| Intervention | Percentage of neonates (Number) |
|---|---|
| Azithromycin + Chloroquine | 2.19 |
| Sulfadoxine + Pyrimethamine | 1.85 |
Adverse pregnancy outcomes were defined as live-borne neonate (singleton) with low birth weight (LBW) (<2,500 g), premature births (<37 weeks as confirmed by the Ballard score), abortion (≤28 weeks), still birth (>28 weeks), lost to follow-up prior to termination of pregnancy or delivery, or missing birth weight of the neonates. (NCT01103063)
Timeframe: Approximately 40 weeks of gestational age
| Intervention | Percentage of participants (Number) |
|---|---|
| Azithromycin + Chloroquine | 26.16 |
| Sulfadoxine + Pyrimethamine | 23.67 |
Number of episodes of sexually transmitted infection episodes per participant were noted. The STI's including Treponema pallidum, Neisseria gonorrhoeae, Chlamydia trachomatis, from first dose to delivery (diagnosis was based on clinical presentation and lab results). (NCT01103063)
Timeframe: Approximately 40 weeks of gestational age .
| Intervention | Number of episodes (Least Squares Mean) |
|---|---|
| Azithromycin + Chloroquine | 0.14 |
| Sulfadoxine + Pyrimethamine | 0.19 |
This outcome measure evaluated the Streptococcus pneumoniae sensitivity against macrolide antibiotics. (NCT01103063)
Timeframe: Visits 6 and 7
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Visit 6 (N = 8 and 17 respectively) | Visit 7 (N = 16 and 11 respectively) | |
| Azithromycin + Chloroquine | 0 | 0 |
| Sulfadoxine + Pyrimethamine | 11.76 | 0 |
This outcome measure evaluated the Streptococcus pneumoniae sensitivity against penicillin antibiotics. (NCT01103063)
Timeframe: Visits 6 and 7
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Visit 6 (N = 8 and 17 respectively) | Visit 7 (N = 16 and 11 respectively) | |
| Azithromycin + Chloroquine | 0 | 0 |
| Sulfadoxine + Pyrimethamine | 0 | 0 |
Passive surveillance to detect episode of fever (temperature > 37.5 C), or a history of fever within the past 48 hours, that is severe enough to require treatment at a health centre and which is accompanied by a positive blood film with a parasite density of 5,000 per µl or more (NCT03143218)
Timeframe: Passive surveillance of clinical episodes of malaria within the study area starting from the date of the first dose of study vaccines (April/May 2017) until 31st March 2020- a total of 36 months.
| Intervention | No. of events/1000 person years at risk (Number) |
|---|---|
| SMC With SP+AQ | 304.8 |
| RTS,S/AS01 | 278.2 |
| RTS,S/AS01 PLUS SMC With SP+AQ | 113.3 |
62 reviews available for pyrimethamine and Malaria, Falciparum
| Article | Year |
|---|---|
Using genetic methods to define the targets of compounds with antimalarial activity.
Topics: Animals; Anopheles; Antimalarials; Drug Resistance; Genetic Association Studies; Genome, Protozoan; | 2013 |
Effectiveness of seasonal malaria chemoprevention (SMC) treatments when SMC is implemented at scale: Case-control studies in 5 countries.
Topics: Africa, Western; Age Factors; Amodiaquine; Antimalarials; Case-Control Studies; Child, Preschool; Co | 2021 |
The efficacy and safety of intermittent preventive treatment with sulphadoxine-pyrimethamine vs artemisinin-based drugs for malaria: a systematic review and meta-analysis.
Topics: Antimalarials; Artemisinins; Drug Combinations; Humans; Infant, Newborn; Malaria; Malaria, Falciparu | 2022 |
Molecular assays for determining sulphadoxine-pyrimethamine drug resistance in India: a systematic review.
Topics: Antimalarials; Drug Combinations; Drug Resistance; Humans; India; Malaria, Falciparum; Plasmodium fa | 2022 |
[Progress of researches on genes associated with sulfadoxine-pyrimethamine resistance in
Topics: Antimalarials; Dihydropteroate Synthase; Drug Combinations; Drug Resistance; Humans; Malaria, Falcip | 2019 |
Efficacy and tolerability of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a systematic review and individual patient data meta-analysis.
Topics: Amodiaquine; Anti-Bacterial Agents; Antimalarials; Artemisinins; Artesunate; Atovaquone; Clindamycin | 2020 |
Animal Embryotoxicity Studies of Key Non-Artemisinin Antimalarials and Use in Women in the First Trimester.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Drug Combinations; Female; Humans; Malaria; Malar | 2017 |
Anti-malarial treatment outcomes in Ethiopia: a systematic review and meta-analysis.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Chloroquine; Drug Combinatio | 2017 |
Mapping sulphadoxine-pyrimethamine-resistant Plasmodium falciparum malaria in infected humans and in parasite populations in Africa.
Topics: Africa; Animals; Antimalarials; Dihydropteroate Synthase; Drug Combinations; Drug Resistance; Humans | 2017 |
Primaquine or other 8-aminoquinolines for reducing Plasmodium falciparum transmission.
Topics: Adult; Antimalarials; Artemisinins; Child; Chloroquine; Drug Combinations; Glucosephosphate Dehydrog | 2018 |
Effect of Plasmodium falciparum sulfadoxine-pyrimethamine resistance on the effectiveness of intermittent preventive therapy for malaria in pregnancy in Africa: a systematic review and meta-analysis.
Topics: Africa; Antimalarials; Drug Combinations; Drug Resistance; Female; Humans; Infant, Low Birth Weight; | 2019 |
Effect of Plasmodium falciparum sulfadoxine-pyrimethamine resistance on the effectiveness of intermittent preventive therapy for malaria in pregnancy in Africa: a systematic review and meta-analysis.
Topics: Africa; Antimalarials; Drug Combinations; Drug Resistance; Female; Humans; Infant, Low Birth Weight; | 2019 |
Effect of Plasmodium falciparum sulfadoxine-pyrimethamine resistance on the effectiveness of intermittent preventive therapy for malaria in pregnancy in Africa: a systematic review and meta-analysis.
Topics: Africa; Antimalarials; Drug Combinations; Drug Resistance; Female; Humans; Infant, Low Birth Weight; | 2019 |
Effect of Plasmodium falciparum sulfadoxine-pyrimethamine resistance on the effectiveness of intermittent preventive therapy for malaria in pregnancy in Africa: a systematic review and meta-analysis.
Topics: Africa; Antimalarials; Drug Combinations; Drug Resistance; Female; Humans; Infant, Low Birth Weight; | 2019 |
Monitoring antifolate resistance in intermittent preventive therapy for malaria.
Topics: Antimalarials; Drug Combinations; Drug Resistance; Humans; Malaria, Falciparum; Mutation; Plasmodium | 2013 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Mapping 'partially resistant', 'fully resistant', and 'super resistant' malaria.
Topics: Africa; Antimalarials; Drug Combinations; Drug Resistance; Geographic Mapping; Malaria, Falciparum; | 2013 |
Mapping 'partially resistant', 'fully resistant', and 'super resistant' malaria.
Topics: Africa; Antimalarials; Drug Combinations; Drug Resistance; Geographic Mapping; Malaria, Falciparum; | 2013 |
Mapping 'partially resistant', 'fully resistant', and 'super resistant' malaria.
Topics: Africa; Antimalarials; Drug Combinations; Drug Resistance; Geographic Mapping; Malaria, Falciparum; | 2013 |
Mapping 'partially resistant', 'fully resistant', and 'super resistant' malaria.
Topics: Africa; Antimalarials; Drug Combinations; Drug Resistance; Geographic Mapping; Malaria, Falciparum; | 2013 |
On the pathway to better birth outcomes? A systematic review of azithromycin and curable sexually transmitted infections.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Clinical Trials as Topic; Drug Combinations; Drug Resist | 2013 |
Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission.
Topics: Antimalarials; Artemisinins; Artesunate; Chloroquine; Drug Combinations; Glucosephosphate Dehydrogen | 2014 |
Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission.
Topics: Antimalarials; Artemisinins; Artesunate; Chloroquine; Drug Combinations; Glucosephosphate Dehydrogen | 2015 |
Fighting fire with fire: mass antimalarial drug administrations in an era of antimalarial resistance.
Topics: Antimalarials; Artemisinins; Chloroquine; Drug Resistance; Drug Therapy, Combination; History, 20th | 2015 |
Influence of malaria transmission intensity and the 581G mutation on the efficacy of intermittent preventive treatment in pregnancy: systematic review and meta-analysis.
Topics: Africa South of the Sahara; Antimalarials; Dihydropteroate Synthase; Drug Combinations; Drug Resista | 2015 |
Prevention and control of malaria in pregnancy - new threats, new opportunities?
Topics: Adult; Animals; Antimalarials; Artemisinins; Culicidae; Drug Combinations; Drug Resistance; Female; | 2017 |
Risk of drug resistance in Plasmodium falciparum malaria therapy-a systematic review and meta-analysis.
Topics: Amodiaquine; Antimalarials; Artemisinins; Chloroquine; Drug Combinations; Drug Resistance; Drug Ther | 2017 |
Changing the policy for intermittent preventive treatment with sulfadoxine-pyrimethamine during pregnancy in Malawi.
Topics: Antimalarials; Chemoprevention; Drug Combinations; Female; Health Policy; Humans; Malaria, Falciparu | 2017 |
Artemisinin-based combination therapy for treating uncomplicated malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines | 2009 |
Artemisinin-based combination therapy for treating uncomplicated malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines | 2009 |
Artemisinin-based combination therapy for treating uncomplicated malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines | 2009 |
Artemisinin-based combination therapy for treating uncomplicated malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines | 2009 |
Artemisinin-based combination therapy for treating uncomplicated malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines | 2009 |
Artemisinin-based combination therapy for treating uncomplicated malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines | 2009 |
Artemisinin-based combination therapy for treating uncomplicated malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines | 2009 |
Artemisinin-based combination therapy for treating uncomplicated malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines | 2009 |
Artemisinin-based combination therapy for treating uncomplicated malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines | 2009 |
Origins and spread of pfdhfr mutant alleles in Plasmodium falciparum.
Topics: Africa; Alleles; Antimalarials; Dihydropteroate Synthase; Drug Resistance; Evolution, Molecular; Hum | 2010 |
Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials.
Topics: Africa; Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; | 2009 |
Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials.
Topics: Africa; Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; | 2009 |
Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials.
Topics: Africa; Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; | 2009 |
Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials.
Topics: Africa; Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; | 2009 |
Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria.
Topics: Antimalarials; Artemisinins; Chloroquine; Drug Combinations; Drug Design; Drug Interactions; Drug Sy | 2009 |
Artemisinin derivatives for treatment of uncomplicated Plasmodium falciparum malaria in Sudan: too early for too much hope.
Topics: Antimalarials; Artemisinins; Artesunate; Chloroquine; Drug Combinations; Drug Therapy, Combination; | 2010 |
Intermittent preventive treatment against malaria: an update.
Topics: Africa South of the Sahara; Animals; Antimalarials; Child; Child, Preschool; Clinical Trials as Topi | 2010 |
Following the path of most resistance: dhps K540E dispersal in African Plasmodium falciparum.
Topics: Africa; Animals; Antimalarials; Chloroquine; Dihydropteroate Synthase; Drug Combinations; Drug Resis | 2010 |
Antimalarial drug resistance of Plasmodium falciparum in India: changes over time and space.
Topics: Antimalarials; Artemisinins; Artesunate; Chloroquine; Drug Combinations; Drug Resistance; Geography; | 2011 |
Azithromycin for treating uncomplicated malaria.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesunate; Atovaquone; Azit | 2011 |
Combination of probenecid-sulphadoxine-pyrimethamine for intermittent preventive treatment in pregnancy.
Topics: Antimalarials; Chemoprevention; Drug Combinations; Drug Therapy, Combination; Female; Humans; Malari | 2012 |
A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Drug-Rela | 2012 |
Primaquine for reducing Plasmodium falciparum transmission.
Topics: Antimalarials; Artemisinins; Artesunate; Chloroquine; Drug Combinations; Glucosephosphate Dehydrogen | 2012 |
Malaria prevention in pregnancy, birthweight, and neonatal mortality: a meta-analysis of 32 national cross-sectional datasets in Africa.
Topics: Adolescent; Adult; Africa; Animals; Antimalarials; Cohort Studies; Drug Combinations; Female; Humans | 2012 |
Sulfadoxine-pyrimethamine resistance in Plasmodium falciparum: a zoomed image at the molecular level within a geographic context.
Topics: Antimalarials; Biomarkers; Clinical Trials as Topic; Dihydropteroate Synthase; Drug Combinations; Dr | 2013 |
Pharmacokinetic profile of artemisinin derivatives and companion drugs used in artemisinin-based combination therapies for the treatment of Plasmodium falciparum malaria in children.
Topics: Antimalarials; Artemisinins; Child; Drug Therapy, Combination; Ethanolamines; Fluorenes; Humans; Lum | 2013 |
Malaria: a rising incidence in the United States.
Topics: Antimalarials; Chemoprevention; Chloroquine; Drug Combinations; Drug Resistance; Female; Global Heal | 2002 |
The mechanisms of resistance to antimalarial drugs in Plasmodium falciparum.
Topics: Africa; Animals; Antimalarials; Antimetabolites; Chloroquine; Drug Resistance; Drug Resistance, Mult | 2003 |
Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum-endemic sub-Saharan Africa.
Topics: Africa South of the Sahara; Antimalarials; Drug Combinations; Endemic Diseases; Female; Humans; Infe | 2003 |
Amodiaquine for treating malaria.
Topics: Amodiaquine; Antimalarials; Chloroquine; Drug Combinations; Humans; Malaria, Falciparum; Pyrimethami | 2003 |
WHO, the Global Fund, and medical malpractice in malaria treatment.
Topics: Africa; Antimalarials; Artemisinins; Child; Chloroquine; Drug Combinations; Drug Costs; Drug Resista | 2004 |
Genetic and biochemical aspects of drug resistance in malaria parasites.
Topics: Animals; Antimalarials; Chloroquine; Dihydropteroate Synthase; Drug Resistance; Drug Resistance, Mul | 2004 |
Malaria in endemic areas.
Topics: Antimalarials; Artemether; Artemisinins; Blood Transfusion; Chloroquine; Deferoxamine; Drug Combinat | 2003 |
Why has the dihydrofolate reductase 164 mutation not consistently been found in Africa yet?
Topics: Africa; Animals; Antimalarials; Drug Combinations; Drug Resistance; Humans; Malaria, Falciparum; Pla | 2005 |
Population biology and antimalarial resistance: The transmission of antimalarial drug resistance in Plasmodium falciparum.
Topics: Animals; Antimalarials; Artemisinins; Disease Transmission, Infectious; Drug Combinations; Drug Resi | 2005 |
Malaria: uncomplicated, caused by Plasmodium falciparum.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Artesunate; Chloroquine; Dapsone; Drug Combina | 2005 |
Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria.
Topics: Adult; Amodiaquine; Chloroquine; Drug Combinations; Drug Therapy, Combination; Humans; Malaria; Mala | 2005 |
Sulfadoxine-pyrimethamine plus artesunate versus sulfadoxine-pyrimethamine plus amodiaquine for treating uncomplicated malaria.
Topics: Amodiaquine; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Humans; Malaria | 2006 |
Comparative efficacy of chloroquine and sulphadoxine--pyrimethamine in pregnant women and children: a meta-analysis.
Topics: Adolescent; Adult; Africa; Antimalarials; Child; Chloroquine; Drug Combinations; Endemic Diseases; F | 2006 |
Therapeutic potential of folate uptake inhibition in Plasmodium falciparum.
Topics: Animals; Antimalarials; Drug Combinations; Drug Resistance; Drug Synergism; Drug Therapy, Combinatio | 2004 |
Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for uncomplicated malaria: a systematic review.
Topics: Amodiaquine; Antimalarials; Chloroquine; Drug Combinations; Drug Therapy, Combination; Humans; Malar | 2006 |
Amodiaquine combined with sulfadoxine/pyrimethamine versus artemisinin-based combinations for the treatment of uncomplicated falciparum malaria in Africa: a meta-analysis.
Topics: Africa; Amodiaquine; Artemisinins; Drug Combinations; Humans; Malaria, Falciparum; Multicenter Studi | 2007 |
From evidence to action? Challenges to policy change and programme delivery for malaria in pregnancy.
Topics: Africa South of the Sahara; Animals; Antimalarials; Delivery of Health Care; Drug Combinations; Fema | 2007 |
Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment.
Topics: Abnormalities, Drug-Induced; Africa; Animals; Antimalarials; Drug Administration Schedule; Drug Comb | 2007 |
[Malaria: the most important emergency in subjects returning from the tropics].
Topics: Animals; Antimalarials; Chloroquine; Drug Combinations; Emergencies; Humans; Malaria; Malaria, Falci | 1993 |
Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine as a treatment for uncomplicated malaria--a systematic review.
Topics: Amodiaquine; Antimalarials; Chloroquine; Drug Therapy, Combination; Humans; Malaria, Falciparum; Pyr | 1998 |
Studies on anti-folate antimalarials in east Africa.
Topics: Africa, Eastern; Animals; Antimalarials; Dapsone; Drug Therapy, Combination; Folic Acid Antagonists; | 1999 |
Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria.
Topics: Adult; Amodiaquine; Chloroquine; Drug Combinations; Drug Therapy, Combination; Humans; Malaria; Mala | 2000 |
Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria.
Topics: Adult; Amodiaquine; Chloroquine; Drug Combinations; Drug Therapy, Combination; Humans; Malaria; Mala | 2001 |
Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next?
Topics: Africa South of the Sahara; Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; | 2001 |
Development of the new antimalarial drug pyronaridine: a review.
Topics: Administration, Oral; Animals; Antimalarials; Cardiovascular System; Chloroquine; Dogs; Drug Evaluat | 1992 |
333 trials available for pyrimethamine and Malaria, Falciparum
| Article | Year |
|---|---|
The influence of Maloprim chemoprophylaxis on cellular and humoral immune responses to Plasmodium falciparum asexual blood stage antigens in schoolchildren living in a malaria endemic area of Mozambique.
Topics: Animals; Antibodies, Protozoan; Antigens, Protozoan; Antimalarials; Child; Cohort Studies; Cross-Sec | 1994 |
Recent military experience with malaria chemoprophylaxis.
Topics: Antimalarials; Australia; Chloroquine; Dapsone; Doxycycline; Drug Administration Schedule; Drug Comb | 1993 |
A comparative study of the efficacies of chloroquine and a pyrimethamine-dapsone combination in clearing Plasmodium falciparum parasitaemia in school children in Tanzania.
Topics: Antimalarials; Child; Chloroquine; Dapsone; Drug Combinations; Female; Humans; Malaria, Falciparum; | 1996 |
Chemoprophylaxis against malaria in Papua New Guinea: a trial of amodiaquine and a combination of dapsone and pyrimethamine.
Topics: Antimalarials; Body Weight; Child; Child, Preschool; Dapsone; Drug Combinations; Drug Resistance; Fe | 1992 |
Overall and Gender-Specific Effects of Intermittent Preventive Treatment of Malaria with Artemisinin-Based Combination Therapies among Schoolchildren in Mali: A Three-Group Open Label Randomized Controlled Trial.
Topics: Amodiaquine; Anemia; Antimalarials; Artemisinins; Artesunate; Child; Drug Combinations; Drug Therapy | 2022 |
Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial.
Topics: Amodiaquine; Anemia, Sickle Cell; Antimalarials; Artemisinins; Chemoprevention; Child; Child, Presch | 2022 |
Effects of anti-malarial prophylaxes on maternal transfer of Immunoglobulin-G (IgG) and association to immunity against Plasmodium falciparum infections among children in a Ugandan birth cohort.
Topics: Antimalarials; Birth Cohort; Child; Drug Combinations; Female; Humans; Immunoglobulin G; Malaria; Ma | 2023 |
A Randomized Open-Label Evaluation of the Antimalarial Prophylactic Efficacy of Azithromycin-Piperaquine versus Sulfadoxine-Pyrimethamine in Pregnant Papua New Guinean Women.
Topics: Adult; Antimalarials; Asymptomatic Diseases; Azithromycin; Chemoprevention; Drug Combinations; Eryth | 2019 |
Microscopic and submicroscopic Plasmodium falciparum infection, maternal anaemia and adverse pregnancy outcomes in Papua New Guinea: a cohort study.
Topics: Adult; Anemia; Anti-Bacterial Agents; Antimalarials; Artemisinins; Asymptomatic Infections; Azithrom | 2019 |
Counter-Selection of Antimalarial Resistance Polymorphisms by Intermittent Preventive Treatment in Pregnancy.
Topics: Adult; Antimalarials; Drug Combinations; Drug Resistance, Multiple; Female; Humans; Infant, Newborn; | 2020 |
Interactions Between Antenatal Sulfadoxine-Pyrimethamine, Drug-Resistant Plasmodium falciparum Parasites, and Delivery Outcomes in Malawi.
Topics: Adolescent; Adult; Animals; Birth Weight; Drug Combinations; Drug Resistance; Female; Genotype; Huma | 2020 |
Infant sex modifies associations between placental malaria and risk of malaria in infancy.
Topics: Adult; Antimalarials; Artemisinins; Drug Combinations; Female; Humans; Incidence; Infant; Infant, Ne | 2020 |
Effect of seasonal malaria chemoprevention plus azithromycin on Plasmodium falciparum transmission: gametocyte infectivity and mosquito fitness.
Topics: Amodiaquine; Animals; Antimalarials; Azithromycin; Chemoprevention; Child, Preschool; Culicidae; Dru | 2021 |
Efficacies of DHA-PPQ and AS/SP in patients with uncomplicated Plasmodium falciparum malaria in an area of an unstable seasonal transmission in Sudan.
Topics: Adolescent; Antimalarials; Artemisinins; Child; Child, Preschool; Drug Therapy, Combination; Female; | 2017 |
Assessment of Clinical Pharmacokinetic Drug-Drug Interaction of Antimalarial Drugs α/β-Arteether and Sulfadoxine-Pyrimethamine.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Chromatography, Liquid; Drug Combinations; Drug Inte | 2017 |
Placental but Not Peripheral Plasmodium falciparum Infection During Pregnancy Is Associated With Increased Risk of Malaria in Infancy.
Topics: Chloroquine; Drug Combinations; Female; Follow-Up Studies; Humans; Infant; Logistic Models; Longitud | 2017 |
Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind, randomised controlled trial.
Topics: Adolescent; Adult; Amodiaquine; Artemisinins; Child; Child, Preschool; Drug Combinations; Humans; Ma | 2018 |
Low risk of recurrence following artesunate-Sulphadoxine-pyrimethamine plus primaquine for uncomplicated Plasmodium falciparum and Plasmodium vivax infections in the Republic of the Sudan.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Female; Humans; Infant; Inf | 2018 |
Efficacy of two artemisinin-based combinations for the treatment of malaria in pregnancy in India: a randomized controlled trial.
Topics: Adult; Antimalarials; Artemisinins; Artesunate; Drug Combinations; Female; Humans; Incidence; India; | 2018 |
Intermittent screening and treatment with artemether-lumefantrine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in pregnancy: a facility-based, open-label, non-inferiority trial in Nigeria.
Topics: Adolescent; Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Chemoprevention; Drug C | 2018 |
Intermittent screening and treatment with artemether-lumefantrine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in pregnancy: a facility-based, open-label, non-inferiority trial in Nigeria.
Topics: Adolescent; Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Chemoprevention; Drug C | 2018 |
Intermittent screening and treatment with artemether-lumefantrine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in pregnancy: a facility-based, open-label, non-inferiority trial in Nigeria.
Topics: Adolescent; Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Chemoprevention; Drug C | 2018 |
Intermittent screening and treatment with artemether-lumefantrine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in pregnancy: a facility-based, open-label, non-inferiority trial in Nigeria.
Topics: Adolescent; Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Chemoprevention; Drug C | 2018 |
Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child, Preschool; Double-Blind Method; Drug Administ | 2018 |
A Balanced Proinflammatory and Regulatory Cytokine Signature in Young African Children Is Associated With Lower Risk of Clinical Malaria.
Topics: Antimalarials; Artemisinins; Cell Extracts; Chemoprevention; Child, Preschool; Cytokines; Double-Bli | 2019 |
The prevalence and antifolate drug resistance profiles of Plasmodium falciparum in study participants randomized to discontinue or continue cotrimoxazole prophylaxis.
Topics: Adolescent; Adult; Antimalarials; Dihydropteroate Synthase; Drug Combinations; Drug Resistance; Foli | 2019 |
Monthly sulfadoxine-pyrimethamine versus dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomised, controlled, superiority trial.
Topics: Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; Drug Combinat | 2019 |
Monthly sulfadoxine-pyrimethamine versus dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomised, controlled, superiority trial.
Topics: Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; Drug Combinat | 2019 |
Monthly sulfadoxine-pyrimethamine versus dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomised, controlled, superiority trial.
Topics: Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; Drug Combinat | 2019 |
Monthly sulfadoxine-pyrimethamine versus dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomised, controlled, superiority trial.
Topics: Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; Drug Combinat | 2019 |
Intermittent screening and treatment with dihydroartemisinin-piperaquine and intermittent preventive therapy with sulfadoxine-pyrimethamine have similar effects on malaria antibody in pregnant Malawian women.
Topics: Adolescent; Adult; Antibodies, Protozoan; Antimalarials; Artemisinins; Drug Combinations; Female; Hu | 2019 |
The effect of antenatal monthly sulphadoxine-pyrimethamine, alone or with azithromycin, on foetal and neonatal growth faltering in Malawi: a randomised controlled trial.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antimalarials; Azithromycin; Birth Weight; Drug Administra | 2013 |
Artesunate/amodiaquine malaria treatment for Equatorial Guinea (Central Africa).
Topics: Amodiaquine; Artemisinins; Child, Preschool; DNA, Protozoan; Drug Combinations; Equatorial Guinea; F | 2013 |
Nonrandomized controlled trial of artesunate plus sulfadoxine-pyrimethamine with or without primaquine for preventing posttreatment circulation of Plasmodium falciparum gametocytes.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Drug Combinations; Drug The | 2013 |
A clinical and molecular study of artesunate + sulphadoxine-pyrimethamine in three districts of central and eastern India.
Topics: Adolescent; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Dihydropteroate Syntha | 2013 |
Effectiveness of two antifolate prophylactic strategies against malaria in HIV-positive pregnant women in Bangui, Central African Republic: study protocol for a randomized controlled trial (MACOMBA).
Topics: Antimalarials; Central African Republic; Clinical Protocols; Coinfection; Drug Administration Schedu | 2013 |
Effectiveness of co-trimoxazole to prevent Plasmodium falciparum malaria in HIV-positive pregnant women in sub-Saharan Africa: an open-label, randomized controlled trial.
Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Female; HIV Infections; Humans; Incidence; Mala | 2014 |
Blood oxidative stress markers and Plasmodium falciparum malaria in non-immune African children.
Topics: Aldehydes; Anemia; Antigens, Protozoan; Antimalarials; Artemisinins; Biomarkers; Child, Preschool; D | 2014 |
Intermittent preventive treatment of malaria with sulphadoxine-pyrimethamine during pregnancy in Burkina Faso: effect of adding a third dose to the standard two-dose regimen on low birth weight, anaemia and pregnancy outcomes.
Topics: Adolescent; Adult; Anemia; Antimalarials; Burkina Faso; Drug Combinations; Female; Humans; Infant, L | 2010 |
Pharmacokinetics of artesunate alone and in combination with sulfadoxine/pyrimethamine in healthy Sudanese volunteers.
Topics: Administration, Oral; Adult; Antimalarials; Artemisinins; Artesunate; Cross-Over Studies; Drug Combi | 2014 |
Impact of age of first exposure to Plasmodium falciparum on antibody responses to malaria in children: a randomized, controlled trial in Mozambique.
Topics: Adaptive Immunity; Age Factors; Antibodies, Protozoan; Antigens, Protozoan; Antimalarials; Artemisin | 2014 |
Host candidate gene polymorphisms and associated clearance of P. falciparum amodiaquine and fansidar resistance mutants in children less than 5 years in Cameroon.
Topics: Amodiaquine; Antimalarials; Cameroon; Child, Preschool; Drug Combinations; Drug Resistance; Female; | 2014 |
Efficacy of sulphadoxine-pyrimethamine + artesunate, sulphadoxine-pyrimethamine + amodiaquine, and sulphadoxine-pyrimethamine alone in uncomplicated falciparum malaria in Mali.
Topics: Amodiaquine; Antimalarials; Artemisinins; Child, Preschool; Drug Combinations; Female; Humans; Infan | 2015 |
In vivo efficacy of sulphadoxine-pyrimethamine for the treatment of asymptomatic parasitaemia in pregnant women in Machinga District, Malawi.
Topics: Adolescent; Adult; Antimalarials; Asymptomatic Infections; Dihydropteroate Synthase; Drug Combinatio | 2015 |
Malaria preventive therapy in pregnancy and its potential impact on immunity to malaria in an area of declining transmission.
Topics: Adult; Antibodies, Protozoan; Antimalarials; Azithromycin; Chloroquine; Drug Combinations; Erythrocy | 2015 |
Insights Into Circulating Cytokine Dynamics During Pregnancy in HIV-Infected Beninese Exposed to Plasmodium falciparum Malaria.
Topics: Adult; Antimalarials; Benin; Drug Combinations; Female; HIV Infections; Humans; Interleukin-10; Inte | 2015 |
High efficacy of two artemisinin-based combinations: artesunate + sulfadoxine-pyrimethamine and artemether-lumefantrine for falciparum malaria in Yemen.
Topics: Adolescent; Adult; Aged; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Child, Pres | 2015 |
Frequent Malaria Drives Progressive Vδ2 T-Cell Loss, Dysfunction, and CD16 Up-regulation During Early Childhood.
Topics: Artemisinins; Child, Preschool; Drug Combinations; GPI-Linked Proteins; Humans; Immune Tolerance; In | 2016 |
Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introduction.
Topics: Adolescent; Adult; Afghanistan; Aged; Antimalarials; Artemisinins; Artesunate; Child; Child, Prescho | 2016 |
Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introduction.
Topics: Adolescent; Adult; Afghanistan; Aged; Antimalarials; Artemisinins; Artesunate; Child; Child, Prescho | 2016 |
Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introduction.
Topics: Adolescent; Adult; Afghanistan; Aged; Antimalarials; Artemisinins; Artesunate; Child; Child, Prescho | 2016 |
Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introduction.
Topics: Adolescent; Adult; Afghanistan; Aged; Antimalarials; Artemisinins; Artesunate; Child; Child, Prescho | 2016 |
Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introduction.
Topics: Adolescent; Adult; Afghanistan; Aged; Antimalarials; Artemisinins; Artesunate; Child; Child, Prescho | 2016 |
Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introduction.
Topics: Adolescent; Adult; Afghanistan; Aged; Antimalarials; Artemisinins; Artesunate; Child; Child, Prescho | 2016 |
Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introduction.
Topics: Adolescent; Adult; Afghanistan; Aged; Antimalarials; Artemisinins; Artesunate; Child; Child, Prescho | 2016 |
Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introduction.
Topics: Adolescent; Adult; Afghanistan; Aged; Antimalarials; Artemisinins; Artesunate; Child; Child, Prescho | 2016 |
Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introduction.
Topics: Adolescent; Adult; Afghanistan; Aged; Antimalarials; Artemisinins; Artesunate; Child; Child, Prescho | 2016 |
Malaria illness mediated by anaemia lessens cognitive development in younger Ugandan children.
Topics: Age Factors; Anemia; Antimalarials; Artemisinins; Child, Preschool; Cognition; Cognition Disorders; | 2016 |
Efficacy and Safety of Azithromycin-Chloroquine versus Sulfadoxine-Pyrimethamine for Intermittent Preventive Treatment of Plasmodium falciparum Malaria Infection in Pregnant Women in Africa: An Open-Label, Randomized Trial.
Topics: Adolescent; Adult; Azithromycin; Chloroquine; Drug Combinations; Female; Humans; Infant, Newborn; In | 2016 |
Efficacy and Safety of Azithromycin-Chloroquine versus Sulfadoxine-Pyrimethamine for Intermittent Preventive Treatment of Plasmodium falciparum Malaria Infection in Pregnant Women in Africa: An Open-Label, Randomized Trial.
Topics: Adolescent; Adult; Azithromycin; Chloroquine; Drug Combinations; Female; Humans; Infant, Newborn; In | 2016 |
Efficacy and Safety of Azithromycin-Chloroquine versus Sulfadoxine-Pyrimethamine for Intermittent Preventive Treatment of Plasmodium falciparum Malaria Infection in Pregnant Women in Africa: An Open-Label, Randomized Trial.
Topics: Adolescent; Adult; Azithromycin; Chloroquine; Drug Combinations; Female; Humans; Infant, Newborn; In | 2016 |
Efficacy and Safety of Azithromycin-Chloroquine versus Sulfadoxine-Pyrimethamine for Intermittent Preventive Treatment of Plasmodium falciparum Malaria Infection in Pregnant Women in Africa: An Open-Label, Randomized Trial.
Topics: Adolescent; Adult; Azithromycin; Chloroquine; Drug Combinations; Female; Humans; Infant, Newborn; In | 2016 |
Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children.
Topics: Amodiaquine; Anorexia; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Artes | 2008 |
Activities of artemether-lumefantrine and amodiaquine-sulfalene-pyrimethamine against sexual-stage parasites in falciparum malaria in children.
Topics: Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Child; Child, Preschool; Drug Therapy | 2008 |
Effect of intermittent preventive treatment of malaria on health and education in schoolchildren: a cluster-randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Amodiaquine; Anemia; Animals; Antimalarials; Child; Child, Preschool; Cluster Analysis; | 2008 |
Mother-to-child transmission of HIV-1: association with malaria prevention, anaemia and placental malaria.
Topics: Adult; Anemia; Anti-HIV Agents; Antimalarials; CD4 Lymphocyte Count; Drug Combinations; Female; HIV | 2008 |
[Gametocytemia in falciparum malaria treated with amodiaquine or artesunate].
Topics: Adolescent; Adult; Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Child, Preschool; | 2008 |
A randomized, controlled trial of intermittent preventive treatment with sulfadoxine-pyrimethamine, amodiaquine, or the combination in pregnant women in Ghana.
Topics: Amodiaquine; Anemia; Animals; Antimalarials; Child, Preschool; Drug Combinations; Drug Therapy, Comb | 2008 |
Therapeutic and prophylactic effect of intermittent preventive anti-malarial treatment in infants (IPTi) from Ghana and Gabon.
Topics: Antimalarials; Drug Administration Schedule; Drug Combinations; Gabon; Ghana; Humans; Infant; Malari | 2008 |
Therapeutic and prophylactic effect of intermittent preventive anti-malarial treatment in infants (IPTi) from Ghana and Gabon.
Topics: Antimalarials; Drug Administration Schedule; Drug Combinations; Gabon; Ghana; Humans; Infant; Malari | 2008 |
Therapeutic and prophylactic effect of intermittent preventive anti-malarial treatment in infants (IPTi) from Ghana and Gabon.
Topics: Antimalarials; Drug Administration Schedule; Drug Combinations; Gabon; Ghana; Humans; Infant; Malari | 2008 |
Therapeutic and prophylactic effect of intermittent preventive anti-malarial treatment in infants (IPTi) from Ghana and Gabon.
Topics: Antimalarials; Drug Administration Schedule; Drug Combinations; Gabon; Ghana; Humans; Infant; Malari | 2008 |
dhfr and dhps genotype and sulfadoxine-pyrimethamine treatment failure in children with falciparum malaria in the Democratic Republic of Congo.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Democratic Republic of the C | 2008 |
A trial of combination antimalarial therapies in children from Papua New Guinea.
Topics: Antimalarials; Artemether; Artemisinins; Artesunate; Child, Preschool; Chloroquine; Drug Therapy, Co | 2008 |
High risk of severe anaemia after chlorproguanil-dapsone+artesunate antimalarial treatment in patients with G6PD (A-) deficiency.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Dapsone; Drug Combina | 2008 |
Artemisinin-based combinations versus amodiaquine plus sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Faladje, Mali.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Child, Preschool; Drug Combinations; Drug Therapy | 2009 |
Individual efficacy of intermittent preventive treatment with sulfadoxine-pyrimethamine in primi- and secundigravidae in rural Burkina Faso: impact on parasitaemia, anaemia and birth weight.
Topics: Adult; Anemia; Animals; Antimalarials; Birth Weight; Burkina Faso; Drug Combinations; Female; Humans | 2009 |
Short report: comparison of chlorproguanil-dapsone with a combination of sulfadoxine-pyrimethamine and chloroquine in children with malaria in northcentral Nigeria.
Topics: Animals; Antimalarials; Child, Preschool; Chloroquine; Dapsone; Drug Combinations; Drug Therapy, Com | 2009 |
Submicroscopic gametocytes and the transmission of antifolate-resistant Plasmodium falciparum in Western Kenya.
Topics: Animals; Artemisinins; Artesunate; Carrier State; Child, Preschool; Drug Combinations; Drug Resistan | 2009 |
In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa.
Topics: Alleles; Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Chl | 2009 |
Efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria: revisiting molecular markers in an area of emerging AQ and SP resistance in Mali.
Topics: Amodiaquine; Animals; Antigens, Protozoan; Antimalarials; Child; Child, Preschool; Chloroquine; Drug | 2009 |
Extended high efficacy of the combination sulphadoxine-pyrimethamine with artesunate in children with uncomplicated falciparum malaria on the Benin coast, West Africa.
Topics: Analysis of Variance; Animals; Antimalarials; Artemisinins; Artesunate; Benin; Child, Preschool; Coh | 2009 |
Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial.
Topics: Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesunate; Child; | 2009 |
Comparison of sulfadoxine-pyrimethamine, unsupervised artemether-lumefantrine, and unsupervised artesunate-amodiaquine fixed-dose formulation for uncomplicated plasmodium falciparum malaria in Benin: a randomized effectiveness noninferiority trial.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Benin; Child, Preschool; Drug Combina | 2009 |
Intermittent preventive treatment using artemisinin-based combination therapy reduces malaria morbidity among school-aged children in Mali.
Topics: Adolescent; Anemia; Artemisinins; Artesunate; Child; Drug Combinations; Drug Therapy, Combination; F | 2009 |
Efficacy of sulphadoxine-pyrimethamine with or without artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in southern Mozambique: a randomized controlled trial.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Female; Follo | 2009 |
Efficacy of sulphadoxine-pyrimethamine with or without artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in southern Mozambique: a randomized controlled trial.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Female; Follo | 2009 |
Efficacy of sulphadoxine-pyrimethamine with or without artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in southern Mozambique: a randomized controlled trial.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Female; Follo | 2009 |
Efficacy of sulphadoxine-pyrimethamine with or without artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in southern Mozambique: a randomized controlled trial.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Female; Follo | 2009 |
Varying efficacy of artesunate+amodiaquine and artesunate+sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in the Democratic Republic of Congo: a report of two in-vivo studies.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Democratic Republic o | 2009 |
Artemisinin-naphthoquine combination (ARCO) therapy for uncomplicated falciparum malaria in adults of Papua New Guinea: a preliminary report on safety and efficacy.
Topics: Adolescent; Adult; Animals; Antimalarials; Artemisinins; Blood; Chloroquine; Drug Combinations; Huma | 2009 |
Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial.
Topics: Antimalarials; Dapsone; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug R | 2009 |
Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial.
Topics: Antimalarials; Dapsone; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug R | 2009 |
Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial.
Topics: Antimalarials; Dapsone; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug R | 2009 |
Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial.
Topics: Antimalarials; Dapsone; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug R | 2009 |
Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial.
Topics: Antimalarials; Dapsone; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug R | 2009 |
Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial.
Topics: Antimalarials; Dapsone; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug R | 2009 |
Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial.
Topics: Antimalarials; Dapsone; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug R | 2009 |
Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial.
Topics: Antimalarials; Dapsone; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug R | 2009 |
Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial.
Topics: Antimalarials; Dapsone; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug R | 2009 |
Pharmacokinetics of sulfadoxine and pyrimethamine in intermittent preventive treatment of malaria in pregnancy.
Topics: Adult; Africa; Antimalarials; Drug Administration Schedule; Drug Combinations; Female; Humans; Malar | 2010 |
Options for the delivery of intermittent preventive treatment for malaria to children: a community randomised trial.
Topics: Amodiaquine; Antimalarials; Child, Preschool; Community Health Services; Drug Combinations; Female; | 2009 |
Options for the delivery of intermittent preventive treatment for malaria to children: a community randomised trial.
Topics: Amodiaquine; Antimalarials; Child, Preschool; Community Health Services; Drug Combinations; Female; | 2009 |
Options for the delivery of intermittent preventive treatment for malaria to children: a community randomised trial.
Topics: Amodiaquine; Antimalarials; Child, Preschool; Community Health Services; Drug Combinations; Female; | 2009 |
Options for the delivery of intermittent preventive treatment for malaria to children: a community randomised trial.
Topics: Amodiaquine; Antimalarials; Child, Preschool; Community Health Services; Drug Combinations; Female; | 2009 |
Options for the delivery of intermittent preventive treatment for malaria to children: a community randomised trial.
Topics: Amodiaquine; Antimalarials; Child, Preschool; Community Health Services; Drug Combinations; Female; | 2009 |
Options for the delivery of intermittent preventive treatment for malaria to children: a community randomised trial.
Topics: Amodiaquine; Antimalarials; Child, Preschool; Community Health Services; Drug Combinations; Female; | 2009 |
Options for the delivery of intermittent preventive treatment for malaria to children: a community randomised trial.
Topics: Amodiaquine; Antimalarials; Child, Preschool; Community Health Services; Drug Combinations; Female; | 2009 |
Options for the delivery of intermittent preventive treatment for malaria to children: a community randomised trial.
Topics: Amodiaquine; Antimalarials; Child, Preschool; Community Health Services; Drug Combinations; Female; | 2009 |
Options for the delivery of intermittent preventive treatment for malaria to children: a community randomised trial.
Topics: Amodiaquine; Antimalarials; Child, Preschool; Community Health Services; Drug Combinations; Female; | 2009 |
Placental malaria and low birth weight in pregnant women living in a rural area of Burkina Faso following the use of three preventive treatment regimens.
Topics: Adult; Animals; Antimalarials; Burkina Faso; Chemoprevention; Chloroquine; Drug Combinations; Female | 2009 |
Molecular correlates of high-level antifolate resistance in Rwandan children with Plasmodium falciparum malaria.
Topics: Analysis of Variance; Antimalarials; Child; Child, Preschool; Drug Combinations; Drug Resistance; Fo | 2010 |
Selection of parasites with diminished drug susceptibility by amodiaquine-containing antimalarial regimens in Uganda.
Topics: Amino Acid Sequence; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisi | 2009 |
The effect of intermittent preventive treatment during pregnancy on malarial antibodies depends on HIV status and is not associated with poor delivery outcomes.
Topics: Antibodies, Protozoan; Antimalarials; Chemoprevention; Drug Administration Schedule; Drug Combinatio | 2010 |
Efficacy of amodiaquine, sulphadoxine-pyrimethamine and their combination for the treatment of uncomplicated Plasmodium falciparum malaria in children in Cameroon at the time of policy change to artemisinin-based combination therapy.
Topics: Administration, Oral; Amodiaquine; Antimalarials; Cameroon; Child, Preschool; Double-Blind Method; D | 2010 |
Therapeutic efficacy and effect on gametocyte carriage of an artemisinin and a non-based combination treatment in children with uncomplicated P. falciparum malaria, living in an area with high-level chloroquine resistance.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Chi | 2010 |
Efficacy of non-artemisinin- and artemisinin-based combination therapies for uncomplicated falciparum malaria in Cameroon.
Topics: Administration, Oral; Amodiaquine; Antimalarials; Artemisinins; Cameroon; Child, Preschool; Drug Adm | 2010 |
In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals.
Topics: Anemia; Anti-Infective Agents; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Dru | 2010 |
In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals.
Topics: Anemia; Anti-Infective Agents; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Dru | 2010 |
In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals.
Topics: Anemia; Anti-Infective Agents; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Dru | 2010 |
In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals.
Topics: Anemia; Anti-Infective Agents; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Dru | 2010 |
In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals.
Topics: Anemia; Anti-Infective Agents; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Dru | 2010 |
In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals.
Topics: Anemia; Anti-Infective Agents; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Dru | 2010 |
In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals.
Topics: Anemia; Anti-Infective Agents; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Dru | 2010 |
In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals.
Topics: Anemia; Anti-Infective Agents; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Dru | 2010 |
In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals.
Topics: Anemia; Anti-Infective Agents; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Dru | 2010 |
The effect of point mutations in dihydrofolate reductase genes and multidrug resistance gene 1-86 on treatment of falciparum malaria in Sudan.
Topics: Alleles; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Drug Combinations; Drug Therapy, | 2010 |
Protective efficacy of intermittent preventive treatment of malaria in infants (IPTi) using sulfadoxine-pyrimethamine and parasite resistance.
Topics: Alcohol Dehydrogenase; Antimalarials; Drug Combinations; Drug Resistance; Female; Humans; Infant; In | 2010 |
The effects of a pre-season treatment with effective antimalarials on subsequent malaria morbidity in under five-year-old children living in high and seasonal malaria transmission area of Burkina Faso.
Topics: Age Distribution; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Burkina Fa | 2010 |
Persistence of Plasmodium falciparum parasites in infected pregnant Mozambican women after delivery.
Topics: Adult; Aging; Antimalarials; Delivery, Obstetric; Drug Administration Schedule; Drug Combinations; F | 2011 |
Influences of intermittent preventive treatment and persistent multiclonal Plasmodium falciparum infections on clinical malaria risk.
Topics: Amodiaquine; Antigens, Protozoan; Antimalarials; Child, Preschool; Cross-Sectional Studies; Drug Com | 2010 |
HIV and placental infection modulate the appearance of drug-resistant Plasmodium falciparum in pregnant women who receive intermittent preventive treatment.
Topics: Adult; Alleles; Antimalarials; Chemoprevention; DNA, Protozoan; Drug Combinations; Drug Resistance; | 2011 |
An open randomized clinical trial in comparing two artesunate-based combination treatments on Plasmodium falciparum malaria in Nigerian children: artesunate/sulphamethoxypyrazine/pyrimethamine (fixed dose over 24 hours) versus artesunate/amodiaquine (fixe
Topics: Adolescent; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Drug Ther | 2010 |
Impact of malaria at the end of pregnancy on infant mortality and morbidity.
Topics: Antimalarials; Drug Combinations; Female; Humans; Infant Mortality; Infant, Newborn; Malaria, Falcip | 2011 |
IgG against Plasmodium falciparum variant surface antigens and growth inhibitory antibodies in Mozambican children receiving intermittent preventive treatment with sulfadoxine-pyrimethamine.
Topics: Age Factors; Antibodies, Protozoan; Antibody Formation; Antigenic Variation; Antigens, Protozoan; An | 2011 |
Pharmacokinetic properties of conventional and double-dose sulfadoxine-pyrimethamine given as intermittent preventive treatment in infancy.
Topics: Antimalarials; Drug Combinations; Female; Humans; Infant; Infant, Newborn; Malaria, Falciparum; Male | 2011 |
Efficacy of chloroquine and sulphadoxine-pyrimethamine either alone or in combination before introduction of ACT as first-line therapy in uncomplicated Plasmodium falciparum malaria in Jalpaiguri District, West Bengal, India.
Topics: Adolescent; Adult; Anti-Infective Agents; Antimalarials; Artemisinins; Child; Chloroquine; Drug Comb | 2011 |
High prevalence of dhfr triple mutant and correlation with high rates of sulphadoxine-pyrimethamine treatment failures in vivo in Gabonese children.
Topics: Amino Acid Substitution; Antimalarials; Child, Preschool; Dihydropteroate Synthase; Drug Combination | 2011 |
Morbidity from malaria in children in the year after they had received intermittent preventive treatment of malaria: a randomised trial.
Topics: Amodiaquine; Anemia; Antimalarials; Body Weight; Burkina Faso; Child, Preschool; Double-Blind Method | 2011 |
Malaria morbidity in children in the year after they had received intermittent preventive treatment of malaria in Mali: a randomized control trial.
Topics: Amodiaquine; Anemia; Antimalarials; Body Weight; Child, Preschool; Drug Administration Schedule; Dru | 2011 |
Effect of transmission reduction by insecticide-treated bednets (ITNs) on antimalarial drug resistance in western Kenya.
Topics: Adolescent; Adult; Antimalarials; Child; Chloroquine; Drug Combinations; Drug Resistance; Female; Ge | 2011 |
Impact of combining intermittent preventive treatment with home management of malaria in children less than 10 years in a rural area of Senegal: a cluster randomized trial.
Topics: Amodiaquine; Anemia; Animals; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesunate; C | 2011 |
Cluster-randomized study of intermittent preventive treatment for malaria in infants (IPTi) in southern Tanzania: evaluation of impact on survival.
Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Drug Therapy; Female; Humans; Infant; Infant, N | 2011 |
Efficacy of different primaquine-based antimalarial regimens against Plasmodium falciparum gametocytemia.
Topics: Adolescent; Adult; Aged; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Child, Prescho | 2012 |
Intermittent preventive treatment with sulfadoxine-pyrimethamine does not modify plasma cytokines and chemokines or intracellular cytokine responses to Plasmodium falciparum in Mozambican children.
Topics: Antimalarials; Chemokines; Child; Drug Combinations; Flow Cytometry; Humans; Incidence; Infant; Intr | 2012 |
Defining Plasmodium falciparum treatment in South West Asia: a randomized trial comparing artesunate or primaquine combined with chloroquine or SP.
Topics: Adolescent; Antimalarials; Artemisinins; Artesunate; Child; Chloroquine; Drug Combinations; Drug Res | 2012 |
Comparative efficacies of artemisinin combination therapies in Plasmodium falciparum malaria and polymorphism of pfATPase6, pfcrt, pfdhfr, and pfdhps genes in tea gardens of Jalpaiguri District, India.
Topics: Adolescent; Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesunat | 2012 |
An analysis of timing and frequency of malaria infection during pregnancy in relation to the risk of low birth weight, anaemia and perinatal mortality in Burkina Faso.
Topics: Adult; Anemia; Antimalarials; Burkina Faso; Drug Administration Schedule; Drug Combinations; Female; | 2012 |
Good efficacy of artemether-lumefantrine for uncomplicated falciparum malaria in eastern Sumba, East Nusatenggara, Indonesia.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinatio | 2012 |
Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxine-pyrimethamine-amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon.
Topics: Administration, Oral; Amodiaquine; Antimalarials; Cameroon; Child; Child, Preschool; Drug Administra | 2002 |
In vivo drug resistance of falciparum malaria in mining areas of Venezuela.
Topics: Adult; Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Female; Health Promo | 2002 |
The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine, and their combination in the treatment of uncomplicated Plasmodium falciparum malaria.
Topics: Amodiaquine; Animals; Antimalarials; Child, Preschool; Drug Combinations; Drug Therapy, Combination; | 2002 |
Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial.
Topics: Antimalarials; Cause of Death; Child, Preschool; Dapsone; Developing Countries; Drug Combinations; D | 2002 |
Chloroquine and sulphadoxine-pyrimethamine efficacy for uncomplicated malaria treatment and haematological recovery in children in Bobo-Dioulasso, Burkina Faso during a 3-year period 1998-2000.
Topics: Anemia; Animals; Antimalarials; Burkina Faso; Child, Preschool; Chloroquine; Drug Combinations; Drug | 2002 |
[Chemosensitivity of Plasmodium falciparum in Sainte Marie island, east coast of Madagascar: in vivo and in vitro studies].
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; | 2000 |
Combination of drug level measurement and parasite genotyping data for improved assessment of amodiaquine and sulfadoxine-pyrimethamine efficacies in treating Plasmodium falciparum malaria in Gabonese children.
Topics: Amodiaquine; Animals; Child; Child, Preschool; Drug Combinations; Female; Gabon; Genotype; Humans; I | 2003 |
Impact of preseason treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara, Mali.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Cohort Studies; Drug Combination | 2002 |
Therapeutic efficacy of chloroquine plus sulphadoxine/ pyrimethamine compared with monotherapy with either chloroquine or sulphadoxine/pyrimethamine in uncomplicated Plasmodium falciparum malaria in Laos.
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Dru | 2003 |
Efficacy of chloroquine, sulfadoxine-pyrimethamine, and mefloquine for the treatment of uncomplicated Plasmodium falciparum malaria on the north coast of Peru.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; | 2003 |
Effects of chloroquine and sulfadoxine/pyrimethamine on gametocytes in patients with uncomplicated Plasmodium falciparum malaria in Colombia.
Topics: Adolescent; Adult; Animals; Antimalarials; Chi-Square Distribution; Child, Preschool; Chloroquine; C | 2002 |
Comparative efficacy of aminoquinoline-antifolate combinations for the treatment of uncomplicated falciparum malaria in Kampala, Uganda.
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinatio | 2003 |
Treatment failure of pyrimethamine-sulphadoxine and induction of Plasmodium falciparum gametocytaemia in children in western Kenya.
Topics: Adolescent; Animals; Antimalarials; Child; Child, Preschool; Cohort Studies; Drug Combinations; Drug | 2003 |
A randomized comparison of chloroquine and chloroquine plus ketotifen in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children.
Topics: Acute Disease; Administration, Oral; Amodiaquine; Analysis of Variance; Antimalarials; Child; Child, | 2003 |
Plasmodium falciparum gametocytaemia in Nigerian children: before, during and after treatment with antimalarial drugs.
Topics: Age Factors; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combina | 2003 |
Assessing the efficacy of chloroquine and sulfadoxine-pyrimethamine for treatment of uncomplicated Plasmodium falciparum malaria in the Democratic Republic of Congo.
Topics: Antimalarials; Child, Preschool; Chloroquine; Democratic Republic of the Congo; Drug Combinations; D | 2003 |
Chloroquine versus sulfadoxine-pyrimethamine for treatment of Plasmodium falciparum malaria in Savannakhet Province, Lao People's Democratic Republic: an assessment of national antimalarial drug recommendations.
Topics: Adolescent; Adult; Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Female; | 2003 |
Treatment of uncomplicated falciparum malaria in southern Vietnam: can chloroquine or sulfadoxine-pyrimethamine be reintroduced in combination with artesunate?
Topics: Adolescent; Adult; Animals; Antimalarials; Artemisinins; Artesunate; Child; Chloroquine; Drug Combin | 2003 |
Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria.
Topics: Animals; Antimalarials; Biomarkers; Child, Preschool; Dihydropteroate Synthase; DNA Primers; DNA, Pr | 2003 |
Antipyretic, parasitologic, and immunologic effects of combining sulfadoxine/pyrimethamine with chloroquine or paracetamol for treating uncomplicated Plasmodium falciparum malaria.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Antimalarials; Body Temperature; Child, Preschool; | 2003 |
The efficacy of chloroquine, sulfadoxine-pyrimethamine and a combination of both for the treatment of uncomplicated Plasmodium falciparum malaria in an area of low transmission in western Uganda.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Resi | 2004 |
Adherence to the combination of sulphadoxine-pyrimethamine and artesunate in the Maheba refugee settlement, Zambia.
Topics: Antimalarials; Artemisinins; Artesunate; Child, Preschool; Drug Combinations; Drug Therapy, Combinat | 2004 |
Efficacy of sulfadoxine/pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria in Republic of Congo.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antimalarials; Child, Preschool; Congo; Drug Combinations; | 2004 |
Efficacy of chloroquine, amodiaquine, sulphadoxine-pyrimethamine and combination therapy with artesunate in Mozambican children with non-complicated malaria.
Topics: Amodiaquine; Animals; Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Drug Therapy, | 2004 |
Efficacy of sulphadoxine-pyrimethamine alone or combined with amodiaquine or chloroquine for the treatment of uncomplicated falciparum malaria in Ugandan children.
Topics: Amodiaquine; Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Therapy, Combination; Huma | 2004 |
Antimalarial efficacy of sulfadoxine-pyrimethamine, amodiaquine and a combination of chloroquine plus sulfadoxine-pyrimethamine in Bundi Bugyo, western Uganda.
Topics: Amodiaquine; Antimalarials; Child, Preschool; Chloroquine; Developing Countries; Drug Combinations; | 2004 |
Patterns of resistance and DHFR/DHPS genotypes of Plasmodium falciparum in rural Tanzania prior to the adoption of sulfadoxine-pyrimethamine as first-line treatment.
Topics: Animals; Antimalarials; Child, Preschool; Chloroquine; Developing Countries; Dihydropteroate Synthas | 2004 |
Open randomized study of pyrimethamine-sulphadoxine vs. pyrimethamine-sulphadoxine plus probenecid for the treatment of uncomplicated Plasmodium falciparum malaria in children.
Topics: Acute Disease; Antimalarials; Child; Child, Preschool; Drug Combinations; Drug Interactions; Drug Re | 2004 |
Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda.
Topics: Adolescent; Adult; Age Distribution; Aged; Animals; Antimalarials; Child; Child, Preschool; Dihydrop | 2004 |
Efficacy of pyrimethamine-sulfadoxine in young children with uncomplicated falciparum malaria in rural Burkina Faso.
Topics: Antimalarials; Burkina Faso; Child, Preschool; Cohort Studies; Drug Combinations; Female; Humans; In | 2004 |
Efficacy of combined chloroquine and sulfadoxine-pyrimethamine in uncomplicated Plasmodium falciparum malaria in Bangladesh.
Topics: Administration, Oral; Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Drug C | 2004 |
Efficacy of rectal artesunate compared with parenteral quinine in initial treatment of moderately severe malaria in African children and adults: a randomised study.
Topics: Administration, Rectal; Adolescent; Adult; Antimalarials; Artemisinins; Artesunate; Child; Child, Pr | 2004 |
Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial.
Topics: Africa; Animals; Antimalarials; Child; Child, Preschool; Dapsone; Double-Blind Method; Drug Combinat | 2004 |
[Gametocyte levels in response to differing malaria treatments in two municipalities of Colombia].
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Colombia; Dru | 2004 |
Intermittent preventive sulfadoxine-pyrimethamine treatment of primigravidae reduces levels of plasma immunoglobulin G, which protects against pregnancy-associated Plasmodium falciparum malaria.
Topics: Animals; Antibodies, Protozoan; Antigens, Protozoan; Antimalarials; Drug Administration Schedule; Dr | 2004 |
Efficacy of chloroquine, sulphadoxine-pyrimethamine and amodiaquine for treatment of uncomplicated Plasmodium falciparum malaria in Kajo Keji county, Sudan.
Topics: Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Therapy, C | 2004 |
[In vivo evaluation of sulfadoxine-pyrimethamine efficacy during uncomplicated falciparum malaria in children of Yopougon (Abidjan, Côte d'Ivoire)].
Topics: Antimalarials; Child, Preschool; Cote d'Ivoire; Drug Combinations; Female; Humans; Infant; Malaria, | 2004 |
Risk factors for gametocyte carriage in uncomplicated falciparum malaria in children.
Topics: Amodiaquine; Animals; Antimalarials; Carrier State; Child; Child, Preschool; Chloroquine; Chlorpheni | 2004 |
Randomized comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People's Democratic Republic.
Topics: Adolescent; Adult; Antimalarials; Artemether; Artemisinins; Artesunate; Child; Child, Preschool; Chl | 2004 |
Plasmodium falciparum hyperparasitaemia in children. Risk factors, treatment outcomes, and gametocytaemia following treatment.
Topics: Age Factors; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combina | 2004 |
Clinical and parasitological response of Plasmodium falciparum to chloroquine and sulfadoxine/pyrimethamine in rural Uganda.
Topics: Adult; Animals; Antimalarials; Cell Proliferation; Child, Preschool; Chloroquine; Drug Combinations; | 2003 |
Efficacies of chloroquine, sulfadoxine-pyrimethamine and quinine in the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Resi | 2004 |
Comparison of chloroquine, sulfadoxine/pyrimethamine, mefloquine and mefloquine-artesunate for the treatment of falciparum malaria in Kachin State, North Myanmar.
Topics: Adolescent; Adult; Age Distribution; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschoo | 2004 |
Comparison of the parasitologic efficacy of amodiaquine and sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malaria in the Bungoma District of western Kenya.
Topics: Amodiaquine; Animals; Antimalarials; Drug Administration Schedule; Drug Combinations; Drug Resistanc | 2004 |
Mefloquine versus quinine plus sulphalene-pyrimethamine (metakelfin) for treatment of uncomplicated imported falciparum malaria acquired in Africa.
Topics: Adult; Africa; Antimalarials; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; End | 2005 |
Efficacy and effectiveness of the combination of sulfadoxine/pyrimethamine and a 3-day course of artesunate for the treatment of uncomplicated falciparum malaria in a refugee settlement in Zambia.
Topics: Antimalarials; Artemisinins; Artesunate; Child, Preschool; Developing Countries; Drug Administration | 2005 |
Evidence basis for antimalarial policy change in Sierra Leone: five in vivo efficacy studies of chloroquine, sulphadoxine-pyrimethamine and amodiaquine.
Topics: Amodiaquine; Animals; Antimalarials; Child, Preschool; Chloroquine; Developing Countries; Drug Combi | 2005 |
A randomized comparative study of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Ghana.
Topics: Amodiaquine; Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Female; Fever; Ghana; | 2005 |
Efficacy of two artemisinin combination therapies for uncomplicated falciparum malaria in children under 5 years, Malakal, Upper Nile, Sudan.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Drug Combinations; Drug Ther | 2005 |
A randomized comparison of sulphadoxine-pyrimethamine and combination of sulphadoxine pyrimethamine with chloroquine in the treatment of uncomplicated falciparum malaria in Eastern Sudan.
Topics: Adolescent; Antimalarials; Chloroquine; Drug Combinations; Drug Therapy, Combination; Humans; Malari | 2005 |
Blood folate concentrations and in vivo sulfadoxine-pyrimethamine failure in Malawian children with uncomplicated Plasmodium falciparum malaria.
Topics: Analysis of Variance; Biomarkers; Child; Child, Preschool; Drug Therapy, Combination; Enzyme Inhibit | 2005 |
Efficacy comparison between anti-malarial drugs in Africans presenting with mild malaria in the Central Republic of Africa: a preliminary study.
Topics: Adolescent; Adult; Animals; Antimalarials; Artemisinins; Central African Republic; Drug Combinations | 2005 |
Therapeutic efficacy of antimalarial drugs along the eastern Indo-Nepal border: a cross-border collaborative study.
Topics: Adolescent; Adult; Age Distribution; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combi | 2005 |
Reduction of malaria transmission to Anopheles mosquitoes with a six-dose regimen of co-artemether.
Topics: Animals; Anopheles; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Female; | 2005 |
Malaria in the Nuba Mountains of Sudan: baseline genotypic resistance and efficacy of the artesunate plus sulfadoxine-pyrimethamine and artesunate plus amodiaquine combinations.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Chloroquine; Drug Combinatio | 2005 |
Antimalarial efficacy of chloroquine, amodiaquine, sulfadoxine-pyrimethamine, and the combinations of amodiaquine + artesunate and sulfadoxine-pyrimethamine + artesunate in Huambo and Bie provinces, central Angola.
Topics: Amodiaquine; Angola; Animals; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Chloroquine | 2005 |
In vivo sulphadoxine-pyrimethamine sentitivity study Tigray Region, Southern Zone, Alamata Town, September--November 2001.
Topics: Animals; Antimalarials; Disease Susceptibility; Drug Combinations; Drug Resistance; Ethiopia; Humans | 2004 |
Efficacy and tolerability of artesunate plus sulfadoxine-pyrimethamine and sulfadoxine-pyrimethamine alone for the treatment of uncomplicated Plasmodium falciparum malaria in Peru.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Artesunate; Child; Drug Combinations; Drug Therapy, | 2005 |
Sulfadoxine-pyrimethamine plus chloroquine or amodiaquine for uncomplicated falciparum malaria: a randomized, multisite trial to guide national policy in Uganda.
Topics: Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Therapy, C | 2005 |
Therapeutic efficacy of sulfadoxine-pyrimethamine for Plasmodium falciparum malaria.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Drug Combinations; Female; Humans; Malaria, Falcip | 2005 |
A randomized, placebo-controlled, double-blind trial on sulfadoxine-pyrimethamine alone or combined with artesunate or amodiaquine in uncomplicated malaria.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Double-Blind Method | 2005 |
Efficacy of combination therapy with artesunate plus amodiaquine compared to monotherapy with chloroquine, amodiaquine or sulfadoxine-pyrimethamine for treatment of uncomplicated Plasmodium falciparum in Afghanistan.
Topics: Adolescent; Adult; Afghanistan; Aged; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; C | 2005 |
A comparison of the efficacy of artesunate plus sulfadoxine-pyrimethamine with that of sulfadoxine-pyrimethamine alone, in the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan.
Topics: Adolescent; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Drug Combinations; Dru | 2005 |
Comparative efficacy of antimalarial drugs including ACTs in the treatment of uncomplicated malaria among children under 5 years in Ghana.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Chloroquine; Drug Combinatio | 2005 |
Efficacy of chloroquine + sulfadoxine--pyrimethamine, mefloquine + artesunate and artemether + lumefantrine combination therapies to treat Plasmodium falciparum malaria in the Chittagong Hill Tracts, Bangladesh.
Topics: Adolescent; Antimalarials; Artemether; Artemisinins; Artesunate; Bangladesh; Child; Child, Preschool | 2005 |
The drug sensitivities of Plasmodium falciparum in the Sonitpur district, Assam, India.
Topics: Adolescent; Adult; Age Factors; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug C | 2005 |
Efficacy of sulfadoxin pyrimethamine for uncomplicated Plasmodium falciparum malaria in a small sample of Sudanese children.
Topics: Adolescent; Animals; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Drug Combinat | 2004 |
Therapeutic efficacy of sulfadoxine-pyrimethamine and amodiaquine among children with uncomplicated Plasmodium falciparum malaria in Zanzibar, Tanzania.
Topics: Amodiaquine; Anemia; Animals; Antimalarials; Child, Preschool; Drug Combinations; Drug Resistance; H | 2005 |
Amplification of Plasmodium falciparum multidrug resistance gene 1 in isolates from Gabon.
Topics: Adolescent; Animals; Antimalarials; ATP-Binding Cassette Transporters; Child; Child, Preschool; Doub | 2005 |
Open randomized study of artesunate-amodiaquine vs. chloroquine-pyrimethamine-sulfadoxine for the treatment of uncomplicated Plasmodium falciparum malaria in Nigerian children.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Chloroquine; Drug Com | 2005 |
Parasitological rebound effect and emergence of pyrimethamine resistance in Plasmodium falciparum after single-dose sulfadoxine-pyrimethamine.
Topics: Animals; Antimalarials; Drug Combinations; Drug Resistance; Humans; Infant; Malaria, Falciparum; Pla | 2005 |
[Evaluation of the therapeutic efficacy of amodiaquine versus chloroquine in the treatment of uncomplicated malaria in Abie, Côte-d'Ivoire].
Topics: Amodiaquine; Animals; Antimalarials; Child, Preschool; Chloroquine; Cote d'Ivoire; Drug Combinations | 2005 |
Amodiaquine, sulfadoxine-pyrimethamine, and combination therapy for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso.
Topics: Adolescent; Adult; Amodiaquine; Animals; Antimalarials; Burkina Faso; Child; Child, Preschool; Drug | 2005 |
A randomized trial comparing the efficacy of four treatment regimens for uncomplicated falciparum malaria in Assam state, India.
Topics: Adolescent; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Chloroquine; Drug Comb | 2006 |
(Sub)microscopic Plasmodium falciparum gametocytaemia in Kenyan children after treatment with sulphadoxine-pyrimethamine monotherapy or in combination with artesunate.
Topics: Animals; Antimalarials; Artemisinins; Artesunate; Carrier State; Child; Child, Preschool; Drug Combi | 2006 |
Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial.
Topics: Antimalarials; Artemisinins; Artesunate; Bedding and Linens; Child, Preschool; Double-Blind Method; | 2006 |
Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial.
Topics: Antimalarials; Artemisinins; Artesunate; Bedding and Linens; Child, Preschool; Double-Blind Method; | 2006 |
Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial.
Topics: Antimalarials; Artemisinins; Artesunate; Bedding and Linens; Child, Preschool; Double-Blind Method; | 2006 |
Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial.
Topics: Antimalarials; Artemisinins; Artesunate; Bedding and Linens; Child, Preschool; Double-Blind Method; | 2006 |
Predictors of the failure of treatment with pyrimethamine-sulfadoxine in children with uncomplicated falciparum malaria.
Topics: Aging; Antimalarials; Artemether; Artemisinins; Child; Child, Preschool; Drug Combinations; Female; | 2006 |
Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance.
Topics: Adolescent; Adult; Aged; Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Comb | 2006 |
Efficacy of sulfadoxine-pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria in East Timor.
Topics: Adolescent; Adult; Aged; Alleles; Animals; Antigens, Protozoan; Antimalarials; Child; Child, Prescho | 2006 |
Existence of antimalarial formulations with low bioavailability in Tanzania.
Topics: Adult; Antimalarials; Area Under Curve; Biological Availability; Cross-Over Studies; Drug Combinatio | 2006 |
Tolerability of amodiaquine and sulphadoxine-pyrimethamine, alone or in combination for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan adults.
Topics: Adult; Amodiaquine; Antimalarials; Blood Cell Count; Double-Blind Method; Drug Combinations; Drug Th | 2006 |
Lack of inhibition of the anti-malarial action of sulfadoxine-pyrimethamine by folic acid supplementation when used for intermittent preventive treatment in Gambian primigravidae.
Topics: Adolescent; Adult; Anemia; Animals; Antimalarials; Dietary Supplements; Drug Combinations; Female; F | 2006 |
Folic acid treatment of Zambian children with moderate to severe malaria anemia.
Topics: Anemia; Animals; Antimalarials; Atovaquone; Child; Child, Preschool; Drug Combinations; Folic Acid; | 2006 |
Efficacy of chloroquine and sulfadoxine/pyrimethamine for the treatment of uncomplicated falciparum malaria in Koumantou, Mali.
Topics: Antimalarials; Artemisinins; Chloroquine; Drug Combinations; Female; Humans; Infant; Malaria, Falcip | 2006 |
Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial.
Topics: Animals; Antimalarials; Chemoprevention; Child, Preschool; Cross-Sectional Studies; Double-Blind Met | 2006 |
Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial.
Topics: Animals; Antimalarials; Chemoprevention; Child, Preschool; Cross-Sectional Studies; Double-Blind Met | 2006 |
Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial.
Topics: Animals; Antimalarials; Chemoprevention; Child, Preschool; Cross-Sectional Studies; Double-Blind Met | 2006 |
Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial.
Topics: Animals; Antimalarials; Chemoprevention; Child, Preschool; Cross-Sectional Studies; Double-Blind Met | 2006 |
Randomized trial of 2-dose versus monthly sulfadoxine-pyrimethamine intermittent preventive treatment for malaria in HIV-positive and HIV-negative pregnant women in Malawi.
Topics: Adolescent; Adult; Antimalarials; Drug Administration Schedule; Drug Combinations; Female; HIV Infec | 2006 |
A randomized, placebo-controlled trial of intermittent preventive treatment with sulphadoxine-pyrimethamine in Gambian multigravidae.
Topics: Adolescent; Adult; Anemia; Antimalarials; Bedding and Linens; Drug Combinations; Female; Gambia; Gra | 2006 |
[Coartem and fansimef in the treatment of falciparum malaria].
Topics: Abdominal Pain; Adolescent; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Child, P | 2006 |
Safety and efficacy of lumefantrine-artemether (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Zambian adults.
Topics: Adult; Animals; Antimalarials; Artemether; Artemisinins; Drug Combinations; Ethanolamines; Fluorenes | 2006 |
A fixed-dose 24-hour regimen of artesunate plus sulfamethoxypyrazine-pyrimethamine for the treatment of uncomplicated Plasmodium falciparum malaria in eastern Sudan.
Topics: Adult; Animals; Antimalarials; Artemisinins; Artesunate; Child; Drug Administration Schedule; Drug T | 2006 |
HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria.
Topics: Adolescent; Adult; Animals; Antimalarials; Artemether; Artemisinins; CD4 Lymphocyte Count; Drug Comb | 2006 |
Artesunate + amodiaquine and artesunate + sulphadoxine-pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulphadoxine and pyrimethamine-resistant haplotypes.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Democratic Republic | 2006 |
A randomised trial to assess the safety and efficacy of artemether-lumefantrine (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwanda.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschoo | 2007 |
The effects of artemether-lumefantrine vs amodiaquine-sulfalene-pyrimethamine on the hepatomegaly associated with Plasmodium falciparum malaria in children.
Topics: Amodiaquine; Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; | 2007 |
Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antimalarials; Child; Child, Preschool; Chloroq | 2007 |
A randomized trial of artesunate-sulfamethoxypyrazine-pyrimethamine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali.
Topics: Adolescent; Adult; Anemia; Antimalarials; Artemether; Artemisinins; Artesunate; Carrier State; Child | 2006 |
Efficacy, safety, and tolerability of amodiaquine plus sulphadoxine-pyrimethamine used alone or in combination for malaria treatment in pregnancy: a randomised trial.
Topics: Adult; Amodiaquine; Antimalarials; Chloroquine; Drug Administration Schedule; Drug Combinations; Fem | 2006 |
A randomised, double-blind, placebo-controlled trial of atovaquone-proguanil vs. sulphadoxine-pyrimethamine in the treatment of malarial anaemia in Zambian children.
Topics: Anemia; Antimalarials; Atovaquone; Child; Child, Preschool; Double-Blind Method; Drug Combinations; | 2006 |
Return of chloroquine antimalarial efficacy in Malawi.
Topics: Animals; Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance; Endemic D | 2006 |
Combined chloroquine, sulfadoxine/pyrimethamine and primaquine against Plasmodium falciparum in Central Java, Indonesia.
Topics: Adolescent; Adult; Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Therapy, Combination | 2006 |
Improved efficacy with amodiaquine instead of chloroquine in sulfadoxine/pyrimethamine combination treatment of falciparum malaria in Uganda: experience with fixed-dose formulation.
Topics: Amodiaquine; Animals; Antimalarials; Child, Preschool; Chloroquine; Drug Administration Schedule; Dr | 2006 |
Short course of quinine plus a single dose of sulfadoxine/pyrimethamine for Plasmodium falciparum malaria.
Topics: Animals; Antimalarials; Child; Child, Preschool; Drug Administration Schedule; Drug Combinations; Dr | 2006 |
Continued efficacy of sulfadoxine-pyrimethamine as second line treatment for malaria in children in Guinea-Bissau.
Topics: Adolescent; Animals; Antimalarials; Child; Child, Preschool; Drug Combinations; Female; Guinea-Bissa | 2006 |
Influence of consecutive-day blood sampling on polymerase chain reaction-adjusted parasitological cure rates in an antimalarial-drug trial conducted in Tanzania.
Topics: Animals; Antigens, Protozoan; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins | 2007 |
Efficacies of artesunate plus either sulfadoxine-pyrimethamine or amodiaquine, for the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Drug Comb | 2007 |
Dihydroartemisinin suppository in moderately severe malaria: comparative efficacy of dihydroartemisinin suppository versus intramuscular artemeter followed by oral sulfadoxine-pyrimethamine in the management of moderately severe malaria in Nigerian childr
Topics: Antimalarials; Artemether; Artemisinins; Child; Child, Preschool; Drug Combinations; Humans; Infant; | 2007 |
Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Burkina Faso; C | 2007 |
Molecular genotyping in a malaria treatment trial in Uganda - unexpected high rate of new infections within 2 weeks after treatment.
Topics: Animals; Antimalarials; Artemisinins; Artesunate; Child; Drug Combinations; Drug Therapy, Combinatio | 2007 |
Thiamin deficiency and uncomplicated falciparum malaria in Laos.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Artesunate; Beriberi; Child | 2007 |
Randomized controlled trial of fosmidomycin-clindamycin versus sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malaria.
Topics: Adolescent; Antimalarials; Child; Child, Preschool; Clindamycin; Drug Combinations; Female; Fosfomyc | 2007 |
Lack of impact of artesunate on the disposition kinetics of sulfadoxine/pyrimethamine when the two drugs are concomitantly administered.
Topics: Adult; Antimalarials; Area Under Curve; Artemisinins; Artesunate; Chromatography, High Pressure Liqu | 2007 |
Sulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women.
Topics: Adolescent; Animals; Antimalarials; Burkina Faso; Child; Child, Preschool; Chloroquine; Drug Adminis | 2007 |
Unusual pattern of Plasmodium falciparum drug resistance in the northwestern Peruvian Amazon region.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; | 2007 |
Efficacy of antimalarial treatment in Guinea: in vivo study of two artemisinin combination therapies in Dabola and molecular markers of resistance to sulphadoxine-pyrimethamine in N'Zérékoré.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Dihydropteroate Syn | 2007 |
Randomized clinical trial of artemisinin versus non-artemisinin combination therapy for uncomplicated falciparum malaria in Madagascar.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Chloroqui | 2007 |
Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial.
Topics: Amodiaquine; Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesu | 2007 |
Effect of artesunate plus sulfadoxine-pyrimethamine on haematological recovery and anaemia, in Kenyan children with uncomplicated, Plasmodium falciparum malaria.
Topics: Anemia; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Drug Combinations; Female; Humans | 2007 |
Intermittent preventive treatment of malaria in pregnancy: a community-based delivery system and its effect on parasitemia, anemia and low birth weight in Uganda.
Topics: Adolescent; Adult; Anemia; Antimalarials; Case-Control Studies; Community Health Workers; Drug Admin | 2008 |
A randomized controlled trial of extended intermittent preventive antimalarial treatment in infants.
Topics: Animals; Antimalarials; Double-Blind Method; Drug Combinations; Female; Ghana; Humans; Infant; Malar | 2007 |
A randomized controlled trial of extended intermittent preventive antimalarial treatment in infants.
Topics: Animals; Antimalarials; Double-Blind Method; Drug Combinations; Female; Ghana; Humans; Infant; Malar | 2007 |
A randomized controlled trial of extended intermittent preventive antimalarial treatment in infants.
Topics: Animals; Antimalarials; Double-Blind Method; Drug Combinations; Female; Ghana; Humans; Infant; Malar | 2007 |
A randomized controlled trial of extended intermittent preventive antimalarial treatment in infants.
Topics: Animals; Antimalarials; Double-Blind Method; Drug Combinations; Female; Ghana; Humans; Infant; Malar | 2007 |
A comparison of sulfadoxine-pyrimethamine with chloroquine and pyrimethamine for prevention of malaria in pregnant Nigerian women.
Topics: Adult; Animals; Antimalarials; Birth Weight; Chloroquine; Drug Combinations; Female; Hematocrit; Hum | 2007 |
Efficacy of artesunate plus amodiaquine, artesunate plus sulfadoxine-pyrimethamine, and chloroquine plus sulfadoxine-pyrimethamine in patients with uncomplicated Plasmodium falciparum in the Comoros Union.
Topics: Adolescent; Adult; Aged; Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Child; Child | 2007 |
Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal.
Topics: Adolescent; Adult; Aged; Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; | 2007 |
Dramatically decreased therapeutic efficacy of chloroquine and sulfadoxine-pyrimethamine, but not mefloquine, in southern Benin.
Topics: Administration, Oral; Animals; Antigens, Protozoan; Antimalarials; Benin; Child, Preschool; Chloroqu | 2007 |
Efficacy of sulfadoxine-pyrimethamine, amodiaquine, and sulfadoxine-pyrimethamine-amodiaquine combination for the treatment of uncomplicated falciparum malaria in the urban and suburban areas of Brazzaville (Congo).
Topics: Amodiaquine; Antimalarials; Carrier State; Child, Preschool; Congo; DNA, Protozoan; Drug Combination | 2007 |
Age interactions in the development of naturally acquired immunity to Plasmodium falciparum and its clinical presentation.
Topics: Age Factors; Anemia; Animals; Antigens, Protozoan; Child, Preschool; Dapsone; Drug Therapy, Combinat | 2007 |
Therapeutic efficacy and effects of artemether-lumefantrine and amodiaquine-sulfalene-pyrimethamine on gametocyte carriage in children with uncomplicated Plasmodium falciparum malaria in southwestern Nigeria.
Topics: Amodiaquine; Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; | 2007 |
Sulfadoxine-pyrimethamine plus artesunate compared with chloroquine for the treatment of vivax malaria in areas co-endemic for Plasmodium falciparum and P. vivax: a randomised non-inferiority trial in eastern Afghanistan.
Topics: Adolescent; Afghanistan; Antimalarials; Artemisinins; Artesunate; Child; Chloroquine; Drug Combinati | 2007 |
Comparison of artemether-lumefantrine with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in eastern Nepal.
Topics: Adolescent; Adult; Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; | 2007 |
Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate.
Topics: Adolescent; Animals; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Drug Combinat | 2007 |
Comparison of the therapeutic efficacy of chloroquine and sulphadoxine-pyremethamine in children and pregnant women.
Topics: Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Female; Humans; Malaria, Falciparum | 2007 |
Immune responses after single-dose sulphadoxine-pyrimethamine indicate underestimation of protective efficacy of intermittent preventive treatment in infants.
Topics: Animals; Antimalarials; Child; Double-Blind Method; Drug Combinations; Ghana; Humans; Immunoglobulin | 2007 |
Ibuprofen does not affect levels of tumor necrosis factor alpha and soluble tumor necrosis factor receptor types I and II in Gabonese children with uncomplicated Plasmodium falciparum malaria.
Topics: Animals; Antimalarials; Child; Double-Blind Method; Etanercept; Gabon; Humans; Ibuprofen; Immunoglob | 2007 |
Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.
Topics: Animals; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug | 2008 |
Comparison of different artemisinin-based combinations for the treatment of Plasmodium falciparum malaria in children in Kigali, Rwanda, an area of resistance to sulfadoxine-pyrimethamine: artesunate plus sulfadoxine/pyrimethamine versus artesunate plus s
Topics: Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Drug Combinations; Drug Resistance | 2007 |
Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against Plasmodium falciparum and P. vivax malaria in Papua New Guinea.
Topics: Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug R | 2007 |
Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso.
Topics: Amodiaquine; Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Burkin | 2007 |
Two-dose versus monthly intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine in HIV-seropositive pregnant Zambian women.
Topics: Adult; AIDS-Related Opportunistic Infections; Anemia; Antimalarials; Birth Weight; Double-Blind Meth | 2007 |
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial.
Topics: Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; | 2007 |
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial.
Topics: Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; | 2007 |
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial.
Topics: Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; | 2007 |
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial.
Topics: Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; | 2007 |
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial.
Topics: Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; | 2007 |
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial.
Topics: Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; | 2007 |
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial.
Topics: Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; | 2007 |
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial.
Topics: Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; | 2007 |
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial.
Topics: Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; | 2007 |
Malaria incidence and efficacy of intermittent preventive treatment in infants (IPTi).
Topics: Animals; Antimalarials; Drug Combinations; Drug Resistance; Humans; Infant; Malaria, Falciparum; Pla | 2007 |
A randomized open-label trial of artesunate- sulfadoxine-pyrimethamine with or without primaquine for elimination of sub-microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Artemisinins; Artesunate; Carrier State; Child; Chi | 2007 |
A randomized open-label trial of artesunate- sulfadoxine-pyrimethamine with or without primaquine for elimination of sub-microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Artemisinins; Artesunate; Carrier State; Child; Chi | 2007 |
A randomized open-label trial of artesunate- sulfadoxine-pyrimethamine with or without primaquine for elimination of sub-microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Artemisinins; Artesunate; Carrier State; Child; Chi | 2007 |
A randomized open-label trial of artesunate- sulfadoxine-pyrimethamine with or without primaquine for elimination of sub-microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Artemisinins; Artesunate; Carrier State; Child; Chi | 2007 |
Antimalarial resistance and DHFR/DHPS genotypes of Plasmodium falciparum three years after introduction of sulfadoxine-pyrimethamine and amodiaquine in rural Tanzania.
Topics: Amodiaquine; Animals; Antimalarials; Child, Preschool; Dihydropteroate Synthase; Drug Combinations; | 2008 |
Adding artesunate to sulphadoxine-pyrimethamine greatly improves the treatment efficacy in children with uncomplicated falciparum malaria on the coast of Benin, West Africa.
Topics: Analysis of Variance; Anemia; Animals; Antimalarials; Artemisinins; Artesunate; Benin; Child, Presch | 2007 |
The antischistosomal efficacies of artesunate-sulfamethoxypyrazine-pyrimethamine and artemether-lumefantrine administered as treatment for uncomplicated, Plasmodium falciparum malaria.
Topics: Adolescent; Adult; Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; | 2008 |
[Randomized clinical trial of two malaria prophylaxis regimens for pregnant women in Faladie, Mali].
Topics: Adult; Anemia; Antimalarials; Chloroquine; Drug Combinations; Endemic Diseases; Female; Humans; Infa | 2007 |
Sulphadoxine/pyrimethamine versus amodiaquine for treating uncomplicated childhood malaria in Gabon: a randomized trial to guide national policy.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Dihydropteroate Syn | 2008 |
Dihydrofolate reductase I164L mutations in Plasmodium falciparum isolates: clinical outcome of 14 Kenyan adults infected with parasites harbouring the I164L mutation.
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Animals; Antimalarials; CD4 Lymphocy | 2008 |
Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Biomarkers; Drug Combinations; Drug R | 2008 |
Single-day, three-dose treatment with fixed dose combination artesunate/sulfamethoxypyrazine/pyrimethamine to cure Plasmodium falciparum malaria.
Topics: Antimalarials; Artemisinins; Child; Cote d'Ivoire; Dose-Response Relationship, Drug; Drug Administra | 2008 |
Molecular markers of resistance to sulfadoxine-pyrimethamine during intermittent preventive treatment for malaria in Mozambican infants.
Topics: Animals; Antimalarials; Biomarkers; Double-Blind Method; Drug Administration Schedule; Drug Combinat | 2008 |
Molecular markers of resistance to sulfadoxine-pyrimethamine during intermittent preventive treatment for malaria in Mozambican infants.
Topics: Animals; Antimalarials; Biomarkers; Double-Blind Method; Drug Administration Schedule; Drug Combinat | 2008 |
Molecular markers of resistance to sulfadoxine-pyrimethamine during intermittent preventive treatment for malaria in Mozambican infants.
Topics: Animals; Antimalarials; Biomarkers; Double-Blind Method; Drug Administration Schedule; Drug Combinat | 2008 |
Molecular markers of resistance to sulfadoxine-pyrimethamine during intermittent preventive treatment for malaria in Mozambican infants.
Topics: Animals; Antimalarials; Biomarkers; Double-Blind Method; Drug Administration Schedule; Drug Combinat | 2008 |
Molecular markers of resistance to sulfadoxine-pyrimethamine during intermittent preventive treatment for malaria in Mozambican infants.
Topics: Animals; Antimalarials; Biomarkers; Double-Blind Method; Drug Administration Schedule; Drug Combinat | 2008 |
Molecular markers of resistance to sulfadoxine-pyrimethamine during intermittent preventive treatment for malaria in Mozambican infants.
Topics: Animals; Antimalarials; Biomarkers; Double-Blind Method; Drug Administration Schedule; Drug Combinat | 2008 |
Molecular markers of resistance to sulfadoxine-pyrimethamine during intermittent preventive treatment for malaria in Mozambican infants.
Topics: Animals; Antimalarials; Biomarkers; Double-Blind Method; Drug Administration Schedule; Drug Combinat | 2008 |
Molecular markers of resistance to sulfadoxine-pyrimethamine during intermittent preventive treatment for malaria in Mozambican infants.
Topics: Animals; Antimalarials; Biomarkers; Double-Blind Method; Drug Administration Schedule; Drug Combinat | 2008 |
Molecular markers of resistance to sulfadoxine-pyrimethamine during intermittent preventive treatment for malaria in Mozambican infants.
Topics: Animals; Antimalarials; Biomarkers; Double-Blind Method; Drug Administration Schedule; Drug Combinat | 2008 |
Herba Artemisiae annuae tea preparation compared to sulfadoxine-pyrimethamine in the treatment of uncomplicated falciparum malaria in adults: a randomized double-blind clinical trial.
Topics: Adult; Animals; Antimalarials; Artemisia annua; Double-Blind Method; Drug Combinations; Drugs, Chine | 2008 |
Impact of intermittent preventive treatment with sulfadoxine-pyrimethamine on antibody responses to erythrocytic-stage Plasmodium falciparum antigens in infants in Mozambique.
Topics: Animals; Antibodies, Protozoan; Antigens, Protozoan; Antimalarials; Child, Preschool; Drug Administr | 2008 |
Response of Plasmodium falciparum to chloroquine and Fansidar in vivo and chloroquine and amodiaquine in vitro in Uganda.
Topics: Amodiaquine; Animals; Antimalarials; Child; Chloroquine; Drug Combinations; Drug Evaluation, Preclin | 1995 |
Sulphadoxine concentrations in plasma, red blood cells and whole blood in healthy and Plasmodium falciparum malaria cases after treatment with Fansidar using high-performance liquid chromatography.
Topics: Adult; Animals; Antimalarials; Chromatography, High Pressure Liquid; Drug Combinations; Erythrocytes | 1994 |
Specific and nonspecific responses to Plasmodium falciparum blood-stage parasites and observations on the gametocytemia in schoolchildren living in a malaria-endemic area of Mozambique.
Topics: Adolescent; Animals; Antibodies, Protozoan; Antigens, Protozoan; Antimalarials; Blotting, Western; C | 1995 |
In vivo sensitivity of Plasmodium falciparum to chloroquine, amodiaquine and sulfadoxine-pyrimethamine in western Uganda.
Topics: Adult; Amodiaquine; Animals; Antimalarials; Child; Chloroquine; Drug Combinations; Drug Resistance; | 1994 |
Prevention of Plasmodium falciparum malaria by Fansimef and Lariam in the northeastern part of Thailand.
Topics: Adult; Animals; Antibodies, Protozoan; Blood; Chloroquine; Drug Combinations; Humans; Malaria, Falci | 1993 |
The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi.
Topics: Analysis of Variance; Antimalarials; Chi-Square Distribution; Chloroquine; Drug Combinations; Drug T | 1994 |
Artemether in moderately severe and cerebral malaria in Nigerian children.
Topics: Antimalarials; Antiprotozoal Agents; Artemether; Artemisinins; Child; Child, Preschool; Drug Combina | 1994 |
Chloroquine and sulfadoxine/pyrimethamine sensitivity in Burkina Faso. In vivo sensitivity of Plasmodium falciparum to chloroquine and sulfadoxine/pyrimethamine in Burkina Faso.
Topics: Animals; Burkina Faso; Child; Child, Preschool; Chloroquine; Drug Resistance; Drug Therapy, Combinat | 1994 |
Response of falciparum malaria to chloroquine and three second line antimalarial drugs in a Kenyan coastal school age population.
Topics: Adolescent; Amodiaquine; Child; Chloroquine; Drug Combinations; Drug Resistance; Humans; Kenya; Mala | 1993 |
Comparative tolerability and kinetics during long-term intake of Lariam and Fansidar for malaria prophylaxis in nonimmune volunteers.
Topics: Adult; Antimalarials; Double-Blind Method; Drug Combinations; Half-Life; Humans; Linear Models; Mala | 1993 |
Mefloquine monitoring in acute uncomplicated malaria treated with Fansimef and Lariam.
Topics: Acute Disease; Adolescent; Adult; Antimalarials; Drug Combinations; Humans; Malaria, Falciparum; Mal | 1993 |
Plasmodium falciparum sensitivity to antimalarials at Humera, northwestern Ethiopia.
Topics: Adolescent; Adult; Animals; Child; Chloroquine; Drug Combinations; Drug Resistance; Ethiopia; Female | 1993 |
Resistance of Plasmodium falciparum to antimalarial drugs in Equatorial Guinea.
Topics: Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug R | 1993 |
Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa.
Topics: Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance; Female; Follow-Up Studies; Hemogl | 1993 |
Sulfadoxine/pyrimethamine or chloroquine/clindamycin treatment of Gabonese school children infected with chloroquine resistant malaria.
Topics: Adolescent; Animals; Anti-Bacterial Agents; Antimalarials; Child; Child, Preschool; Chloroquine; Cli | 1995 |
In vivo study of the response of Plasmodium falciparum to standard mefloquine/sulfadoxine/pyrimethamine (MSP) treatment among gem miners returning from Cambodia.
Topics: Adult; Animals; Antimalarials; Cambodia; Chi-Square Distribution; Drug Combinations; Drug Resistance | 1995 |
Efficacy of sulphadoxine/pyrimethamine for Plasmodium falciparum malaria in Malawian children under five years of age.
Topics: Age Factors; Antimalarials; Child, Preschool; Drug Combinations; Drug Resistance; Follow-Up Studies; | 1996 |
A randomized trial of chloroquine, amodiaquine and pyrimethamine-sulphadoxine in Gambian children with uncomplicated malaria.
Topics: Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance | 1996 |
Efficacy of halofantrine in the treatment of uncomplicated falciparum malaria.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Double-Blind Method; Drug Combinations; D | 1995 |
A randomised controlled trial to assess the relative efficacy of chloroquine, amodiaquine, halofantrine and Fansidar in the treatment of uncomplicated malaria in children.
Topics: Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance | 1996 |
A comparative study of parenteral chloroquine, quinine and pyrimethamine-sulfadoxine in the treatment of Gambian children with complicated, non-cerebral malaria.
Topics: Antimalarials; Child; Child, Preschool; Chloroquine; Data Interpretation, Statistical; Drug Combinat | 1996 |
In vivo efficacy of chloroquine, halofantrine, pyrimethamine-sulfadoxine and qinghaosu (artesunate) in the treatment of malaria in Calabar, Nigeria.
Topics: Adolescent; Antimalarials; Artemisinins; Artesunate; Child; Chloroquine; Drug Combinations; Drug Res | 1996 |
Response of childhood malaria to chloroquine and Fansidar in an area of intermediate chloroquine resistance in Côte d'Ivoire.
Topics: Animals; Antimalarials; Body Temperature; Child; Child, Preschool; Chloroquine; Cote d'Ivoire; Drug | 1996 |
Artemether-pyrimethamine in the treatment of pyrimethamine-resistant falciparum malaria.
Topics: Adolescent; Adult; Animals; Antimalarials; Artemether; Artemisinins; Dose-Response Relationship, Dru | 1996 |
The effect of oral iron therapy during treatment for Plasmodium falciparum malaria with sulphadoxine-pyrimethamine on Malawian children under 5 years of age.
Topics: Antimalarials; Child, Preschool; Drug Combinations; Drug Therapy, Combination; Follow-Up Studies; He | 1996 |
Efficacy of artemether in severe falciparum malaria in African children.
Topics: Adolescent; Animals; Antimalarials; Artemether; Artemisinins; Child; Child, Preschool; Chloroquine; | 1996 |
Responses of multidrug-resistant Plasmodium falciparum parasites to mefloquine in Nigerian children.
Topics: Animals; Anti-Infective Agents; Antimalarials; Child; Child, Preschool; Drug Resistance, Microbial; | 1997 |
Clearance of young parasite forms following treatment of falciparum malaria in humans: comparison of three simple mathematical models.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Drug Therapy, Combination; Humans; Kinetics; Lactone | 1997 |
Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants.
Topics: Adult; Anemia, Iron-Deficiency; Antimalarials; Dapsone; Delayed-Action Preparations; Double-Blind Me | 1997 |
Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants.
Topics: Adult; Anemia, Iron-Deficiency; Antimalarials; Dapsone; Delayed-Action Preparations; Double-Blind Me | 1997 |
Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants.
Topics: Adult; Anemia, Iron-Deficiency; Antimalarials; Dapsone; Delayed-Action Preparations; Double-Blind Me | 1997 |
Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants.
Topics: Adult; Anemia, Iron-Deficiency; Antimalarials; Dapsone; Delayed-Action Preparations; Double-Blind Me | 1997 |
Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants.
Topics: Adult; Anemia, Iron-Deficiency; Antimalarials; Dapsone; Delayed-Action Preparations; Double-Blind Me | 1997 |
Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants.
Topics: Adult; Anemia, Iron-Deficiency; Antimalarials; Dapsone; Delayed-Action Preparations; Double-Blind Me | 1997 |
Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants.
Topics: Adult; Anemia, Iron-Deficiency; Antimalarials; Dapsone; Delayed-Action Preparations; Double-Blind Me | 1997 |
Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants.
Topics: Adult; Anemia, Iron-Deficiency; Antimalarials; Dapsone; Delayed-Action Preparations; Double-Blind Me | 1997 |
Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants.
Topics: Adult; Anemia, Iron-Deficiency; Antimalarials; Dapsone; Delayed-Action Preparations; Double-Blind Me | 1997 |
Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants.
Topics: Adult; Anemia, Iron-Deficiency; Antimalarials; Dapsone; Delayed-Action Preparations; Double-Blind Me | 1997 |
Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants.
Topics: Adult; Anemia, Iron-Deficiency; Antimalarials; Dapsone; Delayed-Action Preparations; Double-Blind Me | 1997 |
Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants.
Topics: Adult; Anemia, Iron-Deficiency; Antimalarials; Dapsone; Delayed-Action Preparations; Double-Blind Me | 1997 |
Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants.
Topics: Adult; Anemia, Iron-Deficiency; Antimalarials; Dapsone; Delayed-Action Preparations; Double-Blind Me | 1997 |
Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants.
Topics: Adult; Anemia, Iron-Deficiency; Antimalarials; Dapsone; Delayed-Action Preparations; Double-Blind Me | 1997 |
Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants.
Topics: Adult; Anemia, Iron-Deficiency; Antimalarials; Dapsone; Delayed-Action Preparations; Double-Blind Me | 1997 |
Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants.
Topics: Adult; Anemia, Iron-Deficiency; Antimalarials; Dapsone; Delayed-Action Preparations; Double-Blind Me | 1997 |
Chlorproguanil-dapsone: effective treatment for uncomplicated falciparum malaria.
Topics: Antimalarials; Child; Child, Preschool; Dapsone; Double-Blind Method; Drug Combinations; Drug Resist | 1997 |
Chloroquine versus pyrimethamine/sulphadoxine in the treatment of uncomplicated P. falciparum malaria in northern Kenya.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Resi | 1997 |
Treatment of chloroquine-resistant malaria using pyrimethamine in combination with berberine, tetracycline or cotrimoxazole.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antimalarials; Berberine; Child; Child, Preschool; C | 1997 |
The differing impact of chloroquine and pyrimethamine/sulfadoxine upon the infectivity of malaria species to the mosquito vector.
Topics: Animals; Anopheles; Antimalarials; Carrier State; Chloroquine; Drug Combinations; Drug Resistance; F | 1998 |
In vivo selection for a specific genotype of dihydropteroate synthetase of Plasmodium falciparum by pyrimethamine-sulfadoxine but not chlorproguanil-dapsone treatment.
Topics: Amino Acid Sequence; Animals; Antimalarials; Arginine; Asparagine; Child; Dapsone; Dihydropteroate S | 1998 |
Malaria chemotherapy trial at a minimal effective dose of mefloquine/sulfadoxine/pyrimethamine compared with equivalent doses of sulfadoxine/pyrimethamine or mefloquine alone.
Topics: Adolescent; Antimalarials; Child; Child, Preschool; Double-Blind Method; Drug Therapy, Combination; | 1998 |
A randomized controlled trial of artemether/benflumetol, a new antimalarial and pyrimethamine/sulfadoxine in the treatment of uncomplicated falciparum malaria in African children.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschool | 1998 |
Viability of Plasmodium falciparum ex vivo: comparison of the effects of artemether and sulfadoxine-pyrimethamine.
Topics: Adolescent; Animals; Antimalarials; Artemether; Artemisinins; Child; Child, Preschool; Drug Combinat | 1998 |
Chloroquine in Africa: critical assessment and recommendations for monitoring and evaluating chloroquine therapy efficacy in sub-Saharan Africa.
Topics: Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Drug Monitoring; Drug Resistance; F | 1998 |
Sulfalene concentrations in plasma and blood cells of Plasmodium falciparum malaria cases after treatment with metakelfin using high-performance liquid chromatography.
Topics: Adult; Antimalarials; Blood Cells; Chromatography, High Pressure Liquid; Drug Combinations; Female; | 1998 |
Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial.
Topics: Anemia; Antimalarials; Bedding and Linens; Double-Blind Method; Drug Administration Schedule; Drug C | 1999 |
Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial.
Topics: Anemia; Antimalarials; Bedding and Linens; Double-Blind Method; Drug Administration Schedule; Drug C | 1999 |
Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial.
Topics: Anemia; Antimalarials; Bedding and Linens; Double-Blind Method; Drug Administration Schedule; Drug C | 1999 |
Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial.
Topics: Anemia; Antimalarials; Bedding and Linens; Double-Blind Method; Drug Administration Schedule; Drug C | 1999 |
Response of falciparum malaria to different antimalarials in Myanmar.
Topics: Adolescent; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Therapy, Combination; Humans; | 1999 |
Atovaquone-proguanil compared with chloroquine and chloroquine-sulfadoxine-pyrimethamine for treatment of acute Plasmodium falciparum malaria in the Philippines.
Topics: Antimalarials; Atovaquone; Chloroquine; Drug Therapy, Combination; Folic Acid Antagonists; Humans; M | 1999 |
Atovaquone and proguanil versus pyrimethamine/sulfadoxine for the treatment of acute falciparum malaria in Zambia.
Topics: Adolescent; Adult; Animals; Blood Cells; Blood Chemical Analysis; Female; Humans; Malaria, Falciparu | 1999 |
Population structure of recrudescent Plasmodium falciparum isolates from western Uganda.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antigens, Protozoan; Antimalarials; Child; Chil | 1999 |
Low-dose treatment with sulfadoxine-pyrimethamine combinations selects for drug-resistant Plasmodium falciparum strains.
Topics: Africa; Animals; Antimalarials; Child; Dihydropteroate Synthase; Drug Combinations; Drug Resistance; | 1999 |
Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial.
Topics: Animals; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Double-Blind Method; Drug | 2000 |
Assessment of therapeutic response of Plasmodium falciparum to chloroquine and sulfadoxine-pyrimethamine in an area of low malaria transmission in Colombia.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Colombia; Disease T | 1999 |
Investigations of incidence of pretreatment, drug sensitivity in vitro, and plasma levels of pyrimethamine in patients with multidrug resistant falciparum malaria following the three combination regimens of artemether/pyrimethamine.
Topics: Adolescent; Adult; Animals; Antimalarials; Artemether; Artemisinins; Dose-Response Relationship, Dru | 1999 |
Monitoring efficacy of commonly used antimalarials by a 14-day in-vivo test in a new settler's camp in endemic zone at Cox's Bazar.
Topics: Adolescent; Adult; Antimalarials; Bangladesh; Child; Chloroquine; Drug Administration Schedule; Drug | 1998 |
Comparative efficacy of chloroquine plus chlorpheniramine alone and in a sequential combination with sulfadoxine-pyrimethamine, for the treatment of acute, uncomplicated, falciparum malaria in children.
Topics: Animals; Antimalarials; Antipruritics; Child; Child, Preschool; Chloroquine; Chlorpheniramine; Drug | 2000 |
In vivo efficacy study of amodiaquine and sulfadoxine/ pyrimethamine in Kibwezi, Kenya and Kigoma, Tanzania.
Topics: Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Drug Resistance, Microbial; Female; Fe | 2000 |
A randomized, parallel-group study in Mumbai (Bombay), comparing chloroquine with chloroquine plus sulfadoxine-pyrimethamine in the treatment of adults with acute, uncomplicated, Plasmodium falciparum malaria.
Topics: Acute Disease; Adolescent; Adult; Aged; Antimalarials; Chloroquine; Cost of Illness; Cost-Benefit An | 2000 |
Micronutrient and iron supplementation and effective antimalarial treatment synergistically improve childhood anaemia.
Topics: Anemia, Iron-Deficiency; Antimalarials; Child, Preschool; Dietary Supplements; Drug Combinations; Dr | 2000 |
Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae.
Topics: Adolescent; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Ch | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
Topics: Anemia, Iron-Deficiency; Antimalarials; Developing Countries; Drug Administration Schedule; Drug Com | 2001 |
Atovaquone and proguani hydrochloride compared with chloroquine or pyrimethamine/sulfodaxine for treatment of acute Plasmodium falciparum malaria in Peru.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Atovaquone; Chloroquine; Drug Combinations; Drug Re | 2001 |
Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial.
Topics: Adolescent; Amodiaquine; Antimalarials; Child; Child, Preschool; Drug Therapy, Combination; Female; | 2001 |
Effectiveness of short-course quinine and single-dose sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malaria in Mpumalanga Province, South Africa.
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Child, Preschool; Drug Combinations; Drug Therapy, Co | 2001 |
Efficacy of Sulphadoxine and Pyrimethamine, Doxycycline and their combination in the treatment of chloroquine resistant Falciparum Malaria.
Topics: Antimalarials; Chi-Square Distribution; Chloroquine; Doxycycline; Drug Resistance; Drug Therapy, Com | 2001 |
Gametocytaemia in Senegalese children with uncomplicated falciparum malaria treated with chloroquine, amodiaquine or sulfadoxine + pyrimethamine.
Topics: Adolescent; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistan | 2001 |
Therapy of uncomplicated falciparum malaria: a randomized trial comparing artesunate plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone in Irian Jaya, Indonesia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antimalarials; Artemisini | 2001 |
Efficacy of mefloquine and sulfadoxine-pyrimethamine for the treatment of uncomplicated Plasmodium falciparum infection in Machinga District, Malawi, 1998.
Topics: Animals; Antimalarials; Child, Preschool; Disease-Free Survival; Drug Administration Schedule; Drug | 2001 |
Cardiac effects of amodiaquine and sulfadoxine-pyrimethamine in malaria-infected African patients.
Topics: Administration, Oral; Adolescent; Adult; Amodiaquine; Antimalarials; Bradycardia; Cameroon; Drug Adm | 2001 |
Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria.
Topics: Antimalarials; Biomarkers; Child; Child, Preschool; Dapsone; Dihydropteroate Synthase; Double-Blind | 2002 |
Therapeutic efficacy of sulfadoxine-pyrimethamine in uncomplicated Plasmodium falciparum malaria 3 years after introduction in Mpumalanga.
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Child, Preschool; Drug Combinations; Female; Follow-U | 2001 |
A randomized comparison of chloroquine, amodiaquine and their combination with pyrimethamine-sulfadoxine in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children.
Topics: Acute Disease; Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Therapy, Combi | 2002 |
Sulphadoxine/pyrimethamine: an appropriate first-line alternative for the treatment of uncomplicated falciparum malaria in Ghanaian children under 5 years of age.
Topics: Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance; Female; Follow-Up | 2002 |
Sulfadoxine-pyrimethamine monotherapy in Tanzanian children gives rapid parasite clearance but slow fever clearance that is improved by chloroquine in combination therapy.
Topics: Acetaminophen; Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance; Dru | 2002 |
Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines.
Topics: Acute Disease; Adolescent; Adult; Antimalarials; Area Under Curve; Child; Chloroquine; Drug Administ | 2002 |
Fansimef for prophylaxis of malaria: a double-blind randomized placebo controlled trial.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Double-Blind Method; Drug Combinations; Humans; Incid | 1992 |
Mefloquine-sulphadoxine-pyrimethamine (Fansimef, Roche) in the prophylaxis of Plasmodium falciparum malaria: a double-blind, comparative, placebo-controlled study.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Double-Blind Method; Drug Combinations; Humans; Malar | 1992 |
Clinical trials of mefloquine with tetracycline.
Topics: Acute Disease; Adolescent; Adult; Chloroquine; Drug Combinations; Drug Resistance; Drug Therapy, Com | 1992 |
Parasitological, clinical and haematological response of children with Plasmodium falciparum to 4-aminoquinolines and to pyrimethamine-sulfadoxine with quinine in western Kenya.
Topics: Amodiaquine; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Drug Therapy, Combinati | 1992 |
Efficacy of dapsone with pyrimethamine (Maloprim) for malaria prophylaxis in Maputo, Mozambique.
Topics: Child; Dapsone; Drug Therapy, Combination; Humans; Malaria, Falciparum; Mozambique; Pyrimethamine | 1992 |
[Self-medication of 193 travelers in the tropics. Recommendations for clinical counseling of tropical travelers and organization of a tropical travel pharmacy].
Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Malaria, Falciparum; Male; Mefloquine; | 1992 |
Evaluation of the relative efficacy of various antimalarial drugs in Nigerian children under five years of age suffering from acute uncomplicated falciparum malaria.
Topics: Acute Disease; Amodiaquine; Antimalarials; Child, Preschool; Chloroquine; Drug Administration Schedu | 1992 |
Malaria chemoprophylaxis using proguanil/dapsone combinations on the Thai-Cambodian border.
Topics: Blood Cells; Cambodia; Dapsone; Doxycycline; Drug Therapy, Combination; Drug Tolerance; Glucosephosp | 1992 |
Development of the new antimalarial drug pyronaridine: a review.
Topics: Administration, Oral; Animals; Antimalarials; Cardiovascular System; Chloroquine; Dogs; Drug Evaluat | 1992 |
Falciparum malaria fully cleared by amodiaquine, pyrimethamine-sulfadoxine and pyrimethamine-sulfalene in areas of chloroquine resistance in Dodoma, Tanzania.
Topics: Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance | 1991 |
Comparison of mefloquine, chloroquine plus pyrimethamine-sulfadoxine (Fansidar), and chloroquine as malarial prophylaxis in eastern Thailand.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Animals; Antimalarials; Cambodia; Chloroquine; Confid | 1991 |
665 other studies available for pyrimethamine and Malaria, Falciparum
| Article | Year |
|---|---|
Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum.
Topics: Animals; Antimalarials; Binding, Competitive; Chlorocebus aethiops; Folic Acid Antagonists; Humans; | 2002 |
High-throughput Plasmodium falciparum growth assay for malaria drug discovery.
Topics: Animals; Biological Assay; Child, Preschool; DNA, Protozoan; Drug Evaluation, Preclinical; Drug Resi | 2007 |
First case of emergence of atovaquone-proguanil resistance in Plasmodium falciparum during treatment in a traveler in Comoros.
Topics: Animals; Antimalarials; Atovaquone; Comoros; Drug Resistance; France; Genotype; Humans; Malaria, Fal | 2008 |
Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes.
Topics: Animals; Antimalarials; Artemisinins; Artesunate; Chloroquine; Disease Models, Animal; Erythrocytes; | 2009 |
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
Topics: Administration, Oral; Animals; Antimalarials; Biological Availability; Drug Resistance; Female; Foli | 2010 |
In vitro efficacy of 7-benzylamino-1-isoquinolinamines against Plasmodium falciparum related to the efficacy of chalcones.
Topics: Aminoquinolines; Antimalarials; Chalcones; Chloroquine; Drug Resistance; Humans; Malaria, Falciparum | 2011 |
Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
Topics: Animals; Anopheles; Antimalarials; Drug Evaluation, Preclinical; Hep G2 Cells; Humans; Inhibitory Co | 2012 |
Synthesis, characterization and antimalarial activity of quinoline-pyrimidine hybrids.
Topics: Animals; Antimalarials; Cell Survival; CHO Cells; Cricetinae; Inhibitory Concentration 50; Malaria, | 2013 |
Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.
Topics: Animals; Antimalarials; Benzimidazoles; Biological Availability; Cell Line, Tumor; Cell Survival; Hi | 2014 |
Synthesis and in vitro evaluation of novel 8-aminoquinoline-pyrazolopyrimidine hybrids as potent antimalarial agents.
Topics: Aminoquinolines; Antimalarials; Humans; Malaria, Falciparum; Molecular Docking Simulation; Parasitic | 2015 |
A Developability-Focused Optimization Approach Allows Identification of in Vivo Fast-Acting Antimalarials: N-[3-[(Benzimidazol-2-yl)amino]propyl]amides.
Topics: Amides; Animals; Antimalarials; Benzamides; Benzimidazoles; Cell Proliferation; Cells, Cultured; Dru | 2015 |
A Novel Pyrazolopyridine with in Vivo Activity in Plasmodium berghei- and Plasmodium falciparum-Infected Mouse Models from Structure-Activity Relationship Studies around the Core of Recently Identified Antimalarial Imidazopyridazines.
Topics: Animals; Antimalarials; Ether-A-Go-Go Potassium Channels; Humans; Liver; Malaria; Malaria, Falciparu | 2015 |
Selective anti-malarial minor groove binders.
Topics: Antimalarials; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Malaria, Falciparum; Molecula | 2016 |
Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria.
Topics: Allosteric Regulation; Animals; Drug Resistance; Electron Transport Complex I; Malaria, Falciparum; | 2017 |
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
Topics: Amides; Animals; Antimalarials; Boron Compounds; Dogs; Female; Humans; Malaria; Malaria, Falciparum; | 2017 |
Green synthesis, biological evaluation, molecular docking studies and 3D-QSAR analysis of novel phenylalanine linked quinazoline-4(3H)-one-sulphonamide hybrid entities distorting the malarial reductase activity in folate pathway.
Topics: Antimalarials; Humans; Malaria, Falciparum; Molecular Docking Simulation; Molecular Structure; Pheny | 2019 |
Synthesis and efficacy of pyrvinium-inspired analogs against tuberculosis and malaria pathogens.
Topics: Antimalarials; Antitubercular Agents; Dose-Response Relationship, Drug; Malaria, Falciparum; Microbi | 2020 |
Discovery and development of 2-aminobenzimidazoles as potent antimalarials.
Topics: Antimalarials; Benzimidazoles; Dose-Response Relationship, Drug; Drug Discovery; HEK293 Cells; Human | 2021 |
Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
Topics: Antimalarials; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Histone Deacetylase 6; H | 2021 |
Discovery and Structure-Activity Relationships of Quinazolinone-2-carboxamide Derivatives as Novel Orally Efficacious Antimalarials.
Topics: Administration, Oral; Animals; Antimalarials; Humans; Malaria, Falciparum; Mice; Molecular Structure | 2021 |
Decreased Susceptibility to Dihydrofolate Reductase Inhibitors Associated With Genetic Polymorphisms in Ugandan Plasmodium falciparum Isolates.
Topics: Antimalarials; Drug Resistance; Folic Acid Antagonists; Humans; Malaria, Falciparum; Plasmodium falc | 2022 |
Risk factors for Plasmodium falciparum infection in pregnant women in Burkina Faso: a community-based cross-sectional survey.
Topics: Adolescent; Adult; Antimalarials; Burkina Faso; Cross-Sectional Studies; Drug Combinations; Female; | 2021 |
High Frequency Mutations in
Topics: Africa; Antimalarials; China; Cross-Sectional Studies; Drug Combinations; Drug Resistance; Humans; M | 2021 |
Modeled Impact of Seasonal Malaria Chemoprevention on District-Level Suspected and Confirmed Malaria Cases in Chad Based on Routine Clinical Data (2013-2018).
Topics: Amodiaquine; Antimalarials; Chad; Chemoprevention; Child, Preschool; Disability-Adjusted Life Years; | 2021 |
New Insights into Antimalarial Chemopreventive Activity of Antifolates.
Topics: Animals; Antimalarials; Drug Resistance; Folic Acid Antagonists; Humans; Malaria, Falciparum; Plasmo | 2022 |
Prevalence of Molecular Markers of Plasmodium Falciparum Resistance to Proguanil and Pyrimethamine in Children with Haemoglobin Phenotypes SS and AA in Benin City, Nigeria.
Topics: Anemia, Sickle Cell; Antimalarials; Drug Combinations; Hemoglobin, Sickle; Humans; Malaria, Falcipar | 2021 |
Identification of polymorphisms in genes associated with drug resistance in Plasmodium falciparum isolates from school-age children in Kinshasa, Democratic Republic of Congo.
Topics: Antimalarials; Child; Democratic Republic of the Congo; Drug Combinations; Drug Resistance; Genetic | 2022 |
Risk of Plasmodium falciparum infection in south-west Burkina Faso: potential impact of expanding eligibility for seasonal malaria chemoprevention.
Topics: Adolescent; Adult; Amodiaquine; Antigens, Protozoan; Antimalarials; Burkina Faso; Child; Child, Pres | 2022 |
Effect of three years' seasonal malaria chemoprevention on molecular markers of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine and amodiaquine in Ouelessebougou, Mali.
Topics: Amodiaquine; Antimalarials; Chemoprevention; Child; Child, Preschool; Cross-Sectional Studies; Drug | 2022 |
Targeted Amplicon Deep Sequencing for Monitoring Antimalarial Resistance Markers in Western Kenya.
Topics: Antimalarials; Child; Chloroquine; Codon; Drug Combinations; Drug Resistance; Folic Acid Antagonists | 2022 |
Intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine and parasite resistance: cross-sectional surveys from antenatal care visit and delivery in rural Ghana.
Topics: Antimalarials; Cross-Sectional Studies; Drug Combinations; Drug Resistance; Female; Ghana; Humans; I | 2022 |
Molecular Markers for Sulfadoxine/Pyrimethamine and Chloroquine Resistance in Plasmodium falciparum in Thailand.
Topics: Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Humans; Malaria, Falciparum; Plasmod | 2022 |
Impact of antimalarial resistance and COVID-19 pandemic on malaria care among pregnant women in Northern Uganda (ERASE): protocol of a prospective observational study.
Topics: Antimalarials; Artemisinins; COVID-19; Drug Combinations; Drug Resistance; Female; Humans; Malaria, | 2022 |
The prevalence of molecular markers of resistance to sulfadoxine-pyrimethamine among pregnant women at first antenatal clinic attendance and delivery in the forest-savannah area of Ghana.
Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Drug Resistance; Female; Forests; Ghana; Humans | 2022 |
Spatiotemporal spread of Plasmodium falciparum mutations for resistance to sulfadoxine-pyrimethamine across Africa, 1990-2020.
Topics: Antimalarials; Bayes Theorem; Drug Combinations; Drug Resistance; Female; Humans; Malaria; Malaria, | 2022 |
Intermittent preventive treatment with Sulphadoxine-Pyrimethamine (IPTp-SP) is associated with protection against sub-microscopic P. falciparum infection in pregnant women during the low transmission dry season in southwestern Cameroon: A Semi - longitudi
Topics: Antimalarials; Birth Weight; Cameroon; Drug Combinations; Female; Humans; Infant, Newborn; Insectici | 2022 |
Molecular surveillance for anti-malarial drug resistance and genetic diversity of Plasmodium falciparum after chloroquine and sulfadoxine-pyrimethamine withdrawal in Quibdo, Colombia, 2018.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Chloroquine; Codon; Colombia; | 2022 |
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Chloroquine; Ghana; Humans; Lu | 2022 |
Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine-pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study.
Topics: Amodiaquine; Antimalarials; Chemoprevention; Child; Drug Combinations; Drug Resistance; Genomics; Ha | 2023 |
Ten-year persistence and evolution of Plasmodium falciparum antifolate and anti-sulfonamide resistance markers pfdhfr and pfdhps in three Asian countries.
Topics: Antimalarials; Dihydropteroate Synthase; DNA Copy Number Variations; Drug Combinations; Drug Resista | 2022 |
Ten-year persistence and evolution of Plasmodium falciparum antifolate and anti-sulfonamide resistance markers pfdhfr and pfdhps in three Asian countries.
Topics: Antimalarials; Dihydropteroate Synthase; DNA Copy Number Variations; Drug Combinations; Drug Resista | 2022 |
Ten-year persistence and evolution of Plasmodium falciparum antifolate and anti-sulfonamide resistance markers pfdhfr and pfdhps in three Asian countries.
Topics: Antimalarials; Dihydropteroate Synthase; DNA Copy Number Variations; Drug Combinations; Drug Resista | 2022 |
Ten-year persistence and evolution of Plasmodium falciparum antifolate and anti-sulfonamide resistance markers pfdhfr and pfdhps in three Asian countries.
Topics: Antimalarials; Dihydropteroate Synthase; DNA Copy Number Variations; Drug Combinations; Drug Resista | 2022 |
Molecular surveillance of anti-malarial drug resistance genes in Plasmodium falciparum isolates in Odisha, India.
Topics: Antimalarials; Artesunate; Chloroquine; Drug Combinations; Drug Resistance; Humans; India; Malaria, | 2022 |
Distinct pattern and prevalence of
Topics: Antimalarials; Cross-Sectional Studies; Dihydropteroate Synthase; Drug Combinations; Drug Resistance | 2022 |
Effect of sulfadoxine-pyrimethamine chemoprophylaxis in pregnant women on selection of the new P. falciparum dhps quintuple mutant carrying the I431V mutation.
Topics: Antimalarials; Cameroon; Chemoprevention; Child; Child, Preschool; Dihydropteroate Synthase; Drug Co | 2023 |
Baseline prevalence of molecular marker of sulfadoxine/pyrimethamine resistance in Ebonyi and Osun states, Nigeria: amplicon deep sequencing of dhps-540.
Topics: Antimalarials; Biomarkers; Child; Child, Preschool; Dihydropteroate Synthase; Drug Combinations; Dru | 2023 |
Comparative efficacy of sulphadoxine-pyrimethamine and dihydroartemisinin-piperaquine against malaria infection during late-stage pregnancy in mice.
Topics: Animals; Antimalarials; Drug Combinations; Drug Therapy, Combination; Female; Malaria; Malaria, Falc | 2023 |
Molecular Markers of Sulfadoxine-Pyrimethamine Resistance in Samples from Children with Uncomplicated Plasmodium falciparum at Three Sites in Angola in 2019.
Topics: Angola; Antimalarials; Child; Drug Combinations; Drug Resistance; Female; Humans; Malaria, Falciparu | 2023 |
Population dynamics and drug resistance mutations in Plasmodium falciparum on the Bijagós Archipelago, Guinea-Bissau.
Topics: Antimalarials; Drug Combinations; Drug Resistance; Folic Acid Antagonists; Guinea-Bissau; Humans; Ma | 2023 |
Susceptibility of Southeast Asian Plasmodium falciparum isolates to P218.
Topics: Antimalarials; Artemisinins; Drug Resistance; Folic Acid Antagonists; Humans; Malaria, Falciparum; P | 2023 |
High burden of asymptomatic malaria and anaemia despite high adherence to malaria control measures: a cross-sectional study among pregnant women across two seasons in a malaria-endemic setting in Ghana.
Topics: Anemia; Antimalarials; Cross-Sectional Studies; Female; Ghana; Humans; Infant, Newborn; Malaria; Mal | 2023 |
Polymorphism analysis of drug resistance markers in Plasmodium falciparum isolates from Benin.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Benin; Drug Combinations; Drug | 2023 |
Drug resistance profiling of asymptomatic and low-density Plasmodium falciparum malaria infections on Ngodhe island, Kenya, using custom dual-indexing next-generation sequencing.
Topics: Antimalarials; Drug Combinations; Drug Resistance; Female; High-Throughput Nucleotide Sequencing; Hu | 2023 |
Plasmodium falciparum drug resistance-associated mutations in isolates from children living in endemic areas of Burkina Faso.
Topics: Antimalarials; Burkina Faso; Child; Codon; Drug Combinations; Drug Resistance; Female; Humans; Malar | 2023 |
Peripheral and Placental Prevalence of Sulfadoxine-Pyrimethamine Resistance Markers in Plasmodium falciparum among Pregnant Women in Southern Province, Rwanda.
Topics: Antimalarials; Birth Weight; Drug Combinations; Drug Resistance; Female; Humans; Malaria; Malaria, F | 2023 |
Fixed prevalence of sulfadoxine-pyrimethamine resistance markers after 3 years of drug pressure.
Topics: Antimalarials; Drug Combinations; Drug Resistance; Humans; Malaria, Falciparum; Plasmodium falciparu | 2023 |
Prevalence of molecular markers of resistance to sulfadoxine-pyrimethamine before and after community delivery of intermittent preventive treatment of malaria in pregnancy in sub-Saharan Africa: a multi-country evaluation.
Topics: Antimalarials; Biomarkers; Child; Child, Preschool; Cross-Sectional Studies; Drug Combinations; Drug | 2023 |
Effect of Seasonal Malaria Chemoprevention on Immune Markers of Exhaustion and Regulation.
Topics: Amodiaquine; Antigens, CD; Antimalarials; Biomarkers; CD4-Positive T-Lymphocytes; Child, Preschool; | 2020 |
The changing landscape of Plasmodium falciparum drug resistance in the Democratic Republic of Congo.
Topics: Adolescent; Adult; Alcohol Dehydrogenase; Antimalarials; Chloroquine; Cross-Sectional Studies; Democ | 2019 |
Widespread resistance mutations to sulfadoxine-pyrimethamine in malaria parasites imported to China from Central and Western Africa.
Topics: Adolescent; Adult; Africa, Central; Africa, Western; Antimalarials; China; Cohort Studies; Communica | 2020 |
Antimalarial Drug Resistance Profiling of Plasmodium falciparum Infections in Ghana Using Molecular Inversion Probes and Next-Generation Sequencing.
Topics: Adolescent; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Combinations; Dr | 2020 |
Molecular characterization of Plasmodium falciparum antifolate resistance markers in Thailand between 2008 and 2016.
Topics: Antimalarials; Cambodia; DNA, Protozoan; Dried Blood Spot Testing; Drug Combinations; Drug Resistanc | 2020 |
Nationwide Monitoring for Plasmodium falciparum Drug-Resistance Alleles to Chloroquine, Sulfadoxine, and Pyrimethamine, Haiti, 2016-2017.
Topics: Alleles; Antimalarials; Chloroquine; Drug Resistance; Haiti; Humans; Malaria, Falciparum; Mutation; | 2020 |
The impact of antimalarial resistance on the genetic structure of Plasmodium falciparum in the DRC.
Topics: Antimalarials; Chloroquine; Democratic Republic of the Congo; Drug Combinations; Drug Resistance; Ge | 2020 |
Prevalence of pfdhfr and pfdhps mutations in Plasmodium falciparum associated with drug resistance among pregnant women receiving IPTp-SP at Msambweni County Referral Hospital, Kwale County, Kenya.
Topics: Adult; Antimalarials; Drug Combinations; Drug Resistance; Female; Genetic Markers; Humans; Kenya; Ma | 2020 |
Occurrence of septuple and elevated Pfdhfr-Pfdhps quintuple mutations in a general population threatens the use of sulfadoxine-pyrimethamine for malaria prevention during pregnancy in eastern-coast of Tanzania.
Topics: Antimalarials; Dihydropteroate Synthase; DNA, Protozoan; Drug Combinations; Drug Resistance, Microbi | 2020 |
Modelling the incremental benefit of introducing malaria screening strategies to antenatal care in Africa.
Topics: Antimalarials; Drug Combinations; Female; Health Policy; Humans; Malaria, Falciparum; Mass Screening | 2020 |
Stable high frequencies of sulfadoxine-pyrimethamine resistance associated mutations and absence of K13 mutations in Plasmodium falciparum 3 and 4 years after the introduction of artesunate plus sulfadoxine-pyrimethamine in Ujjain, Madhya Pradesh, India.
Topics: Adolescent; Adult; Aged; Antimalarials; Artesunate; Child; Child, Preschool; Drug Combinations; Drug | 2020 |
Antibodies to full-length and the DBL5 domain of VAR2CSA in pregnant women after long-term implementation of intermittent preventive treatment in Etoudi, Cameroon.
Topics: Adult; Antibodies, Protozoan; Antigens, Protozoan; Antimalarials; Cameroon; Drug Combinations; Femal | 2020 |
Analysis of sulphadoxine-pyrimethamine resistance-associated mutations in Plasmodium falciparum isolates obtained from asymptomatic pregnant women in Ogun State, Southwest Nigeria.
Topics: Adult; Antimalarials; Dihydropteroate Synthase; Drug Combinations; Drug Resistance; Female; Genotype | 2020 |
Suboptimal Intermittent Preventive Treatment in Pregnancy (IPTp) is Associated With an Increased Risk of Submicroscopic Plasmodium falciparum Infection in Pregnant Women: A Prospective Cohort Study in Benin.
Topics: Antimalarials; Benin; Drug Combinations; Female; Humans; Infant, Newborn; Malaria, Falciparum; Plasm | 2021 |
Establishing a National Molecular Surveillance Program for the Detection of
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Dru | 2020 |
Surveillance of molecular markers for antimalarial resistance in Zambia: Polymorphism of Pfkelch 13, Pfmdr1 and Pfdhfr/Pfdhps genes.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Cross-Sectional Studies; Dihydropteroate S | 2020 |
A snapshot of Plasmodium falciparum malaria drug resistance markers in Sudan: a pilot study.
Topics: Antimalarials; Drug Combinations; Drug Resistance; Humans; Malaria, Falciparum; Pilot Projects; Plas | 2020 |
Prevalence and factors associated with carriage of Pfmdr1 polymorphisms among pregnant women receiving intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) and artemether-lumefantrine for malaria treatment in Burkina Faso.
Topics: Adolescent; Adult; Artemether, Lumefantrine Drug Combination; Burkina Faso; Carrier State; Drug Comb | 2020 |
Topics: Antimalarials; Drug Combinations; Female; Humans; Kenya; Malaria, Falciparum; Mali; Nigeria; Plasmod | 2020 |
Molecular surveillance of anti-malarial resistance Pfdhfr and Pfdhps polymorphisms in African and Southeast Asia Plasmodium falciparum imported parasites to Wuhan, China.
Topics: Africa; Antimalarials; Asia, Southeastern; China; Communicable Diseases, Imported; Drug Combinations | 2020 |
Increased prevalence of pfdhfr and pfdhps mutations associated with sulfadoxine-pyrimethamine resistance in Plasmodium falciparum isolates from Jazan Region, Southwestern Saudi Arabia: important implications for malaria treatment policy.
Topics: Adolescent; Adult; Antimalarials; Cross-Sectional Studies; Dihydropteroate Synthase; Drug Combinatio | 2020 |
Assessment of antimalarial drug resistant markers in asymptomatic Plasmodium falciparum infections after 4 years of indoor residual spraying in Northern Ghana.
Topics: Amodiaquine; Antimalarials; Biomarkers, Pharmacological; Carrier State; Child, Preschool; Chloroquin | 2020 |
Multiple Single-Nucleotide Polymorphism Detection for Antimalarial Pyrimethamine Resistance via Allele-Specific PCR Coupled with Gold Nanoparticle-Based Lateral Flow Biosensor.
Topics: Alleles; Antimalarials; Biosensing Techniques; DNA Primers; Drug Resistance; Gold; Humans; Malaria, | 2021 |
Evidence that seasonal malaria chemoprevention with SPAQ influences blood and pre-erythrocytic stage antibody responses of Plasmodium falciparum infections in Niger.
Topics: Amodiaquine; Antibodies, Protozoan; Antibody Formation; Antimalarials; Chemoprevention; Child, Presc | 2021 |
High Prevalence of Molecular Markers of Plasmodium falciparum Resistance to Sulphadoxine-Pyrimethamine in Parts of Ghana: A Threat to ITPTp-SP?
Topics: Antimalarials; Drug Combinations; Drug Resistance; Female; Ghana; Humans; Malaria, Falciparum; Plasm | 2021 |
Polymorphisms in Plasmodium falciparum dihydropteroate synthetase and dihydrofolate reductase genes in Nigerian children with uncomplicated malaria using high-resolution melting technique.
Topics: Antigens, Protozoan; Antimalarials; Child, Preschool; Dihydropteroate Synthase; Drug Combinations; D | 2021 |
Sulfadoxine-pyrimethamine parasitological efficacy against Plasmodium falciparum among pregnant women and molecular markers of resistance in Zambia: an observational cohort study.
Topics: Adult; Antimalarials; Cohort Studies; Drug Combinations; Female; Genetic Markers; Humans; Malaria, F | 2021 |
Low prevalence of highly sulfadoxine-resistant dihydropteroate synthase alleles in Plasmodium falciparum isolates in Benin.
Topics: Alleles; Antimalarials; Benin; Child, Preschool; Dihydropteroate Synthase; Drug Combinations; Drug R | 2021 |
Predictors for the uptake of optimal doses of sulfadoxine-pyrimethamine for intermittent preventive treatment of malaria during pregnancy in Tanzania: further analysis of the data of the 2015-2016 Tanzania demographic and health survey and malaria indicat
Topics: Adolescent; Adult; Antimalarials; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Co | 2021 |
Reduced Birth Weight Caused by Sextuple Drug-Resistant Plasmodium falciparum Infection in Early Second Trimester.
Topics: Adult; Antimalarials; Birth Weight; Drug Combinations; Drug Resistance; Female; Humans; Infant, Newb | 2021 |
Transgenic pyrimethamine-resistant plasmodium falciparum reveals transmission-blocking potency of P218, a novel antifolate candidate drug.
Topics: Animals; Antimalarials; Drug Resistance; Folic Acid Antagonists; Humans; Malaria, Falciparum; Male; | 2021 |
Temporal evolution of sulfadoxine-pyrimethamine resistance genotypes and genetic diversity in response to a decade of increased interventions against Plasmodium falciparum in northern Ghana.
Topics: Adolescent; Antimalarials; Child; Child, Preschool; Drug Combinations; Drug Resistance; Female; Gene | 2021 |
Malaria Infection Is Common and Associated With Perinatal Mortality and Preterm Delivery Despite Widespread Use of Chemoprevention in Mali: An Observational Study 2010 to 2014.
Topics: Antimalarials; Chemoprevention; Drug Combinations; Female; Humans; Infant, Newborn; Longitudinal Stu | 2021 |
Intermittent preventive treatment comparing two versus three doses of sulphadoxine pyrimethamine (IPTp-SP) in the prevention of anaemia in pregnancy in Ghana: A cross-sectional study.
Topics: Adult; Anemia; Antimalarials; Cross-Sectional Studies; Drug Combinations; Educational Status; Female | 2021 |
Artemisinin combination therapy fails even in the absence of Plasmodium falciparum kelch13 gene polymorphism in Central India.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Drug Resistance; Drug Therapy, Combination; Female; | 2021 |
Evaluation of the usefulness of intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine in a context with increased resistance of Plasmodium falciparum in Kingasani Hospital, Kinshasa in the Democratic Republic of Congo.
Topics: Adolescent; Adult; Antimalarials; Democratic Republic of the Congo; Drug Combinations; Drug Resistan | 2021 |
Herbicidal properties of antimalarial drugs.
Topics: Antimalarials; Arabidopsis; Herbicides; Humans; Malaria, Falciparum; Plasmodium falciparum; Proguani | 2017 |
Increase in the prevalence of mutations associated with sulfadoxine-pyrimethamine resistance in Plasmodium falciparum isolates collected from early to late pregnancy in Nanoro, Burkina Faso.
Topics: Adolescent; Adult; Antimalarials; Burkina Faso; Child; Child, Preschool; Cross-Sectional Studies; Dr | 2017 |
IgG isotypic antibodies to crude Plasmodium falciparum blood-stage antigen associated with placental malaria infection in parturient Cameroonian women.
Topics: Adolescent; Adult; Age Factors; Antibodies, Protozoan; Antigens, Protozoan; Cameroon; Drug Combinati | 2016 |
Polymorphisms in pfdhfr and pfdhps genes after five years of artemisinin combination therapy (ACT) implementation from urban Kolkata, India.
Topics: Adult; Antimalarials; Artemisinins; Child; Cities; Dihydropteroate Synthase; Drug Combinations; Drug | 2017 |
Clinical and molecular monitoring of Plasmodium falciparum resistance to antimalarial drug (artesunate+sulphadoxine-pyrimethamine) in two highly malarious district of Madhya Pradesh, Central India from 2012-2014.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Artesunate; Child; Child, P | 2017 |
Surveillance for sulfadoxine-pyrimethamine resistant malaria parasites in the Lake and Southern Zones, Tanzania, using pooling and next-generation sequencing.
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Child, Preschool; Cross-Sectional Studies; Drug Combi | 2017 |
Pooled-DNA sequencing identifies genomic regions of selection in Nigerian isolates of Plasmodium falciparum.
Topics: Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Gene Frequency; Genetic Variation; H | 2017 |
Optimal antimalarial dose regimens for chloroquine in pregnancy based on population pharmacokinetic modelling.
Topics: Adult; Antimalarials; Chloroquine; Drug Combinations; Female; Humans; Malaria, Falciparum; Metabolic | 2017 |
Presence of quintuple dhfr N51, C59, S108 - dhps A437, K540 mutations in Plasmodium falciparum isolates from pregnant women and the general population in Nanoro, Burkina Faso.
Topics: Adolescent; Adult; Amino Acid Substitution; Antimalarials; Burkina Faso; Child; Child, Preschool; Dr | 2017 |
Mathematical model for the spread of drug resistance in Plasmodium falciparum parasite considering transmission conditions.
Topics: Animals; Antimalarials; Computer Simulation; Culicidae; Disease Eradication; Drug Resistance; Humans | 2017 |
Impact of Intermittent Preventive Treatment During Pregnancy on Plasmodium falciparum Drug Resistance-Mediating Polymorphisms in Uganda.
Topics: Antimalarials; Artemisinins; Drug Combinations; Drug Resistance; Female; Humans; Malaria, Falciparum | 2017 |
Antifolate drug resistance: Novel mutations and haplotype distribution in
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Contraindications, Drug; Di | 2017 |
Molecular identification of sulfadoxine-pyrimethamine resistance in malaria infected women who received intermittent preventive treatment in the Democratic Republic of Congo.
Topics: Adolescent; Adult; Amino Acid Substitution; Antimalarials; Democratic Republic of the Congo; Dihydro | 2018 |
High prevalence of dihydrofolate reductase gene mutations in Plasmodium falciparum parasites among pregnant women in Nigeria after reported use of sulfadoxine-pyrimethamine.
Topics: Adolescent; Adult; Animals; Antimalarials; Asymptomatic Diseases; Cross-Sectional Studies; Drug Comb | 2018 |
Prevalence of the Pfdhfr and Pfdhps mutations among asymptomatic pregnant women in Southeast Nigeria.
Topics: Adult; Antimalarials; Drug Combinations; Female; Genotype; Humans; Malaria, Falciparum; Mutation; Mu | 2018 |
Population Pharmacokinetic Properties of Sulfadoxine and Pyrimethamine: a Pooled Analysis To Inform Optimal Dosing in African Children with Uncomplicated Malaria.
Topics: Africa; Age Factors; Amodiaquine; Antimalarials; Biomarkers, Pharmacological; Body Weight; Chemoprev | 2018 |
Molecular markers of resistance to amodiaquine plus sulfadoxine-pyrimethamine in an area with seasonal malaria chemoprevention in south central Niger.
Topics: Amodiaquine; Antimalarials; Chemoprevention; Child, Preschool; Dihydropteroate Synthase; Drug Combin | 2018 |
Prevalence of Low Birth Weight before and after Policy Change to IPTp-SP in Two Selected Hospitals in Southern Nigeria: Eleven-Year Retrospective Analyses.
Topics: Adult; Drug Combinations; Female; Gravidity; Humans; Infant, Low Birth Weight; Infant, Newborn; Mala | 2018 |
Molecular Markers of
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Cross-Sectional Studies; Dru | 2018 |
Additional Screening and Treatment of Malaria During Pregnancy Provides Further Protection Against Malaria and Nonmalarial Fevers During the First Year of Life.
Topics: Adult; Antimalarials; Burkina Faso; Cohort Studies; Drug Combinations; Female; Humans; Incidence; In | 2018 |
Malaria-related ideational factors and other correlates associated with intermittent preventive treatment among pregnant women in Madagascar.
Topics: Adult; Antimalarials; Cross-Sectional Studies; Drug Combinations; Female; Humans; Madagascar; Malari | 2018 |
Spatio-temporal distribution of PfMDR1 polymorphism among uncomplicated Plasmodium falciparum malaria cases along international border of north east India.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Bangladesh; Chloroquine; Dru | 2018 |
Prevalence of Plasmodium falciparum parasites resistant to sulfadoxine/pyrimethamine in the Democratic Republic of the Congo: emergence of highly resistant pfdhfr/pfdhps alleles.
Topics: Adolescent; Adult; Alleles; Ambulatory Care Facilities; Antimalarials; Child; Child, Preschool; Demo | 2018 |
RETROSPECTIVE INVESTIGATION OF PYRIMETHAMINE-SULFADOXINE RESISTANCE INDICATORS IN FALCIPARUM-MALARIA POSITIVE BLOOD SAMPLES FROM SOUTH-WESTERN SAUDI ARABIA.
Topics: Alleles; Codon; DNA, Protozoan; Drug Combinations; Drug Resistance; Genotype; Humans; Malaria, Falci | 2016 |
Dynamics of Plasmodium falciparum gametocyte carriage in pregnant women under intermittent preventive treatment with sulfadoxine-pyrimethamine in Benin.
Topics: Adolescent; Adult; Antigens, Protozoan; Antimalarials; Benin; Drug Combinations; Female; Humans; Mal | 2018 |
Intermittent Preventive Treatment (IPT): Its Role in Averting Disease-Induced Mortality in Children and in Promoting the Spread of Antimalarial Drug Resistance.
Topics: Antimalarials; Basic Reproduction Number; Child; Computer Simulation; Drug Administration Schedule; | 2019 |
Molecular Evidence for
Topics: Adolescent; Adult; Aged; Alleles; Antimalarials; Artemisinins; Artesunate; Child; Dihydropteroate Sy | 2018 |
A decade since sulfonamide-based anti-malarial medicines were limited for intermittent preventive treatment of malaria among pregnant women in Tanzania.
Topics: Antimalarials; Clinical Competence; Cross-Sectional Studies; Drug Combinations; Female; Humans; Mala | 2018 |
Has doxycycline, in combination with anti-malarial drugs, a role to play in intermittent preventive treatment of Plasmodium falciparum malaria infection in pregnant women in Africa?
Topics: Africa; Antimalarials; Artemisinins; Doxycycline; Drug Combinations; Female; Humans; Malaria, Falcip | 2018 |
Trends in comparative efficacy and safety of malaria control interventions for maternal and child health outcomes in Africa: a study protocol for a Bayesian network meta-regression exploring the effect of HIV and malaria endemicity spectrum.
Topics: Africa South of the Sahara; Antimalarials; Bayes Theorem; Child Health; Child, Preschool; Clinical P | 2019 |
High prevalence of Pfdhfr-Pfdhps quadruple mutations associated with sulfadoxine-pyrimethamine resistance in Plasmodium falciparum isolates from Bioko Island, Equatorial Guinea.
Topics: Antimalarials; Dihydropteroate Synthase; Drug Combinations; Drug Resistance; Equatorial Guinea; Gene | 2019 |
Absence of K13 gene mutations among artesunate/sulfadoxine-pyrimethamine treatment failures of Sudanese Plasmodium falciparum isolates from Damazin, southeast Sudan.
Topics: Antimalarials; Artemisinins; Drug Resistance, Multiple; Humans; Malaria, Falciparum; Plasmodium falc | 2019 |
An analysis of large structural variation in global Plasmodium falciparum isolates identifies a novel duplication of the chloroquine resistance associated gene.
Topics: Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Gene Deletion; Gene Duplication; Gen | 2019 |
Evolution of Plasmodium falciparum drug resistance genes following artemisinin combination therapy in Sudan.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Artesunate; Chloroquine; DNA, Protozoan; Drug | 2019 |
High prevalence of asymptomatic malaria in a tribal population in eastern India.
Topics: Antimalarials; Artemisinins; Asymptomatic Infections; Base Sequence; Drug Combinations; Drug Resista | 2013 |
Malaria control aimed at the entire population in KwaZulu-Natal negates the need for policies to prevent malaria in pregnancy.
Topics: Adolescent; Adult; Antimalarials; Communicable Disease Control; Drug Combinations; Female; Humans; I | 2013 |
Prevalence of antifolate resistance mutations in Plasmodium falciparum isolates in Afghanistan.
Topics: Adult; Afghanistan; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; DNA, Protozoan | 2013 |
Weighing for results: assessing the effect of IPTp - authors' reply.
Topics: Animals; Antimalarials; Female; Humans; Infant, Low Birth Weight; Malaria, Falciparum; Plasmodium fa | 2013 |
Weighing for results: assessing the effect of IPTp.
Topics: Animals; Antimalarials; Female; Humans; Infant, Low Birth Weight; Malaria, Falciparum; Plasmodium fa | 2013 |
Selection of antimalarial drug resistance after intermittent preventive treatment of infants and children (IPTi/c) in Senegal.
Topics: Antimalarials; Artemisinins; Artesunate; Child, Preschool; Cross-Sectional Studies; DNA, Protozoan; | 2013 |
Prevalence of molecular markers of drug resistance in an area of seasonal malaria chemoprevention in children in Senegal.
Topics: Amodiaquine; Antimalarials; Chemoprevention; Child; Child, Preschool; Drug Combinations; Drug Resist | 2013 |
Prevalence of the molecular marker of Plasmodium falciparum resistance to chloroquine and sulphadoxine/pyrimethamine in Benin seven years after the change of malaria treatment policy.
Topics: Adolescent; Antimalarials; Benin; Blood; Child; Child, Preschool; Chloroquine; DNA, Protozoan; Drug | 2013 |
Changing the malaria treatment protocol policy in Timor-Leste: an examination of context, process, and actors' involvement.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Clinical Protocols; Cooperat | 2013 |
Saving babies' lives by antenatal malaria prevention.
Topics: Animals; Antimalarials; Female; Humans; Infant, Low Birth Weight; Malaria, Falciparum; Plasmodium fa | 2013 |
Haplotypes associated with resistance to sulfadoxine-pyrimethamine in Plasmodium falciparum in two malaria endemic locations in Colombia.
Topics: Adult; Antimalarials; Colombia; Dihydropteroate Synthase; Drug Combinations; Drug Resistance; Endemi | 2013 |
Identification and functional analysis of the primary pantothenate transporter, PfPAT, of the human malaria parasite Plasmodium falciparum.
Topics: Amino Acid Sequence; Animals; Antimalarials; Cell Membrane; Chloroquine; Drug Resistance; Erythrocyt | 2013 |
High rates of parasite recrudescence following intermittent preventive treatment with sulphadoxine-pyrimethamine during pregnancy in Benin.
Topics: Adolescent; Adult; Antimalarials; Benin; Dihydropteroate Synthase; Drug Combinations; Female; Haplot | 2013 |
Population genetics analysis during the elimination process of Plasmodium falciparum in Djibouti.
Topics: Antimalarials; Disease Eradication; Djibouti; DNA, Protozoan; Drug Resistance; Genetic Variation; Ge | 2013 |
Malaria risk factors in women on intermittent preventive treatment at delivery and their effects on pregnancy outcome in Sanaga-Maritime, Cameroon.
Topics: Adolescent; Adult; Antimalarials; Cameroon; Drug Combinations; Female; Fetus; Humans; Infant, Newbor | 2013 |
Effectiveness of intermittent preventive treatment with sulfadoxine-pyrimethamine during pregnancy on maternal and birth outcomes in Machinga district, Malawi.
Topics: Adult; Antimalarials; Dose-Response Relationship, Drug; Drug Combinations; Female; HIV Infections; H | 2013 |
Selection of pfdhfr/pfdhps alleles and declining artesunate/sulphadoxine-pyrimethamine efficacy against Plasmodium falciparum eight years after deployment in eastern Sudan.
Topics: Adolescent; Adult; Aged; Artemisinins; Child; Child, Preschool; DNA, Protozoan; Drug Resistance; Fem | 2013 |
[Prevalence of Plasmodium falciparum, anemia and molecular markers of chloroquine and sulfadoxine-pyriméthamine resistance in delivered women in Fana, Mali].
Topics: Adolescent; Adult; Anemia; Chloroquine; Delivery, Obstetric; Drug Combinations; Drug Resistance; Fem | 2013 |
Ordered accumulation of mutations conferring resistance to sulfadoxine-pyrimethamine in the Plasmodium falciparum parasite.
Topics: Amino Acid Sequence; Antimalarials; Dihydropteroate Synthase; Drug Combinations; Drug Resistance; Ev | 2014 |
Trends in antimalarial drug use in Africa.
Topics: Africa; Antimalarials; Artemisinins; Chloroquine; Drug Combinations; Drug Resistance; Health Surveys | 2013 |
Prevalence of sulfadoxine-pyrimethamine resistance-associated mutations in dhfr and dhps genes of Plasmodium falciparum three years after SP withdrawal in Bahir Dar, Northwest Ethiopia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiprotozoal Agents; Child; Child, Preschool; Dihydropt | 2013 |
Low prevalence of the molecular markers of Plasmodium falciparum resistance to chloroquine and sulphadoxine/pyrimethamine in asymptomatic children in Northern Benin.
Topics: Adolescent; Animals; Antimalarials; Benin; Child; Child, Preschool; Chloroquine; DNA, Protozoan; Dru | 2013 |
Prevailing Plasmodium falciparum dihydrofolate reductase 108-asparagine in Hodeidah, Yemen: a questionable sulfadoxine-pyrimethamine partner within the artemisinin-based combination therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Asparagine; Child; Child, P | 2014 |
Submicroscopic infections among children with adequate clinical and parasitological response (ACPR).
Topics: Amodiaquine; Antimalarials; Artemisinins; Blood; Child; Child, Preschool; DNA, Protozoan; Drug Combi | 2014 |
Molecular analysis of chloroquine and sulfadoxine-pyrimethamine resistance-associated alleles in Plasmodium falciparum isolates from Nicaragua.
Topics: Alleles; Antimalarials; Chloroquine; Dihydropteroate Synthase; DNA, Protozoan; Drug Combinations; Dr | 2014 |
Origin of robustness in generating drug-resistant malaria parasites.
Topics: Amino Acid Substitution; Antimalarials; Biological Evolution; Drug Resistance; Epistasis, Genetic; G | 2014 |
High levels of sulphadoxine-pyrimethamine resistance Pfdhfr-Pfdhps quintuple mutations: a cross sectional survey of six regions in Tanzania.
Topics: Adult; Antimalarials; Child; Cross-Sectional Studies; Dihydropteroate Synthase; Drug Combinations; D | 2014 |
A cohort study of Plasmodium falciparum malaria in pregnancy and associations with uteroplacental blood flow and fetal anthropometrics in Kenya.
Topics: Adult; Anthropometry; Antimalarials; Cohort Studies; Drug Combinations; Female; Fetal Development; H | 2014 |
Temporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in Uganda.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Child, Preschool; Chl | 2014 |
Placental malaria is rare among Zanzibari pregnant women who did not receive intermittent preventive treatment in pregnancy.
Topics: Adolescent; Adult; Antimalarials; Dried Blood Spot Testing; Drug Administration Schedule; Drug Combi | 2014 |
Efficacy of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy, Mansa, Zambia.
Topics: Adolescent; Adult; Animals; Antimalarials; Drug Combinations; Drug Resistance; Drug Therapy, Combina | 2014 |
Effectiveness of intermittent preventive treatment with sulfadoxine-pyrimethamine during pregnancy on placental malaria, maternal anaemia and birthweight in areas with high and low malaria transmission intensity in Tanzania.
Topics: Adult; Anemia; Antimalarials; Birth Weight; Drug Combinations; Female; Humans; Infant, Low Birth Wei | 2014 |
Declining efficacy of artesunate plus sulphadoxine-pyrimethamine in northeastern India.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Drug Combinatio | 2014 |
Molecular evidence of increased resistance to anti-folate drugs in Plasmodium falciparum in North-East India: a signal for potential failure of artemisinin plus sulphadoxine-pyrimethamine combination therapy.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Codon; Drug Co | 2014 |
Two novel mutations of pfdhps K540T and I588F, affecting sulphadoxine-pyrimethamine-resistant response in uncomplicated falciparum malaria at Banjar district, South Kalimantan Province, Indonesia.
Topics: Adolescent; Adult; Amino Acid Substitution; Dihydropteroate Synthase; Drug Combinations; Female; Gen | 2014 |
Prevalence and risk factors for Plasmodium falciparum malaria in pregnant women attending antenatal clinic in Bobo-Dioulasso (Burkina Faso).
Topics: Adolescent; Adult; Age Factors; Anemia; Antimalarials; Burkina Faso; Cross-Sectional Studies; Drug C | 2014 |
Coverage and efficacy of intermittent preventive treatment with sulphadoxine pyrimethamine against malaria in pregnancy in Côte d'Ivoire five years after its implementation.
Topics: Adolescent; Adult; Antimalarials; Blood; Chemoprevention; Cote d'Ivoire; Cross-Sectional Studies; Dr | 2014 |
The A581G Mutation in the Gene Encoding Plasmodium falciparum Dihydropteroate Synthetase Reduces the Effectiveness of Sulfadoxine-Pyrimethamine Preventive Therapy in Malawian Pregnant Women.
Topics: Dihydropteroate Synthase; DNA, Protozoan; Drug Combinations; Drug Resistance; Female; Genotype; Huma | 2015 |
Treatment of uncomplicated malaria with artesunate plus sulfadoxine-pyrimethamine is failing in Somalia: evidence from therapeutic efficacy studies and Pfdhfr and Pfdhps mutant alleles.
Topics: Adolescent; Adult; Age Factors; Alleles; Antimalarials; Artemisinins; Child; Child, Preschool; Dihyd | 2015 |
High prevalence of pfdhfr-pfdhps triple mutations associated with anti-malarial drugs resistance in Plasmodium falciparum isolates seven years after the adoption of sulfadoxine-pyrimethamine in combination with artesunate as first-line treatment in Iran.
Topics: Adolescent; Adult; Alcohol Dehydrogenase; Antimalarials; Artemisinins; Child; Child, Preschool; Codo | 2015 |
Persistence of Sulfadoxine-Pyrimethamine Resistance Despite Reduction of Drug Pressure in Malawi.
Topics: Antimalarials; Dihydropteroate Synthase; DNA, Protozoan; Drug Combinations; Drug Resistance; Gene Fr | 2015 |
Evaluation of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy: a retrospective birth outcomes study in Mansa, Zambia.
Topics: Adolescent; Adult; Antimalarials; Cohort Studies; Dose-Response Relationship, Drug; Drug Combination | 2015 |
Increasing prevalence of a novel triple-mutant dihydropteroate synthase genotype in Plasmodium falciparum in western Kenya.
Topics: Adult; Antimalarials; Child; Child, Preschool; Dihydropteroate Synthase; Drug Combinations; Drug Res | 2015 |
High prevalence of sulphadoxine-pyrimethamine resistance-associated mutations in Plasmodium falciparum field isolates from pregnant women in Brazzaville, Republic of Congo.
Topics: Adolescent; Adult; Alleles; Antimalarials; Congo; Drug Combinations; Drug Resistance; Female; Gene F | 2015 |
High prevalence of dhfr and dhps molecular markers in Plasmodium falciparum in pregnant women of Nchelenge district, Northern Zambia.
Topics: Adult; Antimalarials; Cross-Sectional Studies; Dihydropteroate Synthase; Drug Combinations; Drug Res | 2015 |
Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women.
Topics: Adolescent; Adult; Antimalarials; Area Under Curve; Artemisinins; Biological Availability; Dietary F | 2015 |
Use of bacterial surrogates as a tool to explore antimalarial drug interaction: Synergism between inhibitors of malarial dihydrofolate reductase and dihydropteroate synthase.
Topics: Antimalarials; Dapsone; Dihydropteroate Synthase; Drug Interactions; Drug Resistance; Drug Synergism | 2015 |
Prevalence of Plasmodium falciparum parasites resistant to sulfadoxine/pyrimethamine in pregnant women in Yaoundé, Cameroon: emergence of highly resistant pfdhfr/pfdhps alleles.
Topics: Adult; Antimalarials; Cameroon; Dihydropteroate Synthase; Drug Combinations; Drug Resistance; Female | 2015 |
Changing Malaria Prevalence on the Kenyan Coast since 1974: Climate, Drugs and Vector Control.
Topics: Adolescent; Adult; Aged; Antimalarials; Bayes Theorem; Child; Child, Preschool; Chloroquine; Climate | 2015 |
Monitoring artemisinin resistance in Plasmodium falciparum: comparison of parasite clearance time by microscopy and real-time PCR and evaluation of mutations in Pfatpase6 gene in Odisha state of India.
Topics: Adolescent; Adult; Animals; Antimalarials; Artemisinins; Child; Child, Preschool; Drug Resistance; F | 2015 |
Prevalence of Plasmodium falciparum resistance markers to sulfadoxine-pyrimethamine among pregnant women receiving intermittent preventive treatment for malaria in Uganda.
Topics: Antimalarials; Bacterial Proteins; Birth Weight; Drug Combinations; Female; Humans; Malaria, Falcipa | 2015 |
Malaria in pregnancy: challenges for control and the need for urgent action.
Topics: Africa South of the Sahara; Antimalarials; Chemoprevention; Comorbidity; Drug Combinations; Early Di | 2015 |
Frequencies of dhfr/dhps multiple mutations and Plasmodium falciparum submicroscopic gametocyte carriage in Gabonese pregnant women following IPTp-SP implementation.
Topics: Antimalarials; Carrier State; Chemoprevention; Dihydropteroate Synthase; DNA, Protozoan; Drug Combin | 2015 |
Defending the Use of Sulfadoxine-Pyrimethamine for Intermittent Preventive Treatment for Malaria in Pregnancy: A Short-Sighted Strategy.
Topics: Dihydropteroate Synthase; Drug Resistance; Female; Humans; Malaria, Falciparum; Mutation, Missense; | 2016 |
Reply to Harrington et al.
Topics: Dihydropteroate Synthase; Drug Resistance; Female; Humans; Malaria, Falciparum; Mutation, Missense; | 2016 |
Emergence of sulfadoxine-pyrimethamine resistance in Indian isolates of Plasmodium falciparum in the last two decades.
Topics: Antimalarials; Dihydropteroate Synthase; Drug Combinations; Drug Resistance; Humans; India; Malaria, | 2015 |
Prevalence of the dhfr and dhps Mutations among Pregnant Women in Rural Burkina Faso Five Years after the Introduction of Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine.
Topics: Adult; Antimalarials; Burkina Faso; Dihydropteroate Synthase; Drug Combinations; Drug Resistance; Fe | 2015 |
Disagreement in genotyping results of drug resistance alleles of the Plasmodium falciparum dihydrofolate reductase (Pfdhfr) gene by allele-specific PCR (ASPCR) assays and Sanger sequencing.
Topics: Alleles; Antimalarials; Artemisinins; Codon; Dihydropteroate Synthase; DNA Primers; DNA, Protozoan; | 2016 |
Declining trend of Plasmodium falciparum dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutant alleles after the withdrawal of Sulfadoxine-Pyrimethamine in North Western Ethiopia.
Topics: Alleles; Animals; Antimalarials; Dihydropteroate Synthase; Drug Combinations; Ethiopia; Malaria, Fal | 2015 |
Comparative Study of Effectiveness and Resistance Profile of Chloroquine and Sulfadoxine-Pyrimethamine in Uncomplicated Plasmodium falciparum Malaria in Kolkata.
Topics: Adolescent; Adult; Antimalarials; Child; Chloroquine; Drug Combinations; Drug Resistance; Female; Hu | 2015 |
Frequencies distribution of dihydrofolate reductase and dihydropteroate synthetase mutant alleles associated with sulfadoxine-pyrimethamine resistance in Plasmodium falciparum population from Hadhramout Governorate, Yemen.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Child; Child, Preschool; Dihydropteroate | 2015 |
Influence of Intermittent Preventive Treatment on Antibodies to VAR2CSA in Pregnant Cameroonian Women.
Topics: Adolescent; Adult; Antibodies, Protozoan; Antigens, Protozoan; Antimalarials; Cameroon; Drug Adminis | 2016 |
Adaptive Landscape by Environment Interactions Dictate Evolutionary Dynamics in Models of Drug Resistance.
Topics: Antimalarials; Computational Biology; Drug Resistance; Evolution, Molecular; Humans; Inhibitory Conc | 2016 |
In Vivo Efficacy and Parasite Clearance of Artesunate + Sulfadoxine-Pyrimethamine Versus Artemether-Lumefantrine in Mali.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesunate; Child; Child, Pr | 2016 |
Treatment of Malaria in Pregnancy.
Topics: Antimalarials; Artemisinins; Female; Humans; Malaria; Malaria, Falciparum; Pregnancy; Pregnancy Comp | 2016 |
Comparative assessment on the prevalence of mutations in the Plasmodium falciparum drug-resistant genes in two different ecotypes of Odisha state, India.
Topics: Alleles; Antimalarials; Chloroquine; Dihydropteroate Synthase; Drug Combinations; Drug Resistance; E | 2016 |
Absence of Association Between Sickle Trait Hemoglobin and Placental Malaria Outcomes.
Topics: Adult; Antimalarials; Cross-Sectional Studies; Drug Combinations; Female; Genotype; Hemoglobin, Sick | 2016 |
A link between poor quality antimalarials and malaria drug resistance?
Topics: Antimalarials; Artemisinins; Chloroquine; Drug Combinations; Drug Resistance, Microbial; Drug Therap | 2016 |
High efficacy of artemether-lumefantrine and declining efficacy of artesunate + sulfadoxine-pyrimethamine against Plasmodium falciparum in Sudan (2010-2015): evidence from in vivo and molecular marker studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemether, Lumefantrine Drug Combination | 2016 |
Sustained efficacy of artesunate-sulfadoxine-pyrimethamine against Plasmodium falciparum in Yemen and a renewed call for an adjunct single dose primaquine to clear gametocytes.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Drug Combinatio | 2016 |
Malaria research and its influence on anti-malarial drug policy in Malawi: a case study.
Topics: Antimalarials; Artemether; Artemisinins; Biomedical Research; Chloroquine; Drug Combinations; Drug R | 2016 |
Low-grade sulfadoxine-pyrimethamine resistance in Plasmodium falciparum parasites from Lubango, Angola.
Topics: Angola; Antimalarials; Dihydropteroate Synthase; Drug Combinations; Drug Resistance; Humans; Malaria | 2016 |
Decrease of microscopic Plasmodium falciparum infection prevalence during pregnancy following IPTp-SP implementation in urban cities of Gabon.
Topics: Adult; Anemia; Antimalarials; Birth Weight; Cities; Cross-Sectional Studies; Drug Combinations; Fema | 2016 |
Determinants of timely uptake of ITN and SP (IPT) and pregnancy time protected against malaria in Bukoba, Tanzania.
Topics: Adolescent; Adult; Antimalarials; Cross-Sectional Studies; Drug Combinations; Female; Health Facilit | 2016 |
Molecular monitoring of Plasmodium falciparum super-resistance to sulfadoxine-pyrimethamine in Tanzania.
Topics: Antimalarials; Dihydropteroate Synthase; DNA, Protozoan; Drug Combinations; Drug Resistance; Gene Fr | 2016 |
Molecular markers associated with resistance to commonly used antimalarial drugs among Plasmodium falciparum isolates from a malaria-endemic area in Taiz governorate-Yemen during the transmission season.
Topics: Alleles; Antimalarials; Artemisinins; Artesunate; Chloroquine; Cross-Sectional Studies; Dihydroptero | 2016 |
Plasmodium falciparum Drug-Resistant Haplotypes and Population Structure in Postearthquake Haiti, 2010.
Topics: Alleles; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Earthquakes; Genetics, Popu | 2016 |
Efficacy of artemisinin-based combination therapies for the treatment of falciparum malaria in Pakistan (2007-2015): In vivo response and dhfr and dhps mutations.
Topics: Antimalarials; Artemether; Artemisinins; Child; Child, Preschool; Ethanolamines; Female; Fluorenes; | 2016 |
Molecular surveillance of Plasmodium falciparum drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda.
Topics: Adolescent; Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Dru | 2016 |
Efficacy of sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in southern Mauritania.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Drug Combinations; Female; Humans; Malari | 2016 |
Prevalence of Plasmodium falciparum Molecular Markers of Antimalarial Drug Resistance in a Residual Malaria Focus Area in Sabah, Malaysia.
Topics: Adult; Alleles; Antimalarials; Biomarkers; Child; Chloroquine; Drug Combinations; Drug Resistance; G | 2016 |
Plasmodium falciparum Genetic Diversity in Continental Equatorial Guinea before and after Introduction of Artemisinin-Based Combination Therapy.
Topics: Amodiaquine; Antigens, Protozoan; Antimalarials; Artemisinins; Artesunate; Chloroquine; DNA Copy Num | 2017 |
Simple detection of single nucleotide polymorphism in Plasmodium falciparum by SNP-LAMP assay combined with lateral flow dipstick.
Topics: DNA Primers; DNA, Protozoan; Drug Resistance; Folic Acid; Genome, Protozoan; Genotype; Malaria, Falc | 2017 |
Molecular determinants of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum in Nigeria and the regional emergence of dhps 431V.
Topics: Adult; Antimalarials; Child; Dihydropteroate Synthase; DNA, Protozoan; Drug Combinations; Drug Resis | 2016 |
Molecular determinants of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum in Nigeria and the regional emergence of dhps 431V.
Topics: Adult; Antimalarials; Child; Dihydropteroate Synthase; DNA, Protozoan; Drug Combinations; Drug Resis | 2016 |
Molecular determinants of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum in Nigeria and the regional emergence of dhps 431V.
Topics: Adult; Antimalarials; Child; Dihydropteroate Synthase; DNA, Protozoan; Drug Combinations; Drug Resis | 2016 |
Molecular determinants of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum in Nigeria and the regional emergence of dhps 431V.
Topics: Adult; Antimalarials; Child; Dihydropteroate Synthase; DNA, Protozoan; Drug Combinations; Drug Resis | 2016 |
Molecular determinants of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum in Nigeria and the regional emergence of dhps 431V.
Topics: Adult; Antimalarials; Child; Dihydropteroate Synthase; DNA, Protozoan; Drug Combinations; Drug Resis | 2016 |
Molecular determinants of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum in Nigeria and the regional emergence of dhps 431V.
Topics: Adult; Antimalarials; Child; Dihydropteroate Synthase; DNA, Protozoan; Drug Combinations; Drug Resis | 2016 |
Molecular determinants of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum in Nigeria and the regional emergence of dhps 431V.
Topics: Adult; Antimalarials; Child; Dihydropteroate Synthase; DNA, Protozoan; Drug Combinations; Drug Resis | 2016 |
Molecular determinants of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum in Nigeria and the regional emergence of dhps 431V.
Topics: Adult; Antimalarials; Child; Dihydropteroate Synthase; DNA, Protozoan; Drug Combinations; Drug Resis | 2016 |
Molecular determinants of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum in Nigeria and the regional emergence of dhps 431V.
Topics: Adult; Antimalarials; Child; Dihydropteroate Synthase; DNA, Protozoan; Drug Combinations; Drug Resis | 2016 |
Characterizing the impact of sustained sulfadoxine/pyrimethamine use upon the Plasmodium falciparum population in Malawi.
Topics: Antimalarials; Child, Preschool; Drug Combinations; Drug Resistance; Female; Gene Frequency; Genetic | 2016 |
Recent uptake of intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine is associated with increased prevalence of Pfdhfr mutations in Bobo-Dioulasso, Burkina Faso.
Topics: Adolescent; Adult; Anemia; Antimalarials; Burkina Faso; Drug Combinations; Female; Hemoglobins; Huma | 2017 |
Efficacy of artesunate + sulphadoxine/pyrimethamine and artemether + lumefantrine and dhfr and dhps mutations in Somalia: evidence for updating the malaria treatment policy.
Topics: Adolescent; Antimalarials; Artemether; Artemisinins; Artesunate; Child; Child, Preschool; Dihydropte | 2017 |
The Malaria TaqMan Array Card Includes 87 Assays for Plasmodium falciparum Drug Resistance, Identification of Species, and Genotyping in a Single Reaction.
Topics: Antimalarials; Artemisinins; Atovaquone; Chloroquine; Drug Resistance; Epidemiological Monitoring; G | 2017 |
Unexpected selections of Plasmodium falciparum polymorphisms in previously treatment-naïve areas after monthly presumptive administration of three different anti-malarial drugs in Liberia 1976-78.
Topics: Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Humans; Liberia; Malaria, Falc | 2017 |
Characteristics of Plasmodium falciparum dhfr haplotypes that confer pyrimethamine resistance, Kilifi, Kenya, 1987--2006.
Topics: Animals; Antimalarials; Drug Resistance; Gene Frequency; Haplotypes; Humans; Kenya; Malaria, Falcipa | 2008 |
Mutations in PFCRT K76T do not correlate with sulfadoxine-pyrimethamine-amodiaquine failure in Pikine, Senegal.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Amodiaquine; Animals; Antimalar | 2008 |
[Self-medication in the treatment of acute malaria: study based on users of private health drug stores in Ouagadougou, Burkina Faso].
Topics: Acute Disease; Adult; Antimalarials; Artemisinins; Burkina Faso; Child; Chloroquine; Cross-Sectional | 2008 |
Diminished Plasmodium falciparum sensitivity to quinine exposure in vitro and in a sequential multi-drug regimen: A preliminary investigation in Guyana, South America.
Topics: Animals; Antimalarials; Child; Chloroquine; Doxycycline; Drug Administration Schedule; Drug Resistan | 2008 |
Rapid increase of Plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption of sulphadoxine-pyrimethamine as first line treatment in 2002, in southern Mozambique.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Cross-Sectional Studies; Dihydro | 2008 |
Adherence and effectiveness of drug combination in curative treatment among children suffering uncomplicated malaria in rural Senegal.
Topics: Amodiaquine; Animals; Antimalarials; Attitude to Health; Caregivers; Child; Child, Preschool; Drug C | 2008 |
Surveillance for adverse drug reactions to combination antimalarial therapy with sulfadoxine-pyrimethamine plus artesunate in Peru.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Humans; Malar | 2008 |
Molecular epidemiology of drug-resistant malaria in western Kenya highlands.
Topics: Adolescent; Animals; Antimalarials; Child; Chloroquine; Dihydropteroate Synthase; DNA, Protozoan; Dr | 2008 |
Different methodological approaches to the assessment of in vivo efficacy of three artemisinin-based combination antimalarial treatments for the treatment of uncomplicated falciparum malaria in African children.
Topics: Africa; Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; Child, Preschool; | 2008 |
Predictors of antimalarial treatment failure in an area of unstable malaria transmission in eastern Sudan.
Topics: Adolescent; Age Factors; Antimalarials; Child; Child, Preschool; Chloroquine; Cross-Sectional Studie | 2009 |
Plasmodium falciparum strains harboring dihydrofolate reductase with the I164L mutation are absent in Malawi and Zambia even under antifolate drug pressure.
Topics: Adult; Alleles; Animals; Antimalarials; Base Sequence; Child, Preschool; DNA Primers; DNA, Protozoan | 2008 |
Hitchhiking and selective sweeps of Plasmodium falciparum sulfadoxine and pyrimethamine resistance alleles in a population from central Africa.
Topics: Alleles; Animals; Antimalarials; Cameroon; Dihydropteroate Synthase; Drug Resistance; Gene Frequency | 2008 |
[Is the antimalarial fight effective in Mayotte?].
Topics: Adolescent; Adult; Animals; Antimalarials; Chloroquine; Comoros; Drug Combinations; Female; Humans; | 2008 |
Should countries implementing an artemisinin-based combination malaria treatment policy also introduce rapid diagnostic tests?
Topics: Adolescent; Animals; Artemisinins; Child; Child, Preschool; Cost-Benefit Analysis; Diagnostic Tests, | 2008 |
Rapid increase in the prevalence of sulfadoxine-pyrimethamine resistance among Plasmodium falciparum isolated from pregnant women in Ghana.
Topics: Adolescent; Adult; Animals; Antimalarials; DNA, Protozoan; Drug Combinations; Drug Resistance; Femal | 2008 |
Implementation of intermittent preventive treatment in pregnancy with sulphadoxine/pyrimethamine (IPTp-SP) at a district health centre in rural Senegal.
Topics: Adolescent; Adult; Analysis of Variance; Antimalarials; Drug Combinations; Female; Humans; Infant, L | 2008 |
Prevalence of pfmdr1, pfcrt, pfdhfr and pfdhps mutations associated with drug resistance, in Luanda, Angola.
Topics: Adolescent; Angola; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Dihydropteroate Sy | 2008 |
Indigenous evolution of Plasmodium falciparum pyrimethamine resistance multiple times in Africa.
Topics: Amino Acid Substitution; Animals; Antimalarials; Congo; DNA Fingerprinting; DNA, Protozoan; Drug Res | 2009 |
Plasmodium falciparum gametocyte dynamics in areas of different malaria endemicity.
Topics: Adolescent; Animals; Antimalarials; Artemisinins; Carrier State; Child; Child, Preschool; Drug Combi | 2008 |
The therapeutic efficacy of sulfadoxine/pyrimethamine against Plasmodium falciparum in Yemen.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Drug Resistance; Drug Therapy, C | 2009 |
Opposed circulating plasma levels of endothelin-1 and C-type natriuretic peptide in children with Plasmodium falciparum malaria.
Topics: Analysis of Variance; Animals; Antimalarials; Case-Control Studies; Child; Child, Preschool; Drug Co | 2008 |
The evolution of drug-resistant malaria.
Topics: Africa; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Evolution, Molecular; Humans | 2009 |
Sub-microscopic infections and long-term recrudescence of Plasmodium falciparum in Mozambican pregnant women.
Topics: Adult; Animals; Antigens, Protozoan; Antimalarials; Chloroquine; Drug Combinations; Female; Genotype | 2009 |
Feasibility and acceptability of home-based management of malaria strategy adapted to Sudan's conditions using artemisinin-based combination therapy and rapid diagnostic test.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antimalarials; Artemisinins; Community Health W | 2009 |
Mapping the spread of malaria drug resistance.
Topics: Africa; Alleles; Animals; Antimalarials; Dihydropteroate Synthase; Drug Combinations; Drug Resistanc | 2009 |
Multiple origins and regional dispersal of resistant dhps in African Plasmodium falciparum malaria.
Topics: Africa; Alleles; Animals; Antimalarials; Chloroquine; Dihydropteroate Synthase; DNA, Protozoan; Drug | 2009 |
Distinct haplotypes of dhfr and dhps among Plasmodium falciparum isolates in an area of high level of sulfadoxine-pyrimethamine (SP) resistance in eastern Sudan.
Topics: Animals; Antimalarials; Dihydropteroate Synthase; Drug Combinations; Drug Resistance, Multiple; Ende | 2009 |
Genetic structure of Plasmodium falciparum populations between lowland and highland sites and antimalarial drug resistance in Western Kenya.
Topics: Adolescent; Animals; Antimalarials; Child; Chloroquine; Drug Combinations; Drug Resistance; Endemic | 2009 |
Novel pfdhps haplotypes among imported cases of Plasmodium falciparum malaria in the United Kingdom.
Topics: Adult; Alleles; Amino Acid Sequence; Animals; Antimalarials; Atovaquone; Chloroquine; Dihydropteroat | 2009 |
Chloroquine resistance before and after its withdrawal in Kenya.
Topics: Animals; Antimalarials; Chloroquine; Drug Approval; Drug Combinations; Drug Resistance; Genotype; Hu | 2009 |
Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment.
Topics: Adult; Alleles; Animals; Antimalarials; Cohort Studies; Dihydropteroate Synthase; Drug Combinations; | 2009 |
Polymerase chain reaction adjustment in antimalarial trials: molecular malarkey?
Topics: Antimalarials; Drug Therapy, Combination; Humans; Malaria, Falciparum; Polymerase Chain Reaction; Py | 2009 |
Jaundice with hepatic dysfunction in P. falciparum malaria.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Animals; Antimalarials; Female; Humans; Jaundice; Liv | 2009 |
Stepwise acquisition of pyrimethamine resistance in the malaria parasite.
Topics: Alleles; Animals; Biological Assay; Drug Resistance; Evolution, Molecular; Inhibitory Concentration | 2009 |
Chloroquine and sulphadoxine-pyrimethamine sensitivity of Plasmodium falciparum parasites in a Brazilian endemic area.
Topics: Animals; Antimalarials; Brazil; Chloroquine; Drug Combinations; Drug Resistance; Endemic Diseases; H | 2009 |
Monitoring for multidrug-resistant Plasmodium falciparum isolates and analysis of pyrimethamine resistance evolution in Uige province, Angola.
Topics: Angola; Antimalarials; Child; Drug Resistance, Multiple; Genotype; Humans; Malaria, Falciparum; Memb | 2009 |
PfHRP2 and PfLDH antigen detection for monitoring the efficacy of artemisinin-based combination therapy (ACT) in the treatment of uncomplicated falciparum malaria.
Topics: Amodiaquine; Antigens, Protozoan; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisi | 2009 |
Intermittent preventive treatment of malaria in infancy.
Topics: Africa; Antimalarials; Drug Combinations; Global Health; Humans; Immunization Programs; Infant; Infa | 2009 |
Characteristics of genetic hitchhiking around dihydrofolate reductase gene associated with pyrimethamine resistance in Plasmodium falciparum isolates from India.
Topics: Antimalarials; Drug Combinations; Drug Resistance; Geography; Haplotypes; India; Malaria, Falciparum | 2009 |
Epidemic of Plasmodium falciparum malaria involving substandard antimalarial drugs, Pakistan, 2003.
Topics: Adolescent; Adult; Afghanistan; Animals; Anopheles; Antimalarials; Child; Child, Preschool; Disease | 2009 |
Placental malaria among HIV-infected and uninfected women receiving anti-folates in a high transmission area of Uganda.
Topics: Adult; AIDS-Related Opportunistic Infections; Antimalarials; Cross-Sectional Studies; Drug Combinati | 2009 |
Pharmacokinetic disposition of sulfadoxine in children with acute uncomplicated falciparum malaria treated with sulfadoxine-pyrimethamine in South West Nigeria.
Topics: Acute Disease; Age Factors; Antimalarials; Area Under Curve; Child; Child, Preschool; Chromatography | 2012 |
Evidence of selective sweeps in genes conferring resistance to chloroquine and pyrimethamine in Plasmodium falciparum isolates in India.
Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Genes, Protozoan; Genotype; Humans; India; Mal | 2010 |
Plasmodium falciparum resistance to anti-malarial drugs in Papua New Guinea: evaluation of a community-based approach for the molecular monitoring of resistance.
Topics: Adolescent; Aged; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; DNA, Pr | 2010 |
High prevalence of sulfadoxine/pyrimethamine-resistant alleles of Plasmodium falciparum isolates in pregnant women at the time of introduction of intermittent preventive treatment with sulfadoxine/pyrimethamine in Gabon.
Topics: Alleles; Amino Acid Substitution; Animals; Antimalarials; Blood; Dihydropteroate Synthase; DNA Restr | 2010 |
High prevalence of sulfadoxine/pyrimethamine resistance alleles in Plasmodium falciparum parasites from Bangladesh.
Topics: Adolescent; Alleles; Animals; Antimalarials; Bangladesh; Child; Child, Preschool; Drug Combinations; | 2010 |
Intermittent preventive therapy for malaria in pregnancy: is sulfadoxine-pyrimethamine the right drug?
Topics: Africa; Antimalarials; Clinical Trials as Topic; Drug Administration Schedule; Drug Combinations; Fe | 2010 |
Implementing intermittent preventive treatment in infants.
Topics: Antimalarials; Drug Combinations; Humans; Immunization Programs; Infant; Malaria, Falciparum; Meta-A | 2010 |
Burden of malaria during pregnancy at the time of IPTp/SP implementation in Gabon.
Topics: Adolescent; Adult; Age Distribution; Anemia; Antimalarials; Cross-Sectional Studies; Drug Combinatio | 2010 |
Nonlinear mixed effects modeling of gametocyte carriage in patients with uncomplicated malaria.
Topics: Animals; Antimalarials; Carrier State; Drug Combinations; Drug Resistance; Follow-Up Studies; Host-P | 2010 |
Markers of anti-malarial drug resistance in Plasmodium falciparum isolates from Swaziland: identification of pfmdr1-86F in natural parasite isolates.
Topics: Alleles; Amplified Fragment Length Polymorphism Analysis; Animals; Antimalarials; Chloroquine; Drug | 2010 |
Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Burkina Faso; Drug Combinations; Drug Resistan | 2010 |
Antibodies to chondroitin sulfate A-binding infected erythrocytes: dynamics and protection during pregnancy in women receiving intermittent preventive treatment.
Topics: Adolescent; Adult; Antibodies, Protozoan; Antigens, Surface; Antimalarials; Chondroitin Sulfates; Dr | 2010 |
Active case detection, treatment of falciparum malaria with combined chloroquine and sulphadoxine/pyrimethamine and vivax malaria with chloroquine and molecular markers of anti-malarial resistance in the Republic of Vanuatu.
Topics: Adolescent; Adult; Antigens, Protozoan; Antimalarials; Case-Control Studies; Child; Child, Preschool | 2010 |
High prevalence of the 437G mutation associated with sulfadoxine resistance among Plasmodium falciparum clinical isolates from Iran, three years after the introduction of sulfadoxine-pyrimethamine.
Topics: Adolescent; Adult; Aged; Amino Acid Substitution; Antimalarials; Base Sequence; Child; Child, Presch | 2010 |
Five years of large-scale dhfr and dhps mutation surveillance following the phased implementation of artesunate plus sulfadoxine-pyrimethamine in Maputo Province, Southern Mozambique.
Topics: Adolescent; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Dihydropteroate Syntha | 2010 |
Low infectivity of Plasmodium falciparum gametocytes to Anopheles gambiae following treatment with sulfadoxine-pyrimethamine in Mali.
Topics: Animals; Anopheles; Antimalarials; Dihydropteroate Synthase; Drug Combinations; Gene Expression Regu | 2010 |
Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Art | 2010 |
Origin and dissemination across the Colombian Andes mountain range of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum.
Topics: Alleles; Animals; Antimalarials; Colombia; Dihydropteroate Synthase; Drug Combinations; Drug Resista | 2010 |
Analysis of an ordinal outcome in a multicentric randomized controlled trial: application to a 3- arm anti- malarial drug trial in Cameroon.
Topics: Amodiaquine; Antimalarials; Cameroon; Child, Preschool; Drug Combinations; Drug Therapy, Combination | 2010 |
Drug coverage in treatment of malaria and the consequences for resistance evolution--evidence from the use of sulphadoxine/pyrimethamine.
Topics: Alleles; Antimalarials; Cross-Sectional Studies; Drug Combinations; Drug Resistance; Haplotypes; Hum | 2010 |
Monitoring of malaria parasite resistance to chloroquine and sulphadoxine-pyrimethamine in the Solomon Islands by DNA microarray technology.
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Fem | 2010 |
Prevalence of molecular markers of Plasmodium falciparum resistance to sulfadoxine-pyrimethamine during the intermittent preventive treatment in infants coupled with the expanded program immunization in Senegal.
Topics: Antimalarials; Blood; Child, Preschool; Cross-Sectional Studies; Dihydropteroate Synthase; DNA, Prot | 2011 |
Follow-up survey of children who received sulfadoxine-pyrimethamine for intermittent preventive antimalarial treatment in infants.
Topics: Antibodies, Protozoan; Antimalarials; Chemoprevention; Child, Preschool; Drug Combinations; Female; | 2011 |
Prevalence of resistance associated polymorphisms in Plasmodium falciparum field isolates from southern Pakistan.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Dihydropteroate Synthase; Dr | 2011 |
Artemether-Lumefantrin (Coartem) and artesunate with sulfadoxine-pyrimethamine therapeutic efficacy in the treatment of uncomplicated malaria at Gilgel Gibe II (GGII) South-Western Ethiopia.
Topics: Adolescent; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesunate; Chil | 2010 |
Evaluation of prevalence's of pfdhfr and pfdhps mutations in Angola.
Topics: Angola; Antimalarials; Chemoprevention; Child, Preschool; Dihydropteroate Synthase; Drug Combination | 2011 |
Selective sweeps and genetic lineages of Plasmodium falciparum drug -resistant alleles in Ghana.
Topics: Alleles; Amino Acid Substitution; Antimalarials; Biological Evolution; Child, Preschool; Chloroquine | 2011 |
Prevalence of molecular markers of anti-malarial drug resistance in Plasmodium vivax and Plasmodium falciparum in two districts of Nepal.
Topics: Antimalarials; Artemisinins; Chloroquine; Drug Combinations; Drug Resistance; Humans; Malaria, Falci | 2011 |
Selection of drug resistant mutants from random library of Plasmodium falciparum dihydrofolate reductase in Plasmodium berghei model.
Topics: Animals; Antimalarials; Drug Resistance; Female; Folic Acid Antagonists; Gene Expression Regulation, | 2011 |
Fitness trade-offs in the evolution of dihydrofolate reductase and drug resistance in Plasmodium falciparum.
Topics: Drug Resistance; Evolution, Molecular; Folic Acid Antagonists; Malaria, Falciparum; Plasmodium falci | 2011 |
Effectiveness of ACTs in cases of resistance to partner drugs.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Resistance; Drug Therapy, Combinati | 2011 |
Molecular epidemiology of malaria in Cameroon. XXX. sequence analysis of Plasmodium falciparum ATPase 6, dihydrofolate reductase, and dihydropteroate synthase resistance markers in clinical isolates from children treated with an artesunate-sulfadoxine-pyr
Topics: Antimalarials; Artemisinins; Artesunate; Cameroon; Child; Dihydropteroate Synthase; Drug Combination | 2011 |
Molecular markers of resistance to sulphadoxine-pyrimethamine during intermittent preventive treatment of pregnant women in Benin.
Topics: Adult; Antimalarials; Benin; Biomarkers; Chemoprevention; Clinical Trials as Topic; Dihydropteroate | 2011 |
[Effect of intermittent presumptive treatment with sulfadoxine-pyrimethamine on the acquisition of anti-VAR2CSA antibodies in pregnant women living in a hypoendemic area in Senegal].
Topics: Adolescent; Adult; Antibodies, Viral; Antigens, Protozoan; Antimalarials; Drug Combinations; Female; | 2011 |
Molecular markers of anti-malarial drug resistance in Lahj Governorate, Yemen: baseline data and implications.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Dihydropteroate Synthase; Dr | 2011 |
Molecular monitoring of resistant dhfr and dhps allelic haplotypes in Morogoro and Mvomero districts in south eastern Tanzania.
Topics: Adolescent; Adult; Aged; Alleles; Antimalarials; Child; Child, Preschool; Cross-Sectional Studies; D | 2011 |
Plasmodium falciparum: differential selection of drug resistance alleles in contiguous urban and peri-urban areas of Brazzaville, Republic of Congo.
Topics: Adolescent; Alleles; Animals; Anopheles; Antimalarials; Chloroquine; Congo; Drug Resistance; Female; | 2011 |
Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda.
Topics: Alleles; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; | 2011 |
Prolonged elevation of viral loads in HIV-1-infected children in a region of intense malaria transmission in Northern Uganda: a prospective cohort study.
Topics: Antimalarials; CD4 Lymphocyte Count; Child; Child, Preschool; Chloroquine; Disease Progression; Drug | 2010 |
In vitro susceptibility to pyrimethamine of DHFR I164L single mutant Plasmodium falciparum.
Topics: Adult; Amino Acid Substitution; Antimalarials; DNA, Protozoan; Drug Resistance; Female; Humans; Inhi | 2011 |
Quantification of the burden and consequences of pregnancy-associated malaria in the Democratic Republic of the Congo.
Topics: Anemia; Antimalarials; Birth Weight; Cross-Sectional Studies; Democratic Republic of the Congo; Drug | 2011 |
Molecular markers of Plasmodium falciparum drug resistance in southern highland Rwanda.
Topics: Antimalarials; Child, Preschool; Chloroquine; Drug Resistance; Enzyme-Linked Immunosorbent Assay; Fe | 2012 |
Molecular monitoring of Plasmodium falciparum resistance to antimalarial drugs after adoption of sulfadoxine-pyrimethamine plus artesunate as the first line treatment in Iran.
Topics: Adolescent; Adult; Aged; Antimalarials; Artemisinins; Artesunate; Child; DNA Fingerprinting; Drug Co | 2012 |
The evolution of pyrimethamine resistant dhfr in Plasmodium falciparum of south-eastern Tanzania: comparing selection under SP alone vs SP+artesunate combination.
Topics: Adult; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Drug Combinations; Drug Res | 2011 |
Sahel, savana, riverine and urban malaria in West Africa: Similar control policies with different outcomes.
Topics: Africa, Western; Animals; Antimalarials; Artemisinins; Communicable Disease Control; Culicidae; Dise | 2012 |
The effectiveness and perception of the use of sulphadoxine-pyrimethamine in intermittent preventive treatment of malaria in pregnancy programme in Offinso district of Ashanti region, Ghana.
Topics: Adult; Anemia; Antimalarials; Cross-Sectional Studies; Drug Administration Schedule; Drug Combinatio | 2011 |
Identification of pyrimethamine- and chloroquine-resistant Plasmodium falciparum in Africa between 1984 and 1998: genotyping of archive blood samples.
Topics: Africa; Antimalarials; Chloroquine; DNA, Protozoan; Drug Resistance; Genotype; Genotyping Techniques | 2011 |
The F423Y mutation in the pfmdr2 gene and mutations N51I, C59R, and S108N in the pfdhfr gene are independently associated with pyrimethamine resistance in Plasmodium falciparum isolates.
Topics: Antimalarials; Drug Resistance; Folic Acid Antagonists; Genes, Protozoan; Humans; Logistic Models; M | 2012 |
Placental malaria and the relationship to pregnancy outcome at Gushegu District Hospital, Northern Ghana.
Topics: Adult; Animals; Antimalarials; Apgar Score; Drug Combinations; Female; Ghana; Hospitals, District; H | 2012 |
Differences in selective pressure on dhps and dhfr drug resistant mutations in western Kenya.
Topics: Alleles; Antimalarials; Dihydropteroate Synthase; Drug Combinations; Drug Resistance; Drug Therapy, | 2012 |
Antibodies to malaria vaccine candidates are associated with chloroquine or sulphadoxine/pyrimethamine treatment efficacy in children in an endemic area of Burkina Faso.
Topics: Adolescent; Antibodies, Protozoan; Antimalarials; Biomarkers; Burkina Faso; Child; Child, Preschool; | 2012 |
Antenatal receipt of sulfadoxine-pyrimethamine does not exacerbate pregnancy-associated malaria despite the expansion of drug-resistant Plasmodium falciparum: clinical outcomes from the QuEERPAM study.
Topics: Adolescent; Adult; Antibiotic Prophylaxis; Antimalarials; Cross-Sectional Studies; Drug Combinations | 2012 |
Molecular markers in plasmodium falciparum linked to resistance to anti-malarial drugs in samples imported from Africa over an eight-year period (2002-2010): impact of the introduction of artemisinin combination therapy.
Topics: Africa; Alleles; Animals; Antimalarials; Artemisinins; DNA, Protozoan; Drug Combinations; Drug Resis | 2012 |
Artemisinin-based combination therapy does not measurably reduce human infectiousness to vectors in a setting of intense malaria transmission.
Topics: Animals; Antigens, Protozoan; Antimalarials; Artemisinins; Artesunate; Asymptomatic Diseases; Child, | 2012 |
Temporal trends of sulphadoxine-pyrimethamine (SP) drug-resistance molecular markers in Plasmodium falciparum parasites from pregnant women in western Kenya.
Topics: Adult; Antimalarials; Dihydropteroate Synthase; DNA, Protozoan; Drug Combinations; Drug Resistance; | 2012 |
Routine delivery of artemisinin-based combination treatment at fixed health facilities reduces malaria prevalence in Tanzania: an observational study.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Cross-Sectional Studies; Dr | 2012 |
Prevalence of molecular markers of Plasmodium falciparum drug resistance in Dakar, Senegal.
Topics: Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Female; Gene Dosage; Gene Frequency; | 2012 |
Source of drug resistant Plasmodium falciparum in a potential malaria elimination site in Saudi Arabia.
Topics: Antimalarials; Dihydropteroate Synthase; DNA, Protozoan; Drug Combinations; Drug Resistance; Haploty | 2012 |
Intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine: the times they are a-changin'.
Topics: Antimalarials; Female; Humans; Malaria, Falciparum; Plasmodium falciparum; Pregnancy; Pregnancy Comp | 2012 |
Plasmodium falciparum infection in pregnant women attending antenatal care in Luanda, Angola.
Topics: Adolescent; Adult; Angola; Antimalarials; Child; Drug Combinations; Female; Humans; Malaria, Falcipa | 2012 |
Evaluation of dihydrofolate reductase and dihydropteroate synthetase genotypes that confer resistance to sulphadoxine-pyrimethamine in Plasmodium falciparum in Haiti.
Topics: Antimalarials; Dihydropteroate Synthase; Drug Combinations; Drug Resistance; Genotype; Haiti; Humans | 2012 |
Proxies and prevention of malaria in pregnancy.
Topics: Animals; Antimalarials; Drug Combinations; Female; Humans; Infant, Low Birth Weight; Malaria, Falcip | 2012 |
Surveillance of molecular markers of Plasmodium falciparum resistance to sulphadoxine-pyrimethamine 5 years after the change of malaria treatment policy in Ghana.
Topics: Alcohol Oxidoreductases; Alleles; Antimalarials; Biomarkers; Dihydropteroate Synthase; Drug Combinat | 2012 |
The time distribution of sulfadoxine-pyrimethamine protection from malaria.
Topics: Adolescent; Animals; Antimalarials; Child; Child, Preschool; Computer Simulation; Culicidae; Drug Ad | 2012 |
Modeling the evolution of drug resistance in malaria.
Topics: Amino Acid Sequence; Antimalarials; Computer Simulation; Crystallography, X-Ray; Dihydropteroate Syn | 2012 |
Increased prevalence of dhfr and dhps mutants at delivery in Malawian pregnant women receiving intermittent preventive treatment for malaria.
Topics: Antimalarials; Dihydropteroate Synthase; DNA, Protozoan; Drug Combinations; Drug Resistance; Female; | 2013 |
Monitoring antimalarial drug resistance in India via sentinel sites: outcomes and risk factors for treatment failure, 2009-2010.
Topics: Antimalarials; Artemisinins; Chloroquine; Drug Resistance, Microbial; Humans; India; Kaplan-Meier Es | 2012 |
Molecular monitoring of antimalarial drug resistance among Plasmodium falciparum field isolates from Odisha, India.
Topics: Antimalarials; Artemisinins; Chloroquine; Cross-Sectional Studies; Drug Combinations; Drug Resistanc | 2013 |
Molecular modeling of wild-type and antifolate resistant mutant Plasmodium falciparum DHFR.
Topics: Animals; Chickens; Drug Resistance; Folic Acid Antagonists; Humans; Liver; Malaria, Falciparum; Mode | 2002 |
A high malaria reinfection rate in children and young adults living under a low entomological inoculation rate in a periurban area of Bamako, Mali.
Topics: Adolescent; Animals; Anopheles; Antimalarials; Child; Drug Combinations; Female; Humans; Insect Bite | 2002 |
Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Child; Child, Preschool; Dihydropteroate Synthase; | 2002 |
The drug sensitivity and transmission dynamics of human malaria on Nias Island, North Sumatra, Indonesia.
Topics: Adolescent; Adult; Age Distribution; Aged; Animals; Anopheles; Antimalarials; Child; Child, Preschoo | 2002 |
Resistance to antimalarials.
Topics: Africa; Antimalarials; Chloroquine; Developing Countries; Drug Combinations; Drug Resistance, Multip | 2002 |
Molecular epidemiology of malaria in Cameroon. X. Evaluation of PFMDR1 mutations as genetic markers for resistance to amino alcohols and artemisinin derivatives.
Topics: Adolescent; Adult; Amodiaquine; Animals; Antimalarials; Base Sequence; Cameroon; Child; Child, Presc | 2002 |
Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America.
Topics: Alleles; Amino Acid Sequence; Animals; Antimalarials; Chloroquine; Cloning, Molecular; Drug Resistan | 2002 |
Transcriptional analysis of genes encoding enzymes of the folate pathway in the human malaria parasite Plasmodium falciparum.
Topics: Animals; Antimalarials; Drug Combinations; Erythrocytes; Folic Acid; Glycine Hydroxymethyltransferas | 2002 |
Monitoring the drug-sensitivity of Plasmodium falciparum in coastal towns in Madagascar by use of in vitro chemosensitivity and mutation detection tests.
Topics: Animals; Antimalarials; Chloroquine; DNA, Protozoan; Drug Resistance; Drug Resistance, Multiple; Dru | 2002 |
Therapeutic efficacy of chloroquine and sulfadoxine/pyrimethamine against Plasmodium falciparum infection in Somalia.
Topics: Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Evaluation; Drug | 2002 |
Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum must be delayed in Africa.
Topics: Africa; Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Resis | 2002 |
Pyrimethamine/sulfadoxine combination in the treatment of uncomplicated falciparum malaria: relation between dihydropteroate synthase/dihydrofolate reductase genotypes, sulfadoxine plasma levels, and treatment outcome.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Child; Dihydropteroate Synthase; Genotype; Humans; | 2002 |
Increased efficacy of sulfadoxine-pyrimethamine in the treatment of uncomplicated falciparum malaria among children with sickle cell trait in Western Kenya.
Topics: Animals; Antimalarials; Child, Preschool; Drug Combinations; Female; Hemoglobin A; Hemoglobin, Sickl | 2002 |
A safety and efficacy trial of artesunate, sulphadoxine-pyrimethamine and primaquine in P falciparum malaria.
Topics: Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Humans; Malaria, Falciparum; | 2002 |
Massive hepatosplenomegaly in a child with malaria.
Topics: Age Factors; Animals; Antimalarials; Child; Drug Combinations; Drug Therapy, Combination; Female; Gh | 2002 |
Diagnostic value of molecular markers in chloroquine-resistant falciparum malaria in Southern Mauritania.
Topics: Adult; Animals; Antimalarials; Child; Chloroquine; Drug Combinations; Drug Resistance; Female; Genet | 2002 |
A molecular surveillance system for global patterns of drug resistance in imported malaria.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistan | 2003 |
Chloroquine or sulfadoxine-pyrimethamine for the treatment of uncomplicated, Plasmodium falciparum malaria during an epidemic in Central Java, Indonesia.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Disease Outbr | 2002 |
[Comparison of three approaches to prevent falciparum malaria in Chinese who worked in an African country with high endemicity of malaria].
Topics: Adult; Antimalarials; Chloroquine; Communicable Disease Control; Female; Humans; Malaria, Falciparum | 2001 |
[Diagnosis and treatment of a case with cerebral falciparum malaria].
Topics: Adult; Antimalarials; Drug Combinations; Humans; Malaria, Cerebral; Malaria, Falciparum; Male; Pyrim | 2001 |
Short communication: point mutations in the dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum isolates from Colombia.
Topics: Adult; Aged; Animals; Antimalarials; Colombia; Dihydropteroate Synthase; Drug Combinations; Drug Res | 2003 |
Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp.
Topics: Amodiaquine; Animals; Antigens, Protozoan; Antimalarials; Artemisinins; Artesunate; Child, Preschool | 2003 |
Descriptive study on the efficacy and safety of artesunate suppository in combination with other antimalarials in the treatment of severe malaria in Sudan.
Topics: Administration, Rectal; Adolescent; Adult; Aged; Antimalarials; Artemisinins; Artesunate; Doxycyclin | 2003 |
High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi.
Topics: Adolescent; Animals; Antimalarials; Child; Child, Preschool; Dihydropteroate Synthase; DNA, Protozoa | 2003 |
The hospital- and field-based performances of the OptiMAL test, for malaria diagnosis and treatment monitoring in central India.
Topics: Adult; Animals; Antimalarials; Chloroquine; Drug Combinations; False Negative Reactions; False Posit | 2003 |
Antifolate antimalarial resistance in southeast Africa: a population-based analysis.
Topics: Adult; Alleles; Animals; Antimalarials; Child, Preschool; Drug Combinations; Drug Resistance; Humans | 2003 |
In vitro sensitivity of Plasmodium falciparum to amodiaquine compared with other major antimalarials in Madagascar.
Topics: Amodiaquine; Animals; Antimalarials; Chloroquine; Drug Resistance; Drug Resistance, Multiple; Humans | 2002 |
High prevalence of double Plasmodium falciparum dhfr mutations at codons 108 and 59 in the Sistan-Baluchistan province, Iran.
Topics: Animals; Antimalarials; Codon; Drug Combinations; Drug Resistance; Female; Humans; Iran; Malaria, Fa | 2003 |
Malaria in Austria 1990-2000.
Topics: Adolescent; Adult; Age Distribution; Animals; Austria; Chemoprevention; Child; Child, Preschool; Chl | 2003 |
Health seeking behavior by families of children suspected to have malaria in Kabale: Uganda.
Topics: Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Cross-Sectional Studies; Drug Combinat | 2002 |
Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi.
Topics: Animals; Antimalarials; Child; Chloroquine; Drug Combinations; Drug Resistance; Female; Humans; Mala | 2003 |
Dihydrofolate reductase and dihydropteroate synthase genotypes associated with in vitro resistance of Plasmodium falciparum to pyrimethamine, trimethoprim, sulfadoxine, and sulfamethoxazole.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Child; Dihydropteroate Synthase; Drug Resistance; G | 2003 |
Surveillance of in vivo resistance of Plasmodium falciparum to antimalarial drugs from 1992 to 1999 in Malabo (Equatorial Guinea).
Topics: Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance; Eq | 2003 |
A selective sweep driven by pyrimethamine treatment in southeast asian malaria parasites.
Topics: Alleles; Animals; Antimalarials; Asia; Drug Resistance; Genetic Variation; Malaria; Malaria, Falcipa | 2003 |
Efficacy of amodiaquine alone and combined with sulfadoxine-pyrimethamine and of sulfadoxine pyrimethamine combined with artesunate.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Drug Combinations; | 2003 |
Asymptomatic, recrudescent, chloroquine-resistant Plasmodium falciparum infections in Nigerian children: clinical and parasitological characteristics and implications for the transmission of drug-resistant parasites.
Topics: Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance; Fe | 2003 |
Plasmodium falciparum: correlation of in vivo resistance to chloroquine and antifolates with genetic polymorphisms in isolates from the south of Lao PDR.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinat | 2003 |
Experiment to determine if a proguanil-resistant strain of P. falciparum would respond to large doses of pyrimethamine.
Topics: Malaria, Falciparum; Plasmodium falciparum; Proguanil; Pyrimethamine; Pyrimidines | 1953 |
Pyrimethamine (daraprim) as a prophylactic agent against a West African strain of P. falciparum.
Topics: Black People; Humans; Malaria; Malaria, Falciparum; Pyrimethamine; Pyrimidines | 1953 |
Relative pyrimethamine insensitivity in a case of falciparum malaria in Jamaica.
Topics: Antimalarials; Humans; Jamaica; Malaria; Malaria, Falciparum; Pyrimethamine | 1953 |
Intensity of transmission and spread of gene mutations linked to chloroquine and sulphadoxine-pyrimethamine resistance in falciparum malaria.
Topics: Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance, Mu | 2003 |
Resistance of P. falciparum and P. malariae to pyrimethamine (daraprim) following mass treatment with this drug; a preliminary note.
Topics: Antimalarials; Humans; Malaria; Malaria, Falciparum; Pyrimethamine | 1954 |
Effect of pyrimethamine in human malaria (P. falciparum). II.
Topics: Antimalarials; Humans; Malaria, Falciparum; Pyrimethamine | 1952 |
The treatment of Plasmodium falciparum infection with chloroquine, with a note on infectivity to mosquitoes of primaquine- and pyrimethamine-treated cases.
Topics: Animals; Antimalarials; Chloroquine; Culicidae; Humans; Malaria, Falciparum; Plasmodium falciparum; | 1956 |
Suppression of malaria with pyrimethamine in Nigerian schoolchildren.
Topics: Antimalarials; Body Weight; Child; Drug Combinations; Humans; Malaria; Malaria, Falciparum; Pyrimeth | 1956 |
The development of pyrimethamine resistance by Plasmodium falciparum.
Topics: Antimalarials; Communicable Diseases; Humans; Malaria; Malaria, Falciparum; Plasmodium falciparum; P | 1959 |
Field trials with chlorproguanil in the prophylaxis of malaria in Ghana.
Topics: Africa; Antimalarials; Child; Drug Resistance; Ghana; Humans; Infant; Malaria; Malaria, Falciparum; | 1961 |
The appearance of P. falciparum resistant to pyrimethamine in a northern Nigerian village.
Topics: Antimalarials; Malaria, Falciparum; Plasmodium falciparum; Pyrimethamine | 1960 |
The appearance of pyrimethamine resistance in Plasmodium falciparum following self-medication by a rural community in Ghana.
Topics: Antimalarials; Drug Combinations; Drug Resistance; Ghana; Malaria; Malaria, Falciparum; Pilot Projec | 1962 |
DRUG-RESISTANT FALCIPARUM MALARIA FROM CAMBODIA AND MALAYA.
Topics: Animals; Cambodia; Chloroquine; Culicidae; Drug Resistance; Drug Resistance, Microbial; Humans; Mala | 1963 |
STUDIES IN THE ACQUISITION OF IMMUNITY OF PLASMODIUM FALCIPARUM INFECTIONS IN AFRICA.
Topics: Adolescent; Africa; Africa, Western; Allergy and Immunology; Child; Chloroquine; Humans; Infant; Mal | 1964 |
STUDIES ON A STRAIN OF CHLOROQUINE-RESISTANT PLASMODIUM FALCIPARUM FROM THAILAND.
Topics: Amodiaquine; Antimalarials; Asia, Southeastern; Biomedical Research; Chloroquine; Drug Resistance; D | 1964 |
TREATMENT OF ACUTE FALCIPARUM MALARIA WITH SULPHORTHODIMETHOXINE (FANASIL).
Topics: Adolescent; Africa; Africa, Eastern; Antimalarials; Child; Delayed-Action Preparations; Drug Resista | 1965 |
STUDIES ON A STRAIN OF CHLOROQUINE-RESISTANT PLASMODIUM FALCIPARUM FROM VIET-NAM.
Topics: Amodiaquine; Antimalarials; Biomedical Research; Chloroquine; Drug Therapy; Humans; Malaria; Malaria | 1964 |
Molecular epidemiology of malaria in Cameroon. XV. Experimental studies on serum substitutes and supplements and alternative culture media for in vitro drug sensitivity assays using fresh isolates of Plasmodium falciparum.
Topics: Amodiaquine; Animals; Antimalarials; Cameroon; Chloroquine; Culture Media; Humans; Malaria, Falcipar | 2003 |
Molecular epidemiology of malaria in Cameroon. XVI. Longitudinal surveillance of in vitro pyrimethamine resistance in Plasmodium falciparum.
Topics: Adolescent; Adult; Alcohol Oxidoreductases; Animals; Antimalarials; Cameroon; Child; DNA Primers; DN | 2003 |
Evaluation of a simple operational approach for monitoring resistance to antimalarial drugs in Peru.
Topics: Antimalarials; Chloroquine; Drug Combinations; Drug Monitoring; Drug Resistance; Humans; Malaria, Fa | 2003 |
Prevention of increasing rates of treatment failure by combining sulfadoxine-pyrimethamine with artesunate or amodiaquine for the sequential treatment of malaria.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Dihydropteroate Syn | 2003 |
Application of a multi-faceted approach for the assessment of treatment response in falciparum malaria: a study from Malaysian Borneo.
Topics: Animals; Antimalarials; Borneo; Chloroquine; Drug Resistance, Multiple; Genes, MDR; Genes, Protozoan | 2003 |
Diagnosis and treatment of malaria in children.
Topics: Animals; Antimalarials; Atovaquone; Child; Chloroquine; Drug Combinations; Humans; Malaria; Malaria, | 2003 |
Gametocyte sex ratios in children with asymptomatic, recrudescent, pyrimethamine-sulfadoxine-resistant, Plasmodium falciparum malaria.
Topics: Antimalarials; Area Under Curve; Child; Drug Combinations; Drug Resistance; Female; Germ Cells; Huma | 2003 |
Roll back of Plasmodium falciparum antifolate resistance by insecticide-treated nets.
Topics: Animals; Antimalarials; Bedding and Linens; Culicidae; Dapsone; Drug Combinations; Drug Resistance; | 2003 |
Increasing prevalence of wildtypes in the dihydrofolate reductase gene of Plasmodium falciparum in an area with high levels of sulfadoxine/pyrimethamine resistance after introduction of treated bed nets.
Topics: Animals; Antimalarials; Bedding and Linens; Child, Preschool; Culicidae; Dihydropteroate Synthase; D | 2003 |
Genetic markers of resistance to pyrimethamine and sulfonamides in Plasmodium falciparum parasites compared with the resistance patterns in isolates of Escherichia coli from the same children in Guinea-Bissau.
Topics: Adolescent; Animals; Antimalarials; Child; Child, Preschool; Drug Combinations; Drug Resistance; Esc | 2004 |
Prediction of Plasmodium falciparum resistance to sulfadoxine/pyrimethamine in vivo by mutations in the dihydrofolate reductase and dihydropteroate synthetase genes: a comparative study between sites of differing endemicity.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Biomarkers; Child; Dihydropteroate Synthase; Drug C | 2003 |
Genotyping of Plasmodium falciparum pyrimethamine resistance by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry.
Topics: Adult; Animals; Antimalarials; DNA; Drug Resistance; Genotype; Humans; Malaria, Falciparum; Oligonuc | 2004 |
Therapeutic efficacies of antimalarial drugs in the treatment of uncomplicated, Plasmodium falciparum malaria in Assam, north-eastern India.
Topics: Adolescent; Adult; Aged; Animals; Anti-Infective Agents; Antimalarials; Artemisinins; Child; Child, | 2003 |
Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective study.
Topics: Adolescent; Adult; Aged; Anemia; Antimalarials; Child; Child, Preschool; Drug Combinations; Drug Eva | 2004 |
Plasmodium falciparum isolates in India exhibit a progressive increase in mutations associated with sulfadoxine-pyrimethamine resistance.
Topics: Alleles; Animals; Antimalarials; Dihydropteroate Synthase; Drug Combinations; Folic Acid Antagonists | 2004 |
Short communication: Prevalence of mutations associated with resistance to atovaquone and to the antifolate effect of proguanil in Plasmodium falciparum isolates from northern Ghana.
Topics: Animals; Antimalarials; Atovaquone; Child, Preschool; Cytochromes b; Drug Combinations; Drug Resista | 2004 |
Sulfadoxine-pyrimethamine remains efficacious against uncomplicated, Plasmodium falciparum malaria in north-eastern Afghanistan.
Topics: Afghanistan; Antimalarials; Drug Combinations; Humans; Malaria, Falciparum; Pyrimethamine; Sulfadoxi | 2004 |
Evolution of drug-resistance genes in Plasmodium falciparum in an area of seasonal malaria transmission in Eastern Sudan.
Topics: Alleles; Animals; Antimalarials; Chloroquine; Cross-Sectional Studies; DNA, Protozoan; Drug Combinat | 2004 |
Monitoring antimalarial drug efficacy.
Topics: Animals; Antimalarials; Chloroquine; Drug Monitoring; Drug Resistance; Humans; Laos; Malaria, Falcip | 2004 |
Defective DNA repair as a potential mechanism for the rapid development of drug resistance in Plasmodium falciparum.
Topics: Animals; Antimalarials; Artemisinins; Chloroquine; DNA Damage; DNA Repair; Drug Resistance; Drug Res | 2004 |
Implementation of intermittent preventive treatment with sulphadoxine-pyrimethamine for control of malaria in pregnancy in Kisumu, western Kenya.
Topics: Adult; Antimalarials; Attitude to Health; Awareness; Drug Combinations; Female; Gestational Age; Hum | 2004 |
Sulfadoxine-pyrimethamine for uncomplicated falciparum malaria: sulfadoxine-pyrimethamine is not working in Malawi.
Topics: Antimalarials; Drug Combinations; Humans; Malaria, Falciparum; Malawi; Pyrimethamine; Sulfadoxine; T | 2004 |
Sulfadoxine-pyrimethamine for uncomplicated falciparum malaria: treatment failure and resistance in Malawi remain subject for debate.
Topics: Antimalarials; Drug Combinations; Drug Resistance; Humans; Malaria, Falciparum; Pyrimethamine; Sulfa | 2004 |
Comparative efficacy of chloroquine and sulfadoxine-pyrimethamine for uncomplicated Plasmodium falciparum malaria and impact on gametocyte carriage rates in the East Nusatenggara province of Indonesia.
Topics: Adolescent; Adult; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance; Drug Th | 2004 |
Chlorproguanil-dapsone for malaria in Africa.
Topics: Africa; Animals; Antimalarials; Dapsone; Drug Combinations; Drug Resistance; Humans; Malaria, Falcip | 2004 |
Drug resistance in Plasmodium falciparum from the Chittagong Hill Tracts, Bangladesh.
Topics: Adolescent; Adult; Animals; Antimalarials; ATP-Binding Cassette Transporters; Bangladesh; Child; Chi | 2004 |
Plasmodium falciparum gametocyte carriage in asymptomatic children in western Kenya.
Topics: Adolescent; Age Factors; Animals; Antimalarials; Carrier State; Child; Child, Preschool; Cohort Stud | 2004 |
Malaria: use of restriction endonuclease digestion and mutation-specific PCR for antifolate resistance isolate detection.
Topics: Amino Acid Substitution; Animals; Antimalarials; DNA Mutational Analysis; DNA, Protozoan; Drug Resis | 2003 |
Molecular diagnosis of resistance to antimalarial drugs during epidemics and in war zones.
Topics: Animals; Antimalarials; Chloroquine; Cross-Sectional Studies; Disease Outbreaks; DNA, Protozoan; Dru | 2004 |
Risk of Plasmodium falciparum infection during a malaria epidemic in highland Kenya, 1997.
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Child, Preschool; Cohort Studies; Disease Outbreaks; | 2004 |
Monitoring susceptibility to sulfadoxine-pyrimethamine among cases of uncomplicated, Plasmodium falciparum malaria in Saharevo, Madagascar.
Topics: Animals; Antimalarials; Child; Child, Preschool; Drug Combinations; Female; Humans; Madagascar; Mala | 2004 |
Intercontinental spread of pyrimethamine-resistant malaria.
Topics: Africa; Alleles; Animals; Antimalarials; Asia, Southeastern; Chloroquine; Drug Resistance; Drug Ther | 2004 |
Two mutations in dihydrofolate reductase combined with one in the dihydropteroate synthase gene predict sulphadoxine-pyrimethamine parasitological failure in Ugandan children with uncomplicated falciparum malaria.
Topics: Animals; Antimalarials; Child, Preschool; Dihydropteroate Synthase; Drug Combinations; Drug Resistan | 2004 |
Extrapyramidal syndrome after treatment of falciparum malaria with sulphadoxine-pyrimethamine.
Topics: Adult; Animals; Antimalarials; Basal Ganglia Diseases; Drug Hypersensitivity; Drug Therapy, Combinat | 2004 |
Rare, highly pyrimethamine-resistant alleles of the Plasmodium falciparum dihydrofolate reductase gene from 5 African sites.
Topics: Alleles; Amino Acid Substitution; Animals; Antimalarials; Dapsone; Drug Resistance; Gabon; Genes, Pr | 2004 |
Knowledge of malaria influences the use of insecticide treated nets but not intermittent presumptive treatment by pregnant women in Tanzania.
Topics: Adult; Age Factors; Anemia; Antimalarials; Bedding and Linens; Drug Combinations; Educational Status | 2004 |
Stopping the spread of drug-resistant malaria.
Topics: Africa; Animals; Antimalarials; Asia; Communicable Disease Control; Drug Resistance; Humans; Malaria | 2004 |
Plasmodium falciparum resistant to chloroquine and to pyrimethamine in Comoros.
Topics: Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Comoros; DNA, Protozoan; Drug Resistan | 2004 |
Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo re
Topics: Animals; Antimalarials; Child, Preschool; Dihydropteroate Synthase; Drug Combinations; Drug Resistan | 2004 |
Adherence to antimalarial combination therapy with sulfadoxine-pyrimethamine and artesunate in rural Tanzania.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Drug Combinatio | 2004 |
Influence of chemotherapy on the Plasmodium gametocyte sex ratio of mice and humans.
Topics: Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Female; Humans; Inf | 2004 |
Principal role of dihydropteroate synthase mutations in mediating resistance to sulfadoxine-pyrimethamine in single-drug and combination therapy of uncomplicated malaria in Uganda.
Topics: Alleles; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Dihydropteroate | 2004 |
Comparative effects of pyrimethamine-sulfadoxine, with and without probenecid, on Plasmodium falciparum gametocytes in children with acute, uncomplicated malaria.
Topics: Acute Disease; Animals; Antimalarials; Child; Drug Combinations; Drug Therapy, Combination; Endemic | 2004 |
[Assessment of sulfadoxine-pyriméthamine (Fansidar, Paludar) efficacy in patients with uncomplicated malaria in Madagascar: preliminary study to propose a simplified study protocol].
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Climate; Drug Administration Schedule; Dr | 2003 |
Mefloquine--its 20 years in the Thai Malaria Control Program.
Topics: Animals; Antimalarials; Communicable Disease Control; Contraindications; Drug Combinations; Drug Res | 2004 |
Nosocomial Plasmodium falciparum infections confirmed by molecular typing in Medellín, Colombia.
Topics: Adult; Animals; Antigens, Protozoan; Colombia; Cross Infection; Drug Combinations; Equipment Contami | 2005 |
A simple, high-throughput method to detect Plasmodium falciparum single nucleotide polymorphisms in the dihydrofolate reductase, dihydropteroate synthase, and P. falciparum chloroquine resistance transporter genes using polymerase chain reaction- and enzy
Topics: Animals; Antimalarials; Chloroquine; Dihydropteroate Synthase; DNA Primers; DNA, Protozoan; Drug Com | 2005 |
The search for effective and sustainable treatments for Plasmodium falciparum malaria in Africa: a model of the selection of resistance by antifolate drugs and their combinations.
Topics: Africa; Animals; Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Resistance; Drug T | 2005 |
Plasmodium falciparum: evaluation of a quantitative nucleic acid sequence-based amplification assay to predict the outcome of sulfadoxine-pyrimethamine treatment of uncomplicated malaria.
Topics: Animals; Antimalarials; Child, Preschool; Dihydropteroate Synthase; Drug Combinations; Drug Resistan | 2005 |
The quality of sulfadoxine-pyrimethamine prescriptions, counselling and drug-dispensing practices, for children in Kenya.
Topics: Animals; Antimalarials; Child; Community Health Workers; Counseling; Drug Administration Schedule; D | 2005 |
Evaluation of chloroquine (CQ) and sulphadoxine/pyrimethamine (SP) therapy in uncomplicated falciparum malaria in Indo-Myanmar border areas.
Topics: Adolescent; Adult; Age Distribution; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; D | 2005 |
The role of sequential administration of sulphadoxine/pyrimethamine following quinine in the treatment of severe falciparum malaria in children.
Topics: Administration, Oral; Animals; Antimalarials; Child, Preschool; Drug Administration Schedule; Drug C | 2005 |
Efficacy of amodiaquine in uncomplicated falciparum malaria in Nigeria in an area with high-level resistance to chloroquine and sulphadoxine/pyrimethamine.
Topics: Amodiaquine; Animals; Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistan | 2005 |
Reduced variation around drug-resistant dhfr alleles in African Plasmodium falciparum.
Topics: Africa; Alleles; Animals; Antimalarials; Drug Combinations; Drug Resistance; Gene Frequency; Genes, | 2005 |
Plasmodium falciparum: higher incidence of molecular resistance markers for sulphadoxine than for pyrimethamine in Kasangati, Uganda.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Codon; Dihydroptero | 2005 |
Stevens-Johnson syndrome in two children in Ghana following anti-malarial treatment.
Topics: Antimalarials; Child; Drug Combinations; Female; Fever; Ghana; Humans; Malaria, Falciparum; Male; Py | 2005 |
Malaria cure with sulphadoxine/pyrimethamine combination in 12 semi-immune adults from West-Central Africa with high rates of point mutations in Plasmodium falciparum dhfr and dhps genes.
Topics: Africa, Central; Africa, Western; Animals; Antimalarials; Dihydropteroate Synthase; Drug Combination | 2005 |
Rapid increase in resistance of Plasmodium falciparum to chloroquine-Fansidar in Uganda and the potential of amodiaquine-Fansidar as a better alternative.
Topics: Amodiaquine; Animals; Antimalarials; Child, Preschool; Chloroquine; Clinical Trials as Topic; Drug C | 2005 |
Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria.
Topics: Animals; Antimalarials; Child; Child, Preschool; Dihydropteroate Synthase; Drug Combinations; Drug R | 2005 |
Effectiveness of antimalarial drugs.
Topics: Adult; Antimalarials; Child; Chloroquine; Drug Combinations; Drug Resistance; Drug Therapy, Combinat | 2005 |
Effects of antifolates--co-trimoxazole and pyrimethamine-sulfadoxine--on gametocytes in children with acute, symptomatic, uncomplicated, Plasmodium falciparum malaria.
Topics: Acute Disease; Animals; Antimalarials; Child; Child, Preschool; Drug Combinations; Drug Therapy, Com | 2005 |
A molecular epidemiologic study of point mutations for pyrimethamine-sulfadoxine resistance of Plasmodium falciparum isolates from Lao PDR.
Topics: Animals; Antimalarials; Codon; Dihydropteroate Synthase; Drug Resistance; Humans; Laos; Malaria, Fal | 2005 |
Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian children.
Topics: Animals; Antimalarials; Child; Child, Preschool; Drug Combinations; Drug Resistance; Female; Genotyp | 2005 |
Mutations associated with sulfadoxine-pyrimethamine and chlorproguanil resistance in Plasmodium falciparum isolates from Blantyre, Malawi.
Topics: Animals; Antimalarials; DNA Primers; Drug Combinations; Drug Resistance; Folic Acid Antagonists; Hum | 2005 |
Plasmodium falciparum dhfr but not dhps mutations associated with sulphadoxine-pyrimethamine treatment failure and gametocyte carriage in northern Ghana.
Topics: Animals; Antimalarials; Child, Preschool; Dihydropteroate Synthase; Drug Combinations; Drug Resistan | 2005 |
Artesunate plus sulfadoxine-pyrimethamine for treatment of uncomplicated Plasmodium falciparum malaria in Sudan.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Drug Combinatio | 2005 |
Detection of Plasmodium falciparum in pregnancy by laser desorption mass spectrometry.
Topics: Adult; Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Female; Genotype; Hu | 2005 |
Rare Congolese Plasmodium falciparum DHFR alleles.
Topics: Alleles; Animals; Antimalarials; Child, Preschool; Congo; Drug Combinations; Drug Resistance; Genes, | 2005 |
Epidemiology of drug-resistant malaria in Republic of Congo: using molecular evidence for monitoring antimalarial drug resistance combined with assessment of antimalarial drug use.
Topics: Antimalarials; Biomarkers; Child, Preschool; Chloroquine; Congo; Dihydropteroate Synthase; Drug Comb | 2005 |
Adoption of the new antimalarial drug policy in Tanzania--a cross-sectional study in the community.
Topics: Antimalarials; Artemisinins; Child, Preschool; Chloroquine; Cross-Sectional Studies; Drug Combinatio | 2005 |
Research influence on antimalarial drug policy change in Tanzania: case study of replacing chloroquine with sulfadoxine-pyrimethamine as the first-line drug.
Topics: Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Health Policy; Humans; Mala | 2005 |
Increased density but not prevalence of gametocytes following drug treatment of Plasmodium falciparum.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; Drug Combinations; Drug Resistance; H | 2006 |
Efficacy of sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in Ethiopia.
Topics: Adolescent; Animals; Antimalarials; Child; Child, Preschool; Drug Combinations; Drug Therapy, Combin | 2005 |
Use of intermittent preventive treatment for malaria in pregnancy in a rural area of western Kenya with high coverage of insecticide-treated bed nets.
Topics: Adult; Antimalarials; Bedding and Linens; Cross-Sectional Studies; Drug Combinations; Endemic Diseas | 2005 |
Intermittent preventive treatment for malaria in infants: moving forward, cautiously.
Topics: Antimalarials; Chemoprevention; Drug Administration Schedule; Drug Combinations; Humans; Infant; Mal | 2005 |
Efficacy of sulfadoxine-pyrimethamine in Tanzania after two years as first-line drug for uncomplicated malaria: assessment protocol and implication for treatment policy strategies.
Topics: Animals; Antigens, Protozoan; Antimalarials; Body Temperature; Child, Preschool; Drug Combinations; | 2005 |
Efficacy of chloroquine, sulfadoxine-pyrimethamine and amodiaquine for treatment of uncomplicated Plasmodium falciparum malaria among children under five in Bongor and Koumra, Chad.
Topics: Amodiaquine; Animals; Chad; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance; Drug | 2006 |
In vitro processing of donor blood with sulfadoxine-pyrimethamine for eradication of transfusion-induced malaria.
Topics: Adult; Animals; Antimalarials; Blood Coagulation Tests; Blood Donors; Blood Transfusion; Blood-Borne | 2005 |
Molecular surveillance of mutations in dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum in Ethiopia.
Topics: Animals; Antimalarials; Dihydropteroate Synthase; DNA Primers; DNA, Protozoan; Drug Combinations; Dr | 2005 |
Development of resistance by Plasmodium falciparum to sulfadoxine/pyrimethamine in Amhara Region, Northwestern Ethiopia.
Topics: Animals; Antimalarials; Child; Drug Resistance; Drug Therapy, Combination; Ethiopia; Female; Humans; | 2005 |
CD4 T cell activation as a predictor for treatment failure in Ugandans with Plasmodium falciparum malaria.
Topics: Adolescent; Adult; Age Factors; Animals; Antimalarials; Body Temperature; CD4-Positive T-Lymphocytes | 2006 |
The efficacies of artesunate-sulfadoxine-pyrimethamine and artemether-lumefantrine in the treatment of uncomplicated, Plasmodium falciparum malaria, in an area of low transmission in central Sudan.
Topics: Adolescent; Adult; Age Distribution; Antimalarials; Artemether; Artemisinins; Artesunate; Child; Chi | 2006 |
Artesunate plus sulfadoxine-pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria during pregnancy in eastern Sudan.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combina | 2006 |
Pyrimethamine-sulfadoxine treatment of uncomplicated Plasmodium falciparum malaria in Lao PDR.
Topics: Adolescent; Adult; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Laos; Malaria | 2005 |
Point mutations in the dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum and resistance to sulfadoxine-pyrimethamine in Sri Lanka.
Topics: Animals; Antimalarials; Dihydropteroate Synthase; DNA Primers; Drug Combinations; Drug Resistance, M | 2006 |
Frequency distribution of antimalarial drug-resistant alleles among isolates of Plasmodium falciparum in Bangui, Central African Republic.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Central African Rep | 2006 |
Reaching the Abuja target for intermittent preventive treatment of malaria in pregnancy in African women: a review of progress and operational challenges.
Topics: Africa South of the Sahara; Antimalarials; Attitude to Health; Delivery of Health Care, Integrated; | 2006 |
Prevalence of malaria parasitemia among clients seeking treatment for fever or malaria at drug stores in rural Tanzania 2004.
Topics: Adult; Amodiaquine; Analgesics, Non-Narcotic; Anemia; Antimalarials; Child, Preschool; Drug Combinat | 2006 |
The costs of changing national policy: lessons from malaria treatment policy guidelines in Tanzania.
Topics: Amodiaquine; Antimalarials; Chloroquine; Clinical Protocols; Drug Combinations; Health Care Costs; H | 2006 |
Microscopy and outpatient malaria case management among older children and adults in Kenya.
Topics: Adolescent; Adult; Ambulatory Care; Amodiaquine; Antimalarials; Case Management; Child; Cross-Sectio | 2006 |
Prevention of malaria during pregnancy in West Africa: policy change and the power of subregional action.
Topics: Africa, Western; Antimalarials; Chloroquine; Communication Barriers; Drug Combinations; Drug Resista | 2006 |
Rapid selection of dhfr mutant allele in Plasmodium falciparum isolates after the introduction of sulfadoxine/pyrimethamine in combination with 4-aminoquinolines in Papua New Guinea.
Topics: Alleles; Aminoquinolines; Animals; Dihydropteroate Synthase; Drug Combinations; Drug Resistance, Mul | 2006 |
Polymerase chain reaction and molecular genotyping to monitor parasitological response to anti-malarial chemotherapy in the Peruvian Amazon.
Topics: Adolescent; Adult; Animals; Anopheles; Antimalarials; Child; Cohort Studies; DNA, Protozoan; Drug Co | 2006 |
The efficacy of sulfadoxine-pyrimethamine alone and in combination with chloroquine for malaria treatment in rural Eastern Sudan: the interrelation between resistance, age and gametocytogenesis.
Topics: Adolescent; Adult; Age Distribution; Antimalarials; Child; Chloroquine; Cohort Studies; Drug Combina | 2006 |
Plasmodium falciparum infection dynamics and transmission potential following treatment with sulfadoxine-pyrimethamine.
Topics: Algorithms; Animals; Antimalarials; Drug Combinations; Drug Resistance; Humans; Malaria, Falciparum; | 2006 |
Short report: Dynamics of Plasmodium falciparum malaria after sub-optimal therapy in Uganda.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Disease-Free Surviv | 2006 |
Therapeutic efficacy of sulphadoxine-pyrimethamine and chloroquine for the treatment of uncomplicated malaria in pregnancy in Burkina Faso.
Topics: Adolescent; Adult; Burkina Faso; Chloroquine; Contraindications; Drug Combinations; Female; Follow-U | 2006 |
Antifolate resistance in Plasmodium falciparum: multiple origins and identification of novel dhfr alleles.
Topics: Alleles; Animals; Antimalarials; Drug Combinations; Drug Resistance; Folic Acid Antagonists; Genotyp | 2006 |
High prevalence of drug-resistance mutations in Plasmodium falciparum and Plasmodium vivax in southern Ethiopia.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; | 2006 |
Protecting pregnant women from malaria in areas of high HIV infection prevalence.
Topics: Africa South of the Sahara; Antimalarials; Chemoprevention; Disease Outbreaks; Drug Combinations; Fe | 2006 |
From chloroquine to artemisinin-based combination therapy: the Sudanese experience.
Topics: Antimalarials; Artemether; Artemisinins; Artesunate; Chloroquine; Drug Combinations; Drug Therapy, C | 2006 |
[Knowledge and practice among health workers from the Thiès region with regard to new malaria treatment policies].
Topics: Amodiaquine; Antimalarials; Chloroquine; Clinical Competence; Community Health Services; Drug Combin | 2006 |
Correlations between treatment outcome and both anti-MSP119 antibody response and erythrocyte-related genetic factors in Plasmodium falciparum malaria.
Topics: Amodiaquine; Animals; Antibodies, Protozoan; Antigens, Protozoan; Antimalarials; Child; Child, Presc | 2007 |
Relationship between antipyretic effects and cytokine levels in uncomplicated falciparum malaria during different treatment regimes.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Antimalarials; Child, Preschool; Chloroquine; Cyto | 2006 |
Cotrimoxazole prophylaxis and malaria in Africa: Have the important questions been answered?
Topics: HIV Infections; Humans; Malaria, Falciparum; Pyrimethamine; Sulfadoxine; Sulfamethoxazole; Trimethop | 2006 |
Effect of cotrimoxazole prophylaxis taken by human immunodeficiency virus (HIV)-infected persons on the selection of sulfadoxine-pyrimethamine-resistant malaria parasites among HIV-uninfected household members.
Topics: Animals; Antimalarials; Cohort Studies; Drug Combinations; Drug Resistance; Family; HIV Infections; | 2006 |
Molecular epidemiology of malaria in Cameroon. XXI. Baseline therapeutic efficacy of chloroquine, amodiaquine, and sulfadoxine-pyrimethamine monotherapies in children before national drug policy change.
Topics: Amodiaquine; Antimalarials; Cameroon; Child; Chloroquine; Drug Combinations; Health Policy; Humans; | 2006 |
Prevalence of mutations associated with higher levels of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum isolates from Car Nicobar Island and Assam, India.
Topics: Animals; Antimalarials; Codon; Dihydropteroate Synthase; DNA, Protozoan; Drug Combinations; Drug Res | 2006 |
Submicroscopic Plasmodium falciparum infections before and after sulfadoxine-pyrimethamine and artesunate association treatment in Dienga, Southeastern Gabon.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Artemisinins; Artesunate; DNA, Protozoan; Drug Comb | 2006 |
Use of area under the curve to characterize transmission potential after antimalarial treatment.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Area Under Curve; Child; Child, Preschool; Dihydrop | 2006 |
Therapeutic efficacy of quinine plus sulfadoxine-pyremethamine for the treatment of uncomplicated falciparum malaria in Bangladesh.
Topics: Adolescent; Adult; Animals; Antimalarials; Bangladesh; Chloroquine; Drug Combinations; Drug Resistan | 2006 |
Drug resistance to sulphadoxine-pyrimethamine in Plasmodium falciparum malaria in Mlimba, Tanzania.
Topics: Animals; Antimalarials; Child, Preschool; Dihydropteroate Synthase; Drug Combinations; Drug Resistan | 2006 |
HIV immunosuppression and antimalarial efficacy: sulfadoxine-pyrimethamine for the treatment of uncomplicated malaria in HIV-infected adults in Siaya, Kenya.
Topics: Adult; Anemia; Antimalarials; CD4 Lymphocyte Count; Drug Combinations; Female; Fever; HIV Infections | 2006 |
Markers of sulfadoxine-pyrimethamine-resistant Plasmodium falciparum in placenta and circulation of pregnant women.
Topics: Adolescent; Adult; Animals; Antimalarials; Biomarkers; Drug Combinations; Drug Resistance; Female; G | 2007 |
Decreased availability of antimalarials in the private sector following the policy change from chloroquine to sulphadoxine-pyrimethamine in the Kilombero Valley, Tanzania.
Topics: Analgesics, Non-Narcotic; Antimalarials; Chloroquine; Drug Combinations; Health Policy; Humans; Mala | 2006 |
A multiplex ligase detection reaction-fluorescent microsphere assay for simultaneous detection of single nucleotide polymorphisms associated with Plasmodium falciparum drug resistance.
Topics: Animals; Antimalarials; Chloroquine; Dihydropteroate Synthase; Drug Combinations; Drug Resistance; F | 2007 |
Consumers stated and revealed preferences for community health workers and other strategies for the provision of timely and appropriate treatment of malaria in southeast Nigeria.
Topics: Adult; Animals; Antimalarials; Chloroquine; Community Health Services; Community Health Workers; Con | 2006 |
Detection and clinical manifestation of placental malaria in southern Ghana.
Topics: Animals; Antigens, Protozoan; Antimalarials; Female; Ghana; Humans; Malaria, Falciparum; Microscopy, | 2006 |
Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications.
Topics: Adolescent; Adult; Aging; Area Under Curve; Child; Child, Preschool; Dose-Response Relationship, Dru | 2006 |
Rapid dissemination of Plasmodium falciparum drug resistance despite strictly controlled antimalarial use.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Fe | 2007 |
Independent evolution of pyrimethamine resistance in Plasmodium falciparum isolates in Melanesia.
Topics: Animals; Antimalarials; Biological Evolution; Cross-Sectional Studies; DNA, Protozoan; Drug Resistan | 2007 |
Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Dihydropteroate Synthase; Drug C | 2007 |
Common origin and fixation of Plasmodium falciparum dhfr and dhps mutations associated with sulfadoxine-pyrimethamine resistance in a low-transmission area in South America.
Topics: Adult; Animals; Antimalarials; Dihydropteroate Synthase; Drug Combinations; Drug Resistance; Genotyp | 2007 |
Antimalarial drug combinations in vastly different settings.
Topics: Amodiaquine; Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Burkin | 2007 |
Effects of pyrimethamine-sulphadoxine, chloroquine plus chlorpheniramine, and amodiaquine plus pyrimethamine-sulphadoxine on gametocytes during and after treatment of acute, uncomplicated malaria in children.
Topics: Acute Disease; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Chlorpheni | 2006 |
Sustained use of insecticide-treated curtains is not associated with greater circulation of drug-resistant malaria parasites, or with higher risk of treatment failure among children with uncomplicated malaria in Burkina Faso.
Topics: Animals; Antimalarials; Bedding and Linens; Burkina Faso; Child, Preschool; Chloroquine; Cross-Secti | 2007 |
Sulfadoxine-pyrimethamine susceptibilities and analysis of the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum isolates from Côte d'Ivoire.
Topics: Animals; Antimalarials; Child, Preschool; Cote d'Ivoire; Dihydropteroate Synthase; Drug Combinations | 2007 |
Efficacy of combined treatment with alpha/beta-arteether and sulfadoxine-pyrimethamine, for cases of Plasmodium falciparum malaria in Jharkhand, India.
Topics: Adolescent; Adult; Aged; Antimalarials; Artemisinins; Child; Drug Combinations; Female; Humans; Indi | 2007 |
Analysis of sulphadoxine/pyrimethamine resistance-conferring mutations of Plasmodium falciparum from Mozambique reveals the absence of the dihydrofolate reductase 164L mutant.
Topics: Adolescent; Animals; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Codon; Dihydr | 2007 |
Diagnosis and treatment of malaria in peripheral health facilities in Uganda: findings from an area of low transmission in south-western Uganda.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care Facilities; Animals; Child; Child, Presc | 2007 |
Therapeutic efficacy of sulfadoxin/pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria in Enseno, Meskan Woreda, Gurage zone, SNNPR, Ethiopia.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Cross-Sectional Studies; Drug Combination | 2006 |
Subclinical Plasmodium falciparum infection and HIV-1 viral load.
Topics: Adult; Animals; Antimalarials; Drug Combinations; HIV Infections; HIV-1; Humans; Infant; Kenya; Mala | 2007 |
A shared Asian origin of the triple-mutant dhfr allele in Plasmodium falciparum from sites across Africa.
Topics: Africa; Alleles; Amino Acid Substitution; Animals; Antimalarials; Child; Child, Preschool; Drug Resi | 2007 |
Molecular surveillance for drug-resistant Plasmodiumfalciparum malaria in Malawi.
Topics: Animals; Antimalarials; Chloroquine; Dihydropteroate Synthase; DNA, Protozoan; Drug Combinations; Dr | 2007 |
[Assessment of the efficacy of antimalarial drugs in Tarapacá, in the Colombian Amazon basin].
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Child; Child, Preschool; Colombia; Female; Humans; In | 2007 |
High prevalence of molecular markers for resistance to chloroquine and pyrimethamine in Plasmodium falciparum from Zimbabwe.
Topics: Adolescent; Adult; Animals; Antimalarials; Chloroquine; DNA, Protozoan; Drug Combinations; Drug Resi | 2007 |
Detection of drug resistance markers for chloroquine and pyrimethamine-sulfadoxine in Jazan area, Saudi Arabia using PCR and restriction digestion.
Topics: Animals; Antimalarials; Biomarkers; Chloroquine; Codon; Drug Combinations; Drug Resistance; Humans; | 2007 |
Combined molecular and clinical assessment of Plasmodium falciparum antimalarial drug resistance in the Lao People's Democratic Republic (Laos).
Topics: Adolescent; Animals; Antimalarials; Drug Combinations; Drug Resistance; Female; Humans; Laos; Malari | 2007 |
Molecular epidemiology of malaria in Cameroon. XXVII. Clinical and parasitological response to sulfadoxine-pyrimethamine treatment and Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase alleles in Cameroonian children.
Topics: Alleles; Animals; Antimalarials; Cameroon; Child; Child, Preschool; Dihydropteroate Synthase; Drug C | 2007 |
The implication of dihydrofolate reductase and dihydropteroate synthetase gene mutations in modification of Plasmodium falciparum characteristics.
Topics: Animals; Antimalarials; Chloroquine; Dihydropteroate Synthase; Drug Combinations; Drug Therapy, Comb | 2007 |
The influence of genetic innate resistance and acquired immunity on drug treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania.
Topics: Animals; Antimalarials; Awards and Prizes; Child, Preschool; Comorbidity; Cross-Sectional Studies; D | 2006 |
Molecular epidemiology of malaria in Cameroon. XXVI. Twelve-year in vitro and molecular surveillance of pyrimethamine resistance and experimental studies to modulate pyrimethamine resistance.
Topics: Adolescent; Animals; Antimalarials; Cameroon; DNA, Protozoan; Drug Resistance; Drug Therapy, Combina | 2007 |
The effect of health care worker training on the use of intermittent preventive treatment for malaria in pregnancy in rural western Kenya.
Topics: Adolescent; Adult; Antimalarials; Child; Cross-Sectional Studies; Drug Combinations; Endemic Disease | 2007 |
Selection of antifolate-resistant Plasmodium falciparum by sulfadoxine-pyrimethamine treatment and infectivity to Anopheles mosquitoes.
Topics: Animals; Anopheles; Antimalarials; Dihydropteroate Synthase; Drug Combinations; Drug Resistance; Fol | 2007 |
Therapeutic efficacy of sulfadoxine-pyrimethamine and the prevalence of molecular markers of resistance in under 5-year olds in Brazzaville, Congo.
Topics: Animals; Antimalarials; Child, Preschool; Congo; Dihydropteroate Synthase; Drug Combinations; Drug R | 2007 |
Decline of placental malaria in southern Ghana after the implementation of intermittent preventive treatment in pregnancy.
Topics: Adolescent; Adult; Anemia; Animals; Antimalarials; Birth Weight; Chemoprevention; Drug Administratio | 2007 |
Prevalence of mutations associated with antimalarial drugs in Plasmodium falciparum isolates prior to the introduction of sulphadoxine-pyrimethamine as first-line treatment in Iran.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Dihydropteroate Syn | 2007 |
Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum.
Topics: Amodiaquine; Animals; Antibodies, Protozoan; Child, Preschool; Drug Combinations; Drug Resistance; F | 2007 |
Decline in sulfadoxine-pyrimethamine-resistant alleles after change in drug policy in the Amazon region of Peru.
Topics: Alleles; Animals; Antimalarials; Dihydropteroate Synthase; Drug Combinations; Drug Resistance; Healt | 2008 |
Drug-resistant malaria parasites introduced into Madagascar from Comoros Islands.
Topics: Adult; Animals; Antimalarials; Child, Preschool; Chloroquine; Comoros; Drug Resistance, Multiple; Fe | 2007 |
Access and barriers to measures targeted to prevent malaria in pregnancy in rural Kenya.
Topics: Adolescent; Adult; Antimalarials; Bedding and Linens; Delivery of Health Care; Drug Combinations; Fe | 2008 |
Chloroquine resistant Plasmodium falciparum malaria in Osogbo Nigeria: efficacy of amodiaquine + sulfadoxine-pyrimethamine and chloroquine + chlorpheniramine for treatment.
Topics: Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Chlorpheniramine; Clinica | 2008 |
The usefulness of twenty-four molecular markers in predicting treatment outcome with combination therapy of amodiaquine plus sulphadoxine-pyrimethamine against falciparum malaria in Papua New Guinea.
Topics: Amodiaquine; Animals; Antimalarials; Biomarkers; Drug Combinations; Malaria, Falciparum; Papua New G | 2008 |
Assessment of the therapeutic efficacy of chloroquine in the treatment of uncomplicated Plasmodium falciparum malaria in a tribal block of the Kalahandi district of Orissa, India.
Topics: Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Humans; India; Malaria, Fal | 2008 |
Increased gametocytemia after treatment: an early parasitological indicator of emerging sulfadoxine-pyrimethamine resistance in falciparum malaria.
Topics: Adolescent; Adult; Animals; Antimalarials; Area Under Curve; Child; Dihydropteroate Synthase; Drug C | 2008 |
Escalating Plasmodium falciparum antifolate drug resistance mutations in Macha, rural Zambia.
Topics: Animals; Antimalarials; Child; Child, Preschool; DNA, Protozoan; Drug Resistance; Folic Acid Antagon | 2008 |
Severe malaria in children at Port Moresby General Hospital, Papua New Guinea.
Topics: Antimalarials; Child; Child, Preschool; Drug Combinations; Female; Glasgow Coma Scale; Hospitals, Ge | 1995 |
Tumour necrosis factor alpha in uncomplicated malaria in young adults.
Topics: Adolescent; Adult; Antimalarials; Case-Control Studies; Chloroquine; Drug Combinations; Enzyme-Linke | 1995 |
In vitro susceptibility of Plasmodium falciparum to chloroquine, amodiaquine, quinine, mefloquine, and sulfadoxine/pyrimethamine in Equatorial Guinea.
Topics: Amodiaquine; Animals; Antimalarials; Child; Chloroquine; Drug Combinations; Equatorial Guinea; Human | 1995 |
Congenital malaria in a hyperendemic area: a preliminary study.
Topics: Chloroquine; Cross-Sectional Studies; Developing Countries; Drug Administration Schedule; Female; Hu | 1993 |
Impact of transmission intensity and age on Plasmodium falciparum density and associated fever: implications for malaria vaccine trial design.
Topics: Age Factors; Animals; Anopheles; Antimalarials; Child; Child, Preschool; Clinical Trials as Topic; C | 1995 |
Efficacy of a 3-day oral regimen of quinine in an area of northern Nigeria with low-grade resistance of Plasmodium falciparum to chloroquine and sulphadoxine-pyrimethamine.
Topics: Administration, Oral; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Administrat | 1995 |
Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa.
Topics: Animals; Base Sequence; Child; DNA Primers; DNA, Protozoan; Drug Resistance; Folic Acid Antagonists; | 1995 |
Genetic changes in the population of Plasmodium falciparum in a Sudanese village over a three-year period.
Topics: Alleles; Aminohydrolases; Animals; Antigens, Protozoan; Antigens, Surface; Chloroquine; Electrophore | 1995 |
Sensitivity to antimalarial drugs by Plasmodium falciparum in Goundry, Oubritenga province, Burkina Faso.
Topics: Amodiaquine; Animals; Antimalarials; Burkina Faso; Child; Child, Preschool; Chloroquine; Drug Resist | 1994 |
Drug-resistant Plasmodium falciparum malaria in the eastern Transvaal.
Topics: Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Humans; Malaria, Falciparum | 1994 |
Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in Plasmodium falciparum.
Topics: Amino Acid Sequence; Animals; Base Sequence; Drug Resistance, Multiple; Humans; Malaria, Falciparum; | 1995 |
Antimalarials during pregnancy: a cost-effectiveness analysis.
Topics: Antimalarials; Chloroquine; Cost-Benefit Analysis; Decision Support Techniques; Drug Combinations; F | 1995 |
Congenitally acquired chloroquine-resistant P. falciparum malaria in an infant born in the United States.
Topics: Adult; Chloroquine; Drug Combinations; Drug Resistance; Female; Humans; Infant; Malaria, Falciparum; | 1995 |
Resistance of Plasmodium falciparum in vivo to 3 days' treatment with quinine and single-dose Fansidar.
Topics: Animals; Antimalarials; Child, Preschool; Drug Combinations; Drug Resistance; Humans; Infant; Malari | 1994 |
Treatment of hyperreactive malarial splenomegaly syndrome.
Topics: Adult; Female; Humans; Leucovorin; Malaria, Falciparum; Male; Pyrimethamine; Splenomegaly; Syndrome | 1994 |
Response of chloroquine-resistant falciparum malaria to sulfadoxine/pyrimethamine in Gokwe area of Zimbabwe.
Topics: Adult; Antimalarials; Child; Chloroquine; Drug Combinations; Drug Monitoring; Drug Resistance; Follo | 1994 |
Ten-year surveillance of drug-resistant malaria in Burkina Faso (1982-1991).
Topics: Adolescent; Animals; Antimalarials; Burkina Faso; Child; Chloroquine; Drug Resistance; Humans; Longi | 1994 |
Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa.
Topics: Adult; Antimalarials; Chloroquine; Female; Humans; Kenya; Malaria, Falciparum; Male; Mefloquine; Mid | 1993 |
Chloroquine-resistant falciparum malaria in an area of rising endemicity in Zimbabwe.
Topics: Absenteeism; Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Diseas | 1994 |
Mefloquine level monitoring in patients with multidrug resistant Plasmodium falciparum on the Thai Myanmar border.
Topics: Administration, Oral; Adolescent; Adult; Antimalarials; Cambodia; Chromatography, High Pressure Liqu | 1993 |
Sulphadoxine-pyrimethamine and chloroquine resistant Plasmodium falciparum infection in Sri Lanka.
Topics: Adult; Animals; Chloroquine; Drug Combinations; Drug Resistance; Humans; Malaria, Falciparum; Male; | 1994 |
Stable molecular transformation of Toxoplasma gondii: a selectable dihydrofolate reductase-thymidylate synthase marker based on drug-resistance mutations in malaria.
Topics: Animals; Cells, Cultured; Chromosome Mapping; DNA, Protozoan; Drug Resistance; Genes, Protozoan; Gen | 1993 |
[Acute respiratory failure in tropical malaria during pregnancy. Successful treatment using extracorporeal CO2 elimination].
Topics: Acute Disease; Adult; Carbon Dioxide; Cesarean Section; Chloroquine; Drug Therapy, Combination; Extr | 1993 |
Assessment of the response in vivo and in vitro of Plasmodium falciparum to sulphadoxine-pyrimethamine in the malarious areas of Iran.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amodiaquine; Animals; Child; Child, Preschool; Chloroqui | 1993 |
Falciparum malaria: differential effects of antimalarial drugs on ex vivo parasite viability during the critical early phase of therapy.
Topics: Animals; Antimalarials; Drug Combinations; Drug Therapy, Combination; Humans; Malaria, Falciparum; P | 1993 |
Sensitivity of Plasmodium falciparum to pyrimethamine in vivo and to sulphadoxine/pyrimethamine combination in vitro in pregnant women of northern Nigeria.
Topics: Adolescent; Adult; Animals; Drug Combinations; Drug Resistance; Female; Follow-Up Studies; Humans; M | 1993 |
[Mefloquine and sulfadoxine/pyrimethamine overdose in malaria tropica].
Topics: Adult; Diazepam; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combi | 1993 |
A case of dual chloroquine and halofantrine treatment failure in Zimbabwe.
Topics: Adult; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Humans; Malaria, Falciparum; | 1995 |
Malaria among United States troops in Somalia.
Topics: Anti-Bacterial Agents; Antimalarials; Chemoprevention; Chloroquine; Clothing; Cohort Studies; Doxycy | 1996 |
Clinical algorithm for malaria in Africa.
Topics: Antimalarials; Clinical Protocols; Drug Combinations; Humans; Malaria, Falciparum; Pyrimethamine; Su | 1996 |
Clinical algorithm for malaria in Africa.
Topics: Africa; Antimalarials; Child; Clinical Protocols; Drug Combinations; Humans; Malaria, Falciparum; Py | 1996 |
Evaluation of maternal practices, efficacy, and cost-effectiveness of alternative antimalarial regimens for use in pregnancy: chloroquine and sulfadoxine-pyrimethamine.
Topics: Antimalarials; Chloroquine; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Health Knowled | 1996 |
Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea.
Topics: Animals; Antimalarials; Base Sequence; Dihydropteroate Synthase; DNA Primers; Drug Resistance; Folic | 1996 |
Minimal effective dose of mefloquine/sulfadoxine/pyrimethamine in mild Plasmodium falciparum malaria.
Topics: Adolescent; Antimalarials; Child; Drug Therapy, Combination; Female; Humans; Malaria, Falciparum; Ma | 1995 |
Plasmodium falciparum: mutation pattern in the dihydrofolate reductase-thymidylate synthase genes of Vietnamese isolates, a novel mutation, and coexistence of two clones in a Thai patient.
Topics: Animals; Antimalarials; Base Sequence; DNA, Protozoan; Drug Resistance; Folic Acid Antagonists; Huma | 1996 |
Community pyrimethamine-sulfadoxine use and prevalence of resistant Plasmodium falciparum genotypes in Mali: a model for deterring resistance.
Topics: Adolescent; Adult; Africa; Animals; Antimalarials; Cross-Sectional Studies; Drug Combinations; Drug | 1996 |
[Mechanisms and epidemiology of resistances to antimalarials].
Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Drug Resistance, Multiple; Humans; Malaria, Fa | 1996 |
Chloroquine resistance of Plasmodium falciparum malaria in Ethiopia and Eritrea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Child; Child, Preschool; Chloroquine; Dru | 1996 |
High prevalence of chloroquine resistant Plasmodium falciparum infection in Rajasthan epidemic.
Topics: Animals; Antibodies, Protozoan; Antimalarials; Chloroquine; Disease Outbreaks; Drug Resistance, Micr | 1996 |
Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization.
Topics: Alleles; Animals; Antimalarials; Dihydropteroate Synthase; Drug Antagonism; Drug Combinations; Drug | 1997 |
Resurgence of malaria and drug resistance in plasmodium falciparum and plasmodium vivax species in Bombay.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Cross-Section | 1995 |
Resistance to pyrimethamine/sulfadoxine in Plasmodium falciparum in 12 villages in north east Tanzania and a test of chlorproguanil/dapsone.
Topics: Anti-Infective Agents; Antimalarials; Child; Child, Preschool; Dapsone; Drug Resistance, Microbial; | 1997 |
Malaria in Mvumi, central Tanzania and the in vivo response of Plasmodium falciparum to chloroquine and sulphadoxine pyrimethamine.
Topics: Adolescent; Adult; Aged; Animals; Anopheles; Antimalarials; Child; Chloroquine; Cross-Sectional Stud | 1997 |
In vivo sensitivity of Plasmodium falciparum to chloroquine and sulfadoxine-pyrimethamine in school children in Hoima district, western Uganda.
Topics: Antimalarials; Child; Chloroquine; Drug Combinations; Drug Resistance; Humans; Malaria, Falciparum; | 1997 |
Efficacy of sulfadoxine-pyrimethamine in chloroquine resistant falciparum malaria in Bombay.
Topics: Adult; Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Female; Humans; Indi | 1996 |
Modified antimalarial treatment for chloroquin resistant plasmodium falciparum infection.
Topics: Antimalarials; Chloroquine; Drug Resistance; Endemic Diseases; Humans; Malaria, Falciparum; Pyrimeth | 1995 |
In vitro sensitivity of Plasmodium falciparum to anti-folinic agents (trimethoprim, pyrimethamine, cycloguanil): a study of 29 African strains.
Topics: Animals; Antimalarials; Confidence Intervals; Drug Resistance; Folic Acid Antagonists; Humans; Letha | 1997 |
Parasitological and haematological responses to treatment of Plasmodium falciparum malaria with sulphadoxine-pyrimethamine in southern Malawi.
Topics: Anemia; Antimalarials; Child, Preschool; Drug Combinations; Female; Follow-Up Studies; Hemoglobins; | 1997 |
Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins.
Topics: Africa; Alleles; Animals; Antimalarials; Dihydropteroate Synthase; DNA Mutational Analysis; Drug Com | 1997 |
Plasmodium falciparum: evaluation of lactate dehydrogenase in monitoring therapeutic responses to standard antimalarial drugs in Nigeria.
Topics: Adolescent; Adult; Antimalarials; Artemether; Artemisinins; Child; Child, Preschool; Chloroquine; Dr | 1997 |
Resistance of falciparum malaria to chloroquine and sulfadoxine-pyrimethamine in Afghan refugee settlements in western Pakistan: surveys by the general health services using a simplified in vivo test.
Topics: Adolescent; Adult; Afghanistan; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinatio | 1997 |
High prevalence of mutations in the dihydrofolate reductase gene of Plasmodium falciparum in isolates from Tanzania without evidence of an association to clinical sulfadoxine/pyrimethamine resistance.
Topics: Animals; Antimalarials; Child; Child, Preschool; DNA, Protozoan; Drug Combinations; Drug Resistance; | 1997 |
Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance.
Topics: Africa; Amino Acid Sequence; Animals; Antimalarials; Base Sequence; Bolivia; Cloning, Molecular; Dih | 1997 |
A simplified in vivo drug sensitivity test for malaria in the field.
Topics: Adult; Animals; Antimalarials; Child; Chloroquine; Drug Combinations; Drug Resistance; Female; Human | 1997 |
The use of personal protective measures in control of malaria in a defined community.
Topics: Adult; Antimalarials; Bedding and Linens; Case-Control Studies; Child; Clothing; Female; Humans; Inf | 1997 |
Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain.
Topics: Animals; Antimalarials; Humans; Kenya; Malaria, Falciparum; Plasmodium falciparum; Point Mutation; P | 1998 |
Enhanced gametocyte production in Fansidar-treated Plasmodium falciparum malaria patients: implications for malaria transmission control programmes.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Culicidae; Drug Combinations; Female; Humans; Inse | 1997 |
Antifolate-resistant malaria infections in Mpumalanga.
Topics: Antimalarials; Chloroquine; Drug Resistance, Multiple; Folic Acid Antagonists; Humans; Malaria, Falc | 1998 |
Identification of a subpopulation of immune Nigerian adult volunteers by antibodies to the circumsporozoite protein of Plasmodium falciparum.
Topics: Adult; Animals; Antigens, Protozoan; Antimalarials; Cohort Studies; Drug Combinations; Female; Human | 1998 |
Molecular assays for surveillance of antifolate-resistant malaria.
Topics: Animals; Antimalarials; Child; Dihydropteroate Synthase; DNA, Protozoan; Drug Resistance; Folic Acid | 1998 |
An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi.
Topics: Adolescent; Adult; Antimalarials; Birth Weight; Drug Therapy, Combination; Female; Humans; Infant, L | 1998 |
Molecular basis of in vivo resistance to sulfadoxine-pyrimethamine in African adult patients infected with Plasmodium falciparum malaria parasites.
Topics: Adolescent; Adult; Animals; Antimalarials; Drug Combinations; Drug Resistance; Female; Humans; Malar | 1998 |
A systematic approach to the development of a rational malaria treatment policy in Zambia.
Topics: Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Evaluation; Drug Resist | 1998 |
Surveillance of antifolate-resistant malaria.
Topics: Africa; Animals; Antimalarials; Codon; Dihydropteroate Synthase; Drug Resistance; Folic Acid; Genoty | 1998 |
Polymorphisms in the dihydrofolate reductase (DHFR) and dihydropteroate synthetase (DHPS) genes of Plasmodium falciparum and in vivo resistance to sulphadoxine/pyrimethamine in isolates from Tanzania.
Topics: Animals; Antimalarials; Child; Child, Preschool; Dihydropteroate Synthase; DNA Primers; Drug Resista | 1998 |
[The proper use of antimalarial drugs currently available].
Topics: Animals; Antimalarials; Chemoprevention; Chloroquine; Contraindications; Drug Combinations; Drug Res | 1998 |
Increased prevalence of malaria in HIV-infected pregnant women and its implications for malaria control.
Topics: Adult; AIDS-Related Opportunistic Infections; Antimalarials; Cross-Sectional Studies; Drug Combinati | 1999 |
More on 'the efficacy of antifolate antimalarial combinations in Africa'.
Topics: Africa; Animals; Antimalarials; Dihydropteroate Synthase; Drug Combinations; Drug Resistance; Humans | 1999 |
Selection and synergy in Plasmodium falciparum.
Topics: Africa; Animals; Antimalarials; Dihydropteroate Synthase; Drug Combinations; Drug Resistance; Drug S | 1999 |
In vivo responses to antimalarials by Plasmodium falciparum and Plasmodium vivax from isolated Gag Island off northwest Irian Jaya, Indonesia.
Topics: Adolescent; Adult; Age Distribution; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; D | 1999 |
Averting a malaria disaster.
Topics: Animals; Antimalarials; Artemisinins; Costs and Cost Analysis; Drug Resistance; Drug Therapy, Combin | 1999 |
Utilization of exogenous folate in the human malaria parasite Plasmodium falciparum and its critical role in antifolate drug synergy.
Topics: 4-Aminobenzoic Acid; Animals; Antimalarials; Dose-Response Relationship, Drug; Drug Combinations; Dr | 1999 |
Does the availability of blood slide microscopy for malaria at health centers improve the management of persons with fever in Zambia?
Topics: Ambulatory Care Facilities; Animals; Antimalarials; Child, Preschool; Chloroquine; Drug Combinations | 1999 |
Efficacy and tolerability of a low-dose mefloquine-sulfadoxine-pyrimethamine combination compared with chloroquine in the treatment of acute malaria infection in a population with multiple drug-resistant Plasmodium falciparum.
Topics: Adolescent; Adult; Animals; Antimalarials; Blood; Child; Child, Preschool; Chloroquine; Drug Combina | 1999 |
Chemotherapy of malaria and resistance to antimalarial drugs in Guayana area, Venezuela.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Drug | 1999 |
Identification and analysis of dihydrofolate reductase alleles from Plasmodium falciparum present at low frequency in polyclonal patient samples.
Topics: Alleles; Animals; Antimalarials; DNA Primers; DNA Restriction Enzymes; DNA, Protozoan; Humans; Inhib | 1999 |
Lack of an association between the ASN-108 mutation in the dihydrofolate reductase gene and in vivo resistance to sulfadoxine/pyrimethamine in Plasmodium falciparum.
Topics: Animals; Antimalarials; Drug Combinations; Drug Resistance; Electrophoresis, Agar Gel; Gene Amplific | 1999 |
Plasmodium falciparum: drug-resistant malaria complicating leukemias and lymphomas in children.
Topics: Adolescent; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Drug Ther | 1999 |
Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali.
Topics: Animals; Antimalarials; Blood; Child; Dihydropteroate Synthase; DNA Restriction Enzymes; DNA, Protoz | 1999 |
Short report: high prevalence and imbalanced age distribution of the Plasmodium falciparum dihydrofolate reductase gene Asn108 mutation in an area of low pyrimethamine usage in Nigeria.
Topics: Age Distribution; Animals; Antimalarials; Child; Child, Preschool; Cross-Sectional Studies; DNA, Pro | 1999 |
Point mutations in dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum isolates from Venezuela.
Topics: Animals; Antimalarials; Dihydropteroate Synthase; DNA Restriction Enzymes; DNA, Protozoan; Drug Comb | 1999 |
Plasmodium falciparum resistance to sulfadoxine/pyrimethamine in Uganda: correlation with polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes.
Topics: Animals; Antimalarials; Child, Preschool; Dihydropteroate Synthase; DNA, Protozoan; Drug Combination | 1999 |
Current clinical efficacy of chloroquine for the treatment of Plasmodium falciparum infections in urban Dar es Salaam, United Republic of Tanzania.
Topics: Age Factors; Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Drug Evaluation; Human | 1999 |
Association of the ICAM-1Kilifi mutation with protection against severe malaria in Lambaréné, Gabon.
Topics: Animals; Anti-Bacterial Agents; Antimalarials; Case-Control Studies; Child; Clindamycin; Deoxyribonu | 1999 |
Molecular epidemiology of malaria in Yaounde, Cameroon IV. Evolution of pyrimethamine resistance between 1994 and 1998.
Topics: Adolescent; Adult; Animals; Antimalarials; Cameroon; Child; DNA Primers; DNA, Protozoan; Drug Combin | 1999 |
Atovaquone-proguanil for falciparum malaria in the Philippines.
Topics: Antimalarials; Atovaquone; Chloroquine; Drug Combinations; Humans; Malaria, Falciparum; Naphthoquino | 2000 |
[Chloroquine sensitivity of Plasmodium falciparum at the Gamkalley Clinic and the Nigerian armed forces PMI (Niamey, Niger)].
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Hu | 1999 |
Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites.
Topics: Alleles; Animals; Antimalarials; Child, Preschool; Dihydropteroate Synthase; Drug Resistance; Female | 2000 |
Gametocytocidal activity of pyronaridine and DNA topoisomerase II inhibitors against multidrug-resistant Plasmodium falciparum in vitro.
Topics: Amsacrine; Animals; Antimalarials; Chloroquine; Drug Resistance, Multiple; Enzyme Inhibitors; Etopos | 2000 |
Population dynamics of Plasmodium falciparum in an unstable malaria area of eastern Sudan.
Topics: Alleles; Animals; Antigens, Protozoan; Antimalarials; Chloroquine; Cohort Studies; DNA Primers; DNA, | 2000 |
Antibiotics for prophylaxis of Plasmodium falciparum infections: in vitro activity of doxycycline against Senegalese isolates.
Topics: Amodiaquine; Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antimalarials; Artemether; Arte | 2000 |
Malaria, intestinal parasites, and schistosomiasis among Barawan Somali refugees resettling to the United States: a strategy to reduce morbidity and decrease the risk of imported infections.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Child; Child, Preschool; Coccidiosis; Cryptosporidi | 2000 |
Epidemiologic tools for malaria surveillance in an urban setting of low endemicity along the Colombian Pacific coast.
Topics: Animals; Antimalarials; Blood; Blotting, Southern; Chloroquine; Colombia; Cross-Sectional Studies; D | 2000 |
Management of a case of chloroquine-resistant falciparum malaria in a pregnant woman with glucose-6-phosphate dehydrogenase (G6PD) deficiency.
Topics: Adult; Animals; Antimalarials; Chloroquine; Drug Resistance, Microbial; Drug Therapy, Combination; F | 1999 |
Gametocytemia and infectivity to mosquitoes of patients with uncomplicated Plasmodium falciparum malaria attacks treated with chloroquine or sulfadoxine plus pyrimethamine.
Topics: Acetaminophen; Adolescent; Adult; Analgesics, Non-Narcotic; Animals; Anopheles; Antimalarials; Child | 2000 |
Molecular epidemiology of malaria in Yaounde, Cameroon. VI. Sequence variations in the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene and in vitro resistance to pyrimethamine and cycloguanil.
Topics: Animals; Antimalarials; Cameroon; DNA Primers; DNA, Protozoan; Drug Resistance; Folic Acid Antagonis | 2000 |
Chloroquine resistant malaria.
Topics: Africa South of the Sahara; Anti-Bacterial Agents; Antimalarials; Chloroquine; Doxycycline; Drug Ant | 2000 |
Efficacy of sulphadoxine-pyrimethamine for acute uncomplicated malaria due to Plasmodium falciparum in Malawian children under five years old.
Topics: Acute Disease; Antimalarials; Child, Preschool; Drug Therapy, Combination; Female; Humans; Infant; M | 2000 |
Sequence variations in the genes encoding dihydropteroate synthase and dihydrofolate reductase and clinical response to sulfadoxine-pyrimethamine in patients with acute uncomplicated falciparum malaria.
Topics: Adolescent; Adult; Child; Child, Preschool; Dihydropteroate Synthase; Drug Combinations; Drug Resist | 2000 |
In vivo sensitivity of Plasmodium falciparum to chloroquine and sulfadoxine-pyrimethamine among schoolchildren in rural Uganda: a comparison between 1995 and 1998.
Topics: Animals; Antimalarials; Child; Chloroquine; Drug Combinations; Humans; Malaria, Falciparum; Parasite | 2000 |
Chloroquine- and sulfadoxine-pyrimethamine-resistant Falciparum malaria in vivo - a pilot study in rural Zambia.
Topics: Animals; Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance; Female; F | 2000 |
Chemoresistance of Plasmodium falciparum in the urban region of Yaounde, Cameroon. Part 2: Evaluation of the efficacy of amodiaquine and sulfadoxine-pyrimethamine combination in the treatment of uncomplicated Plasmodium falciparum malaria in Yaounde, Came
Topics: Adolescent; Adult; Aged; Amodiaquine; Animals; Antimalarials; Cameroon; Child; Drug Combinations; Fe | 2000 |
Comparative clinical characteristics and response to oral antimalarial therapy of children with and without Plasmodium falciparum hyperparasitaemia in an endemic area.
Topics: Adolescent; Age Factors; Analysis of Variance; Antimalarials; Child; Child, Preschool; Chloroquine; | 2000 |
Treatment of uncomplicated Plasmodium falciparum malaria in Myanmar: a clinical decision analysis.
Topics: Antimalarials; Chloroquine; Cost-Benefit Analysis; Decision Support Techniques; Decision Trees; Drug | 2000 |
Parasitaemia and gametocytaemia after treatment with chloroquine, pyrimethamine/sulfadoxine, and pyrimethamine/sulfadoxine combined with artesunate in young Gambians with uncomplicated malaria.
Topics: Animals; Antimalarials; Artemisinins; Artesunate; Child; Chloroquine; Cost-Benefit Analysis; Disease | 2001 |
[Resistance of Plasmodium falciparum to 3 antimalarials in Turbo (Antioquia, Colombia), 1998].
Topics: Adolescent; Adult; Aged; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; | 2001 |
[Drug resistance of Plasmodium falciparum in coastal regions of Madagascar].
Topics: Adolescent; Animals; Child; Child, Preschool; Chloroquine; Drug Resistance; Drug Therapy, Combinatio | 2000 |
HIV infection may adversely affect clinical response to chloroquine therapy for uncomplicated malaria in children.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antimalarials; Child; Child, Preschool; Ch | 2001 |
Imported malaria in a Japanese male: an autopsy report.
Topics: Animals; Antimalarials; DNA, Protozoan; Drug Combinations; Fatal Outcome; Humans; Malaria, Falciparu | 2001 |
Therapeutic efficacy of sulphadoxine/pyrimethamine and susceptibility in vitro of P. falciparum isolates to sulphadoxine-pyremethamine and other antimalarial drugs in Malawian children.
Topics: Animals; Antimalarials; Child, Preschool; Drug Monitoring; Drug Resistance; Drug Therapy, Combinatio | 2001 |
Plasmodium falciparum: gene mutations and amplification of dihydrofolate reductase genes in parasites grown in vitro in presence of pyrimethamine.
Topics: Amino Acids; Animals; Antimalarials; Blotting, Southern; Culture Media; DNA, Protozoan; Drug Resista | 2001 |
Plasmodium falciparum dihydrofolate reductase alleles and pyrimethamine use in pregnant Ghanaian women.
Topics: Alleles; Animals; Antimalarials; DNA, Protozoan; Drug Resistance; Female; Ghana; Humans; Malaria, Fa | 2001 |
Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine.
Topics: Africa; Alleles; Animals; Antimalarials; Child; Drug Resistance; Genotype; Humans; Malaria, Falcipar | 2001 |
Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Dapsone; Drug Combinations; Drug | 2001 |
Plasmodium falciparum pfcrt and pfmdr1 polymorphisms are associated with the pfdhfr N108 pyrimethamine-resistance mutation in isolates from Ghana.
Topics: Adolescent; Adult; Animals; Antimalarials; ATP-Binding Cassette Transporters; Chloroquine; DNA, Prot | 2001 |
Prevalence of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum isolates from southern Mauritania.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Dihydropteroate Syn | 2001 |
History and importance of antimalarial drug resistance.
Topics: Africa; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; History, 20th Century; Histo | 2001 |
Time of treatment influences the appearance of drug-resistant parasites in Plasmodium falciparum infections.
Topics: Animals; Antibodies, Protozoan; Antimalarials; Atovaquone; Computer Simulation; Drug Resistance; Hum | 2001 |
Failure of sulphadoxine-pyrimethamine in treating Plasmodium falciparum malaria in KwaZulu-Natal.
Topics: Antimalarials; Drug Combinations; Drug Resistance; Humans; Malaria, Falciparum; Pyrimethamine; Sulfa | 2001 |
Treatment of imported malaria in an ambulatory setting: prospective study.
Topics: Adolescent; Adult; Africa; Aged; Ambulatory Care; Antimalarials; Follow-Up Studies; Humans; Malaria, | 2002 |
[In vivo sensitivity of Plasmodium falciparum to amino-4-quinolines and sulfadoxine pyrimethamine in Agou (Ivory Coast)].
Topics: Adolescent; Aminoquinolines; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Cote d'Iv | 2002 |
Death from a severe case of Plasmodium falciparum in a Canadian.
Topics: Adult; Animals; Antimalarials; Cause of Death; Chloroquine; Drug Combinations; Female; Humans; Malar | 1992 |
Sensitivity status of Plasmodium falciparum to chloroquine, amodiaquine, quinine, mefloquine and sulfadoxine/pyrimethamine in a tribal population of District Sundargarh, Orissa.
Topics: Amodiaquine; Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Drug Therapy, | 1992 |
Malaria therapy in 452 patients, with special reference to the use of quinine.
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Drug Resistance; Drug Therapy, Combination; Female; H | 1992 |
Antimalarial drug sensitivity patterns in the western province of Zambia. Implications for the management of primary health care (PHC).
Topics: Adolescent; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Female; Humans; Malaria, | 1992 |
Efficacies of chloroquine, pyrimethamine/sulphadoxine and pyrimethamine/sulphalene against P. falciparum in northeastern Nigeria.
Topics: Animals; Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Humans; Incidence; Infant; | 1992 |
Treatment of chloroquine-resistant malaria in African children: a cost-effectiveness analysis.
Topics: Africa; Amodiaquine; Animals; Antimalarials; Child, Preschool; Chloroquine; Cost-Benefit Analysis; D | 1992 |
The disposition of oral and intramuscular pyrimethamine/sulphadoxine in Kenyan children with high parasitaemia but clinically non-severe falciparum malaria.
Topics: Administration, Oral; Child; Child, Preschool; Drug Combinations; Humans; Infant; Injections, Intram | 1992 |
Pyrimethamine resistant mutations in Plasmodium falciparum.
Topics: Animals; Base Sequence; Drug Resistance; Humans; Malaria, Falciparum; Molecular Sequence Data; Multi | 1992 |
Mefloquine for multidrug-resistant malaria.
Topics: Animals; Antimalarials; Drug Combinations; Drug Resistance; Humans; Malaria, Falciparum; Mefloquine; | 1991 |
A study of current practices in the treatment of malaria in industrial complexes in India.
Topics: Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Humans; Malaria, Falciparum | 1991 |
In vivo response of multi-resistant Plasmodium falciparum infections to mefloquine and its combination with sulfadoxine/pyrimethamine in Cambodia.
Topics: Animals; Cambodia; Drug Combinations; Drug Resistance; Humans; Malaria, Falciparum; Mefloquine; Plas | 1991 |